NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF

The present invention relates to novel 2,3-dihydro-1H-imidazo{1,2-a} pyrimidin-5-one and 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one chemical compounds comprising a substituted morpholine, to pyrimidinone derivatives, to the process for preparing same, to the novel intermediates obtained, to the use thereof as medicaments, to the pharmaceutical compositions containing them and to the novel use of such derivatives.

The present invention thus also relates to the use of said derivatives for preparing a medicament intended for treating humans.

More particularly, the invention relates to novel pyrimidinone derivatives and to the pharmaceutical use thereof for preventing and treating conditions capable of being modulated by inhibiting the Vps34/PIK3C3 pathway. Vps34/PIK3C3 is a key contributor in autophagy. Vps34/PIK3C3 is also involved in phenomena of vesicular trafficking such as endocytosis and phagocytosis (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). Vps34 also has a role in the signalling of the mTOR protein (X. Zhou et al. Plos One 2011, N. Jaber et al. PNAS 2011, MS Yoon et al. J Cell Biol 2011). Finally, Vps34 has been shown to be involved in cell proliferation (EE Johnson et al. J Cell Science 2005, X. Zhou et al. Plos One 2011, N. Jaber et al. PNAS 2012).

Inhibition and regulation of the Vps34/PIK3C3 pathway constitutes in particular a new mechanism of action for treating a large number of cancer diseases including solid and liquid tumours.

Role of the Vps34/PIK3C3 pathway

The Vps34/PIK3C3 signalling pathway is a complex network which regulates multiple cell functions summarised under the name vesicular trafficking (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). This signalling pathway is an important target in the treatment of cancer, since

vesicular trafficking phenomena such as autophagy, endocytosis and phagocytosis are modified in human tumours (F. Janku et al. Nat Rev Clinical Oncol 2011, Y. Mosesson Nat Rev Cancer 2008).

The class III PI3K lipid kinase (Vps34/PIK3C3) forms a heterodimer with the Vps15 protein. Vps15 is a protein which is myristoylated, thus enabling the Vps34/Vps15 complex to be anchored in membranes. This heterodimer is found in various multiprotein complexes, thus underlining its various biological functions (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). Vps34/PIK3C3 phosphorylates phosphatidylinositol (PI) on the position 3 of the inositol, so as to give phosphatidylinositol 3 phosphate (PI3P). PI3P is a secondary messenger. Myotubularin (MTM) phosphatase lipids dephosphorylate PI3P on position 3. Among the 16 MTMs described, the MTMR3, 6, 7 and 14 (JUMPY) proteins are thought to be involved in the inhibition of autophagosome formation and therefore of autophagy (I. Vergne FEBS Lett 2010, N. Taguchi-Atarashi et al. Traffic 2010).

Role of Vps34/PIK3C3 in autophagy

The PI3P formed by Vps34/PIK3C3 is a key secondary messenger in autophagosome formation by the recruitment of proteins such as WIPI, DFCP1 and Alfy (S. Tooze et al, Nat Cell Biol 2010). The autophagosomes formed will then fuse with lysosomes, making it possible to degrade constituents of the cytoplasm (organelles, long-lived proteins, etc.) (Z Yang et al. Nat Cell Biol 2010).

Autophagy is a mechanism of cell survival which enables the cell to survive in a situation of stress, for instance faced with a metabolic stress. In the case of cancer, autophagy is implicated in the resistance of tumour cells faced with environmental stresses, such as: hypoxia, oxidative stresses, nutrient deficiency, but also faced with therapeutic stresses: treatments with anticancer agents, ionizing radiation. Furthermore, this signalling pathway is a major factor of resistance to chemotherapy, to radiotherapy and to targeted therapies such as inhibitors of EGFR, HER2 or Bcr-Abl for example (QW. Fan

et al., Since signaling 2010, A. Gupta et al. PNAS 2010, X Li et al. Cancer Res 2010, A Vazquez-Martin et al. PLos One 2009, Z. Wu et al. Genes Cancer 2010).

Role of Vps34/PIK3C3 in endocytosis

At the endosome level, PI3P makes it possible to recruit molecules bearing FYVE (Fab1 YOTB, Vac1 and EEA1) or PX (Phox-homology) motifs, such as EEA1, HRS or SNXs, thus resulting in the fusion of endocytic vesicles. The Vps34/PIK3C3 protein has been described as being involved in the endosomal trafficking of certain transmembrane receptors such as receptor tyrosine kinases (EGF receptor, PDGF receptor) or the transferrin receptor, for example (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010). Finally, Vps34, via the regulation of endosomes, has been shown to participate in the cytokinesis phenomenon during cell division (AP Sagona et al. Nat Cell Biol 2010).

Role of Vps34/PIK3C3 in phagocytosis

PI3P is also generated at the membranes of phagosomes. The role of the Vps34/PIK3C3 protein does not appear to be involved in phagosome membrane initiation, but in phagosome maturation. Finally, the PI3P formed by the Vps34/PIK3C3 protein is thought to be involved in the activation of NADPH oxidase at the phagosome level (B. Vanhaesebroeck et al. Nat Rev Mol Cell Biol 2010).

Kinase-inhibiting morpholinopyrimidinone derivatives are known to those skilled in the art.

Application WO2008/148074 describes products which have an mTOR-inhibiting activity. These products are pyrido[1,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.


Application WO2008/064244 describes the application of the PI3Kβ-inhibiting products TGX-221 and TGX-155 which are of use in the treatment of cancer, and in particular in breast cancer. These products are pyrido[1,2-

a]pyrimidin-4-ones previously described in applications WO2004/016607 and WO2001/053266, which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Applications WO2006/109081, WO2006/109084 and WO2006/126010 describe DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

Application WO2003/024949 describes DNA-PK-inhibiting products which are of use in the treatment of ATM deficient cancers. These products are pyrido[1,2-a]pyrimidin-4-ones which differ from the products of the present invention owing to their entirely aromatic nature and to their substitutions.

The subject of the present invention is the products of formula (I):



in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e):

a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

b) R1 is a $-(CH_2)_m$-Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO2Rd or -CONRxRy radical;

c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyl radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyl, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

d) R1 is an $-SO_2$-Rb radical;

e) R1 is a -CO-Re radical;

Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical;

Rc is a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyl, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF_3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and –NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and –NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R11 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals:

 and the isomer of configuration R,R 

the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals;

all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and

alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO_2alk radical, where appropriate on a nitrogen atom;

all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms,


it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom;

it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

Thus, in the products of formula (I) as defined above, R2 and R3, which may be identical or different, are such that R2 is a hydrogen atom or an alkyl radical optionally substituted with one or more fluorine atoms and R3 is an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF_3; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical as defined above.

A subject of the present invention is the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals:



the radicals p, q, R1, R2, R3 and R4 having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0;

the radicals R1, R2, R3 and R4 and the morpholine residue having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0;

the radicals R1, R2, R3 and R4 and the morpholine residue having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

In the products of formula (I) according to the present invention,

- the term alkyl (or alk) radical denotes linear and branched radicals containing from 1 to 10 carbon atoms, such as: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl, and also the linear or branched positional isomers thereof: preference is given to the alkyl radicals containing from 1 to 6 carbon atoms and more particularly the alkyl radicals containing from 1 to 4 carbon atoms of the list above;

- the term alkenyl radical denotes linear and branched radicals containing from 2 to 10 carbon atoms, chosen from the alkyl radicals defined above containing one or more double bonds, such as allyl, but-3-enyl or pent-4-enyl, and also the linear or branched positional isomers thereof: preference is given to the allyl and but-3-enyl radicals;

-the term alkoxy radical denotes the linear and branched radicals, containing from 1 to 10 carbon atoms, methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy or hexoxy, and also the linear or branched positional isomers thereof: preference is given to the alkoxy radicals containing from 1 to 4 carbon atoms of the list above;

-the term alkythio or –S(O)x alkyl denotes the linear, and where appropriate branched, radicals in which the alkyl residue has the definition indicated above for the alkyl radical; –S(O)x alkyl thus in particular represents -S(O)x methyl, -S(O)x ethyl, -S(O)x propyl, -S(O)x isopropyl, linear, secondary or tertiary -S(O)x butyl, -S(O)x pentyl or -S(O)x hexyl and also the

linear or branched positional isomers thereof: preference is given to the -S(O)x alkyl radicals containing from 1 to 4 carbon atoms of the list above;

-the term halogen atom denotes chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom;

-the term cycloalkyl radical denotes a saturated carbocyclic radical containing from 3 to 10 carbon atoms, and thus denotes in particular the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and quite particularly the cyclopropyl, cyclopentyl and cyclohexyl radicals;

- in the -O-cycloalkyl radical, the cycloalkyl radical is as defined above;

-the term heterocycloalkyl radical thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 ring members, interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms: mention may, for example, be made of morpholinyl, thiomorpholinyl, homomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydropyran, oxodihydropyridazinyl, or else oxetanyl radicals, all these radicals being optionally substituted; mention may in particular be made of morpholinyl, thiomorpholinyl, homomorpholinyl, piperazinyl, piperidyl, homopiperazinyl or else pyrrolidinyl radicals;

-the terms aryl and heteroaryl denote monocyclic or bicyclic, respectively, carbocyclic and heterocyclic, unsaturated or partially unsaturated radicals containing at most 12 ring members, which can optionally contain a –C(O) ring member, the heterocyclic radicals containing one or more heteroatoms, which may be identical or different, chosen from O, N or S with N, where appropriate, optionally substituted;

-the term aryl radical thus denotes monocyclic or bicyclic radicals containing from 6 to 12 ring members, such as, for example, phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly phenyl and

naphthyl radicals and even more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a –C(O) ring member is, for example, the tetralone radical;

- the term heteroaryl radical thus denotes monocyclic or bicyclic radicals containing from 5 to 12 ring members: monocyclic heteroaryl radicals such as, for example, the radicals: thienyl such as 2-thienyl and 3-thienyl, furyl such as 2-furyl or 3-furyl, pyrannyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, triazolyl, thiatriazolyl, oxadiazolyl, isoxazolyl such as 3- or 4-isoxazolyl, furazanyl, free or salified tetrazolyl, all these radicals being optionally substituted, among which are more particularly the radicals: thienyl such as 2-thienyl and 3-thienyl, thiazolyl, furyl such as 2-furyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these radicals being optionally substituted; bicyclic heteroaryl radicals such as, for example, the radicals: benzothienyl (benzothiophene) such as 3-benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, quinolone, tetralone, adamentyl, benzofuryl, isobenzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, imidazopyridine, benzoxazinyl, benzoxazolyl, thionaphthyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, purinyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, dihydropyrrolopyridyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl or oxodihydropyridinopyrazolyl, all these radicals being optionally substituted.

As examples of heteroaryl or bicyclic radicals, mention may be made more particularly of pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl, benzothiazolyl or benzimidazolyl radicals optionally substituted with one or more substituents, which may be identical or different, as indicated above.

The carboxy radical(s) of the products of formula (I) may be salified or esterified with the various groups known to those skilled in the art, among which mention may be made, for example, of:

-among the salification compounds, inorganic bases such as, for example, an equivalent of sodium, of potassium, of lithium, of calcium, of magnesium or of ammonium, or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine or N-methylglucamine,

-among the esterification compounds, the alkyl radicals for forming alkoxycarbonyl groups, such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, it being possible for these alkyl radicals to be substituted with radicals chosen, for example, from halogen atoms, and hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals, for instance in the chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl or phenethyl groups.

The compounds of formula (I) can exist in the salt form, such salts being part of the invention; these salts can be prepared with pharmaceutically acceptable acids or bases (P. Stahl, C. Wermuth; Handbook of pharmaceutical salts; Wiley Ed.), but other salts, obtained, for example, for the purification or isolation of the compounds of formula (I), are part of the invention.

The compounds of formula (I) can comprise one or more asymmetric centres. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and also mixtures thereof, including racemic mixtures, are part of the invention.

It may be recalled that the stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same structural formula, but the

various groups of which are arranged differently in space, such as, in particular, in monosubstituted cyclohexanes, the substituent of which can be in the axial or equatorial position, and the various possible rotational conformations of ethane derivatives. However, there is another type of stereoisomerism, owing to the different spatial arrangements of substituents attached either on double bonds or on rings, which is often referred to as geometric isomerism or cis-trans isomerism. The term stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.

In the products of formula (I) according to the present invention, when R1 is an optionally substituted phenyl or pyridyl radical, then in particular R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when R1 is a $-(CH_2)_m$-Ra radical, then m is the integer 1 or 2 and in particular Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO_2Rd; -CONRxRy; a -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO-piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO_2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or

more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical; and NRxRy being as defined above or hereinafter;

the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from piperidyl, morpholinyl, homomorpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine, {1,2}oxazinane, pyrrolidinyl, pyrazolidinyl, pyrazolinyl, azepinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter.

More particularly, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1,2}oxazinane radicals.

In the products of formula (I) according to the present invention, when R1 is the SO_2Rb radical, then R1 is in particular the -SO_2-phenyl radical optionally substituted with an alkyl radical or a halogen atom, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when R1 is an alkyl radical, then in particular R1 is an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when R1 is a cycloalkyl radical, then R1 is in particular a cyclobutyl, cyclopentyl or cyclohexyl radical, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, when R1 is a heterocycloalkyl radical, then R1 is in particular an oxetane, tetrahydrofuran or tetrahydropyran radical, the other substituents R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF_3, the other substituents R1, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 is a methyl radical and R3 is the trifluoromethyl radical CF_3, the other substituents R1, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, in particular R2 and R3 may be such that R2 and R3 are both a methyl radical, the other substituents R1, R4, R5, R6, R7, R8, R9, R10, R11, R12, p and q of said products of formula (I) having the meanings indicated above.

In the products of formula (I) according to the present invention, one or more of the hydrogen atoms that R4, R5, R6, R7, R8, R9, R10, R11 and R12 of said products of formula (I) may represent can be a deuterium atom.

In the products of formula (I) according to the present invention, the cyclic radical that R2 and R3 may optionally form with the carbon atom to which they are bonded, as defined above, can thus be a carbocyclic (spirocycloalkyl) radical such as the spirocyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical, or else be a heterocyclic radical such as, for example, the oxetane radical, all these radicals being optionally substituted as defined above.

In the products of formula (I) according to the present invention, when NRxRy forms a ring as defined above, such an aminated ring can be chosen in particular from pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, azepinyl, morpholinyl, homomorpholinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter.

A subject of the present invention is the products of formula (I) as defined above, in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; a $-(CH_2)_m$-Ra radical; an $–SO_2$-phenyl radical optionally substituted with an alkyl radical; a -CO-alkyl radical; an alkylene radical; or an alkyl

radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms;

m is the integer 1 or 2;

Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO_2Rd; -CONRxRy; a -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO-piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO_2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, heterocyloalkyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

NRxRy are such that Rx and Ry, which may be identical or different, are a hydrogen atom or an alkyl, alkoxy or phenyl radical or else together form a piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1,2}oxazinane radical;

R2 and R3 are such that:


either R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF_3;

or R2 is a methyl radical and R3 is the trifluoromethyl radical CF_3;

or R2 and R3 are both a methyl radical;


R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is chosen from the following radicals:



said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).


A subject of the present invention is thus the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals:



the other substituents R1, R2, R3, R4, p and q of said products of formula (I) having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is thus the products of formula (I) as defined above, in which the morpholine residue is chosen from the following radicals:



the other substituents R1, R2, R3, R4, p and q of said products of formula (I) having the meanings indicated above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

In the products of formula (I) according to the present invention, Rb can in particular be one of the following radicals as defined above: alkyl, such as, for example, methyl, ethyl or isopropyl; phenyl, pyridyl, thiazole, isoxazole, oxazole and oxadiazole; all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, piperidyl, morpholinyle, phenyl, pyridyl, alkyl and alkoxy radicals, the latter phenyl, pyridyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals.

In particular, Rd can be an alkyl or cyclopentyl radical.

In the products of formula (I) according to the present invention, R4 can be a hydrogen atom or a fluorine atom.

In the products of formula (I) according to the present invention, when R1 is a $-(CH_2)_m$-Ra radical with m being the integer 1 or 2 and Ra being -CO-cycloalkyl or -CO-heterocycloalkyl, then these cycloalkyl and heterocycloalkyl radicals are chosen, for example, from cyclopropyl, cyclopentyl, cyclohexyl, morpholinyl, piperidyl, tetrahydrofuran, tetrahydropyran and pyrrolidine radicals, all optionally substituted with one or more alkyl radicals and, in addition, optionally with CO_2alk on the nitrogen of the pyrrolidine.

In the products of formula (I) according to the present invention, when R1 is a $-(CH_2)_m$-Ra radical with m being the integer 1 or 2 and Ra being -CO-Rb, then Rb can be, for example, an alkyl radical such as, in particular, methyl, ethyl, propyl, butyl or pentyl, all linear or branched, such as, for example isopropyl, *tert*-butyl, linear or branched butyl, linear or branched pentyl, which are optionally substituted as indicated above.

A subject of the present invention is most particularly the products of formula (I) as defined above, corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Imidazo[1,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6-trifluoromethylpyridin-3-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Isopropoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]thiadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1,2,3]thiadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl-[1,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- single stereoisomer.

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-Methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-5-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-4-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1R,5S)-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(1-Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetyl}pyrrolidine-1-carboxylic acid tert-butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1,2,4]triazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofuran-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-Isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorpholin-4-yl)-pyridin-4-yl]-2-oxoethyl}-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydropyran-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1-azaspiro[3.3]hept-1-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the present invention is also any process for preparing the products of formula (I) as defined above.

The products according to the invention can be prepared using conventional organic chemistry methods.

A subject of the present invention is thus in particular a process for synthesis of the products of formula (I) as defined above, described in scheme 1 or scheme 2.

Preparation of compounds of formula (I)

The products of formula (I) according to the present invention, as defined above, can be prepared according to the usual methods known to those skilled in the art, and in particular according to the process described in scheme 1 below.


Scheme 1 below illustrates the methods used for preparing the products of formula (I). In this respect, they could not constitute a limitation of the scope of the invention, with regard to the methods for preparing the compounds claimed.

A subject of the present invention is thus also the process for preparing products of formula (I) according to scheme 1 as defined hereinafter.

A subject of the present invention is thus also the process for preparing products of formula (I) according to scheme 2 as defined hereinafter.


The products of formula (I) as defined above according to the present invention can thus in particular be prepared according to the process described in scheme 3 as defined hereinafter.

Scheme 1:


Hydrolysis
n = 0 or 1
Amidation
n = 0 or 1
Reduction
n = 0 or 1
Deprotection
n = 0 or 1
Reductive amination
n = 0 or 1
CNBr
n = 0 or 1
CNBr
n = 0 or 1
Hydrogenation
Deprotection
n = 0 or 1
Base
Base
route b
Deprotection
route a
Chlorination
Chlorination
Deprotection
via route a: p = 1 or 2 and q = 0
and
via route b: p = 0 and q = 1 or 2
R1X T1
R1OH T2
T3
Electrophile
R1X T1
R1OH T2
T3
Electrophile
p = 1 or 2
q = 0
L
M
N
G
A
C
B
H
D
I
E
F
J
Q
P
(I)

in which the substituents n, p, q, PG, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and alkyl have the meanings indicated above for the products of formula (I).


In particular, when n = 1, the intermediate L can be prepared according to the following scheme under the conditions indicated hereinafter:



K L (n = 1)


in which the substituents R2 and R3 have the meanings indicated above for the products of formula (I).

Scheme 2:



in which the substituents n, p, q, PG, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and alkyl have the meanings indicated above for the products of formula (I).

Scheme 3:



in which the substituents n, p, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 have the meanings indicated above for the products of formula (I).

In schemes 1, 2 and 3 as defined above, the procedure can be carried out according to the usual methods known to those skilled in the art and in particular according to the conditions described hereinafter.

The diamines A are either commercially available, or prepared, in the achiral, chiral or racemic version, according to the methods known to those skilled in the art, such as, in particular, by analogy and homologation with the process described by Brigaud, T. et al. in J. Org. Chem. 2006, 71(18), 7075-7078, for the values of n, R2 and R3 as defined above.

Alternatively, the diamines A can be obtained according to the methods known to those skilled in the art, such as in particular from the amino esters L (alpha-amino esters n = 0, or beta-amino esters n = 1), which are either commercially available or prepared respectively as described, for example, by Robert M. Williams in Synthesis of Optically Active α-Amino Acids from Pergamon Press or, for example (n = 1), by 1,4 Michael addition of an amine such as aqueous ammonia, for example, on the corresponding acrylates K as described, for example, by P. Perlmutter in Tetrahedron Organic Chemistry Series Volume 9 Conjugate Addition Reactions in Organic

Synthesis from Pergamon Press, by stringing together the conventional sequences of hydrolysis of the ester function L to give the acid M, followed by an N amidation in the presence of an amine such as, for example, benzylamine, para-methoxybenzylamine, dimethoxybenzylamine or 4-methoxyphenylethylamine, followed by reduction of the amide function N to give the amine G in the presence, for example, of lithium aluminium tetrahydride, then by deprotection of the amine G, if necessary, given that all of the sequences can be carried out by conventional methods as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH and by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience, for the values of R2, R3, PG and n as defined above.

Alternatively, the diamines G can be obtained in particular by means of a reductive amination reaction of the commercially available diamines A via a conventional method as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH and by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience, for the values of R2, R3, PG and n as defined above.

The guanidines B (n = 1) are either commercially available or prepared from C according to the methods known to those skilled in the art, such as, in particular, according to the processes described in Lochead, A.W. et al. (EP1460076 2002), Lochead, A.W. et al. (EP1340761 2003), Lochead, A.W. et al. (EP1454909 2004), Lochead, A.W. et al. (WO2005058908 2005), and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2) or by analogy with this same reference in the other cases, for the values of n, R2 and R3 as defined above.

The guanidines B can be obtained in particular by reacting a diamine A and cyanogen bromide in a solvent such as water or acetonitrile, at a temperature between 0°C and the boiling point of the solvent, according to

the conditions described, for example, by Gallet, T. et al. (EP1340761 2003) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of n, R2 and R3 as defined above.

Alternatively, the guanidines B can be obtained by deprotection of the guanidines H according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience, for the values of n, R2, R3 and PG as defined above.

The guanidines H can be obtained in particular by reacting a diamine G and cyanogen bromide in a solvent such as water or acetonitrile, at a temperature between 0°C and the boiling point of the solvent, according to the conditions described, for example, by Gallet, T. et al. (EP1340761 2003) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of n, R2, R3 and PG as defined above.

The compounds E can be obtained in particular by condensation of the guanidines B with a dialkyl malonate (preferably dimethyl or diethyl malonate) D, in the presence of a base such as sodium methoxide, at a temperature between 0°C and 150°C, as described, for example, by Badawey E.-S.A.M. et al. (Eur J Med Chem, 1998, 33(5), 349-361) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of n, p, q, R2, R3 and R4 as defined above.

Alternatively, the compound E can be obtained by deprotection of the compound I according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience, for the values of p, q, R2, R3, R4 and PG as defined above.

The compounds I can be obtained in particular by condensation of the guanidines H with a dialkyl malonate (preferably dimethyl or diethyl malonate) D, in the presence of a base such as sodium methoxide, at a temperature between 0°C and 150°C, as described, for example, by Badawey E.-S.A.M. et

al. (Eur J Med Chem, 1998, 33(5), 349-361) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of n, p, q, R2, R3, R4 and PG as defined above.

The compounds F can be obtained in particular from the compounds E by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of solvent, at a temperature between 20°C and 150°C, or in the presence of a solvent such as dichloroethane, at a temperature between 20°C and the boiling point of the solvent, for instance under the conditions described by Yamashita, A. et al. (Syn. Commun. (2004), 34(5), 795-803) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of p, q, R2, R3 and R4 as defined above.

Alternatively, the compound F can be obtained by deprotection of the compound J according to the conventional methods known to those skilled in the art as described, for example, by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience, for the values of R2, R3, R4, p and q as defined above.

The compounds J can be obtained in particular from the compounds I by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of solvent, at a temperature between 20°C and 150°C, or in the presence of a solvent such as dichloroethane, at a temperature between 20°C and the boiling point of the solvent, for instance under the conditions described by Yamashita, A. et al. (Syn. Commun. (2004), 34(5), 795-803) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of p, q, R2, R3, R4 and PG as defined above.

The compounds P can be obtained from the compounds F by reacting with a substituted morpholine, in the absence or in the presence of a solvent such as acetonitrile, at a temperature between 20°C and 200°C, in the presence or absence of a base such as triethylamine or sodium carbonate for example, by analogy as described, for example, by Aliabiev S.B. (Lett. Org. Chem. (2007), 4(4), 273-280) and Bacque, Eric et al. (WO2011001112A1 and

WO2011001113A2), for the values of p, q, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 as defined above.

The products of formulae (I) can be obtained from the compounds Q by reacting with a substituted morpholine, in the absence or in the presence of a solvent such as acetonitrile, at a temperature between 20°C and 200°C, in the presence or absence of a base such as triethylamine or sodium carbonate for example, by analogy as described, for example, by Aliabiev S.B. (Lett. Org. Chem. (2007), 4(4), 273-280) and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2), for the values of p, q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 as defined above.

The compounds Q or alternatively the products of formulae (I), as indicated on the schemes above, can be obtained respectively from the compounds F and P, for example by reacting with an electrophile by addition of a compound T1, T2 or T3 as defined above and as follows:

- T1 is R1'-X in which R1' represents values of R1 as defined above for the products of formula (I): when R1' represents the values of R1 with the exception of the aryl and heteroaryl values, then the addition reaction of R1'X in which X is in particular Cl, Br, I, OMs, OTs or OTf, respectively with the compounds F and P, can be carried out, for example, in the presence of a base such as caesium carbonate, potassium phosphate or sodium hydride in excess, in a solvent such as acetonitrile, tetrahydrofuran, N,N-dimethylformamide or dimethyl sulfoxide, at a temperature between ambient temperature and 200°C, as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH in the case of the alkylation reaction. When R1' represents the aryl and heteroaryl values of R1, then the addition reaction of R1'X, in which X is in particular I or Br, respectively with the compounds P, can be carried out, for example, by a reaction or a coupling

of Ullmann type in the presence of a base such as potassium phosphate in excess with cuprous iodide, in a solvent such as N,N-dimethylformamide, at a temperature between 100 and 200°C, as described, for example, by Ulmann, F. in Chem. Ber. 1903, *36*, 2389 and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2) in the case of the Ullmann-type reaction.

- T2 is R1''-OH in which R1'' represents values of R1 with the exception of the aryl and heteroaryl values as defined above for the products of formula (I): the addition reaction of T2, respectively with the compounds F and P, can be carried out, for example, in the presence of supported or nonsupported triphenylphosphine and of diethyl azodicarboxylate and of a base such as diisopropylethylamine, in a solvent such as tetrahydrofuran, at a temperature between ambient temperature and 100°C, as described, for example, by Mitsunobu, O. in "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products" Synthesis 1981 (1) 1-28 in the case of the Mitsunobu reaction.

- T3 is an epoxyethylene radical disubstituted in position 1 with substituents Y,Z, which may be identical or different, chosen from a hydrogen atom and alkyl (such as, for example, methyl or ethyl), aryl or heteroaryl radicals, all optionally substituted as indicated for R1 in the products of formula (I) as defined above: the addition reaction of T3, respectively with the compounds F and P, can be carried out, for example, in the presence of a base such as sodium hydride, sodium hydroxide, potassium phosphate or caesium carbonate in excess, in the absence of solvent or in a solvent such as tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, or an acetone and water mixture with a phase-

transfer agent such as, for example, benzyltriethylammonium chloride, at a temperature between 20°C and 200°C, as described, for example, by Hepperle, Michael E. et al., PCT Int. Appl., 2007097981, 30 Aug 2007 and Bacque, Eric et al. (WO2011001112A1 and WO2011001113A2).

In general schemes 2 and 3 above:

- The compound B can be obtained according to the 3 routes indicated in scheme 1 from the compounds A, C and H as defined above and according to the steps also defined above.
- The compound E can be obtained according to the 2 routes indicated in scheme 1 from the compounds I and B as defined above and according to the steps also defined above.
- The compound F can be obtained according to the 2 routes indicated in scheme 1 from the compounds E and J as defined above and according to the steps also defined above.
- The products of formula (I) can be obtained according to the 2 routes indicated in scheme 1 from the compounds P and Q as defined above and according to the steps also defined above.

When R2 is different from R3 and if the synthesis is not stereoselective, the enantiomers or the possible diastereoisomers of the synthesis intermediates or of the compounds (I) can be separated by chromatography on a chiral support.

The following examples of products of formula (I) illustrate the invention without, however, limiting it.

Among the starting products of formulae A, B, C, D, G, H, K, L, M, N, O and T, some are known and can be obtained either commercially, or according to the usual methods known to those skilled in the art as described, for example, by Larock, Richard, C. et al., in Comprehensive Organic

Transformations A Guide to Functional Group Preparations from VCH, for example starting from commercial products.

It is understood by those skilled in the art that, in order to implement the processes according to the invention previously described, it may be necessary to introduce function-protective groups, such as, for example, the PG protective group, as described in particular by Theodora W. Greene and Peter G. M. Wuts in Protective Groups in Organic Synthesis Third Edition from Wiley-Interscience. Thus, the amine group protected by PG may be, for example, a benzylamine, para-methoxybenzylamine, 2,4-dimethoxybenzylamine or 4-methoxyphenylethylamine.

It may be noted that, if desired and if necessary, it is possible to subject intermediate products or products of formula (I) thus obtained by means of the processes indicated above, in order to obtain other intermediates or other products of formula (I), to one or more conversion reactions known to those skilled in the art, as described, for example, by Larock, Richard, C. et al. in Comprehensive Organic Transformations A Guide to Functional Group Preparations from VCH.

The products of formula (I) as defined above and also the addition salts thereof with acids exhibit advantageous pharmacological properties, in particular owing to their kinase-inhibiting properties as is indicated above.

The products of the present invention are in particular of use for antitumour therapies.

The products of the invention can thus also increase the therapeutic effects of commonly used antitumour agents.

The products of the invention can thus also increase the therapeutic effects of commonly used radiotherapies.

These properties justify the therapeutic application thereof, and the subject of the invention is in particular, as medicaments, the products of formula (I) as defined above, said products of formula (I) being in any of the

possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

A subject of the invention is quite particularly, as medicaments, the products corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Imidazo[1,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6-trifluoromethylpyridin-3-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Isopropoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]thiadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1,2,3]thiadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl-[1,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- single stereoisomer.

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-ethylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-5-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-4-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-terahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1R,5S)-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(1-Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetyl}pyrrolidine-1-carboxylic acid tert-butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1,2,4]triazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofuran-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-Isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorpholin-4-yl)-pyridin-4-yl]-2-oxoethyl}-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydropyran-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1-azaspiro[3.3]hept-1-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

The invention also relates to pharmaceutical compositions containing, as active ingredient, at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate, a pharmaceutically acceptable carrier.

The invention also extends to the pharmaceutical compositions containing, as active ingredient, at least one of the medicaments as defined above.

Such pharmaceutical compositions of the present invention can also, where appropriate, contain active ingredients of other anti-mitotic medicaments, such as, in particular, those based on taxol, cisplatin, DNA-intercalating agents, and the like.

These pharmaceutical compositions can be administered orally, parenterally or locally by topical application to the skin and the mucous membranes or by intravenous or intramuscular injection.

These compositions may be solid or liquid and be in any of the pharmaceutical forms commonly used in human medicine, for instance simple or sugar-coated tablets, pills, lozenges, gel capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods. The active ingredient may be incorporated therein with excipients normally used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or nonaqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, or preservatives.

The usual dosage, which is variable according to the product used, the individual treated and the condition in question, can be, for example, from 0.05 to 5 g per day in adults, or preferably from 0.1 to 2 g per day.

A subject of the present invention is also the use of products of formula (I) as defined above, for preparing a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of the activity of a protein or lipid kinase.

Such a medicament can in particular be intended for the treatment or prevention of a disease in a mammal.

A subject of the present invention is in particular the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of diseases associated with an uncontrolled proliferation.

A subject of the present invention is thus quite particularly the use of a product of formula (I) as defined above, for preparing a medicament intended for the treatment or prevention of diseases in oncology, and in particular intended for the treatment of cancers. A subject of the present invention is the products of formula (I) as defined above, for use thereof in the treatment of solid or liquid tumours.

The cited products of the present invention can in particular be used for the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate, endometrial and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

A subject of the present invention is also the use of the products of formula (I) as defined above, for preparing medicaments intended for cancer chemotherapy. A subject of the present invention is therefore the products of formula (I) as defined above, for use thereof in cancer chemotherapy, alone or in combination. The products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or else in combination, for example, with other therapeutic agents. Such therapeutic agents may be commonly used antitumour agents.

A therapeutic benefit can in particular be expected when administering the products of the present application in combinations with varied targeted therapies. These targeted therapies are in particular the following: i) targeted therapies which inhibit kinases or pseudo-kinases such as EGFR, HER2, HER3, PI3K, AKT, mTOR, Bcr-Abl, Kit, PDGFR or Src (QW.

Fan et al., Since signaling 2010, A. Gupta et al. PNAS 2010, X Li et al. Cancer Res 2010, A Vazquez-Martin et al. PLos One 2009, Z. Wu et al. Genes Cancer 2010) ii) targeted therapies which inhibit the oestrogen receptor, the proteasome, the HDAC protein (JS Samaddar et al. Mol Cancer Ther 2008, B; Hoang et al. Mol Cancer Ther 2009, JS Carew et al. Blood 2007). A therapeutic effect can also be expected when combining the products of the present application with chemotherapy agents such as camptothecin, taxotere or 5-FU, for example; or else when combining them with radiotherapy (J Li et al. Eur J of Cancer 2010, A. Appel et al. Cancer Res 2008).

A subject of the present invention is in particular the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease, for example (N. Raben et al., Autophagy 2010, B Levine et al. Cell 2008, N. Mizushima et al. Nature 2008). Such medicaments intended for the treatment of lysosomal diseases can be used alone or in combination, for example, with other therapeutic agents.

A subject of the present invention is also the use of a product of formula (I) as defined above, for preparing a medicament intended for the prevention or treatment of X-linked myotubular myopathies, Charcot-Marie-Tooth disease; where mutations of the proteins of the myotubularin family have been described (I. Vergne et al., FEBS Lett, 2010). A subject of the present invention is thus the use as defined above, in which said products of formula (I) are alone or in combination.

Among the cancers, the treatment of solid or liquid tumours, and the treatment of cancers resistant to cytotoxic agents are of interest.

The products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or else in combination, for example, with other therapeutic agents.

Such therapeutic agents may be commonly used antitumour agents.

As kinase inhibitors, mention may be made of butyrolactone, flavopiridol, 2(2-hydroxyethylamino)-6-benzylamino-9-methylpurine known as olomucine, sorafenib, imatinib, erlotinib, gefitinib and lapatinib. Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof as a VPS34 inhibitor.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of cancers.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of solid or liquid tumours.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of cancers resistant to cytotoxic agents.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in cancer chemotherapy.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in cancer chemotherapy, alone or in combination.


Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease.

Thus, the present application relates in particular to the products of formula (I) as defined above, for use thereof in the treatment of X-linked myotubular myopathies and Charcot-Marie-Tooth disease.

A subject of the present invention is also, as novel industrial products, certain starting products or synthesis intermediates of formulae A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, T1, T2 and T3 as defined above.


A subject of the present invention is thus in particular, as novel industrial products, the starting products or synthesis intermediates as defined above and hereinafter:

- of formulae A, B, G and N:




in which n = 1, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and PG is a protective group for amine;

- of formulae E, F, I and J:




in which q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated above and hereinafter;

- of formulae P and H:



in which the substituents n, p, q, PG, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 have the definitions indicated above and hereinafter;

- of formula Q:



in which either q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated above and hereinafter, or R1 is $-(CH_2)_m$-Ra with Ra being -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, $-CO_2Rd$ or -CONRxRy, and the substituents p, q, R2, R3 and R4 have the definitions indicated above and hereinafter.

The following examples which are products of formula (I) illustrate the invention without, however, limiting it.

The following examples which are products of formula (I) according to the present invention can be prepared according to the usual methods known to those skilled in the art, and in particular as indicated above or below, and in the schemes and Tables 1 to 10.

Experimental section

The nomenclature of the compounds of this present invention was performed with the ACDLABS version 10.0 software.

The microwave oven used is a Biotage, Initiator™ Eight, 400W max, 2450 MHz apparatus.

The ^{1}H NMR spectra at 400 MHz and ^{1}H NMR spectra at 500 MHz were carried out on a Bruker Avance 250 or Bruker Avance DRX-400 or Bruker Avance DPX-500 spectrometer with the chemical shifts (δ in ppm) in the solvent dimethyl sulfoxide-d_6 (DMSO-d_6) referenced at 2.5 ppm at the temperature of 303K.

The mass spectra (MS) were obtained either by method A or by method B.

Method A:

Waters UPLC-SQD apparatus; Ionization: positive and/or negative mode electrospray (ES+/-); Chromatographic conditions: Column: Acquity BEH C18 1.7 µm - 2.1 x 50 mm; Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid); Column temperature: 50°C; Flow rate: 1 ml/min; Gradient (2 min): from 5% to 50% of B in 0.8 min; 1.2 min: 100% of B; 1.85 min: 100% of B; 1.95 min: 5% of B; Retention time = Tr (min).

Method B:


Waters ZQ apparatus; Ionization: positive and/or negative mode electrospray (ES+/-); Chromatographic conditions: Column: XBridge C18 2.5 µm - 3 x 50 mm; Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid); Column temperature: 70°C; Flow rate: 0.9 ml/min; Gradient (7 min): from 5% to 100% of B in 5.3 min; 5.5 min: 100% of B; 6.3 min: 5% of B; Retention time = Tr (min).

The optical rotations (ORs) were measured on a model 341 polarimeter from Perkin Elmer. Wavelength: sodium α line (589 nm).

The intermediates of type F as defined in the schemes above, i.e. F1 to F9 defined in Table 1 below, resulting in Examples 1 to 295, can be prepared in the following way:

Intermediate F1

(S)-2-Chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




The separation of the two enantiomers of (8R,8S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one (17 g) is carried out by chiral chromatography: stationary phase: Chiralpak AD; mobile phase: EtOH (20%) / Heptane (80%). The laevorotatory enantiomer is concentrated so as to give 8.52 g of (R)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a white powder. The dextrorotatory enantiomer is concentrated so as to obtain 8.21 g of (S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a white powder, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51

$[\alpha]_D^{25}$ at 589 nm = + 21.3 +/- 0.5 (MeOH)

(8R, 8S)-2-Chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a] pyrimidin-4-one can be prepared in the following way.




60 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 34 g of (8R,8S)-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one in 500 ml of 1,2-dichloroethane. The mixture obtained is then heated to 65°C. After three hours of stirring at 65°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 100 ml of cold water and 400 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 6. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under

reduced pressure, so as to give an orange residue. This residue is purified by chromatography on silica (eluent: CH_2Cl_2/MeOH: 97/03) so as to give 20 g of (8R,8S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51


(8R,8S)-2-Hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



10 g of (4R,4S)-4-(trifluoromethyl)-1,4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride and 10 g of sodium methoxide are added to 50 ml of diethyl malonate. The mixture obtained is brought to 100°C for 75 minutes. The heterogeneous mixture thickens and becomes yellow, with a slight release of gas. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is triturated with ethyl ether. The solid formed is filtered off through a sintered glass funnel and then taken up with 20 ml of cold water. 12N hydrochloric acid is added to the thick suspension obtained, to pH = 5-6. The suspension obtained is filtered through a sintered glass funnel and the insoluble matter is rinsed with ethyl ether so as to give 11.5 g of (8R,8S)-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 236; [M-H]-: m/z 234; Tr (min) = 0.26

(4R,4S)-4-(Trifluoromethyl)-1,4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride can be prepared in the following way.




A mixture of 1.1 g of 10% Pd/C, 22 g of 2-amino-4-(trifluoromethyl)pyrimidine dissolved in 200 ml of water, 50 ml of methanol and 50 ml of 12N HCl is hydrogenated at 3 bar, at 22°C, for 24 hours in an autoclave. The resulting mixture is then filtered and the filtrate is concentrated under reduced pressure. The residue obtained is oven-dried, in the presence of P_2O_5, so as to give 27 g of (4R,4S)-4-(trifluoromethyl)-1,4,5,6-tetrahydropyrimidin-2-ylamine hydrochloride, in the form of a grey solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 168; Tr (min) = 0.17

Intermediate F2

(8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




The separation of the enantiomers of (8R,8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one is carried out by chiral chromatography (Chiralpak AD 20µm 80x350 mm 250 ml/min 254 nm; 5% EtOH 5% MeOH 90% Heptane +0.1% TEA), using 6.8 g of a racemic mixture. The dextrorotatory enantiomer is concentrated so as to obtain 3.13 g of (8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a white solid, the characteristics of which are the following:

$[\alpha]_D^{25}$ at 589 nm= + 19.6 +/- 0.6 (c = 2.488 mg / 0.5 ml MeOH)

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 272; [M-H]-: m/z 270; Tr (min) = 0.62


(8R, 8S)-2-Chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



8 ml of phosphorus oxychloride are added to a solution of 6.5 g of (8R, 8S)-3-fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one in 80 ml of 1,2-dichloroethane. After stirring for 4 hours at a temperature of 65°C and returning to a temperature of about 20°C, the reaction mixture is concentrated to dryness under reduced pressure. The residue is diluted in 150 ml of ethyl acetate and 10 ml of ice-cold water. At a temperature between 0°C and 10°C, a concentrated sodium hydroxide solution is added until a pH between 6 and 7 is obtained. The solid form is filtered off so as to give 3.5 g of a beige solid S1. The filtrate is separated by settling out, and the organic phase is dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced pressure. After purification of the residue on a silica column (eluent: 97/03 CH_2Cl_2 / MeOH), 3.3 g of a pale yellow solid S2 are obtained. The two solids S1 and S2 are combined so as to give 6.8 g of (8R, 8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a pale yellow powder, the characteristics of which are the following:

Mass spectrum (method B) (ES+/-) [M+H]+: m/z 272; [M-H]-: m/z 270; Tr (min) = 2.9

(8R, 8S)-3-Fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




5.6 g of sodium methoxide are added to a suspension of 7 g of (4R,4S)-4-(trifluoromethyl)-1,4,5,6-tetrahydropyrimidin-2-ylamine

hydrochloride in 35 ml of dimethyl fluoropropanedioate. After stirring the suspension for 3 hours at a temperature of 100°C, the medium obtained is concentrated to dryness under reduced pressure. The residue is taken up in diethyl ether and then dried with suction under vacuum. The solid obtained is taken up in 14 ml of water, and the resulting mixture is cooled in ice, before acidification to pH 5-6 by addition of concentrated hydrochloric acid (25%). After 2 hours of stirring at a temperature of 0°C and then overnight at a temperature of about 20°C, the suspension is filtered and then the solid is dried with suction and dried under vacuum over P_2O_5. 6.5 g of (8R, 8S)-3-fluoro-2-hydroxy-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained in the form of a yellow powder, the characteristics of which are the following:

Mass spectrum (method A) (ES +/-) [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.28


Intermediate F3

(R)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.



The separation of the two enantiomers of (4R,4S)-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one (4.5 g) is carried out by chiral chromatography: stationary phase: AS 20µm; mobile phase: 5% MeOH; 10% EtOH; 85% Heptane; 0.1% TEA. The laevorotatory enantiomer is concentrated so as to give 2.07 g of (R)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white powder, $[\alpha]_D^{25}$ at 589 nm = -32.7 +/- 0.7 (DMSO). The dextrorotatory enantiomer is concentrated so as to obtain 2.19 g of (S)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a cream powder, $[\alpha]_D^{25}$ at 589 nm = +29.2 +/- 0.8 (DMSO).


8-Chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.



16 ml of trifluoromethanesulfonic acid are added, at ambient temperature and under an argon atmosphere, to a solution of 8.1 g of 2-chloro-9-(2,4-dimethoxybenzyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one in 200 ml of 1,2-dichloromethane. The mixture obtained is then stirred at ambient temperature for one hour. The reaction is complete according to the verification by LC/MS. The reaction medium is cooled in an ice bath. 32% sodium hydroxide is added dropwise to pH = 10. The white solid formed is filtered off so as to give 7 g of the solid S1. After separation of the filtrate by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure, so as to give 0.9 g of the solid S2. The solid S1 is taken up with water and ethyl acetate. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure, so as to give 3.5 g of the solid S3. The two solids S2 and S3 are combined for purification by chromatography on silica (eluent: CH_2Cl_2/EtOAc: 90/10) so as to give 4.08 g of 8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56

2-Chloro-9-(2,4-dimethoxybenzyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



14 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 11.5 g of 9-(2,4-dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one in 140 ml of 1,2-dichloroethane. The mixture obtained is then heated to 65°C. After one hour of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 30 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 8. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents:


dichloromethane/EtOAc: 97/03, so as to give 8.2 g of 2-chloro-9-(2,4-dimethoxybenzyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, the characteristics of which are the following:

Mass spectrum (method B): ES+/-: [M+H]+: m/z 404; Tr (min) = 4.54

then CH_2Cl_2/EtOAc: 85/15, so as to give 0.64 g of 8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56


9-(2,4-Dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



35 ml of methyl malonate and 13 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 19.1 g of 1-(2,4-dimethoxybenzyl)-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine in 175 ml of methanol. The mixture obtained is then heated at reflux. After six hours of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 20 ml of cold water and 400 ml of ethyl acetate. 36% HCl is added dropwise to pH = 5-6. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH: 98/02, so as to give 11.6 g of 9-(2,4-dimethoxybenzyl)-2-hydroxy-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 386; [M-H]-: m/z 384; Tr (min) = 0.78


1-(2,4-Dimethoxybenzyl)-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine can be prepared in the following way.



5.7 g of cyanogen bromide are added, in small amounts, at ambient temperature and under an argon atmosphere, to a solution of 14.2 g of N1-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutane-1,3-diamine in 150 ml of acetonitrile. At the end of the addition, the mixture obtained is then heated at reflux for three hours in an oil bath preheated to 100°C. After cooling, the reaction mixture is evaporated to dryness under reduced pressure, so as to give 19.11 g of 1-(2,4-dimethoxybenzyl)-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine in the form of a pale yellow foam, which will be used as it is in the next step and the characteristics of which are the following:

Mass spectrum (method B): ES+/-: [M+H]+: m/z 318; Tr (min) = 2.67


N1-(2,4-Dimethoxybenzyl)-4,4,4-trifluorobutane-1,3-diamine can be prepared in the following way.



8 g of $LiAlH_4$ are added, in small portions, at ambient temperature and under an argon atmosphere, to a solution of 10.6 g of 3-amino-N-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutyramide in 500 ml of anhydrous ethyl ether. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 11 ml of water, followed by 11 ml of 4N NaOH and then 22 ml of water are added dropwise. The white precipitate formed is filtered off. The filtrate is dried over magnesium sulfate and then concentrated under reduced pressure, so as to give 9.5 g of N1-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutane-1,3-diamine, in the form of a colourless oil, which is used as it is in the next step.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 293; ES+ base peak: m/z 151; Tr (min) = 0.33


3-Amino-N-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutyramide can be prepared in the following way.



23.4 g of 2,4-dimethoxybenzylamine are added in one step to a suspension of 20 g of 3-amino-4-trifluorobutyric acid in 120 ml of DMF, followed, dropwise, by 41 g of phenylsilane, said additions being carried out while maintaining the temperature of the reaction medium between 20 and 28°C. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 200 ml of water, followed by 300 ml of ethyl acetate, are added dropwise. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with 500 ml of methanol. The white solid formed is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH: 95/05, so as to give 25 g of 3-amino-N-(2,4-dimethoxybenzyl)-4,4,4-trifluorobutyramide, in the form of a pasty white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 307; ES+ base peak: m/z 151; Tr (min) = 2.38

Alternative intermediate F3: Alternatively, (R)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.




3.7 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 3.2 g of (R)-8-hydroxy-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one in 37 ml

of 1,2-dichloroethane. The mixture obtained is then heated to 65°C. After 4 hours of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 50 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: CH_2Cl_2/MeOH: 96/04), so as to give 2.53 g of (R)-8-chloro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.56

(R)-8-Hydroxy-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.




50 ml of trifluoroacetic acid are added, at ambient temperature and under an argon atmosphere, to a suspension of 7.5 g of (R)-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one in 50 ml of 1,2-dichloromethane. The reaction medium is stirred at ambient temperature for 18 hours. After a verification by LC/MS, 51% of the starting product remains. 25 ml of trifluoroacetic acid are added. After 40 hours of stirring, the reaction is complete according to the verification by LC/MS. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with 10 ml of ice-cold water. 32% sodium hydroxide is added dropwise to pH = 6. The mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up with an

80/20 dichloromethane/MeOH mixture and filtered, and then the filtrate is concentrated to dryness under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: CH_2Cl_2/MeOH: 75/25), so as to give 2.4 g of (R)-8-hydroxy-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

OR= -22.5+/-0.6. C=2.702mg/0.5ml DMSO. On 589 nm.

(R)-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.




29 g of methyl malonate and 10 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 11 g of (S)-1-[(S)-1-(4-methoxyphenyl)ethyl]-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine in 150 ml of methanol. The mixture obtained is then heated at reflux. After 4 hours of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: dichloromethane/MeOH: 95/05, so as to give 11.6 g of (R)-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 370; [M-H]-: m/z 368; Tr (min) = 1.06

OR=-96.3 +/- 1.7 at 589nm weighed 1.623mg ds 0.5ml DMSO

(S)-1-[(S)-1-(4-Methoxyphenyl)ethyl]-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine can be prepared in the following way.




4.6 g of cyanogen bromide are added, in small amounts, at ambient temperature and under an argon atmosphere, to a solution of 11 g of (S)-4,4,4-trifluoro-N1-[(S)-1-(4-methoxyphenyl)ethyl]butane-1,3-diamine in 100 ml of acetonitrile. At the end of the addition, the mixture obtained is then heated at reflux for two hours in an oil bath preheated to 100°C. After cooling, the reaction mixture is evaporated to dryness under reduced pressure, so as to give 11 g of a brown foam. 50 ml of water and 200 ml of EtOAc are added to this foam, followed by 32% sodium hydroxide to pH = 14. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and then concentrated under reduced pressure, so as to give a residue of 11 g of a thick oil.

This residue is purified on a silica column, eluent: dichloromethane/MeOH/28% NH_4OH: 90/10/0.5 then dichloromethane/MeOH/28% NH_4OH: 60/40/5, so as to give 8 g of (S)-1-[(S)-1-(4-methoxyphenyl)ethyl]-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine, in the form of a pale yellow foam, which will be used as it is in the next step and the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 302; Tr (min) = 0.57


(S)-4,4,4-Trifluoro-N1-[(S)-1-(4-methoxyphenyl)ethyl]butane-1,3-diamine can be prepared in the following way.




11.7 g of $LiAlH_4$ are added, in small portions, at ambient temperature and under an argon atmosphere, to a solution of 15 g of (S)-3-amino-4,4,4-trifluoro-N-[(S)-1-(4-methoxyphenyl)ethyl]butyramide in 600 ml of anhydrous ethyl ether. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 72 hours. The reaction medium is cooled to 4°C in an ice bath, and then 9.7 ml of water, followed by 9.7 ml of 4N NaOH and then 19.4 ml of water, are added dropwise. The white precipitate formed is filtered off. The filtrate is dried over $MgSO_4$ and then concentrated under reduced pressure, so as to give 11.2 g of (S)-4,4,4-trifluoro-N1-[(S)-1-(4-methoxyphenyl)ethyl]butane-1,3-diamine, in the form of a colourless oil, which is used as it is in the next step and the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 277; Tr (min) = 0.32

(S)-3-Amino-4,4,4-trifluoro-N-[(S)-1-(4-methoxyphenyl)ethyl]butyramide and (R)-3-amino-4,4,4-trifluoro-N-[(S)-1-(4-methoxyphenyl)ethyl]butyramide can be prepared in the following way.



and



32.8 g of (S)-(-)-1-(4-methoxyphenyl)ethylamine are added in one step to a suspension of 31 g of 3-amino-4-trifluorobutyric acid in 300 ml of DMF, followed, dropwise, by 64 g of phenylsilane, said additions being carried out while maintaining the temperature of the reaction medium between 25 and 35°C. At the end of the addition, the reaction medium, a suspension, is stirred at ambient temperature for 48 hours. The reaction medium is cooled to 4°C in an ice bath, and then 200 ml of water,

followed by 400 ml of ethyl acetate, are added dropwise. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with 500 ml of methanol. The white solid formed is filtered off. The filtrate is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents: 90/10 dichloromethane/EtOAc, so as to give 15 g of (S)-3-amino-4,4,4-trifluoro-N-[(S)-1-(4-methoxyphenyl)ethyl]butyramide, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 291; [M-H]-: m/z 289; ES+ base peak: m/z 135; Tr (min) = 0.46

$[\alpha]_D^{25}$ at 589 nm = -31.8 +/- 0.9 (DMSO)


Then eluent with 50/50 dichloromethane/EtOAc, so as to give 12 g of (R)-3-amino-4,4,4-trifluoro-N-[(S)-1-(4-methoxyphenyl)ethyl]butyramide, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 291; ES+ base peak: m/z 135; Tr (min) = 0.47

$[\alpha]_D^{25}$ at 589 nm = -78 +/- 1.5 (DMSO)

Intermediate F4:


(R)-8-Chloro-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.



30 ml of trifluoroacetic acid are added, at ambient temperature and under an argon atmosphere, to a solution of 4 g of (R)-8-chloro-7-fluoro-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one in 30 ml of 1,2-dichloromethane. The

reaction medium is stirred at ambient temperature for 18 hours. The reaction medium turns a dark violet colour. The reaction is complete according to the verification by LC/MS. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with 100 ml of dichloromethane and 50 ml of ice-cold water. 32% sodium hydroxide is added dropwise to pH = 10. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is taken up with ethyl ether and the white solid formed is filtered off, so as to give 2.1 g of the solid S1. The filtrate is concentrated to dryness under reduced pressure and the residue obtained is purified by chromatography on silica (eluent: CH_2Cl_2/EtOAc: 97/03), so as to give 0.35 g of the solid S2. The two solids S1 and S2 are combined so as to give 2.45 g of (R)-8-chloro-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid, used as it is in the next step.

(R)-8-Chloro-7-fluoro-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.




10.8 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 15 g of (R)-7-fluoro-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one in 100 ml of 1,2-dichloroethane. The mixture obtained is then heated to 65°C. After 3 hours of stirring at 60°C, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The

residue obtained is taken up in 100 ml of cold water and 300 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The resulting organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica, eluents:

- dichloromethane/EtOAc: 98/02, so as to give 4 g of (R)-8-chloro-7-fluoro-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, used in the next step.

- CH_2Cl_2/EtOAc: 95/05, so as to give 2.5 g of (R)-8-chloro-7-fluoro-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, in the form of a white solid.

(R)-7-Fluoro-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one can be prepared in the following way.




30 g of methyl fluoromalonate and 10.8 g of anhydrous sodium methoxide are added, at ambient temperature and under an argon atmosphere, to a suspension of 12 g of (S)-1-[(S)-1-(4-methoxyphenyl)ethyl]-4-trifluoromethyl-1,4,5,6-tetrahydropyrimidin-2-ylamine in 150 ml of methanol. The mixture obtained is then heated at reflux. After one hour of stirring at reflux, the reaction is complete according to the verification by LC/MS. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up with 100 ml of cold water. 36% HCl is added dropwise to pH = 6. The solid formed is filtered off and then washed three times with ethyl ether. The solid is oven-dried under vacuum in

the presence of P_2O_5, so as to give 15 g of (R)-7-fluoro-8-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, which is used as it is in the next step.

Intermediate F5:

(8S)-2-Chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one and (8R)-2-chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




A suspension of 410 mg (1.645 mmol) of 2-hydroxy-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one in 22 ml of 1,2-dichloroethane is treated at ambient temperature with 0.767 ml of phosphorus trichloride. The reaction medium is heated at 65°C for 7 h 15 min. It is then evaporated to dryness under reduced pressure (2.7 kPa). The residue obtained is taken up with 3 ml of water and 30 ml of ethyl acetate, cooled in an ice bath and basified to pH 9 with 32% aqueous NaOH, and then the organic phase is separated. The aqueous phase is extracted with 20 ml of ethyl acetate. The organic phases are combined, dried over magnesium sulfate and then filtered through a sintered glass funnel, and the filtrate is evaporated to dryness under reduced pressure (2.7 kPa). The crude obtained is purified by flash chromatography on silica [eluent: dichloromethane/1-propanol/acetonitrile (100/0/0 then 96/2/2 by volume)]. After evaporation of the fractions under reduced pressure, 217 mg of 2-chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained, in the form of a white solid (mixture of enantiomers).

Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.58

The mixture of enantiomers is purified by preparative chromatography on a chiral column under the following conditions:

Technique: Prochrom
Chiral stationary phase: AD 20µm, lot CFB03
Mobile phase: 85% Heptane - 15% EtOH
Flow rate: 260 ml/min
Detection: UV 254 nm

After evaporation of the fractions under reduced pressure, 93 mg of (8R)-2-chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained, in the form of a white solid.




The characteristics of this product are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.59

Retention time by chiral phase HPLC: 6.6 minutes
Conditions used for the chiral phase HPLC:
Technique: Gilson
Chiral stationary phase: AD-H 5µm 250x4.6 mm
Mobile phase: 85% Heptane - 15% EtOH
Flow rate: 1 ml/min
Detection: UV 254 nm

After evaporation of the fractions, 104 mg of (8S)-2-chloro-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are also obtained, in the form of a white solid.




The characteristics of this product are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 268; [M-H]-: m/z 266; Tr (min) = 0.59

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.45 (q, J=0.5 Hz, 3 H); 2.00 (m, 1 H); 2.35 (td, J=4,4 and 14.7 Hz, 1 H); 3.45 (m, 1 H); 4.11 (m, 1 H); 5.81 (s, 1 H); 9.16 (broad s, 1H).

Retention time by chiral phase HPLC: 15.6 minutes
Conditions used for the chiral phase HPLC:
Technique: Gilson
Chiral stationary phase: AD-H 5µm 250x4.6 mm
Mobile phase: 85% Heptane - 15% EtOH
Flow rate: 1 ml/min
Detection: UV 254 nm

2-Hydroxy-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




44 mg (1.927 mmol) of sodium are dissolved in 4 ml of methanol under argon and then 101 mg (0.385 mmol) of 4-methyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-imine hydrobromide in 2 ml of methanol are added, followed by 305 mg (2.312 mmol) of methyl malonate at ambient temperature. The reaction medium is heated at reflux for 5 h 45 min. After cooling, the reaction medium is evaporated to dryness under reduced pressure. The residue obtained is taken up in 0.5 ml of water and then, after cooling in a water-ice bath, 0.1 ml of an aqueous 8N hydrochloric acid solution is added to approximately pH = 5. The reaction medium is stirred in the cold bath for approximately 15 minutes and then, after having added approximately 3 ml of ethyl ether to the reaction medium, the latter is filtered through a sintered glass funnel. After drying under vacuum, 92 mg of 2-hydroxy-8-methyl-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained, in the form of a beige solid.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 250; [M-H]-: m/z 248; Tr (min) = 0.32

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.40 (s, 3 H); 1.92 (m, 1 H); 2.22 (m, 1 H); 3.45 (m, 1 H); 3.95 (m, 1 H); 4.61 (broad s, 1 H); 10,30 (broad m, 2 H).

4-Methyl-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-imine hydrobromide can be prepared in the following way.




A solution of 458 mg (2.933 mmol) of 2-methyl-2-(trifluoromethyl)butane-1,4-diamine in 4 ml of acetonitrile is treated at ambient temperature with 311 mg (2.933 mmol) of cyanogen bromide. 12 ml of acetonitrile are then added and the solution is heated at reflux for 2 h 30 min. After evaporation to dryness under reduced pressure, 695 mg of 4-methyl-4-

(trifluoromethyl)tetrahydropyrimidin-2(1H)-imine hydrobromide are obtained in the form of a yellow solid.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 182; Tr (min) (ELSD) = 0.24

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.45 (s, 3 H); 1.94 (m, 1 H); 2.17 (m, 1 H); 3.11 to 3.44 (partially masked m, 2 H); 6.97 (broad s, 2 H); 8.17 (broad s, 1 H); 8.60 (broad s, 1 H).

2-Methyl-2-(trifluoromethyl)butane-1,4-diamine can be prepared in the following way.




A suspension of 1.17 g (4.751 mmol) of N^1-benzyl-4,4,4-trifluoro-3-methylbutane-1,3-diamine and 758 mg (0.713 mmol) of palladium-on-carbon (10%) in 55 ml of ethanol and 2.090 ml (10.45 mmol) of an aqueous 5N hydrochloric acid solution is hydrogenated at 50°C under 10 bar of hydrogen for 68 h. The reaction medium is then filtered through celite and the filtrate is then evaporated to dryness. Toluene is added to the residue obtained and then the resulting product is evaporated to dryness, so as to give 1.231 g of a yellow solid. This yellow solid is dissolved in 5 ml of water and then the solution is basified with approximately 2 ml of an aqueous 32% sodium hydroxide solution to pH = 12. The aqueous phase is extracted with ethyl ether, then the organic phases are combined, dried over magnesium sulfate and then filtered through a sintered glass funnel, and the filtrate is evaporated in a rotary evaporator under reduced pressure (the bath temperature is maintained below 25°C and the pump vacuum is maintained above 100 mbar). 469 mg of 2-methyl-2-(trifluoromethyl)butane-1,4-diamine are obtained, in the form of a yellow liquid.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 157; Tr (min) = 0.11

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.11 (s, 3 H); 1.55 (m, 2 H); 1.87 (broad m, 4 H); 2.68 (m, 2 H).

N^1-benzyl-4,4,4-trifluoro-3-methylbutane-1,3-diamine can be prepared in the following way.




A solution of 2.494 g (9.583 mmol) of 3-amino-N-benzyl-4,4,4-trifluoro-3-methylbutanamide in 80 ml of ethyl ether is treated at ambient temperature, under a light argon stream, with 2.182 g (57.500 mmol) of powdered lithium aluminium hydride. The reaction medium is stirred at ambient temperature for 72 h and is then diluted with 80 ml of ethyl ether and 15 ml of THF and cooled to approximately 0°C, and 2.18 ml of water, 2.18 ml of an aqueous 15% sodium hydroxide solution and 6.54 ml of water are successively added slowly, and the mixture is filtered through a sintered glass funnel. The filtrate is dried over magnesium sulfate and then, after filtration through a sintered glass funnel, the filtrate obtained is evaporated to dryness under reduced pressure (2.7 kPa). The crude is purified by flash chromatography on silica [eluent: dichloromethane/methanol/acetonitrile (90/5/5 to 80/10/10 by volume)]. After evaporation of the fractions under reduced pressure, 1.176 g of N^1-benzyl-4,4,4-trifluoro-3-methylbutane-1,3-diamine are obtained, in the form of a yellow oil.

Mass spectrum (method B): ES+/-: [M+H]+: m/z 247; Tr (min) = 7.74 (ELSD).

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.10 (q, J=0.6 Hz, 3 H); 1.52 to 1.74 (m, 2 H); 2.02 (broad m, 3 H); 2.53 to 2.76 (m, 2 H); 3.68 (s, 2 H); 7.15 to 7.39 (m, 5 H).

3-Amino-N-benzyl-4,4,4-trifluoro-3-methylbutanamide can be prepared in the following way.




A suspension of 3.100 g (14.93 mmol) of 3-amino-4,4,4-trifluoro-3-methylbutanoic acid hydrochloride, 2.862 g (14.93 mmol) of N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride and 2.017 g (14.93 mmol) of 1-hydroxybenzotriazole in 100 ml of methylene chloride is treated at ambient temperature with 4.363 ml (31.350 mmol) of triethylamine and then with 1.631 ml (14.93 mmol) of benzylamine. The reaction medium is stirred at ambient temperature for 62 h and then 3.26 ml (29.86 mmol) of benylamine are added. The reaction medium is stirred at ambient temperature for 27 h and then evaporated to dryness under reduced pressure (2.7 kPa). The crude obtained is purified by flash chromatography on silica [eluent: dichloromethane/1-propanol/acetonitrile (96/2/2 then 90/5/5 by volume)]. After evaporation of the fractions under reduced pressure, 2.504 g of 3-amino-N-benzyl-4,4,4-trifluoro-3-methylbutanamide are obtained, in the form of a brown oil.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 261; [M-H]-: m/z 259; Tr (min) = 0.38

^{1}H NMR spectrum (300 MHz, δ in ppm, DMSO-d6): 1.23 (broad s, 3 H); 2.27 (s, 2 H); 2.31 (d, J=13.8 Hz, 1 H); 2.43 (d, J=13.8 Hz, 1 H); 4.30 (d, J=5.7 Hz, 2 H); 7.18 to 7.38 (m, 5 H); 8.53 (broad t, J=5.7 Hz, 1 H).

3-Amino-4,4,4-trifluoro-3-methylbutanoic acid hydrochloride can be prepared in the following way.




A mixture of 4.460 g (22.393 mmol) of ethyl 3-amino-4,4,4-trifluoro-3-methylbutanoate and 1.776 g (9.592 mmol) of methyl 3-amino-4,4,4-trifluoro-3-methylbutanoate is treated at ambient temperature with an aqueous 5N hydrochloric acid solution. The reaction medium is heated at 90°C for 4 h. A mixture of acetonitrile and toluene is added and then the mixture is evaporated to dryness under reduced pressure. 4.61 g of 3-amino-4,4,4-trifluoro-3-methylbutanoic acid hydrochloride are obtained, in the form of a beige solid.

Mass spectrum (method A): ES+/-: [M+H]+: m/z 172; [M-H]-: m/z 170; Tr (min) = 0.13

^{1}H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1.60 (s, 3 H); 2.93 (m, 2 H); 10.11 (broad m, 3 H).

Ethyl 3-amino-4,4,4-trifluoro-3-methylbutanoate and methyl 3-amino-4,4,4-trifluoro-3-methylbutanoate can be prepared in the following way.



A solution of 1.5 g (8.235 mmol) of ethyl 3-(trifluoromethyl)crotonate in 6 ml of acetonitrile and 11.76 ml (82.350 mmol) of 7N aqueous ammonia in methanol is microwave-heated at 130°C for 1 h 20 min. The reaction medium is diluted with 20 ml of methylene chloride and then evaporated to dryness under reduced pressure (the bath temperature is maintained below 25°C and

the pump vacuum is maintained above 100 mbar). A mixture of 969 mg (4.865 mmol) of ethyl 3-amino-4,4,4-trifluoro-3-methylbutanoate and 386 mg (2.085 mmol) of methyl 3-amino-4,4,4-trifluoro-3-methylbutanoate (70% ethyl ester – 30% methyl ester ratio) is obtained, in the form of a yellow liquid, the characteristics of which are the following:

Mass spectrum (method A): ES+/-: [M+H]+: m/z 200; Tr (min) = 0.32 (ethyl ester).


Mass spectrum (method A): ES+/-: [M+H]+: m/z 186; Tr (min) = 0.21 (methyl ester).

^{1}H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1.19 (t, *J*=7.1 Hz, 3 H); 1.28 (s, 3 H); 2.19 (broad m, 2 H); 3.17 (m, 2 H); 4.08 (q, *J*=7.1 Hz, 2 H) (ethyl ester).

^{1}H NMR spectrum (400 MHz, δ in ppm, DMSO-d6): 1.28 (s, 3 H); 2.19 (broad m, 2 H); 3.17 (m, 2 H); 3.61 (s, 3 H) (methyl ester).

Intermediate F6

2-Chloro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




1.7 g of 2-hydroxy-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are placed in suspension in 24 ml of 1,2-dichloroethane. 2.4 ml of $POCl_3$ are added and then the medium is heated at 65°C for 2 h. The medium is concentrated to dryness. The residue is taken up in 50 ml of ethyl acetate and 10 ml of water and then cooled in an ice bath. 32% NaOH is added to pH = 7. The aqueous phase is extracted with ethyl acetate and then the organic phase is dried over magnesium sulfate. After the solvent has been evaporated off, 0.9 g (yield = 55%) of 2-chloro-8,8-dimethyl-6,7,8,9-

tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained, in the form of a brown solid, the characteristics of which are the following:

Mass spectrum (method A) ES+/-: Tr: 2.14 min, m/z = 214.


2-Hydroxy-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



A mixture of 2 g of 4,4-dimethyl-1,4,5,6-tetrahydropyrimidin-2-amine hydrobromide, 10 ml of ethyl malonate and 2.6 g of sodium methoxide is heated to 100°C. After 4 h of heating, the reaction medium is concentrated to dryness. The oil obtained is taken up in ethyl ether. The precipitate is filtered off and then the residue is taken up in 7 ml of water and acidified with 25% HCl to pH 6. The precipitate formed is filtered off, washed with ethyl ether and oven-dried under vacuum. 1.7 g (yield = 90%) of 2-hydroxy-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained, in the form of a beige solid, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 196; [M-H]-: m/z 194; Tr (min) = 0.22

4,4-Dimethyl-1,4,5,6-tetrahydropyrimidin-2-amine hydrobromide can be prepared in the following way.




1.95 g of 3-methylbutane-1,3-diamine dihydrobromide are placed in suspension in 20 ml of MeOH and 1.2 g of sodium methanolate are added.

The mixture is stirred at ambient temperature for 2 h. The mixture is filtered and then evaporated to dryness. The reaction crude is solubilised in 20 ml of water, cooled with an ice bath. 0.78 g of CNBr is added and the mixture is stirred at ambient temperature for 12 h. The mixture is evaporated to dryness, and 3 g (yield = quantitative) of 4,4-dimethyl-1,4,5,6-tetrahydropyrimidin-2-amine hydrobromide are obtained, in the form of a translucent oil, which will subsequently be used as it is.

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 128; Tr (min) = 0.12


3-Methylbutane-1,3-diamine dihydrobromide can be prepared in the following way.



2.8 g of ethyl (3-amino-1,1-dimethylpropyl)carbamate are cooled using an ice bath. 9.9 ml of HBr at 33% in acetic acid are added dropwise and then the mixture is heated at reflux for 2 h. After a return to ambient temperature, the product is precipitated with ethyl ether and filtration is carried out. The powder obtained is oven-dried at 70°C. 2.34 g (yield = 55%) of 3-methylbutane-1,3-diamine dihydrobromide are obtained, in the form of a white powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 103; Tr (min) = 0.12


Ethyl (3-amino-1,1-dimethylpropyl)carbamate can be prepared in the following way.



5.12 g of ethyl [3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-1,1-dimethylpropyl] carbamate are placed in solution in 47 ml of ethanol. 4 ml of hydrazine hydrate are added and then the mixture is heated at reflux for 30 minutes. After a return to ambient temperature, the reaction medium is filtered and then the solvent is evaporated off. 2.8 g (yield = 88%) of ethyl (3-amino-1,1-dimethylpropyl)carbamate are obtained in the form of a brown gum, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 175; Tr (min) = 0.22


Ethyl [3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-1,1-dimethylpropyl]carbamate can be prepared in the following way.



34.2 g of ethyl carbamate are placed in solution in toluene, 22 ml of $BF_3.Et_2O$ are added and the mixture is heated for 1 h 30 min at 70°C. 11 g of 2-(3-methylbut-2-en-1-yl)-1H-isoindole-1,3-dione are added and the mixture is heated at reflux for 12 h. After a return to ambient temperature, the mixture is evaporated to dryness and then taken up in an H_2O/EtOAc mixture. The organic phase is separated by settling out, washed with a saturated NaCl solution and then dried over magnesium sulfate. The crude is purified by flash chromatography on silica gel (CH_2Cl_2/MeOH, 99/1). 5.12 g (yield = 31%) of ethyl [3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-1,1-dimethylpropyl]carbamate are obtained, in the form of a brown powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 305; Tr (min) = 0.86

2-(3-Methylbut-2-en-1-yl)-1H-isoindole-1,3-dione can be prepared in the following way.




20 g of 1-bromo-3-methylbut-2-ene and 26.1 g of phthalimide are placed in suspension in anhydrous DMF and then the mixture is heated at reflux for 12 h. After a return to ambient temperature, the reaction medium is filtered and then taken up with a saturated aqueous NH_4Cl solution. The aqueous phase is extracted with ethyl acetate, washed with an NaCl solution, then dried over magnesium sulfate and evaporated to dryness. The solid obtained is placed in suspension in 100 ml of water and stirred. The precipitated product is filtered off, rinsed with ether and then oven-dried under vacuum at 65°C. 18.3 g (yield = 63%) of 2-(3-methylbut-2-en-1-yl)-1H-isoindole-1,3-dione are obtained, in the form of a white powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 216; Tr (min) = 0.99

Intermediate F7

2-Chloro-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.




3.15 g of 2-hydroxy-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are placed in suspension in 42 ml of 1,2-dichloroethane. 4.15 ml of $POCl_3$ are added and then the medium is heated at 65°C for 3 h. The medium is concentrated to dryness. The residue is taken up in 150 ml of ethyl acetate and 10 ml of water and then cooled in an ice bath. Concentrated NaOH is added to pH 10. After separation by settling out, the organic phase is dried over magnesium sulfate, filtered, and then concentrated to dryness under reduced pressure. The residue obtained is

triturated from ethyl ether and the solid is filtered and then dried, so as to give 2.23 g of 2-chloro-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one in the form of a brown solid, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 214; [M-H]-: m/z 212; Tr (min) = 0.42


2-Hydroxy-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one can be prepared in the following way.



A suspension of 5 g of 4,4-dimethyl-1,4,5,6-tétrahydropyrimidin-2-amine, 29 g of dimethyl fluoromalonate and 3.9 g of sodium methoxide is heated at 100°C for 3 hours. The reaction medium is concentrated to dryness under reduced pressure. The residue obtained is taken up with ethyl ether. The solid formed is filtered off and then dried. 10 ml of water are added to the solid obtained, and the resulting mixture is cooled on ice, before acidification to pH 5-6 by adding concentrated hydrochloric acid (25%). The suspension is filtered and then the solid is washed with 5 ml of water and then dried under vacuum over P_2O_5, so as to give 3.15 g of 2-Hydroxy-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one, in the form of a yellow powder, the characteristics of which are the following:

Mass spectrum (method A) (ES+/-) [M+H]+: m/z 232; [M-H]-: m/z 230; Tr (min) = 0.86

Intermediate F8: (S)-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one can be prepared in the following way.




11 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 5.6 g of (S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one in 100 ml of 1,2-dichloroethane. The resulting mixture is then heated to 70°C. After two hours of stirring and after verification by LC/MS, the reaction is complete. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 5 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 6. The organic phase is then separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure, so as to give 6 g of (S)-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 254; [M-H]-: m/z 252; Tr (min) = 0.51

$[\alpha]_D^{25}$ at 589 nm = -64.8 +/- 1.1 (c = 2.2 mg / 0.5 ml DMSO)

(S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one can be prepared in the following way.




8.4 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide and 2.16 g of sodium methoxide are added to a mixture of 5.4 g of diethyl malonate in 50 ml of methanol. The resulting mixture is refluxed for 18 hours. After cooling, the mixture obtained is concentrated to dryness under reduced pressure. 20 ml of cold water are added to the residue obtained, so as to obtain a thick suspension, to which is added 25%

hydrochloric acid to pH = 5. The resulting suspension is stirred in an ice bath for two hours and then filtered through a sintered glass funnel. The insoluble matter obtained is rinsed with water (twice 4 ml) and then dried so as to give 5.6 g of (S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 236; [M-H]-: m/z 234; Tr (min) = 0.32

$[\alpha]_D^{25}$ at 589 nm = - 5.6 +/- 0.6 (c = 1.789 mg / 0.5 ml DMSO)

(S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide can be prepared in the following way.




, HBr

1.7 g of cyanogen bromide are added, in small amounts, to a solution, cooled to 5°C, of 2.3 g of (S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine in 10 ml of water, while maintaining the temperature between 5 and 10°C. At the end of the addition, the reaction mixture is stirred at 5°C for 30 minutes. The ice bath is then withdrawn and the mixture obtained is stirred at ambient temperature for 3 hours. The resulting mixture is then concentrated under reduced pressure. The residue obtained is taken up twice with 100 ml of ethanol and then twice with 100 ml of toluene, and evaporated to dryness each time. The solid obtained is triturated with ethyl ether and then filtered off, so as to give 4.5 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide, in the form of a white solid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 168; Tr (min) = 0.14

$[\alpha]_D^{25}$ at 589 nm: - 5.2 +/- 0.3 (c = 4.909 mg / 0.5 ml DMSO)

(S)-3,3,3-Trifluoro-2-methylpropane-1,2-diamine can be prepared in the following way.




4.8 g of (S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine hydrochloride, 2.5 ml of water and 100 ml of ethyl ether are placed in a round-bottomed flask. 4.5 ml of 32% sodium hydroxide are added, dropwise, to the resulting mixture, to pH = 12. The aqueous phase is subsequently separated by settling out and then extracted with 4 times 200 ml of ethyl ether. The organic phases are combined, dried over magnesium sulfate, filtered, and then concentrated under reduced pressure (300 mbar/bath temperature = 25°C), so as to give 2.3 g of (S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine, in the form of a pale yellow oil, the characteristics of which are the following:

Mass spectrum (method B), ES+/-: [M+H]+: m/z 143; base peak: m/z 126; Tr (min) = 0.34

$[\alpha]_D^{25}$ at 589 nm = - 4.3 +/- 0.6 (c = 1.778 mg / 0.5 ml DMSO)

(S)-3,3,3-Trifluoro-2-methylpropane-1,2-diamine dihydrochloride can be prepared in the following way.



A mixture of 7 g of (2R)-2-((S)-1-aminomethyl-2,2,2-trifluoro-1-methylethylamino)-2-phenylethanol in 40.5 ml of methanol, 23.5 ml of 3N hydrochloric acid and 0.94 g of $Pd(OH)_2/C$ (20%) is hydrogenated at 22°C in an autoclave, under a hydrogen pressure of 5 bar, for 18 hours. The mixture obtained is then filtered and the filtrate is evaporated to dryness. The oil obtained is taken up with a 3N hydrochloric acid solution (50 ml). The mixture obtained is extracted with diethyl ether (3 × 50 ml). The aqueous phase is then evaporated to dryness, taken up with methanol, and then again


evaporated to dryness. The yellowish solid obtained is dried under vacuum, so as to give 5.54 g (yield 79%) of (S)-3,3,3-trifluoro-2-methylpropane-1,2-diamine dihydrochloride, in the form of an off-white solid, the characteristics of which are the following:

^{1}H NMR spectrum (400 MHz, D_2O): 1.55 (s, 3 H), 3.40 (d, J = 14.6 Hz, 1 H), 3.51 (d, J = 14.6 Hz, 1 H).

^{19}F NMR spectrum (400 MHz, D_2O): - 81.08 (not calibrated with C_6F_6)

$[\alpha]_D^{25}$ at 589 nm = + 4.65 +/- 0.6 (c = 2.2; MeOH)

(2R)-2-((S)-1-Aminomethyl-2,2,2-trifluoro-1-methylethylamino)-2-phenylethanol can be prepared in the following way.




1.6 g of lithium aluminium hydride are added, in small portions, to a solution, cooled to 4°C, of 2.5 g of (2S)-3,3,3-trifluoro-2-((R)-2-hydroxy-1-phenylethylamino)-2-methylpropionitrile in 250 ml of anhydrous ethyl ether, in a three-necked flask under argon. Substantial evolution of gas and a temperature rise to 8°C are observed. At the end of the addition, the temperature is left to come back up to ambient temperature, and then the reaction mixture is left stirring for 18 h. The mixture obtained is cooled to 4°C, followed by very slow dropwise addition of 2 ml of water. Substantial evolution of gas and a temperature rise to 12°C are observed. 2 ml of 15% potassium hydroxide are added, dropwise and very slowly, to the resulting mixture, maintained at 4°C, followed, still dropwise and very slowly, by 4 ml of water. The white precipitate formed is filtered off and the filtrate obtained is dried over magnesium sulfate and then concentrated under reduced pressure, so as to give 2.2 g of (2R)-2-((S)-1-aminomethyl-2,2,2-trifluoro-1-

methylethylamino)-2-phenylethanol, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 263; Tr (min) = 0.43

$[\alpha]_D^{25}$ at 589 nm = - 51.2 +/- 1.3 (c = 1.576 mg / 0.5 ml DMSO)

(2S)-3,3,3-Trifluoro-2-((R)-2-hydroxy-1-phenylethylamino)-2-methylpropionitrile can be prepared in the following way.



and


3.4 g of trimethylsilyl cyanide are added, dropwise, to a solution, cooled to 0°C, of 5.3 g of (2R,2S)-2-methyl-4-(R)-phenyl-2-(trifluoromethyl)oxazolidine in 100 ml of dichloromethane in a three-necked flask under argon, followed by dropwise addition of 4.9 g of boron trifluoride etherate. The cold bath is then withdrawn to allow the mixture to warm up to ambient temperature. The resulting mixture is stirred at ambient temperature for 18 hours, followed by addition of a saturated sodium bicarbonate solution to pH = 8. The organic phase is separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: cyclohexane/EtOAc: 80/20), so as to give 3 g of (2R)-3,3,3-trifluoro-2-((R)-2-hydroxy-1-phenylethylamino)-2-methylpropionitrile, in the form of a colourless oil, and 2.5 g of (2S)-3,3,3-trifluoro-2-((R)-2-hydroxy-1-phenylethylamino)-2-methylpropionitrile, in the form of a white solid, the characteristics of which are:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 259; [M-H+HCO_2H]-: m/z 303; Tr (min) = 0.86

$[\alpha]_D^{25}$ at 589 nm = - 89.0 +/- 1.4 (c = 2.444 mg / 0.5 ml $CHCl_3$)

$[\alpha]_D^{25}$ at 589 nm = - 77.6 +/- 1.4 (c = 1.818 mg / 0.5 ml DMSO)

(2R,2S)-2-Methyl-4-(R)-phenyl-2-(trifluoromethyl)oxazolidine can be prepared in the following way.




4.8 g of (R)-phenylglycinol and then, in one step, 0.8 g of pyridinium para-toluenesulfonate are added to a solution of 5 g of trifluoroacetone in 180 ml of toluene in a three-necked flask on which is mounted a Dean-Stark apparatus. The mixture obtained is then heated at reflux for 18 hours, during which time 0.3 ml of water is collected. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by filtration on silica (eluent: dichloromethane), so as to give 5.3 g of (2R,2S)-2-methyl-4-(R)-phenyl-2-(trifluoromethyl)oxazolidine, in the form of a colourless liquid, the characteristics of which are the following:

Mass spectrum (method A), ES+/-: [M+H]+: m/z 232; Tr (min) = 0.96

$[\alpha]_D^{25}$ at 589 nm = - 23.4 +/- 0.8 (c = 1.794 mg / 0.5 ml MeOH)

Intermediate F9:

(S)- 6-Fluoro-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one can be obtained in the following way.




9 ml of phosphorus oxychloride are added, at ambient temperature and under an argon atmosphere, to a suspension of 8.20 g of (S)-6-fluoro-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one in 90 ml of 1,2-dichloroethane. The resulting mixture is then heated to 70°C. After 3 hours of stirring and after verification by LC/MS, the reaction

is complete. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 50 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained, to pH = 10. The organic phase is then separated and then dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue obtained is purified by silica column chromatography (eluent: 98.5/1.5 dichloromethane/methanol), so as to give 4 g of (S)-6-fluoro-7-chloro-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)-one, the characteristics of which are the following:

Mass Spectrometry: Method B:








Retention time Tr (min) = 2.92, [M+H]+: m/z 272; [M-H]-: m/z 270



(S)-6-Fluoro-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one can be obtained in the following way.





11 g of (S)-4-methyl-4-(trifluoromethyl)imidazolidin-2-ylideneamine hydrobromide and 4.79 g of sodium methoxide are added to a mixture of 6.7 g of diethyl fluoromalonate in 110 ml of methanol. The resulting mixture is refluxed for 3 hours. After cooling, the mixture obtained is concentrated to dryness under reduced pressure. 15 ml of cold water are added to the residue obtained, so as to obtain a thick suspension, to which is added 25% hydrochloric acid to pH = 5-6. The reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up with an 80/20 dichloromethane/MeOH mixture and then filtered. The filtrate is concentrated under reduced pressure and the residue obtained is purified by chromatography on silica (eluent: 70/30 dichloromethane/MeOH), so as to give 8.14 g of (2S)-7-hydroxy-2-methyl-2-(trifluoromethyl)-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one, in the form of a pale orange foam, which is used as it is in the next step.






Table 1: Starting intermediates of type F






Intermediate of type F	Structure	Substituents
F1		R4=H; p=0; q=2; R2=H; R3=CF3 (S)
F2		R4=F; p=0; q=2; R2=H; R3=CF3 (S)
F3		R4=H; p=2; q=0; R2=H; R3=CF3 (R)
F4		R4=F; p=2; q=0; R2=H; R3=CF3 (R)
F5		R4=H; p=0; q=2; R2=Me; R3=CF3 (S)
F6		R4=H; p=0; q=2; R2=Me; R3=Me
F7		R4=F; p=0; q=2; R2=Me; R3=Me






F8		R4=H; p=0; q=1; R2=Me; R3=CF3 (S)
F9		R4=F; p=0; q=1; R2=Me; R3=CF3 (S)






Experimental section: Table 2: Examples from 1 to 295, starting intermediates of type F and amount of each example isolated






EXAMPLE	Example name	Intermediate of type F	Example structure	Amount isolated (mg)
EXAMPLE-1	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	1300
EXAMPLE-2	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	109





EXAMPLE-3	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		151
EXAMPLE-4	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxo-butyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		65
EXAMPLE-5	(S)-3-Fluoro-9-(2-fluoropyridin-4-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		1200
EXAMPLE-6	(S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		1450
EXAMPLE-7	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		45





EXAMPLE-8	(S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		181
EXAMPLE-9	(S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		95
EXAMPLE-10	(S)-9-[2-(2-Chloro-pyridin-4-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		35
EXAMPLE-11	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-3-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		35
EXAMPLE-12	(S)-9-(3-Methyl-isoxazol-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		186





EXAMPLE-13	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	 Chiral	120
EXAMPLE-14	[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid ethyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	134
EXAMPLE-15	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	75
EXAMPLE-16	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	25
EXAMPLE-17	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	50





EXAMPLE-18	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	140
EXAMPLE-19	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	95
EXAMPLE-20	(S)-3-Fluoro-9-(2-methoxy-ethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	38
EXAMPLE-21	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)		86
EXAMPLE-22	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	62





EXAMPLE-23	2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-N-methoxy-N-methyl-acetamide	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	550
EXAMPLE-24	(S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	84
EXAMPLE-25	(S)-9-[2-(2-Fluoro-pyridin-4-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	46
EXAMPLE-26	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	 Chiral	98
EXAMPLE-27	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	 Chiral	77





EXAMPLE-28	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	 Chiral	139
EXAMPLE-29	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	 Chiral	44
EXAMPLE-30	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	 Chiral	87
EXAMPLE-31	(S)-1-(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	 Chiral	45





EXAMPLE-32	(S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-33	(S)-9-Isoxazol-3-yl-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	50
EXAMPLE-34	(S)-9-(2-Chloro-thiazol-5-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	25
EXAMPLE-35	(S)-9-(6-Chloro-pyridin-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	45





EXAMPLE-36	(S)-9-Isoxazol-5-yl-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	45
EXAMPLE-37	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30
EXAMPLE-38	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	20
EXAMPLE-39	(S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]yrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	46





EXAMPLE-40	(S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	98
EXAMPLE-41	(S)-9-(2-Chloro-pyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	48
EXAMPLE-42	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	85
EXAMPLE-43	(S)-9-(6-Cyclopropyl-pyridin-3-yl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40





EXAMPLE-44	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	46
EXAMPLE-45	(S)-9-(2-Chloro-pyridin-4-yl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	62
EXAMPLE-46	(S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	68
EXAMPLE-47	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	21





EXAMPLE-48	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoro-ethoxy)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	17
EXAMPLE-49	(S)-3-Fluoro-9-(2-hydroxy-2-methyl-propyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30
EXAMPLE-50	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	16
EXAMPLE-51	(S)-3-Fluoro-9-(6-fluoropyridin-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	80





EXAMPLE-52	(S)-9-(6-Chloro-pyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	73
EXAMPLE-53	(S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40
EXAMPLE-54	(S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-yl-methyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	70
EXAMPLE-55	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30





EXAMPLE-56	(S)-3-Fluoro-9-(5-fluoropyridin-2-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	65
EXAMPLE-57	(S)-3-Fluoro-9-(5-fluoropyridin-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	62
EXAMPLE-58	(S)-3-Fluoro-9-(2-fluoropyridin-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	65
EXAMPLE-59	(S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	80





EXAMPLE-60	(S)-9-[2-(3-Fluoro-pyridin-2-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	130
EXAMPLE-61	(S)-9-[2-(2-Methoxy-pyridin-4-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	18
EXAMPLE-62	(S)-3-Fluoro-9-(3-methylisoxazol-4-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	104
EXAMPLE-63	(S)-9-[2-(6-Fluoro-pyridin-2-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30





EXAMPLE-64	(S)-9-Imidazo[1,2-a]-pyridin-2-ylmethyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	62
EXAMPLE-65	(S)-9-(4-Chloro-pyridin-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	87
EXAMPLE-66	(S)-9-(3-Chloro-pyridin-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	81
EXAMPLE-67	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-3-pyridin-2-yl-propyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	20





EXAMPLE-68	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40
EXAMPLE-69	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	48
EXAMPLE-70	(S)-9-[2-(5-Fluoro-pyridin-2-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	24
EXAMPLE-71	3-Fluoro-8,8-dimethyl-2-((R)-3-methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=Me; R3=Me	Chiral 	60





EXAMPLE-72	9-(2-Difluoromethyl-2H-pyrazol-3-yl-methyl)-8,8-dimethyl-2-((R)-3-methyl-morpholin-4-yl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=Me	Chiral 	50
EXAMPLE-73	3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methyl-morpholin-4-yl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=Me; R3=Me	Chiral 	80
EXAMPLE-74	9-(2-Difluoromethyl-2H-pyrazol-3-yl-methyl)-3-fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=Me; R3=Me	Chiral 	60
EXAMPLE-75	(S)-9-(3-Fluoro-phenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	96





EXAMPLE-76	(S)-9-(2-Chloro-pyridin-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	29
EXAMPLE-77	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	80
EXAMPLE-78	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	94
EXAMPLE-79	(S)-9-(2-Chloro-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	66





EXAMPLE-80	(S)-9-(2-Methoxy-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	25
EXAMPLE-81	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-9-(6-trifluoromethylpyridin-3-yl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	147
EXAMPLE-82	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-(2,2,2-trifluoro-ethoxy)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	74
EXAMPLE-83	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	20





EXAMPLE-84	(S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	42
EXAMPLE-85	(S)-9-(6-Isopropoxy-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	25
EXAMPLE-86	(S)-9-(5-Chloro-pyridin-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	105
EXAMPLE-87	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	96





EXAMPLE-88	(S)-9-(6-Cyclobutyl-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	128
EXAMPLE-89	(S)-9-(2-Cyclopropyl-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	96
EXAMPLE-90	(S)-9-(2-Methoxy-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	69
EXAMPLE-91	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40





EXAMPLE-92	(S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110
EXAMPLE-93	(S)-9-(2,5-Dimethyl-oxazol-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	66
EXAMPLE-94	(S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	95
EXAMPLE-95	(S)-9-(5-Chloro-pyridin-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	6





EXAMPLE-96	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(5-methyl-[1,3,4]oxadiazol-2-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	90
EXAMPLE-97	(S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	104
EXAMPLE-98	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	29
EXAMPLE-99	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	128





EXAMPLE-100	(S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	39
EXAMPLE-101	(S)-9-(3-Methyl-isoxazol-5-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	350
EXAMPLE-102	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	15
EXAMPLE-103	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	1000





EXAMPLE-104	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	277
EXAMPLE-105	(R)-9-Isoxazol-5-yl-methyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	34
EXAMPLE-106	(R)-9-Isoxazol-3-yl-methyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	39
EXAMPLE-107	(R)-9-(6-Cyclopropyl-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	60




EXAMPLE-108	(R)-9-(2-Chloro-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	106
EXAMPLE-109	(R)-9-(2-Methoxy-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	208
EXAMPLE-110	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	54
EXAMPLE-111	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	34




EXAMPLE-112	(R)-9-(2-Chloro-pyridin-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	82
EXAMPLE-113	(R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	51
EXAMPLE-114	(R)-9-(2-Isopropoxy-pyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	95
EXAMPLE-115	(R)-9-(6-Chloro-pyridin-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	96





EXAMPLE-116	(R)-9-(6-Isopropoxy-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	68
EXAMPLE-117	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	57
EXAMPLE-118	(R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	90
EXAMPLE-119	(R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	55





EXAMPLE-120	(R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	70
EXAMPLE-121	(R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	41
EXAMPLE-122	(R)-9-(2-Chloro-pyridin-4-yl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	52
EXAMPLE-123	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(5-methyl-[1,3,4]thiadiazol-2-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	198






EXAMPLE-124	(S)-9-(6-Difluoromethoxy-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	 Chiral	53
EXAMPLE-125	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(4-methyl-[1,2,3]thiadiazol-5-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	42
EXAMPLE-126	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	131
EXAMPLE-127	(R)-9-(6-Difluoromethoxy-pyridin-3-yl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	55





EXAMPLE-128	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxo-butyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	74
EXAMPLE-129	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	44
EXAMPLE-130	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	53





EXAMPLE-131	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	133
EXAMPLE-132	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	133
EXAMPLE-133	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40





EXAMPLE-134	9-(6-Difluoromethyl-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	23
EXAMPLE-135	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	17
EXAMPLE-136	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[1-(tetrahydro-furan-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	56
EXAMPLE-137	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	62





EXAMPLE-138	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	74
EXAMPLE-139	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	94
EXAMPLE-140	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl-[1,3,4]oxadiazol-2-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	33
EXAMPLE-141	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-3-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	86





EXAMPLE-142	(S)-9-(5-Cyclopropyl-[1,3,4]oxadiazol-2-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	211
EXAMPLE-143	(R)-9-(3-Methyl-isoxazol-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	99
EXAMPLE-144	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	183
EXAMPLE-145	(R)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	93
EXAMPLE-146	(R)-3-Fluoro-9-(3-methylisoxazol-4-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	86





EXAMPLE-147	(R)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl-methyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	78
EXAMPLE-148	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	64
EXAMPLE-149	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-yl-methyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=2; q=0; R2=H; R3=CF3 (R)	Chiral 	36
EXAMPLE-150	(S)-2-(3,3-Dimethyl-morpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	26





EXAMPLE-151	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one Single stereoisomer.	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	57
EXAMPLE-152	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	73
EXAMPLE-153	(S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenyl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	57
EXAMPLE-154	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5-dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	99





EXAMPLE-155	(S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methyl-isoxazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	55
EXAMPLE-156	(S)-9-(6-Chloro-pyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	42
EXAMPLE-157	(S)-9-(2-Chloro-pyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	53
EXAMPLE-158	(S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	121





EXAMPLE-159	(S)-9-(2-Chloro-pyridin-4-yl)-2-((3R,5R)-3,5-dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	116
EXAMPLE-160	(S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	93
EXAMPLE-161	(S)-9-(3,5-Difluoro-phenyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	20
EXAMPLE-162	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	86





EXAMPLE-163	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenyl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	127
EXAMPLE-164	(S)-9-Isoxazol-5-yl-methyl-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	56
EXAMPLE-165	(S)-9-(2-Chloro-thiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	95
EXAMPLE-166	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	103





EXAMPLE-167	(S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	75
EXAMPLE-168	(S)-9-(6-Chloro-pyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	76
EXAMPLE-169	(S)-9-Isoxazol-3-yl-methyl-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	88
EXAMPLE-170	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	16






EXAMPLE-171	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	41
EXAMPLE-172	(S)-2-(-2-Ethyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	42
EXAMPLE-173	(S)-2-(-2-Ethyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40
EXAMPLE-174	(S)-2-(-2-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	41





EXAMPLE-175	(S)-2-(-2-Methyl-morpholin-4-yl)-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	38
EXAMPLE-176	(S)-9-(3,5-Difluoro-phenyl)-2-(3-hydroxymethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	32
EXAMPLE-177	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-(-3-hydroxymethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40
EXAMPLE-178	(S)-9-(5-Chloro-thiophen-2-ylmethyl)-2-((S)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	54





EXAMPLE-179	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	29
EXAMPLE-180	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	66
EXAMPLE-181	(S)-1-(2-Chloro-pyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	77
EXAMPLE-182	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-5-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	25





EXAMPLE-183	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-4-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	56
EXAMPLE-184	(S)-1-(2-Chloro-pyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	117
EXAMPLE-185	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	45
EXAMPLE-186	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	360





EXAMPLE-187	(S)-1-(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	63
EXAMPLE-188	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxo-butyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	15
EXAMPLE-189	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-(2-oxo-2-pyridin-3-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	172
EXAMPLE-190	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	188





EXAMPLE-191	(S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	83
EXAMPLE-192	(S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	70
EXAMPLE-193	(S)-9-Benzyl-2-(2-fluoromethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	227
EXAMPLE-194	(S)-9-Benzyl-2-(2-fluoromethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	88
EXAMPLE-195	(S)-9-Benzyl-2-(2-fluoromethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	89





EXAMPLE-196	N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	127
EXAMPLE-197	N-Methoxy-2-[(S)-8-((R)-3-methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-198	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	17
EXAMPLE-199	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-(2-oxo-2-pyridin-2-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	1112





EXAMPLE-200	(S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	62
EXAMPLE-201	(S)-9-(5-Isopropyl-[1,2,4]oxadiazol-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	103
EXAMPLE-202	(S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	112
EXAMPLE-203	(S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	108





EXAMPLE-204	(S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	107
EXAMPLE-205	(S)-9-((S)-2-Hydroxy-propyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	114
EXAMPLE-206	(S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1R,5S)-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	87
EXAMPLE-207	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-yl-methyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	47





EXAMPLE-208	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-yl-methyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=F; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	147
EXAMPLE-209	(S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	44
EXAMPLE-210	(S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	67
EXAMPLE-211	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	43





EXAMPLE-212	(S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	75
EXAMPLE-213	(S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	38
EXAMPLE-214	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	140
EXAMPLE-215	(S)-9-Isoxazol-3-yl-methyl-8-methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	35





EXAMPLE-216	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	43
EXAMPLE-217	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110
EXAMPLE-218	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110
EXAMPLE-219	(S)-9-[2-(4-Fluoro-phenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40





EXAMPLE-220	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	6
EXAMPLE-221	(S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110
EXAMPLE-222	N,N-Dimethyl-2-[(S)-8-((R)-3-methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	150
EXAMPLE-223	N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	90





EXAMPLE-224	(S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	135
EXAMPLE-225	(S)-9-(2-Isopropoxy-pyridin-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	65
EXAMPLE-226	(S)-9-(3-Isopropyl-[1,2,4]oxadiazol-5-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	46
EXAMPLE-227	(S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	130





EXAMPLE-228	(S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	130
EXAMPLE-229	(S)-9-(6-Isopropoxy-pyridin-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	165
EXAMPLE-230	(S)-9-(2-Isopropoxy-pyridin-3-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-231	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	69





EXAMPLE-232	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	40
EXAMPLE-233	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-piperidin-1-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	153
EXAMPLE-234	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-morpholin-4-yl-2-oxo-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	125
EXAMPLE-235	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	170





EXAMPLE-236	2-[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-N-phenyl-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	136
EXAMPLE-237	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	89
EXAMPLE-238	(S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30
EXAMPLE-239	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	106





EXAMPLE-240	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	R4=H; p=0; q=1; R2=Me; R3=CF3 (S)	Chiral 	120
EXAMPLE-241	(S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	600
EXAMPLE-242	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-thiazol-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	55
EXAMPLE-243	[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid cyclopentyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	145





EXAMPLE-244	(S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	165
EXAMPLE-245	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	200
EXAMPLE-246	(S)-3-Fluoro-9-(5-isopropyl-[1,2,4]oxadiazol-3-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110
EXAMPLE-247	(S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-yl-methyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110





EXAMPLE-248	(S)-3-Fluoro-9-(3-isopropyl-[1,2,4]oxadiazol-5-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-249	(S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl-methyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	125
EXAMPLE-250	(S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-yl-methyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-251	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	77





EXAMPLE-252	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxo-butyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)	Chiral 	35
EXAMPLE-253	(S)-9-[2-(1-Methyl-cyclopentyl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	165
EXAMPLE-254	[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid isopropyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	103
EXAMPLE-255	(S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	144





EXAMPLE-256	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	129
EXAMPLE-257	(S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	150
EXAMPLE-258	(S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	114
EXAMPLE-259	(S)-2-((R)-3-methyl-morpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	86





EXAMPLE-260	[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid tert-butyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	112
EXAMPLE-261	2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetyl}-pyrrolidine-1-carboxylic acid tert-butyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	137
EXAMPLE-262	[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid methyl ester	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-263	2-[(S)-8-((R)-3-Methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-acetamide	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	88






EXAMPLE-264	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(4H-[1,2,4]triazol-3-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100
EXAMPLE-265	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-oxo-2-piperidin-4-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	48
EXAMPLE-266	(S)-9-(3-Methyl-but-2-enyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	16
EXAMPLE-267	(S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	11





EXAMPLE-268	(S)-9-[2-(3-Methyl-isoxazol-4-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	30
EXAMPLE-269	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-oxo-2-(tetrahydro-furan-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	57
EXAMPLE-270	(S)-9-(5-Methyl-[1,2,4]oxadiazol-3-yl-methyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	133
EXAMPLE-271	(S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	197





EXAMPLE-272	(S)-9-(3-Methyl-2-oxo-butyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	200
EXAMPLE-273	(S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	200
EXAMPLE-274	(S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	160
EXAMPLE-275	(S)-3-Fluoro-9-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	157






EXAMPLE-276	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(4-methyl-2-oxo-pentyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	106
EXAMPLE-277	(S)-2-((S)-3-Methyl-morpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	245
EXAMPLE-278	(S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxo-butyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	191
EXAMPLE-279	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxo-hexyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	45





EXAMPLE-280	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxo-pentyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	109
EXAMPLE-281	(S)-9-(3-Ethyl-2-oxo-pentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	138
EXAMPLE-282	(S)-9-(3-Ethyl-2-oxo-pentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	144
EXAMPLE-283	[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]acetic acid methyl ester	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	4320




EXAMPLE-284	(S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	15
EXAMPLE-285	(S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	14
EXAMPLE-286	(S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	7
EXAMPLE-287	(S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	150
EXAMPLE-288	(S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	110





EXAMPLE-289	(S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one single stereoisomer	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	14
EXAMPLE-290	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(5-methyl-2-oxo-hexyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	172
EXAMPLE-291	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(3-methyl-2-oxo-pentyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	150
EXAMPLE-292	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	80






EXAMPLE-293	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	59
EXAMPLE-294	(S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	19
EXAMPLE-295	(S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	45
EXAMPLE-296	(S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)	Chiral 	100





EXAMPLE-297	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		160
EXAMPLE-298	9-Isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=CH3; R3=CH3		27
EXAMPLE-299	(S)-3-Fluoro-9-(3-methylisoxazol-5-yl-methyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		67
EXAMPLE-300	(S)-9-(2-Isopropoxy-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		90
EXAMPLE-301	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		107




EXAMPLE-302	(S)-9-(6-Cyclopropyl-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		155
EXAMPLE-303	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-{2-[2-((R)-3-methyl-morpholin-4-yl)pyridin-4-yl]-2-oxoethyl}-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		6,3
EXAMPLE-304	(S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]-ethyl}-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		70,4
EXAMPLE-305	(S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]-ethyl}-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		106,9




EXAMPLE-306	(S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]-ethyl}-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		72
EXAMPLE-307	(S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]-ethyl}-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		48
EXAMPLE-308	(S)-9-(2-Cyclopropyl-oxetan-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		84,5




EXAMPLE-309	(S)-9-(2-Cyclopropyl-oxetan-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		131,4
EXAMPLE-310	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-(4-methyl-tetrahydro-pyran-4-yl)-2-oxo-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		138,5
EXAMPLE-311	(S)-9-[2-(5-Methyl-isoxazol-3-yl)-2-oxo-ethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		9
EXAMPLE-312	(S)-9-(2-Chloro-thiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		73




EXAMPLE-313	(S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		90
EXAMPLE-314	(S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		95
EXAMPLE-315	(S)-9-(2-Hydroxy-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		100
EXAMPLE-316	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1-aza-spiro[3.3]hept-1-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		72
EXAMPLE-317	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		46

EXAMPLE-318	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		39
EXAMPLE-319	(S)-9-(2-Isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		59
EXAMPLE-320	(S)-2-(2-Methyl-morpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		118
EXAMPLE-321	(S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		113

EXAMPLE-322	(S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		114
EXAMPLE-323	(S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		30
EXAMPLE-324	(S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		21

EXAMPLE-325	(S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclo-propyl-2-fluoroethyl chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		73
EXAMPLE-326	(S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclo-propyl-2-fluoroethyl chain	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		73
EXAMPLE-327	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=Me; R3=CF3 (S)		47

EXAMPLE-328	(S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		68
EXAMPLE-329	(S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		63
EXAMPLE-330	(S)-2-((R)-3-Methyl-morpholin-4-yl)-9-[2-(1-oxa-6-aza-spiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=H; p=0; q=2; R2=H; R3=CF3 (S)		28

EXAMPLE-331	(S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclo-propyl-2-fluoroethyl chain	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		98
EXAMPLE-332	(S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclo-propyl-2-fluoroethyl chain	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		96
EXAMPLE-333	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1-oxa-6-aza-spiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one	R4=F; p=0; q=2; R2=H; R3=CF3 (S)		12

Experimental section: Table 3: Synthesis routes, number of steps used in the preparation of the examples claimed above

EXAMPLE	Synthesis route	Number of steps
EXAMPLE-1	Via intermediate of type "Q"	2
EXAMPLE-2	Via intermediate of type "P"	2
EXAMPLE-3	Via intermediate of type "P"	2
EXAMPLE-4	Via intermediate of type "P"	2
EXAMPLE-5	Via intermediate of type "P"	2
EXAMPLE-6	Via intermediate of type "P"	2
EXAMPLE-7	Via intermediate of type "P"	2
EXAMPLE-8	Via intermediate of type "P"	3
EXAMPLE-9	Via intermediate of type "P"	2
EXAMPLE-10	Via intermediate of type "Q"	2
EXAMPLE-11	Via intermediate of type "Q"	2
EXAMPLE-12	Via intermediate of type "P"	2
EXAMPLE-13	Via intermediate of type "P"	2
EXAMPLE-14	Via intermediate of type "P"	2
EXAMPLE-15	Via intermediate of type "P"	2
EXAMPLE-16	Via intermediate of type "P"	3
EXAMPLE-17	Via intermediate of type "P"	2
EXAMPLE-18	Via intermediate of type "P"	2
EXAMPLE-19	Via intermediate of type "P"	2

EXAMPLE-20	Via intermediate of type "P"	2
EXAMPLE-21	Via intermediate of type "P"	2
EXAMPLE-22	Via intermediate of type "P"	2
EXAMPLE-23	Via intermediate of type "P"	2
EXAMPLE-24	Via intermediate of type "Q"	2
EXAMPLE-25	Via intermediate of type "P"	3
EXAMPLE-26	Via intermediate of type "P"	2
EXAMPLE-27	Via intermediate of type "P"	2
EXAMPLE-28	Via intermediate of type "Q"	2
EXAMPLE-29	Via intermediate of type "P"	2
EXAMPLE-30	Via intermediate of type "P"	2
EXAMPLE-31	Via intermediate of type "Q"	2
EXAMPLE-32	Via intermediate of type "P"	2
EXAMPLE-33	Via intermediate of type "P"	2
EXAMPLE-34	Via intermediate of type "P"	2
EXAMPLE-35	Via intermediate of type "P"	2
EXAMPLE-36	Via intermediate of type "P"	2
EXAMPLE-37	Via intermediate of type "P"	2
EXAMPLE-38	Via intermediate of type "Q"	2
EXAMPLE-39	Via intermediate of type "P"	2
EXAMPLE-40	Via intermediate of type "P"	2
EXAMPLE-41	Via intermediate of type "P"	2

EXAMPLE-42	Via intermediate of type "P"	2
EXAMPLE-43	Via intermediate of type "P"	2
EXAMPLE-44	Via intermediate of type "P"	2
EXAMPLE-45	Via intermediate of type "P"	2
EXAMPLE-46	Via intermediate of type "P"	2
EXAMPLE-47	Via intermediate of type "P"	2
EXAMPLE-48	Via intermediate of type "P"	2
EXAMPLE-49	Via intermediate of type "P"	2
EXAMPLE-50	Via intermediate of type "P"	2
EXAMPLE-51	Via intermediate of type "Q"	2
EXAMPLE-52	Via intermediate of type "Q"	2
EXAMPLE-53	Via intermediate of type "P"	2
EXAMPLE-54	Via intermediate of type "P"	2
EXAMPLE-55	Via intermediate of type "P"	2
EXAMPLE-56	Via intermediate of type "P"	2
EXAMPLE-57	Via intermediate of type "P"	2
EXAMPLE-58	Via intermediate of type "P"	2
EXAMPLE-59	Via intermediate of type "P"	3
EXAMPLE-60	Via intermediate of type "P"	3
EXAMPLE-61	Via intermediate of type "P"	3
EXAMPLE-62	Via intermediate of type "P"	2
EXAMPLE-63	Via intermediate of type "P"	3

EXAMPLE-64	Via intermediate of type "P"	2
EXAMPLE-65	Via intermediate of type "P"	2
EXAMPLE-66	Via intermediate of type "P"	2
EXAMPLE-67	Via intermediate of type "P"	3
EXAMPLE-68	Via intermediate of type "P"	3
EXAMPLE-69	Via intermediate of type "P"	2
EXAMPLE-70	Via intermediate of type "P"	3
EXAMPLE-71	Via intermediate of type "Q"	3
EXAMPLE-72	Via intermediate of type "Q"	2
EXAMPLE-73	Via intermediate of type "Q"	2
EXAMPLE-74	Via intermediate of type "Q"	2
EXAMPLE-75	Via intermediate of type "P"	2
EXAMPLE-76	Via intermediate of type "P"	2
EXAMPLE-77	Via intermediate of type "P"	2
EXAMPLE-78	Via intermediate of type "P"	2
EXAMPLE-79	Via intermediate of type "P"	2
EXAMPLE-80	Via intermediate of type "P"	2
EXAMPLE-81	Via intermediate of type "P"	2
EXAMPLE-82	Via intermediate of type "P"	2
EXAMPLE-83	Via intermediate of type "P"	2
EXAMPLE-84	Via intermediate of type "P"	2
EXAMPLE-85	Via intermediate of type "P"	2

EXAMPLE-86	Via intermediate of type "P"	2
EXAMPLE-87	Via intermediate of type "Q"	2
EXAMPLE-88	Via intermediate of type "P"	2
EXAMPLE-89	Via intermediate of type "P"	2
EXAMPLE-90	Via intermediate of type "P"	2
EXAMPLE-91	Via intermediate of type "Q"	2
EXAMPLE-92	Via intermediate of type "Q"	2
EXAMPLE-93	Via intermediate of type "Q"	2
EXAMPLE-94	Via intermediate of type "Q"	2
EXAMPLE-95	Via intermediate of type "Q"	2
EXAMPLE-96	Via intermediate of type "Q"	2
EXAMPLE-97	Via intermediate of type "P"	2
EXAMPLE-98	Via intermediate of type "P"	2
EXAMPLE-99	Via intermediate of type "P"	2
EXAMPLE-100	Via intermediate of type "Q"	2
EXAMPLE-101	Via intermediate of type "P"	2
EXAMPLE-102	Via intermediate of type "Q"	2
EXAMPLE-103	Via intermediate of type "P"	2
EXAMPLE-104	Via intermediate of type "P"	2
EXAMPLE-105	Via intermediate of type "P"	2
EXAMPLE-106	Via intermediate of type "P"	2
EXAMPLE-107	Via intermediate of type "P"	2

EXAMPLE-108	Via intermediate of type "P"	2
EXAMPLE-109	Via intermediate of type "P"	2
EXAMPLE-110	Via intermediate of type "Q"	2
EXAMPLE-111	Via intermediate of type "Q"	2
EXAMPLE-112	Via intermediate of type "P"	2
EXAMPLE-113	Via intermediate of type "P"	2
EXAMPLE-114	Via intermediate of type "P"	2
EXAMPLE-115	Via intermediate of type "P"	2
EXAMPLE-116	Via intermediate of type "P"	2
EXAMPLE-117	Via intermediate of type "Q"	2
EXAMPLE-118	Via intermediate of type "P"	2
EXAMPLE-119	Via intermediate of type "P"	2
EXAMPLE-120	Via intermediate of type "P"	2
EXAMPLE-121	Via intermediate of type "P"	2
EXAMPLE-122	Via intermediate of type "P"	2
EXAMPLE-123	Via intermediate of type "P"	2
EXAMPLE-124	Via intermediate of type "P"	2
EXAMPLE-125	Via intermediate of type "P"	2
EXAMPLE-126	Via intermediate of type "Q"	2
EXAMPLE-127	Via intermediate of type "P"	2
EXAMPLE-128	Via intermediate of type "P"	2
EXAMPLE-129	Via intermediate of type "P"	2

EXAMPLE-130	Via intermediate of type "Q"	2
EXAMPLE-131	Via intermediate of type "Q"	2
EXAMPLE-132	Via intermediate of type "Q"	2
EXAMPLE-133	Via intermediate of type "Q"	2
EXAMPLE-134	Via intermediate of type "P"	2
EXAMPLE-135	Via intermediate of type "Q"	2
EXAMPLE-136	Via intermediate of type "P"	2
EXAMPLE-137	Via intermediate of type "P"	2
EXAMPLE-138	Via intermediate of type "P"	2
EXAMPLE-139	Via intermediate of type "P"	2
EXAMPLE-140	Via intermediate of type "P"	2
EXAMPLE-141	Via intermediate of type "Q"	2
EXAMPLE-142	Via intermediate of type "Q"	2
EXAMPLE-143	Via intermediate of type "P"	2
EXAMPLE-144	Via intermediate of type "Q"	2
EXAMPLE-145	Via intermediate of type "Q"	2
EXAMPLE-146	Via intermediate of type "P"	2
EXAMPLE-147	Via intermediate of type "P"	2
EXAMPLE-148	Via intermediate of type "P"	2
EXAMPLE-149	Via intermediate of type "P"	2
EXAMPLE-150	Via intermediate of type "P"	2
EXAMPLE-151	Via intermediate of type "P"	2

EXAMPLE-152	Via intermediate of type "P"	2
EXAMPLE-153	Via intermediate of type "P"	2
EXAMPLE-154	Via intermediate of type "P"	2
EXAMPLE-155	Via intermediate of type "P"	2
EXAMPLE-156	Via intermediate of type "P"	2
EXAMPLE-157	Via intermediate of type "P"	2
EXAMPLE-158	Via intermediate of type "P"	2
EXAMPLE-159	Via intermediate of type "P"	2
EXAMPLE-160	Via intermediate of type "P"	2
EXAMPLE-161	Via intermediate of type "P"	2
EXAMPLE-162	Via intermediate of type "P"	2
EXAMPLE-163	Via intermediate of type "P"	2
EXAMPLE-164	Via intermediate of type "P"	2
EXAMPLE-165	Via intermediate of type "P"	2
EXAMPLE-166	Via intermediate of type "P"	2
EXAMPLE-167	Via intermediate of type "P"	2
EXAMPLE-168	Via intermediate of type "P"	2
EXAMPLE-169	Via intermediate of type "P"	2
EXAMPLE-170	Via intermediate of type "Q"	2
EXAMPLE-171	Via intermediate of type "Q"	2
EXAMPLE-172	Via intermediate of type "Q"	2
EXAMPLE-173	Via intermediate of type "Q"	2

EXAMPLE-174	Via intermediate of type "Q"	2
EXAMPLE-175	Via intermediate of type "Q"	2
EXAMPLE-176	Via intermediate of type "P"	2
EXAMPLE-177	Via intermediate of type "P"	2
EXAMPLE-178	Via intermediate of type "P"	2
EXAMPLE-179	Via intermediate of type "Q"	2
EXAMPLE-180	Via intermediate of type "Q"	2
EXAMPLE-181	Via intermediate of type "P"	2
EXAMPLE-182	Via intermediate of type "Q"	2
EXAMPLE-183	Via intermediate of type "Q"	2
EXAMPLE-184	Via intermediate of type "P"	2
EXAMPLE-185	Via intermediate of type "P"	2
EXAMPLE-186	Via intermediate of type "P"	2
EXAMPLE-187	Via intermediate of type "P"	2
EXAMPLE-188	Via intermediate of type "Q"	2
EXAMPLE-189	Via intermediate of type "Q"	2
EXAMPLE-190	Via intermediate of type "Q"	2
EXAMPLE-191	Via intermediate of type "Q"	2
EXAMPLE-192	Via intermediate of type "Q"	2
EXAMPLE-193	Via intermediate of type "Q"	2
EXAMPLE-194	Via intermediate of type "Q"	2
EXAMPLE-195	Via intermediate of type "Q"	2

EXAMPLE-196	Via intermediate of type "P"	2
EXAMPLE-197	Via intermediate of type "P"	4
EXAMPLE-198	Via intermediate of type "P"	3
EXAMPLE-199	Via intermediate of type "Q"	2
EXAMPLE-200	Via intermediate of type "P"	2
EXAMPLE-201	Via intermediate of type "P"	2
EXAMPLE-202	Via intermediate of type "P"	2
EXAMPLE-203	Via intermediate of type "P"	2
EXAMPLE-204	Via intermediate of type "Q"	2
EXAMPLE-205	Via intermediate of type "P"	3
EXAMPLE-206	Via intermediate of type "P"	2
EXAMPLE-207	Via intermediate of type "P"	2
EXAMPLE-208	Via intermediate of type "P"	2
EXAMPLE-209	Via intermediate of type "P"	2
EXAMPLE-210	Via intermediate of type "P"	2
EXAMPLE-211	Via intermediate of type "P"	2
EXAMPLE-212	Via intermediate of type "P"	2
EXAMPLE-213	Via intermediate of type "P"	2
EXAMPLE-214	Via intermediate of type "P"	2
EXAMPLE-215	Via intermediate of type "P"	2
EXAMPLE-216	Via intermediate of type "P"	2
EXAMPLE-217	Via intermediate of type "P"	2

EXAMPLE-218	Via intermediate of type "P"	2
EXAMPLE-219	Via intermediate of type "P"	2
EXAMPLE-220	Via intermediate of type "Q"	2
EXAMPLE-221	Via intermediate of type "P"	2
EXAMPLE-222	Via intermediate of type "P"	2
EXAMPLE-223	Via intermediate of type "P"	2
EXAMPLE-224	Via intermediate of type "P"	2
EXAMPLE-225	Via intermediate of type "P"	2
EXAMPLE-226	Via intermediate of type "P"	2
EXAMPLE-227	Via intermediate of type "P"	2
EXAMPLE-228	Via intermediate of type "P"	2
EXAMPLE-229	Via intermediate of type "P"	2
EXAMPLE-230	Via intermediate of type "P"	2
EXAMPLE-231	Via intermediate of type "P"	2
EXAMPLE-232	Via intermediate of type "P"	2
EXAMPLE-233	Via intermediate of type "P"	2
EXAMPLE-234	Via intermediate of type "P"	2
EXAMPLE-235	Via intermediate of type "P"	2
EXAMPLE-236	Via intermediate of type "P"	2
EXAMPLE-237	Via intermediate of type "P"	2
EXAMPLE-238	Via intermediate of type "P"	2
EXAMPLE-239	Via intermediate of type "P"	2

EXAMPLE-240	Via intermediate of type "P"	2
EXAMPLE-241	Via intermediate of type "P"	2
EXAMPLE-242	Via intermediate of type "Q"	2
EXAMPLE-243	Via intermediate of type "P"	2
EXAMPLE-244	Via intermediate of type "P"	2
EXAMPLE-245	Via intermediate of type "P"	2
EXAMPLE-246	Via intermediate of type "P"	2
EXAMPLE-247	Via intermediate of type "P"	2
EXAMPLE-248	Via intermediate of type "P"	2
EXAMPLE-249	Via intermediate of type "P"	2
EXAMPLE-250	Via intermediate of type "P"	2
EXAMPLE-251	Via intermediate of type "P"	2
EXAMPLE-252	Via intermediate of type "P"	2
EXAMPLE-253	Via intermediate of type "P"	2
EXAMPLE-254	Via intermediate of type "P"	2
EXAMPLE-255	Via intermediate of type "P"	2
EXAMPLE-256	Via intermediate of type "P"	2
EXAMPLE-257	Via intermediate of type "P"	2
EXAMPLE-258	Via intermediate of type "P"	2
EXAMPLE-259	Via intermediate of type "Q"	2
EXAMPLE-260	Via intermediate of type "P"	2
EXAMPLE-261	Via intermediate of type "P"	2

EXAMPLE-262	Via intermediate of type "P"	2
EXAMPLE-263	Via intermediate of type "P"	2
EXAMPLE-264	Via intermediate of type "P"	4
EXAMPLE-265	Via intermediate of type "P"	3
EXAMPLE-266	Via intermediate of type "P"	4
EXAMPLE-267	Via intermediate of type "P"	4
EXAMPLE-268	Via intermediate of type "Q"	2
EXAMPLE-269	Via intermediate of type "P"	2
EXAMPLE-270	Via intermediate of type "P"	2
EXAMPLE-271	Via intermediate of type "P"	2
EXAMPLE-272	Via intermediate of type "P"	2
EXAMPLE-273	Via intermediate of type "P"	2
EXAMPLE-274	Via intermediate of type "P"	2
EXAMPLE-275	Via intermediate of type "P"	2
EXAMPLE-276	Via intermediate of type "P"	2
EXAMPLE-277	Via intermediate of type "P"	2
EXAMPLE-278	Via intermediate of type "P"	2
EXAMPLE-279	Via intermediate of type "P"	2
EXAMPLE-280	Via intermediate of type "P"	2
EXAMPLE-281	Via intermediate of type "P"	2
EXAMPLE-282	Via intermediate of type "P"	2
EXAMPLE-283	Via intermediate of type "P"	2

EXAMPLE-284	Via intermediate of type "P"	2
EXAMPLE-285	Via intermediate of type "P"	2
EXAMPLE-286	Via intermediate of type "P"	3
EXAMPLE-287	Via intermediate of type "P"	3
EXAMPLE-288	Via intermediate of type "P"	4
EXAMPLE-289	Via intermediate of type "P"	4
EXAMPLE-290	Via intermediate of type "P"	2
EXAMPLE-291	Via intermediate of type "P"	2
EXAMPLE-292	Via intermediate of type "P"	2
EXAMPLE-293	Via intermediate of type "P"	4
EXAMPLE-294	Via intermediate of type "P"	2
EXAMPLE-295	Via intermediate of type "P"	2
EXAMPLE-296	Via intermediate of type "P"	2
EXAMPLE-297	Via intermediate of type "P"	2
EXAMPLE-298	Via intermediate of type "Q"	2
EXAMPLE-299	Via intermediate of type "P"	2
EXAMPLE-300	Via intermediate of type "P"	2
EXAMPLE-301	Via intermediate of type "P"	2
EXAMPLE-302	Via intermediate of type "P"	2
EXAMPLE-303	Via intermediate of type "Q"	2
EXAMPLE-304	Via intermediate of type "P"	3
EXAMPLE-305	Via intermediate of type "P"	3

EXAMPLE-306	Via intermediate of type "P"	3
EXAMPLE-307	Via intermediate of type "P"	3
EXAMPLE-308	Via intermediate of type "P"	3
EXAMPLE-309	Via intermediate of type "P"	3
EXAMPLE-310	Via intermediate of type "P"	3
EXAMPLE-311	Via intermediate of type "P"	2
EXAMPLE-312	Via intermediate of type "P"	2
EXAMPLE-313	Via intermediate of type "P"	2
EXAMPLE-314	Via intermediate of type "P"	4
EXAMPLE-315	Via intermediate of type "Q"	2
EXAMPLE-316	Via intermediate of type "P"	4
EXAMPLE-317	Via intermediate of type "P"	4
EXAMPLE-318	Via intermediate of type "P"	4
EXAMPLE-319	Via intermediate of type "P"	4
EXAMPLE-320	Via intermediate of type "P"	2
EXAMPLE-321	Via intermediate of type "P"	2
EXAMPLE-322	Via intermediate of type "P"	2
EXAMPLE-323	Via intermediate of type "P"	2
EXAMPLE-324	Via intermediate of type "P"	2
EXAMPLE-325	Via intermediate of type "P"	2
EXAMPLE-326	Via intermediate of type "P"	2
EXAMPLE-327	Via intermediate of type "Q"	2

EXAMPLE-328	Via intermediate of type "P"	2
EXAMPLE-329	Via intermediate of type "P"	2
EXAMPLE-330	Via intermediate of type "P"	4
EXAMPLE-331	Via intermediate of type "P"	2
EXAMPLE-332	Via intermediate of type "P"	2
EXAMPLE-333	Via intermediate of type "P"	4

Experimental section: Table 4: Description of the reaction sequences: starting from the intermediates of type F, according to the synthesis route selected (Tables 1 and 2), the intermediate is treated with the reagent specified according to the method specified

EXAM-PLE	Name of reagent used	Num. eq. reagent used	Ref. Step 1	Reference chiral phase purification	Name of intermediate isolated
EXAMPLE-1	2-(Bromo-acetyl)-pyridine hydro-bromide	2	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-one
EXAMPLE-2	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-3	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-4	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-5	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-6	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-7	3-(R)-Methyl-morpholine	1.2	Method-42	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-8	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-9	(3R,5R)-3,5-Dimethyl-morpholine	2	Method-39	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-10	2-Bromo-1-(2-chloro-pyridin-4-yl)-ethanone	2	Method-17	None	2-Chloro-9-[2-(2-chloro-pyridin-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-11	2-Bromo-1-pyridin-3-ylethanone	1.5-2.0	Method-22	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-12	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-13	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-14	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-15	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-16	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-17	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-18	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-19	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-20	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-21	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-22	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-23	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-24	5-Bromomethyl-2-fluoro-pyridine	1.5-2.0	Method-10	None	2-Chloro-9-(6-fluoro-pyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-25	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-26	3-(R)-Methyl-morpholine	2	Method-1	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-27	3-(R)-Methyl-morpholine	2	Method-1	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-28	5-(Chloro-methyl)-3-(trifluoro-methyl)-1,2,4-oxadiazole	1.5-2.0	Method-10	None	(R)-2-Chloro-3-fluoro-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-29	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-30	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-31	2-Bromo-1-cyclopropyl ethanone	1.5-2.0	Method-10	None	(S)-7-Chloro-1-(2-cyclopropyl-2-oxoethyl)-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-32	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-33	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-34	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-35	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-36	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-37	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-38	2-bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-23	None	(S)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-39	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-40	3-(R)-Methyl-morpholine	4	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-41	3-(R)-Methyl-morpholine	4	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-42	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-43	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-44	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-45	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-46	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-47	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-48	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-49	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-50	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-51	5-Bromo-methyl-2-fluoro-pyridine	1.5-2.0	Method-12	None	(S)-2-Chloro-3-fluoro-9-(6-fluoropyridin-3-yl-methyl)-8-trifluoro-methyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-52	5-Bromomethyl-2-chloro-pyridine	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(6-chloro-pyridin-3-ylmethyl)-3-fluoro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-53	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-54	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-55	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-56	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-57	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-58	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-59	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-60	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-61	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-62	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-63	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-64	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-65	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-66	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-67	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-68	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-69	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-70	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-71	2-Oxiranyl-pyridine	2	Method-10	None	2-Chloro-3-fluoro-9-(2-hydroxy-2-pyridin-2-yl-ethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-72	5-Bromo-methyl-1-difluoro-methyl-1H-pyrazole	1.5-2.0	Method-11	None	2-Chloro-9-(2-difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-73	3-Chloro-methyl-isoxazole	1.5-2.0	Method-12	None	2-Chloro-3-fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-74	5-Bromo-methyl-1-difluoro-methyl-1H-pyrazole	1.5-2.0	Method-15	None	2-Chloro-9-(2-difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-75	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-76	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-77	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-78	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-79	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-80	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-81	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-82	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-83	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-84	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-85	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-86	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-87	5-Bromomethyl-thiazole	1.5-2.0	Method-24	None	(S)-2-Chloro-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-88	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-89	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-90	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-91	Oxazole-5-methanol	1.5-2.0	Method-44	None	(S)-2-Chloro-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-92	2-(Bromo-methyl)-5-fluoro-pyridine hydro-bromide	1.5-2.0	Method-22	None	(S)-2-Chloro-9-(5-fluoro-pyridin-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-93	4-(Chloro-methyl)-2,5-dimethyl-1,3-oxazole	1.5-2.0	Method-22	None	(S)-2-Chloro-9-(2,5-dimethyloxazol-4-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-94	3-(Chloro-methyl)-5-fluoro-pyridine	1.5-2.0	Method-22	None	(S)-2-Chloro-9-(5-fluoro-pyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-95	3-Chloro-5-(chloro-methyl)-pyridine	1.5-2.0	Method-22	None	(S)-2-Chloro-9-(5-chloro-pyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-96	2-(chloro-methyl)-5-methyl 1,3,4-oxadiazole	1.5-2.0	Method-43	None	2-Chloro-9-(5-methyl-[1,3,4]oxadiazol-2-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-97	3-(R)-Methyl-morpholine	1.2	Method-42	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-98	3-(R)-Methyl-morpholine	1.5	Method-42	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-99	3-(R)-Methyl-morpholine	1.2	Method-42	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-100	(S)-2-Methoxy-2-phenylethyl para-toluene-sulphonate	1.5-2.0	Method-26	None	(S)-2-Chloro-9-((S)-2-methoxy-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-101	3-(R)-Methyl-morpholine	1.3	Method-38	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-102	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-103	3-(R)-Methyl-morpholine	1.2	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-104	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-105	3-(R)-Methyl-morpholine	2	Method-37	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-106	3-(R)-Methyl-morpholine	2	Method-37	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-107	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-108	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-109	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-110	4-(Bromo-methyl)-1,3-oxazole	1.5-2.0	Method-10	None	(R)-2-Chloro-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-111	Oxazol-5-ylmethanol	1.5-2.0	Method-44	None	(R)-2-Chloro-3-fluoro-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-112	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-113	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-114	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-115	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-116	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-117	Oxazol-5-ylmethanol	1.5-2.0	Method-44	None	(R)-2-Chloro-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-118	3-(R)-Methyl-morpholine	3	Method-5	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-119	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-120	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-121	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-122	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-123	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-124	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-125	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-126	2-Bromo-1-pyridin-3-ylethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-3-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-127	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-128	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-129	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-130	1-Bromo-3-methyl-2-butanone	1.5-2.0	Method-22	None	2-Chloro-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-131	2-Bromo-1-(tetra-hydro-pyran-4-yl)-ethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-132	2-Bromo-1-(tetra-hydro-pyran-4-yl)-ethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-3-fluoro-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-133	Oxetan-3-ylmethanol	1.5-2.0	Method-44	None	(S)-2-Chloro-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-134	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-135	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-2-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-136	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-137	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-138	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-139	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-140	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-141	2-Bromo-1-pyridin-3-ylethanone	1.5-2.0	Method-10	None	(R)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-142	2-(Chloro-methyl)-5-cyclo-propyl-1,3,4-oxadiazole	1.5-2.0	Method-10	None	2-Chloro-9-(5-cyclopropyl-[1,3,4]oxadiazol-2-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-143	3-(R)-Methyl-morpholine	2	Method-1	None	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-144	5-(Chloro-methyl)-3-(trifluoro-methyl)-1,2,4-oxadiazole	1.5-2.0	Method-10	None	(R)-2-Chloro-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-145	Chloro-acetone	1.5-2.0	Method-10	None	2-Chloro-9-(2-oxo-propyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-146	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-147	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-148	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-149	3-(R)-Methyl-morpholine	3	Method-1	None	(R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-150	3,3-Dimethyl-morpholine	1.3	Method-6	None	(S)-2-(3,3-Dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-151	(3R,5R)-3,5-Dimethyl-morpholine	3	Method-7	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-152	(3R,5R)-3,5-Dimethyl-morpholine	3	Method-7	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-153	(3R,5R)-3,5-Dimethyl-morpholine	3	Method-7	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-154	(3R,5R)-3,5-Dimethyl-morpholine	2	Method-39	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-155	(3R,5R)-3,5-Dimethyl-morpholine	2	Method-39	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-156	(3R,5R)-3,5-Dimethyl-morpholine	2	Method-39	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-157	(3R,5R)-3,5-Dimethyl-morpholine	2	Method-21	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-158	(3R,5R)-3,5-Dimethyl-morpholine	1.5	Method-21	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-159	(3R,5R)-3,5-Dimethyl-morpholine	1.5	Method-21	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-160	(3R,5R)-3,5-Dimethyl-morpholine	1.5	Method-21	None	(S)-2-((R)-3-Methyl-5-(R)-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-161	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.2	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-162	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.2	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-163	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-164	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-165	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-166	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-167	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-168	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-169	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.5	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-170	2-Bromo-1-pyridin-3-ylethanone	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-171	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-172	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	Chiral Purification-21	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-173	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	Chiral Purification-21	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-174	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-175	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-176	8-Oxa-3-azabicyclo-[3.2.1]-octane	2	Method-41	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-177	3-Hydroxy-methyl-morpholine	2	Method-41	Chiral Purification-1	(S)-2-(3-Hydroxymethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-178	3-(R)-Methyl-morpholine	1.5	Method-42	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-179	2-Bromo-1-pyridin-2-ylethanone	1.5-2.0	Method-10	None	(S)-7-Chloro-2-methyl-1-(2-oxo-2-pyridin-2-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-180	2-Bromo-1-pyridin-3-ylethanone	1.5-2.0	Method-10	None	(S)-7-Chloro-2-methyl-1-(2-oxo-2-pyridin-3-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-181	3-(R)-Methyl-morpholine	3	Method-4	None	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-182	Oxazol-5-ylmethanol	1.5-2.0	Method-44	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-183	4-(Bromo-methyl)-1,3-oxazole	1.5-2.0	Method-10	None	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-184	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-185	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-186	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-187	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-188	1-Bromo-3-methyl-butan-2-one	1.5-2.0	Method-10	None	(S)-7-Chloro-2-methyl-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-189	2-Bromo-1-(pyridin-3-yl)-ethanone hydro-bromide	1.5-2.0	Method-10	None	(S)-7-Chloro-6-fluoro-2-methyl-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

EXAMPLE-190	2-Bromo-1-(tetra-hydro-pyran-4-yl)-ethanone	2	Method-10	None	(S)-7-Chloro-2-methyl-1-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-191	Benzyl bromide	1.1	Method-10	None	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-192	Benzyl bromide	1.1	Method-10	None	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-193	Benzyl bromide	1.5-2.0	Method-34	None	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-194	Benzyl bromide	1.5-2.0	Method-34	None	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-195	Benzyl bromide	1.5-2.0	Method-34	None	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-196	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-197	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-198	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-199	2-(Bromo-acetyl)-pyridine hydro-bromide	1.3	Method-10	None	(S)-7-Chloro-6-fluoro-2-methyl-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-200	3-(R)-Methyl-morpholine	10	Method-33	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-201	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-202	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-203	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-204	Bromo-ethanol	1.5-2.0	Method-23	None	(S)-2-Chloro-3-fluoro-9-(2-hydroxyethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-205	3-(R)-Methyl-morpholine	5	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-206	8-Oxa-3-azabicyclo-[3.2.1]-octane	1.2	Method-8	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-207	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

EXAMPLE-208	3-(R)-Methyl-morpholine	3	Method-3	None	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-209	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-210	3-(R)-Methyl-morpholine	3	Method-2	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-211	3-(R)-Methyl-morpholine	3	Method-4	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-212	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-213	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-214	3-(R)-Methyl-morpholine	5	Method-9	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-215	3-(R)-Methyl-morpholine	5	Method-9	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-216	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-217	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-218	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-219	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-220	2-(2-Hydroxy-ethyl)-pyridine	1.5-2.0	Method-44	None	(S)-2-Chloro-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-221	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-222	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-223	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-224	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-225	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-226	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-227	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-228	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-229	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-230	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-231	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-232	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-233	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-234	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-235	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-236	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-237	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-238	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-239	3-(R)-Methyl-morpholine	3	Method-4	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-240	3-(R)-Methyl-morpholine	3	Method-3	None	(S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
EXAMPLE-241	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-242	2-Bromo-1-(thiazol-2-yl)-ethanone	1.1	Method-17	None	2-Chloro-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-243	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-244	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-245	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-246	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-247	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-248	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-249	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-250	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-251	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-252	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-253	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-254	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-255	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-256	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-257	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-258	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-259	Pyridazin-4-yl-methanol	1.5-2.0	Method-45	None	(S)-2-Chloro-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-260	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-261	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-262	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-263	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-264	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-265	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-266	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-267	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-268	2-Bromo-1-(3-methyl-isoxazol-4-yl)-ethanone	1.1	Method-17	None	(S)-2-Chloro-9-[2-(3-methylisoxazol-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-269	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-270	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-271	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-272	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-273	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-3-Fluoro-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-274	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-3-Fluoro-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-275	8-Oxa-3-azabicyclo-[3.2.1]-octane	10	Method-1	None	(S)-3-Fluoro-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-276	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-277	3-(S)-Methyl-morpholine	1.5-2.0	Method-1	None	(S)-2-('S)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-278	3-(S)-Methyl-morpholine	1.5-2.0	Method-1	None	(S)-3-Fluoro-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-279	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-280	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-281	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-282	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-283	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-284	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-285	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-286	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-287	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-288	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-289	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-290	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-291	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-292	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-293	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-294	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-295	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-296	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-297	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-298	3-Chloro-methyl)-isoxazole	1.2	Method-23	None	2-Chloro-9-(Isoxazol-3-ylmethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-299	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-300	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-301	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-302	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-303	2-Bromo-1-(2-chloro-pyridin-4-yl)-ethanone	1,1	K_3PO_4/ MeCN 20°C	None	(S)-8-Chloro-1-(2-(2-chloropyridin-4-yl)-2-oxoethyl)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one

EXAMPLE-304	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-305	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-306	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-307	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-308	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-309	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one

EXAMPLE-310	3-(R)-methyl-morpholine	1,1	Method 1	None	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one
EXAMPLE-311	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-312	3-(R)-5-(R)-Dimethyl-morpholine	1.7	Method-39	None	(S)-8-((3R,5R)-3,5-Dimethylmorpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-]pyrimidin-6(2H)-one
EXAMPLE-313	3-(R)-5-(R)-Dimethyl-morpholine	1.7	Method-39	None	(S)-8-((3R,5R)-3,5-Dimethylmorpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-]pyrimidin-6(2H)-one
EXAMPLE-314	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-315	Bromo-ethanol	1.5-2.0	Method-23	None	(S)-2-Chloro-9-(2-hydroxyethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-316	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-317	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-318	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-319	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-320	3-(R)-Methyl-morpholine prepared internally and contami-nated with 2-methyl-morpholine	3	Method-1	None	(S)-2-(2-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

EXAMPLE-321	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-322	3-(R)-Methyl-morpholine prepared internally and contami-nated with 2-methyl-morpholine	3	Method-1	None	(S)-2-(2-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine
EXAMPLE-323	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-324	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-325	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-326	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-327	Chloro-acetone	3	Method-10	None	(S)-2-Chloro-8-methyl-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-328	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-329	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-330	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-331	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

EXAMPLE-332	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one
EXAMPLE-333	3-(R)-Methyl-morpholine	3	Method-1	None	(S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one

Experimental section: Table 5. Synthesis steps 2 (optionally 3 and 4) starting from the intermediates isolated after step 1 (see Table 4)

EXAMPLE	Name of starting intermediate Q or P	Ref. step 2				Ref. method step 3	Ref. method step 4
		Reagent name step 2	Number eq. reagent used for reaction	Method	Chiral purification method (if required)		
EXAMPLE-1	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-2	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.2	Method-11		None	None
EXAMPLE-3	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methylbutan-2-one	1.2	Method-10		None	None
EXAMPLE-4	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-2-butanone	1.5	Method-10		None	None

EXAMPLE-5	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-2-fluoro-pyridine	1.1	Method-10		None	None
EXAMPLE-6	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.5	Method-10		None	None
EXAMPLE-7	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Chloro-propan-2-one	1.2	Method-22		None	None
EXAMPLE-8	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(S)-(-)-Propylene oxide	2	Method-18	Chiral Purifi-cation-20	None	None
EXAMPLE-9	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-isoxazole	1.1	Method-19		None	None

EXAMPLE-10	2-Chloro-9-[2-(2-chloropyridin-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-11	(S)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2.6	Method-38		None	None
EXAMPLE-12	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Chloro-methyl-3-methyl-isoxazole	1.2	Method-10		None	None
EXAMPLE-13	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-methyl-oxazole	1.3	Method-10		None	None
EXAMPLE-14	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Ethyl 2-bromo-acetate	1.1	Method-10		None	None

EXAMPLE-15	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-methyl-5-methyl-[1,2,4]-oxadiazole	1.2	Method-10		None	None
EXAMPLE-16	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Ethyl-magnesium bromide	1.2	Method-11		Method-46	None
EXAMPLE-17	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-methyl-1,2,4-oxadiazole	1.2	Method-14		None	None
EXAMPLE-18	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(tetrahydro-pyran-4-yl)-ethanone	1.2	Method-10		None	None
EXAMPLE-19	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-methyl-1,2,4-oxadiazole	1.1	Method-13		None	None

EXAMPLE-20	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromethyl methyl ether	1.2	Method-10		None	None
EXAMPLE-21	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.1	Method-19		None	None
EXAMPLE-22	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-2-butanone	1.5	Method-10		None	None
EXAMPLE-23	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide	1.1	Method-11		None	None
EXAMPLE-24	2-Chloro-9-(6-fluoropyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	16.6	Method-1		None	None

EXAMPLE-25	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide	1.5	Method-11		Method-46	None
EXAMPLE-26	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-2-butanone	1.2	Method-19		None	None
EXAMPLE-27	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.2	Method-19		None	None
EXAMPLE-28	(R)-2-Chloro-3-fluoro-6-trifluoromethyl-9-(3-trifluoro-methyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2.5	Method-1		None	None
EXAMPLE-29	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-2-butanone	1.3	Method-19		None	None

EXAMPLE-30	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.2	Method-19		None	None
EXAMPLE-31	(S)-7-Chloro-1-(2-cyclopropyl-2-oxoethyl)-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-32	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-methyl-1-difluoro-methyl-1H-pyrazole	1.2	Method-12		None	None
EXAMPLE-33	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-methyl-isoxazole	1.2	Method-12		None	None
EXAMPLE-34	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiazole	1.1	Method-12		None	None

EXAMPLE-35	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-pyridine	1.1	Method-12		None	None
EXAMPLE-36	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-isoxazole	1.1	Method-12		None	None
EXAMPLE-37	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-1-(difluoro-methyl)-1H-pyrazole	1.1	Method-12		None	None
EXAMPLE-38	(S)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2	Method-42		None	None
EXAMPLE-39	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, single stereoisomer	2-Fluoro-2-phenylethyl-4-methyl-benzene-sulphonate		Method-27	Chiral Purifi-cation-19	None	None

EXAMPLE-40	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Bromo-2-methoxy-pyridine	1	Method-29		None	None
EXAMPLE-41	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-(chloro-methyl)-pyridine	1	Method-12		None	None
EXAMPLE-42	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-methyl-oxazole	1.1	Method-14		None	None
EXAMPLE-43	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-6-(cyclo-propyl)-pyridine	1.1	Method-29		None	None
EXAMPLE-44	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-1,3-oxazole	1.5	Method-12		None	None

EXAMPLE-45	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodopyridine	3	Method-29		None	None
EXAMPLE-46	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-1,3-oxazole	1.1	Method-12		None	None
EXAMPLE-47	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-pyridine	4	Method-29		None	None
EXAMPLE-48	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(2-Chloro-ethoxy)-1,1,1-trifluoro-ethane	1.3	Method-10		None	None
EXAMPLE-49	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Isobutylene oxide	1	Method-35		None	None

EXAMPLE-50	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(pyridin-3-yl)ethanone	1.5	Method-12		None	None
EXAMPLE-51	(S)-2-Chloro-3-fluoro-9-(6-fluoropyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	1.2	Method-1		None	None
EXAMPLE-52	(S)-2-Chloro-9-(6-chloropyridin-3-ylmethyl)-3-fluoro-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	1	Method-1		None	None
EXAMPLE-53	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(difluoro-methyl)-pyridine	1.5	Method-30		None	None
EXAMPLE-54	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(tert-Butyl)-3-(chloro-methyl)-1,2,4-oxadiazole	1.3	Method-10		None	None

EXAMPLE-55	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Iodopyridine	1.5	Method-30		None	None
EXAMPLE-56	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Bromo-methyl)-5-fluoro-pyridine hydro-bromide	1.2	Method-10		None	None
EXAMPLE-57	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Bromo-methyl)-5-fluoro-pyridine	1.5	Method-10		None	None
EXAMPLE-58	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-2-fluoro-pyridine	1.5	Method-10		None	None
EXAMPLE-59	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-46	None

EXAMPLE-60	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-46	None
EXAMPLE-61	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-47	None
EXAMPLE-62	(S)-3-Fluoro-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Chloro-methyl-3-methyl-isoxazole	1.2	Method-10		None	None
EXAMPLE-63	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-47	None
EXAMPLE-64	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Chloro-methyl)-imidazo-[1,2-a]-pyridine	1.5	Method-10		None	None

EXAMPLE-65	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Chloro-2-(chloro-methyl)-pyridine	1.2	Method-10		None	None
EXAMPLE-66	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-4-(chloro-methyl)-pyridine	1	Method-10		None	None
EXAMPLE-67	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-47	None
EXAMPLE-68	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11		Method-47	None
EXAMPLE-69	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Bromo-methyl)-thiazole		Method-12	Chiral Purifi-cation-6	None	None

EXAMPLE-70	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide		Method-11	Chiral Purifi-cation-7	Method-47	Chiral Purifi-cation 7
EXAMPLE-71	2-Chloro-3-fluoro-9-(2-hydroxy-2-pyridin-2-yl-ethyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Dess-Martin periodinane	1.2	#N/A		Method-1	None
EXAMPLE-72	2-Chloro-9-(2-difluoromethyl-2H-pyrazol-3-yl-methyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-73	2-Chloro-3-fluoro-9-isoxazol-3-yl-methyl-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-74	2-Chloro-9-(2-difluoromethyl-2H-pyrazol-3-yl-methyl)-3-fluoro-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None

EXAMPLE-75	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Fluoro-iodo-benzene	3	Method-30		None	None
EXAMPLE-76	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Bromo-methyl-2-chloro-pyridine	1.1	Method-11		None	None
EXAMPLE-77	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-methyl-oxazole	11	Method-11		None	None
EXAMPLE-78	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-thiazole hydro-chloride	1.1	Method-11		None	None
EXAMPLE-79	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodo-pyridine, 99%	3	Method-30		None	None

EXAMPLE-80	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Iodo-2-methoxy-pyridine	3	Method-30		None	None
EXAMPLE-81	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(trifluoro-methyl)-pyridine	3	Method-30		None	None
EXAMPLE-82	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(2-Chloro-ethoxy)-1,1,1-trifluoro-ethane	3	Method-11		None	None
EXAMPLE-83	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-methyl-pyridine	2	Method-30		None	None
EXAMPLE-84	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Isobutylene oxide	xs	Method-35		None	None

EXAMPLE-85	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-isopropoxy-pyridine, 97%	1	Method-30		None	None
EXAMPLE-86	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Chloro-2-(chloro-methyl)-pyridine	3	Method-11		None	None
EXAMPLE-87	(S)-2-Chloro-9-thiazol-5-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-88	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-6-(cyclobutyl)-pyridine	1.1	Method-30		None	None
EXAMPLE-89	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Bromo-2-(cyclo-propyl)-pyridine	1.1	Method-30		None	None

EXAMPLE-90	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromethyl methyl ether	1.1	Method-11		None	None
EXAMPLE-91	(S)-2-Chloro-9-oxazol-5-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-92	(S)-2-Chloro-9-(5-fluoropyridin-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	5	Method-1		None	None
EXAMPLE-93	(S)-2-Chloro-9-(2,5-dimethyl-oxazol-4-yl-methyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	5	Method-1		None	None
EXAMPLE-94	(S)-2-Chloro-9-(5-fluoropyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	8	Method-1		None	None

EXAMPLE-95	(S)-2-Chloro-9-(5-chloropyridin-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	7	Method-1		None	None
EXAMPLE-96	2-Chloro-9-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	5	Method-1		None	None
EXAMPLE-97	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Chloro-pinacolone, 95%	1.2	Method-22		None	None
EXAMPLE-98	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiophene	1.1	Method-10		None	None
EXAMPLE-99	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-aceto-phenone	1.5	Method-10		None	None

EXAMPLE-100	(S)-2-Chloro-9-((S)-2-methoxy-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2	Method-42		None	None
EXAMPLE-101	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-3-methyl-isoxazole	1.2	Method-10		None	None
EXAMPLE-102	(R)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-38		None	None
EXAMPLE-103	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Oxazol-4-yl-methyl 4-methyl-benzene-sulphonate (ref. reagent-1 table)		Method-10		None	None

EXAMPLE-104	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Oxazol-4-yl-methyl-4-methyl-benzene-sulphonate (ref. reagent-1 table). EX-104 isolated during the purification of EX-103 is a by-product obtained during the synthesis because of the excess of tosyl chloride in the starting reagent	1.2	Method-10		None	None
EXAMPLE-105	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-isoxazole	1.5	Method-10		None	None
EXAMPLE-106	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-methyl-isoxazole	2	Method-10		None	None
EXAMPLE-107	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-6-(cyclo-propyl)-pyridine		Method-29		None	None

EXAMPLE-108	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodopyridine	1	Method-29		None	None
EXAMPLE-109	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Iodo-2-methoxy-pyridine	1	Method-29		None	None
EXAMPLE-110	(R)-2-Chloro-9-oxazol-4-yl-methyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	4	Method-1		None	None
EXAMPLE-111	(R)-2-Chloro-3-fluoro-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-112	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-(chloro-methyl)-pyridine	1.2	Method-10		None	None

EXAMPLE-113	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Isobutylene oxide	10	Method-17		None	None
EXAMPLE-114	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Bromo-2-(iso-propoxy)-pyridine	1.2	Method-29		None	None
EXAMPLE-115	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-pyridine	1.2	Method-10		None	None
EXAMPLE-116	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-isopropoxy-pyridine	1.2	Method-29		None	None
EXAMPLE-117	(R)-2-Chloro-9-oxazol-5-yl-methyl-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2	Method-1		None	None

EXAMPLE-118	(R)-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.2	Method-10		None	None
EXAMPLE-119	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Iodo-2-methoxy-pyridine	1.5	Method-29		None	None
EXAMPLE-120	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.2	Method-10		None	None
EXAMPLE-121	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(difluoro-methyl)-pyridine	1.3	Method-29		None	None
EXAMPLE-122	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodopyridine	1.1	Method-29		None	None

EXAMPLE-123	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Chloro-methyl)-5-methyl-1,3,4-thiadiazole	1.1	Method-10		None	None
EXAMPLE-124	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(difluoro-methoxy)-pyridine	1.3	Method-29		None	None
EXAMPLE-125	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-4-methyl-1,2,3-thiadiazole	1.2	Method-10		None	None
EXAMPLE-126	(R)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-3-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-127	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(difluoro-methoxy)-pyridine	12	Method-29		None	None

EXAMPLE-128	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-bromo-3-methyl-2-butanone	1.1	Method-19		None	None
EXAMPLE-129	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-methyl-oxazole	1.2	Method-19		None	None
EXAMPLE-130	2-Chloro-9-(3-methyl-2-oxo-butyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-131	(R)-2-Chloro-9-[2-oxo-2-(tetra-hydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2.5	Method-1		None	None
EXAMPLE-132	(R)-2-Chloro-3-fluoro-9-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	4	Method-1		None	None

EXAMPLE-133	(S)-2-Chloro-9-oxetan-3-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-134	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-Bromo-2-(difluoro-methyl)-pyridine	1.3	Method-29		None	None
EXAMPLE-135	(R)-2-Chloro-3-fluoro-9-(2-oxo-2-pyridin-2-yl-ethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-136	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-methyl-tetra-hydrofuran	1.5	Method-10		None	None
EXAMPLE-137	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-methyl-tetra-hydrofuran	1.5	Method-10		None	None

EXAMPLE-138	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Bromo-methyl)tetra-hydro-2 h-pyran	1.5	Method-10		None	None
EXAMPLE-139	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Bromo-methyl)tetra-hydro-2 h-pyran	1.5	Method-10		None	None
EXAMPLE-140	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-2-(trifluoro-methyl)-1,3,4-oxadiazole	1.1	Method-10		None	None
EXAMPLE-141	(R)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2	Method-1		None	None
EXAMPLE-142	2-Chloro-9-(5-cyclopropyl-[1,3,4]oxadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2.67	Method-1	Chiral Purifi-cation-5	None	None

EXAMPLE-143	(R)-2-((R)-3-Methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Chloro-methyl-3-methyl-isoxazole	1.2	Method-19		None	None
EXAMPLE-144	(R)-2-Chloro-6-trifluoromethyl-9-(3-trifluoro-methyl-[1,2,4]-oxadiazol-5-yl-methyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2.5	Method-1		None	None
EXAMPLE-145	2-Chloro-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	2	Method-1		None	None
EXAMPLE-146	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-Chloro-methyl-3-methyl-isoxazole	1.1	Method-19		None	None
EXAMPLE-147	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-cyclopropyl-1,2,4-oxadiazole	1.2	Method-19		None	None

EXAMPLE-148	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Chloro-acetone	1.2	Method-19		None	None
EXAMPLE-149	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-methyl-1,2,4-oxadiazole	1.2	Method-19		None	None
EXAMPLE-150	(S)-2-(3,3-Dimethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-aceto-phenone	1.2	Method-10		None	None
EXAMPLE-151	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiophene	1.2	Method-31		None	None
EXAMPLE-152	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiophene	1.2	Method-31		None	None

EXAMPLE-153	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromoacetophenone	1.2	Method-10		None	None
EXAMPLE-154	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-1-(difluoro-methyl)-1h-pyrazole	1.2	Method-19		None	None
EXAMPLE-155	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-3-methyl-isoxazole	1.2	Method-19		None	None
EXAMPLE-156	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-pyridine	1.2	Method-19		None	None
EXAMPLE-157	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-(chloro-methyl)-pyridine	1.4	Method-19		None	None

EXAMPLE-158	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-methyl-oxazole	1.5	Method-19		None	None
EXAMPLE-159	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodopyridine	1.2	Method-29		None	None
EXAMPLE-160	(S)-2-((R)-3-Methyl-5-(R)-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-pyridine	1.2	Method-29		None	None
EXAMPLE-161	(S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3,5-Difluoro-iodo-benzene	1.5	Method-29		None	None
EXAMPLE-162	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiophene	1.3	Method-31		None	None

EXAMPLE-163	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-aceto-phenone	1.2	Method-31		None	None
EXAMPLE-164	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-isoxazole	1.2	Method-10		None	None
EXAMPLE-165	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-thiazole	1.2	Method-10		None	None
EXAMPLE-166	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-1-(difluoro-methyl)-1h-pyrazole	1.2	Method-10		None	None
EXAMPLE-167	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Oxa-8-azabicyclo-[3.2.1]-octane hydro-chloride	1.2	Method-10		None	None

EXAMPLE-168	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-pyridine	1.2	Method-10		None	None
EXAMPLE-169	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-isoxazole	1.2	Method-10		None	None
EXAMPLE-170	(S)-2-Chloro-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	5	Method-39		None	None
EXAMPLE-171	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	1.5	Method-42		None	None
EXAMPLE-172	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one,	(2RS)-Ethyl morpholine		Method-38	Chiral Purifi-cation-21	None	None

EXAMPLE-173	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(2RS)-Ethyl morpholine	3.2	Method-38	Chiral Purification-21	None	None
EXAMPLE-174	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	1.31	Method-39		None	None
EXAMPLE-175	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	1.31	Method-39		None	None
EXAMPLE-176	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3,5-Difluoro-iodo-benzene		Method-29		None	None
EXAMPLE-177	(S)-2-(3-Hydroxymethyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-chloro-methyl-thiophene		Method-31		Method-31	None

EXAMPLE-178	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-5-(chloro-methyl)-thiophene	1.1	Method-10		None	None
EXAMPLE-179	(S)-7-Chloro-2-methyl-1-(2-oxo-2-pyridin-2-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	1.3	Method-39		None	None
EXAMPLE-180	(S)-7-Chloro-2-methyl-1-(2-oxo-2-pyridin-3-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	1.5	Method-39		None	None
EXAMPLE-181	(S)-2-Methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	2-Chloro-4-(chloro-methyl)-pyridine	1.2	Method-10		None	None
EXAMPLE-182	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	6	Method-1		None	None
EXAMPLE-183	(S)-2-Chloro-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None

EXAMPLE-184	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	2-Chloro-4-(chloro-methyl)-pyridine	1.2	Method-10		None	None
EXAMPLE-185	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	1-Bromo-3-methyl-2-butanone	1.2	Method-19		None	None
EXAMPLE-186	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	2-Bromo-1-(tetrahydro-2h-pyran-4-yl)ethanone	1.1	Method-19		None	None
EXAMPLE-187	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	2-Bromo-1-cyclopropyl-ethanone	1	Method-19		None	None
EXAMPLE-188	(S)-7-Chloro-2-methyl-1-(3-methyl-2-oxo-butyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	2	Method-1		None	None

EXAMPLE-189	(S)-7-Chloro-6-fluoro-2-methyl-1-(2-oxo-2-pyridin-3-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-190	(S)-7-Chloro-2-methyl-1-[2-oxo-2-(tetrahydro-pyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	2.76	Method-1	Chiral Purifi-cation-10	None	None
EXAMPLE-191	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Methyl-morpholine	10	Method-1	Chiral Purifi-cation-11	None	None
EXAMPLE-192	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Methyl-morpholine	10	Method-1	Chiral Purifi-cation-11	None	None
EXAMPLE-193	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-methyl-morpholine	1.5	Method-40		None	None
EXAMPLE-194	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(2RS)-2-Fluoro-methyl-morpholine	1.5	Method-40	Chiral Purifi-cation-12	None	None

EXAMPLE-195	(S)-9-Benzyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-methyl morpholine	1.5	Method-40	Chiral Purifi-cation-12	None	None
EXAMPLE-196	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methoxy-N-methyl-acetamide	1.2	Method-11		None	None
EXAMPLE-197	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	4	Method-10		Method-48	Method-55
EXAMPLE-198	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-4-iodopyridine		Method-29		Method-54	None
EXAMPLE-199	(S)-7-Chloro-6-fluoro-2-methyl-1-(2-oxo-2-pyridin-2-yl-ethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	(3R)-Methyl-morpholine	15	Method-1		None	None
EXAMPLE-200	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Isobutylene oxide	1.3	Method-36		None	None

EXAMPLE-201	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-(propan-2-yl)-1,2,4-oxadiazole	1.2	Method-11		None	None
EXAMPLE-202	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-cyclopropyl-1,2,4-oxadiazole	1.2	Method-11		None	None
EXAMPLE-203	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(tert-Butyl)-3-(chloro-methyl)-1,2,4-oxadiazole	1.2	Method-11		None	None
EXAMPLE-204	(S)-2-Chloro-3-fluoro-9-(2-hydroxyethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	10	Method-1		None	None
EXAMPLE-205	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(S)-(-)-Propylene oxide	12	Method-18		None	None

EXAMPLE-206	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(S)-2-methoxy-2-phenylethyl para-toluene-sulphonate	1.2	Method-28		None	None
EXAMPLE-207	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	5-(Chloro-methyl)-3-methyl-1,2,4-oxadiazole	1	Method-10		None	None
EXAMPLE-208	(S)-6-Fluoro-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	5-(Chloro-methyl)-3-methyl-1,2,4-oxadiazole	1	Method-10		None	None
EXAMPLE-209	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Oxiran-2-yl)pyridine	1.3	Method-20		None	None
EXAMPLE-210	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Oxiran-2-yl)pyridine		Method-20	Chiral Purifi-cation-18	None	None

EXAMPLE-211	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.1	Method-23		None	None
EXAMPLE-212	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Oxiran-2-yl)pyridine,	1.2	Method-25		None	None
EXAMPLE-213	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Oxiran-2-yl)pyridine,	1.2	Method-25		None	None
EXAMPLE-214	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-1-(difluoro-methyl)-1H-pyrazole	1	Method-16		None	None
EXAMPLE-215	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-isoxazole	1.2	Method-14		None	None

EXAMPLE-216	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-pyridine	1.2	Method-22		None	None
EXAMPLE-217	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-pyridine.HCl	1.2	Method-22		None	None
EXAMPLE-218	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-(Bromo-methyl)-pyridine	1.2	Method-22		None	None
EXAMPLE-219	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-(2-Chloro-ethyl)-4-fluoro-benzene	1.2	Method-32		None	None
EXAMPLE-220	(S)-2-Chloro-9-(2-pyridin-2-yl-ethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None

EXAMPLE-221	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-2-fluoro-pyridine	1.2	Method-22		None	None
EXAMPLE-222	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N,N-dimethyl-acetamide	1.2	Method-22		None	None
EXAMPLE-223	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-methyl-acetamide	1.2	Method-22		None	None
EXAMPLE-224	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-methyl-6-fluoro-pyridine	1.2	Method-22		None	None
EXAMPLE-225	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-2-(propan-2-yloxy)-pyridine	1.2	Method-22		None	None

EXAMPLE-226	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-isopropyl-1,2,4-oxadiazole	1.2	Method-14		None	None
EXAMPLE-227	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-cyclopropyl-1,2,4-oxadiazole	1.2	Method-14		None	None
EXAMPLE-228	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-tert-Butyl-5-(chloro-methyl)-1,2,4-oxadiazole	1.1	Method-14		None	None
EXAMPLE-229	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-2-(propan-2-yloxy)-pyridine	1.2	Method-22		None	None
EXAMPLE-230	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-2-(propan-2-yloxy)-pyridine	1.2	Method-22		None	None

EXAMPLE-231	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Thiazol-2-yl-methyl 4-methyl-benzene-sulphonate (ref. Reagent-2 table)	1.5	Method-10		None	None
EXAMPLE-232	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Thiazol-2-yl-methyl 4-methyl-benzene-sulphonate (ref. Reagent-2 table)	1.5	Method-11		None	None
EXAMPLE-233	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-1-piperidin-1-ylethanone	1.2	Method-14		None	None
EXAMPLE-234	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(2-Chloro-acetyl)-morpholine	1.2	Method-14		None	None
EXAMPLE-235	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(2-Chloro-acetyl)-morpholine	1.5	Method-14		None	None

EXAMPLE-236	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-N-phenyl-acetamide		Method-22	Chiral Purifi-cation-13	None	None
EXAMPLE-237	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-1-piperidin-1-ylethanone	2	Method-14	Chiral Purifi-cation-14	None	None
EXAMPLE-238	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole		Method-11	Chiral Purifi-cation-15	None	None
EXAMPLE-239	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Chloro-methyl-oxazole		Method-23	Chiral Purifi-cation-16	None	None
EXAMPLE-240	(S)-2-Methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.2	Method-22		None	None
EXAMPLE-241	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method-10		None	None

EXAMPLE-242	2-Chloro-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	4	Method-1		None	None
EXAMPLE-243	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Cyclopentyl 2-bromo-acetate	1.1	Method-10		None	None
EXAMPLE-244	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopentyl-ethanone	1.1	Method-10		None	None
EXAMPLE-245	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(tetrahydro-pyran-4-yl)-ethanone	1.1	Method-10		None	None
EXAMPLE-246	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-isopropyl-1,2,4-oxadiazole	1.2	Method-13		None	None

EXAMPLE-247	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-cyclopropyl-1,2,4-oxadiazole	1.1	Method-13		None	None
EXAMPLE-248	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-isopropyl-1,2,4-oxadiazole	1.1	Method-13		None	None
EXAMPLE-249	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-cyclopropyl-1,2,4-oxadiazole	1.1	Method-15		None	None
EXAMPLE-250	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(tert-Butyl)-5-(chloro-methyl)-1,2,4-oxadiazole	1.1	Method-15		None	None
EXAMPLE-251	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-(trifluoro-methyl)-1,2,4-oxadiazole	1.5	Method-15		None	None

EXAMPLE-252	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.1	Method-10		None	None
EXAMPLE-253	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(tetrahydro-pyran-4-yl)-ethanone	1.2	Method-10		None	None
EXAMPLE-254	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Isopropyl 2-bromo-acetate	1.1	Method-10		None	None
EXAMPLE-255	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Chloro-3,3-dimethyl-butan-2-one	1.1	Method-10		None	None
EXAMPLE-256	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Chloro-propan-2-one	1.2	Method-10		None	None

EXAMPLE-257	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	4-(Chloro-methyl)-2-fluoro-pyridine	1.2	Method-10		None	None
EXAMPLE-258	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclohexyl-ethanone	1.1	Method-10		None	None
EXAMPLE-259	(S)-2-Chloro-9-pyridazin-4-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-260	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	tert-Butyl 2-bromo-acetate	1.2	Method-10		None	None
EXAMPLE-261	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	tert-Butyl 2-(2-chloro-acetyl)-pyrrolidine-1-carboxylate	1.1	Method-10		None	None

EXAMPLE-262	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		None	None
EXAMPLE-263	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-acetamide	1.2	Method-10		None	None
EXAMPLE-264	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-acetamide		Method-10		Method-56	Method-51
EXAMPLE-265	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	tert-Butyl 4-(2-bromo-acetyl)-piperidine-1-carboxylate		Method-10		None	None
EXAMPLE-266	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.2	Method-10		Method-50	None

EXAMPLE-267	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.2	Method-10		None	Method-50
EXAMPLE-268	(S)-2-Chloro-9-[2-(3-methyl-isoxazol-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	(3R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-269	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(tetrahydro-furan-3-yl)ethanone	1.2	Method-10		None	None
EXAMPLE-270	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	2	Method-10		None	None
EXAMPLE-271	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.2	Method-10		None	None

EXAMPLE-272	(S)-2-(8-Oxa-3-azabicyclo-[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.2	Method-10		None	None
EXAMPLE-273	(S)-3-Fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.3	Method-10		None	None
EXAMPLE-274	(S)-3-Fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-bromo-3-methyl-butan-2-one	1.3	Method-10		None	None
EXAMPLE-275	(S)-3-Fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(Chloro-methyl)-5-methyl-1,2,4-oxadiazole	1.2	Method-10		None	None
EXAMPLE-276	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-4-methyl-pentan-2-one	1.2	Method-10		None	None

EXAMPLE-277	(S)-2-('S)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.5	Method-10		None	None
EXAMPLE-278	(S)-3-Fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one	1.2	Method-10		None	None
EXAMPLE-279	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-5-methyl-hexan-2-one	1.1	Method-10		None	None
EXAMPLE-280	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-4-methyl-pentan-2-one	1.1	Method-10		None	None
EXAMPLE-281	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-ethylpentan-2-one	1.2	Method-10		None	None

EXAMPLE-282	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-ethylpentan-2-one	1.2	Method-10		None	None
EXAMPLE-283	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.2	Method-10		None	None
EXAMPLE-284	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-butane		Method-32	Chiral Purifi-cation-12	None	None
EXAMPLE-285	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-butane		Method-32	Chiral Purifi-cation-2	None	None
EXAMPLE-286	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one		Method-10	Chiral Purifi-cation-3	Method -52	None

EXAMPLE-287	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-butan-2-one		Method-10	Chiral Purifi-cation-3	Method-52	None
EXAMPLE-288	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	EX-286 and EX-287 not separated		Method-10	Chiral Purifi-cation-4	Method-52	Method-53
EXAMPLE-289	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	EX-286 and EX-287 not separated		Method-10	Chiral Purifi-cation-4	Method-52	Method-53
EXAMPLE-290	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-5-methyl-hexan-2-one		Method-10	Chiral Purifi-cation-8	None	None
EXAMPLE-291	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	1-Bromo-3-methyl-pentan-2-one		Method-10	Chiral Purifi-cation-9	None	None

EXAMPLE-292	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-3-(trifluoro-methyl)-1,2,4-oxadiazole	1.2	Method-15		None	None
EXAMPLE-293	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-294	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-(5-methyl-isoxazol-3-yl)ethanone (preparation described, see table Reagent-5)	2	Method-17		None	None
EXAMPLE-295	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-2-phenylethyl 4-methyl-benzene-sulphonate		Method-27	Chiral Purifi-cation-19	None	None
EXAMPLE-296	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Chloro-methyl)-isoxazole	1.2	Method-10		None	None

EXAMPLE-297	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Chloro-methyl)-1-(difluoro-methyl)-1H-pyrazole	1.2	Method-10		None	None
EXAMPLE-298	2-Chloro-9-(Isoxazol-3-yl-methyl)-8,8-dimethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-299	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	5-(Bromo-methyl)-3-methyl-isoxazole	1.5	Method-10		None	None
EXAMPLE-300	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Isopropoxy-ethyl-4-methyl-benzene-sulphonate	3	Method-24		None	None
EXAMPLE-301	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-pyridine	3	Method-29		None	None
EXAMPLE-302	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-Bromo-6-(cyclo-propyl)-pyridine	1	Method-29		None	None

EXAMPLE-303	(S)-8-Chloro-1-(2-(2-chloropyridin-4-yl)-2-oxoethyl)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	(R)-3-Methyl-morpholine	2.5	130°C microwaves for 2 hours	Chiral Purification-22	None	None
EXAMPLE-304	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -59	None
EXAMPLE-305	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -59	None
EXAMPLE-306	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -60	None
EXAMPLE-307	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -60	None

EXAMPLE-308	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -61	None
EXAMPLE-309	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-cyclopropyl-ethanone	1.1	Method 10		Method -61	None
EXAMPLE-310	(S)-8-((R)-3-Methyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]-pyrimidin-6(2H)-one	2-Bromo-1-(4-methyltetra-hydro-2H-pyran-4-yl)ethanone prepared according to methods described in "advanced synthesis inter-mediate"	1.1	Method 10	Chiral Purifi-cation - 22	None	None
EXAMPLE-311	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-bromo-1-(5-methyl-isoxazol-3-yl)ethanone	1.1	Method-17		None	None
EXAMPLE-312	(S)-8-((3R,5R)-3,5-Dimethyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-]pyrimidin-6(2H)-one	2-Chloro-5-chloro-methyl-thiazole	1.8	Method-10		None	None

EXAMPLE-313	(S)-8-((3R,5R)-3,5-Dimethyl-morpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-]pyrimidin-6(2H)-one	3-Chloro-methyl)-isoxazole	1.6	Method-10		None	None
EXAMPLE-314	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-315	(S)-2-Chloro-9-(2-hydroxyethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(R)-Methyl-morpholine	3	Method-1		None	None
EXAMPLE-316	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-317	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-318	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58

EXAMPLE-319	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-320	(S)-2-(2-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	1-Bromo-3-methyl-butan-2-one	1.5	Method-10		None	None
EXAMPLE-321	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Bromo-1-cyclopropyl-ethanone	1.5	Method-10		None	None
EXAMPLE-322	(S)-2-(2-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	2-Bromo-1-cyclopropyl-ethanone	1.5	Method-10		None	None

EXAMPLE-323	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-3-methylbutyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purification - 27	None	None
EXAMPLE-324	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-3-methylbutyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purification - 27	None	None
EXAMPLE-325	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Cyclopropyl-2-fluoroethyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purification - 28	None	None
EXAMPLE-326	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Cyclopropyl-2-fluoroethyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purification - 28	None	None
EXAMPLE-327	(S)-2-Chloro-8-methyl-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	3-(R)-Methyl-morpholine	5	Method-1		None	None

EXAMPLE-328	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-3-methylbutyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purifi-cation - 29	None	None
EXAMPLE-329	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Fluoro-3-methylbutyl 4-methyl-benzene-sulphonate	1.2	Method-27	Chiral Purifi-cation - 29	None	None
EXAMPLE-330	(S)-2-((R)-3-Methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58
EXAMPLE-331	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Cyclopropyl-2-fluoroethyl 4-methyl-benzene sulphonate	1.3	Method-27	Chiral Purifi-cation - 30	None	None
EXAMPLE-332	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	2-Cyclopropyl-2-fluoroethyl 4-methyl-benzene-sulphonate	1.3	Method-27	Chiral Purifi-cation - 30	None	None

EXAMPLE-333	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]-pyrimidin-4-one	Methyl 2-bromo-acetate	1.1	Method-10		Method-48	Method-58

Experimental section: Table 6: Methods used (Method-1 to Method-45 mentioned in Tables 4 and 5)

In a suitable reactor, the chosen intermediate of type F is reacted with the selected reagent (see Tables 1 to 5) in the presence or absence of solvent or of cosolvent. The mixture is treated under the conditions specified below.	
Method reference	Conditions:
Method-1	No Solvent /100°C
Method-2	No Solvent /120°C
Method-3	No Solvent /130°C
Method-4	No Solvent /150°C/microwaves
Method-5	No Solvent /170°C/microwaves
Method-6	No Solvent /210°C
Method-7	No Solvent /240°C
Method-8	CH3CN/140°C
Method-9	CH3CN/200°C/microwaves
Method-10	CH3CN/Cs2CO3/20°C
Method-11	CH3CN/Cs2CO3/80°C
Method-12	CH3CN/Cs2CO3/50°C
Method-13	CH3CN/Cs2CO3/75°C
Method-14	CH3CN/Cs2CO3/100°C
Method-15	CH3CN/Cs2CO3/100°C/ microwaves
Method-16	CH3CN/Cs2CO3/150°C/ microwaves
Method-17	CH3CN/K3PO4/100°C / microwaves
Method-18	CH3CN/K3PO4/120°C (autoclave)
Method-19	CH3CN/DMF/Cs2C03/20°C
Method-20	CH3CN/DMF/Cs2C03/150°C/microwaves
Method-21	DIEA/180°C
Method-22	DMF/Cs2CO3/20°C
Method-23	DMF/Cs2CO3/80-90°C
Method-24	DMF/Cs2CO3/120°C
Method-25	DMF/Cs2CO3/120°C/microwaves
Method-26	DMF/Cs2CO3/150°C
Method-27	DMF/Cs2CO3/140°C/microwaves

Method-28	DMF/Cs2CO3/150°C/microwaves
Method-29	DMF/K3PO4/CuI/ 150-160°C
Method-30	DMF/K3PO4/160°C
Method-31	DMF/NaH/0°C then 20°C
Method-32	DMF/NaH/0°C then 50°C
Method-33	DMF/Na2CO3/160°C/microwaves
Method-34	DMSO/TEA/20°C
Method-35	DMSO/K3PO4/60°C
Method-36	Me2C0/water/NaOH
Method-37	NMP/180°C
Method-38	NMP/TEA/170°C
Method-39	NMP/DIEA/170-220°C
Method-40	TEA/DMSO/80°C
Method-41	TEA/160°C
Method-42	TEA/185°C
Method-43	THF/Cs2CO3/20°C
Method-44	THF/DEAD/PPh3/20°C
Method-45	THF/DEAD/sup. PPh3/20°C

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
Method-46	**EX-16**: In a 25 ml three-necked reactor, under static argon pressure, equipped with an internal thermometer, the intermediate obtained in the previous step (amount and number of equivalents indicated in the table of the examples) is introduced into THF (5 ml). The solution is cooled to -20°C in a dry ice/isopropanol bath. Ethylmagnesium bromide (amount and number of equivalents indicated in the table of the Examples) is added. After 10 minutes of stirring at -20°C, the cooling bath is withdrawn and the reaction mixture is stirred at ambient temperature for 3 hours. 5 ml of a saturated NH_4Cl solution and 10 ml of EtOAc are added. After separation by settling out, the organic phase is dried over $MgSO_4$, filtered, and then concentrated under reduced pressure. The expected compound is isolated.

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
	EX-25, 59 & 60: In a dry 10 ml round-bottomed flask, under static argon pressure, the halogenated derivative (amount and number of equivalents indicated in the table of the Examples) is introduced into 2 ml of dry THF and the mixture is cooled to -78°C, then isopropylmagnesium bromide (amount and number of equivalents indicated in the table of the examples) at 2.9 M/THF is added dropwise. The mixture is left to stir at this temperature for 30 min and then the intermediate (see Table 5) is added, portionwise, and the mixture is left to warm up to AT over a period of 18 h. The reaction mixture is cold-hydrolysed by adding saturated NH_4Cl solution, extracted with EtOAc, dried over $MgSO_4$, filtered and evaporated. The compound obtained is purified on a 12 g Varian silica column, elution being carried out with 8 CH_2Cl_2/2 solution B (38 CH_2Cl_2/17 MeOH/2 20% NH_4OH), at a flow rate of 40 ml/min with manual collection. The fractions containing the product are concentrated under reduced pressure. The expected compounds are isolated (see table of the Examples).
Method-47	THF (2 ml) and the isopropyl magnesium chloride-lithium chloride complex (number of equivalents, see table of the Examples) are introduced into a 10 ml round-bottomed flask, under static argon pressure, and then the mixture is cooled to -15°C and the halogenated derivative (number of equivalents, see table of the Examples) is added dropwise. The reaction mixture is stirred for 30 minutes at -10°C. The intermediate obtained in the previous step (number of equivalents, see table of the examples) is then added portionwise and the mixture is left to warm up to AT over a period of 18 h. The reaction mixture is cold-hydrolysed by adding saturated NH_4Cl solution, extracted with EtOAc, dried over $MgSO_4$, filtered and evaporated. Where appropriate, the compound is purified on chiral phase (Example-70, Chiral Purif ref., see Examples table) or else on a 12 g silica column, elution being carried out with 8 CH_2Cl_2/2 solution B

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
	(38 CH_2Cl_2/17 MeOH/2 20% NH_4OH), at a flow rate of 40 ml/min with manual collection. The fractions containing the product are concentrated under reduced pressure. The expected compounds are isolated (see table of the Examples) (Example-61, 63, 67, 68).
Method-48	The alkyl carboxylate derivative is placed in solution in methanol and then treated with a sodium hydroxide solution until the ester has disappeared. Subsequent acid-base treatment makes it possible to isolate the acid intermediate which is used in the subsequent step.
Method-49	The intermediate obtained via the previous reaction (1 eq) is placed in solution in dioxane and a solution of hydrochloric acid in dioxane (4M, 10 eq) is added to the reaction mixture. The reaction mixture is stirred at 20°C until the protective group has been eliminated. The reaction mixture is poured into water, separated by settling out, and extracted with ethyl acetate. The organic extracts are combined, washed with a saturated sodium chloride solution, dried over magnesium sulphate, filtered, and evaporated under reduced pressure. The expected compound is isolated.
Method-50	Diethylaminosulphur trifluoro (1 eq) is added to a solution of the intermediate obtained during the previous reaction (200 mg, 1 eq) in dichloromethane at -78°C. After returning to 20°C, the reaction mixture is poured into a solution of $NaHCO_3$, extracted with dichloromethane, dried over magnesium sulphate, and then evaporated to dryness. The compound obtained is chromatographed on a 15 g (15-40 µm) Merck column at a flow rate of 20 ml/min, elution being carried out with isopropyl ether (1 min) and then isopropyl ether/MeOH at 99/01 (2 min), 98/02 (2 min), 95/05 (5 min) and 90/10 (for 10 min). The fractions containing the fluorination compound (Example-266) and also the elimination compound (Example-267) are brought to dryness in a rotary evaporator.
Method-51	The intermediate obtained by the previous reaction (1 eq, 150 mg) is treated with hydrazine hydrate (number of equivalents, see table of the

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
	Examples) in the presence of acetic acid at 90°C for 2 h. After returning to 20°C, the reaction mixture is brought to dryness; a white solid is obtained, water is added, filtration is carried out, and washing is carried out with a 10% sodium bicarbonate solution and twice with water, drying is carried out under vacuum for 1 h, then washing is carried out with diisopropyl ether, rinsing is carried out once and twice with pentane, and drying is carried out under vacuum overnight. The expected compound is isolated.
Method-52	The carbonylated derivative is placed in solution in cold methanol, and then sodium borohydride (3 eq) is added. The progression of the reduction is monitored by TLC. After treatment, the mixture of the two diastereoisomers is obtained, which is separated by chiral-phase chromatography (Example-286 & Example-287) or which is kept as it is and which is used in the next step (see Examples table).
Method-53	The hydroxylated derivative is placed in solution in THF at 20°C, then treated with sodium hydride (4 eq). After 30 min at ambient temperature, iodomethane (4 eq) is added. After treatment, a mixture of the diastereoisomers is obtained, and separated by chiral-phase chromatography (Example-288 & Example-289, see Examples table).
Method-54	In a 25 ml three-necked reactor, the synthesis intermediate previously obtained (number of equivalents, see table of the Examples) is introduced into ethanol and then palladium (number of equivalents, see table of the Examples) is added. The reaction medium is heated to 65°C and then hydrazine hydrate (number of equivalents, see table of the Examples) is added dropwise. The mixture is kept at this temperature for 30 minutes. After returning to 20°C, the compound obtained is purified by silica chromatography, elution being carried out with 96/04 dichloromethane/MeOH. The expected compound is obtained.
Method-55	In a 50 ml three-necked reactor, with stirring, 2-chloro-4,6-dimethoxy-1,3,5-triazine (number of equivalents, see table of the Examples) and the intermediate obtained in the previous step (number of equivalents, see

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
	table of the Examples) and also O-methylhydroxylamine hydrochloride (number of equivalents, see table of the Examples) are introduced into acetonitrile (10 ml) and N-methylmorpholine (number of equivalents, see table of the Examples). The suspension is stirred at ambient temperature for 18 hours. 2 ml of water and 20 ml of EtOAc are added. After separation by settling out, the organic phase is dried over $MgSO_4$, filtered, and then concentrated under reduced pressure.
Method-56	The intermediate obtained in the previous reaction (150 mg, 1 eq) is treated with an excess of N,N-dimethylformamide dimethyl acetal at 110°C for 3 hours. After returning to 20°C, the reaction mixture is poured into 15 ml of water and extracted with 3 × 15 ml of ethyl acetate. The organic extracts are combined, washed with a saturated sodium chloride solution, dried over magnesium sulphate, filtered, and evaporated under reduced pressure. The expected compound is isolated and is used in the next step.
Method-57	The intermediate obtained during the previous reaction (1 eq) is placed in solution in dichloromethane and then stirred for 3 h at 20°C. The reaction mixture is poured into a saturated $NaHCO_3$ solution, separated by settling out and extracted with dichloromethane, and then washed with an $Na_2S_2O_3$ solution. The organic extracts are dried over magnesium sulphate, filtered and evaporated. The expected compound is obtained and is used in the next step.
Method-58	The carboxylated intermediate is placed in solution in DMF in the presence of 2.2 eq of the amino derivative to be coupled (see table reference), of hydroxybenzotriazole (2.4 eq), of EDCI (2.4 eq) and of DIPEA (6 eq). The reaction mixture is stirred at 20°C. After treatment, the caboxyamide derivative is isolated.

Methods used for carrying out the conversions required for obtaining the examples from the intermediates of type I	
Method-59	The intermediate obtained during the previous reaction (1 eq) is placed in solution in ethanol in the presence of hydroxylamine hydrochloride (3 eq) and of triethylamine, and then stirred at 60°C. Chiral purification -23
Method-60	The intermediate obtained during the previous reaction (1 eq) is placed in solution in pyridine in the presence of O-methylhydroxyamine hydrochloride (4 eq) and of triethylamine, and then stirred at 100°C for 4 h. Chiral purification -24
Method-61	The intermediate obtained during the previous reaction (1 eq) is treated with trimethylsulphoxonium iodide (4 eq) suspended in a mixture of tBuOH (15 ml) and tBuOK (4 eq) at 50°C for 48 h. Chiral purification -25

Experimental section: Table 8: Specific preparations of Reagent-1 to Reagent-5 cited in Tables 4 and/or 5

Preparation of specific reagents used in the synthesis pathways described above		
Reagent-1	Oxazol-4-ylmethyl para-toluene sulphonate	Oxazol-4-ylmethanol (325 mg, 3.28 mmol) is introduced into 10 ml of CH_2Cl_2, the colourless solution is cooled to -20°C, and TEA (0.55 ml, 3.90 mmol) and p-toluenesulphonyl chloride (664 mg, 3.41 mmol) are added. The cooling bath is withdrawn, the temperature is allowed to return to AT and the colourless solution is stirred for 1 h 00. The reaction medium is concentrated. The intermediate is used as it is in the next reaction.
Reagent-2	Thiazol-2-ylmethyl para-toluenesulphonate	1 eq of thiazol-2-ylmethanol [358-87-1] is treated with 1.5 eq of tosyl chloride [98-59-9] in the

		presence of 2 eq of TEA [121-44-8] in CH_2Cl_2 at 0°C, and then the mixture is allowed to return to 20°C for 1 h at AT. After treatment, the compound is used as it is in the next step.
Reagent-3	(s)-2-Methoxy-2-phenyl-ethylene para-toluenesulphonate (ref. Reagent-3 table)	(S)-(+)-2-Methoxy-2-phenylethanol (1 g) is treated with para-toluenesulphonic acid chloride (1.5 g) in the presence of TEA in dichloro-methane at 0°C, and then the mixture is stirred for one hour at 20°C. After treatment, the compound obtained is used as it is in the next reaction.
Reagent-4	(2S)-1-(2-Hydroxy-3-methylbutyl)-8-((R)-3-methylmorpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one	The $NaBH_4$-reduction compound of EX-03 is used without prior separation of the diastereoisomers.
Reagent-5	2-Bromo-1-(5-methylisoxazol-3-yl)ethanone	The 2-bromo-1-(5-methylisoxazol-3-yl)ethanone is obtained according to the procedure described in J. Med. Chem.,1991, 34, 600-605.
Reagent-6	2-Bromo-1-(4-methyltetrahydro-2H-pyran-4-yl)ethanone	The 2-bromo-1-(4-methyltetrahydro-2H-pyran-4-yl)ethanone is prepared by bromination of 1-(4-methyltetrahydro-2H-pyran-4-yl)-ethanone in methanol (1:1) at 0°C.
Reagent-7	1-(4-Methyltetrahydro-2H-pyran-4-yl)ethanone	The 1-(4-methyltetrahydro-2H-pyran-4-yl)ethanone is prepared by reacting methyl magnesium bromide (3M, ethyl ether, 64 mmol) with the N-methoxy-N,4-dimethyltetrahydro-2H-pyran-4-carboxamide derivative (32 mmol) in THF (100 ml). Addition at 0°C and return to 20°C over a period of 16 hours.
Reagent-8	N-Methoxy-N,4-dimethyltetrahydro-2H-pyran-4-carboxamide	The N-methoxy-N,4-dimethyltetra-hydro-2H-pyran-4-carboxamide is obtained from 4-methyltetrahydro-2H-pyran-4-carboxylic acid (34 mmol) by coupling with N,O-dimethylhydroxyl-amine hydrochloride (35 mmol) in the presence of DMAP (35 mmol), EDCI (35 mmol) and N-methylmorpholine (35 mmol) in 75 ml of

		dichloromethane.
Reagent-9	2-Cyclopropyl-2-fluoroethyl 4-methylbenzene-sulphonate	The 2-cyclopropyl-2-fluoroethyl 4-methylbenzenesulphonate is prepared from a solution of 2-cyclopropyl-2-fluoroethanol (532 mg, 5.11 mmol) (prepared as in Bioorganic and Medicinal Chemistry Letters 2011, Vol. 21, 276-279) and p-toluenesulphonyl chloride (1.25 g, 6.49 mmol) in dichloromethane (15 ml) which is cooled to -10°C in an ice/acetone bath and then treated with triethylamine (907.72 µl, 6.49 mmol). After 5 min, the cold bath is removed and the reaction medium is stirred at 20°C for 17 h. The reaction medium is diluted with dichloromethane and then the organic phase is washed with water (20 ml) and then dried on a Chromoptic IST hydrophobic column. The filtrate is evaporated to dryness. The crude is purified by flash chromatography on a silica gel column (70 g), elution being carried out with 20-80 to 80-20 by volume dichloromethane-pentane. After evaporation of the solvents to dryness, 1.164 g (88%) of a colourless oil are thus obtained.

Experimental section: Table 9: Chiral-phase purification methods used and cited in Tables 4 and 5

Purification reference	Tech-nique	Support	Eluent	Wave-length	Flow rate
Chiral Purification-1 (EX-177)	Prep HPLC	Chiralpak AD 20 µm, 80x350 mm	Heptane 80% Ethanol 15% Methanol 5% then at t=30 min Heptane 70% Ethanol 20% Methanol 10%	l=254 nm	250 ml/min
Chiral Purification-2 (EX-284 & EX-285)	Super-critical fluid chroma-tography (SFC)	Chiralpak AD-H 5 µm, 30x250 mm	CO2 95% MeOH 5% TEA 0.1%	l=230 nm	120 ml/min, 100 bar, 35°C
Chiral Purification-3 (EX-286 & EX-287)	Prep HPLC	Chiralpak IC 20 µm, 76.5x300 mm	Heptane 70% EtOH 30% TEA 0.1%	l=254 nm	270 ml/min
Chiral Purification-4 (EX-288 & EX-289)	Prep HPLC	Reverse phase Kromasil C18, 10 µm, 80x350 mm	Acetonitrile 40% Water 60%	l=254 nm	250 ml/min
Chiral Purification-5 (EX-142)	Prep HPLC	Column: Chiralpak AY 20 µm Size: 23 x 10cm	Heptane 70% EtOH 30%	l=254 nm	400 ml/min
Chiral Purification-6 (EX-69)	Semi prep HPLC	Chiralpak AD-H 5 µm, 30x250 mm	Heptane 85% EtOH 15%	l=235 nm	45 ml/min
Chiral Purification-7 (EX-70)	Semi prep HPLC	Chiralpak AD-H 5 µm, 30x250 mm	Heptane 80% EtOH 20% TEA 0.1%	l=254 nm	40 ml/min

Chiral Purification-8 (EX-290)	Semi prep HPLC	Column: Phenomenex Cellulose-4, 5 µm, 30x250 mm	Heptane 80% EtOH 20% TEA 0.1%	l=280 nm	30 ml/min
Chiral Purification-9 (EX-291)	Semi prep HPLC	Chiralpak AD-H 5 µm, 30x250 mm	Heptane 90% EtOH 10% TEA 0.1%	l=254 nm	40 ml/min
Chiral Purification-10 (EX-190)	Semi prep HPLC	Chiralpak IC 5 µm, 20x250 mm	Heptane 70% Ethanol 1% methanol 15% TEA 0.1%	l=280 nm	20 ml/min
Chiral Purification-11 (EX-191 & EX-192)	Prep HPLC	Chiralpak 50801 20 µm, 60x350 mm	ACN 90% isopropanol 10%	l=254 nm	120 ml/min
Chiral Purification-12 (EX-194 & 196)	Prep HPLC	Chiralpak AD 20 µm, 8x35 cm	Heptane 80% EtOH 10% MeOH 10%	l=254 nm	200 ml/min
Chiral Purification-13 (EX-236)	Prep HPLC	Whelk 01 SS 10 µm; 76.5x350 mm	Heptane 70% EtOH 20% MeOH 10%	l=230 nm	250 ml/min
Chiral Purification-14 (EX-237)	Prep HPLC	Chiralcel OZ 20 µm, 80x350 mm	Heptane 70% EtOH 30% TEA 0.1%	l=254 nm	250 ml/min
Chiral Purification-15 (EX-238)	Semi prep HPLC	Chiralcel OD 10 µm, 30x250 mm	Heptane 85% EtOH 15% TEA 0.1%	l=254 nm	35 ml/min
Chiral Purification-16 (EX-239)	Prep HPLC	Chiralpak AS, 20 µm, 76.5x400 mm	Heptane 75% EtOH 25%	l=235 nm	260 ml/min
Chiral Purification-17 (EX-10)	Semi prep HPLC	Chiralpak AD-H 5 µm, 30x250 mm	Heptane 75% EtOH 25%	l=235 nm	45 ml/min
Chiral Purification-18 (EX-210)	Semi prep HPLC	Column: Cellulose-4 5 µm Size: 30 x 250 mm	Heptane 70% EtOH 30%	l=235 nm	45 ml/min
Chiral	Semi	Column:	Heptane 70%	l=280 nm	40 ml/min

Purification-19 (EX-295)	prep HPLC	Phenomenex Cellulose-4, 5 µm, 30x250 mm	EtOH 30% TEA 0.1%		
Chiral Purification-20 (EX-8)	Semi prep HPLC	Column: Cellulose-4 5 µm Size: 30 x 250 mm	Heptane 85% EtOH 15% TEA 0.1%	l=235 nm	30 ml/min
Chiral Purification - 21 (EX-172, 173)	Semi prep HPLC	Chiralpak AY 20 µm 100 x 230 mm	Heptane 70% Ethanol 30%	l=230 nm	250 ml/min
Chiral Purification - 22 (EX-303)	Semi prep HPLC	Column: Chiralpak AD 20 µm batch CFB003 Size:7.65x35 cm	70% EtOH 30% TEA 0.1%	l=280 nm	250 ml/min
Chiral Purification - 23 (Method-59)	Prep HPLC	Column: Chiralpak AY 20 µm Size: 23 x 10 cm	Heptane 92% EtOH 8%	l=235 nm	300 ml/min
Chiral Purification - 24 (Method-60)	Prep HPLC	Column: Chiralpak AD 20 µm batch CFB003 Size:7.65x35 cm	Heptane 92% EtOH 8%	l=230 nm	280 ml/min
Chiral Purification - 25 (Method-61)	Prep HPLC	A: Column: Chiralpak AY 20 µm Size: 23 x 10 cm Then B: Column: Lux Cellulose-4 5 µm Size: 250 x 30 mm	Heptane 85 EtOH 15 Heptane 70 EtOH 30	l=254 nm cell 2.0 Detection: 280 nm	300 ml/min Flow rate: 45 ml/min
Chiral Purification - 26 (EX-310)	Prep HPLC	Column: Chiralpak AD 20 µm lot CFB003 Size:7.65x35 cm	Heptane 70% EtOH 30%	l=280 nm	250 ml/min
Chiral Purification - 27 (EX-323, 324)	Prep HPLC	Column: Chiralpak AD-H 5 µm Size: 250x4.6 mm	Heptane 80 EtOH 20	l=254 nm	45 ml/min
Chiral Purification - 28 (EX-325, 326)	Prep HPLC	Column: Chiralpak AD 10 µm Size: 3x25 cm	Heptane 90 IprOH 10 TEA 0.1	l=280 nm	45 ml/min

Chiral Purification - 29 (EX-328, 329)	Prep HPLC	Column: Cellulose 4 5 µm di=30 mm x L=250 mm The 225 mg are solubilized in 21 ml of mobile phase. 7 injections in total. 5 l of solvents. Prep cell 4	EtOH 20-TEA 0.1	I=254 nm	45 ml/min
Chiral Purification - 30 (EX-331, 332)	Prep HPLC	Column: Chiralpak IC 20 µm Size: 350x76.5 mm	Heptane 60 EtOH 40	I=240 nm	300 ml/min

Experimental section: Table 10: Physicochemical characteristics of the examples (RT = retention time, expressed in minutes)

Example	Name	MH+	MH-	RT	% PURITY	Chromatographic conditions; other m/z; Observations	DESCRIPTION 1H NMR Spectrum (d in ppm, DMSO-d6) - BRUKER spectrometer - 400 MHz
EXAMPLE 1	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	438		1.03	98	b	0.67 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.44 (m, 1 H); 2.81 (dt, J=3.4 and 12.7 Hz, 1 H); 3.06 to 3.34 (partially masked m, 4 H); 3.59 (m, 1 H); 3.84 (broad q, J=6.8 Hz, 1 H); 4.36 (m, 1 H); 4.70 (m, 1 H); 4.83 (d, J=18.1 Hz, 1 H); 4.87 (s, 1 H); 5.69 (d, J=18.1 Hz, 1 H); 7.72 (m, 1 H); 7.97(d, J=7.8 Hz, 1 H); 8.04 (dt, J=1.5 and 7.8 Hz, 1 H); 8.76 (broad d, J=5.0 Hz, 1 H) -
EXAMPLE 2	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	415		0.92	98	b	0.85 (d, J=6.6 Hz, 3 H); 2.17 (m, 1 H); 2.44 (m, 1 H); 2.55 (s, 3 H); 2.92 (dt, J=3.9 and 12.7 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.43 to 3.55 (m, 2 H); 3.60 (d, J=11.5 Hz, 1 H); 3.81 (dd, J=3.3 and 11.4 Hz, 1 H); 4.09 (m, 1 H); 4.27 (dd, J=5.6 and 14.2 Hz, 1 H); 4.58 (d, J=16.6 Hz, 1 H); 4.79 (m, 1 H); 4.90 (s, 1 H); 5.21 (d, J=16.6 Hz, 1 H)

EXAMPLE 3	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	403	401	1.05	98	b	1.03 (m, 9 H); 2.16 (m, 1 H); 2.37 (m, 1 H); 2.69 (m, 1 H); 2.97 (m, 1 H); 3.15 to 3.36 (partially masked m, 2 H); 3.45 to 3.65 (m, 3 H); 3.82 (m, 1 H); 4.09 (broad q, J=6.6 Hz, 1 H); 4.23 (d, J=18.3 Hz, 1 H); 4.30 (m, 1 H); 4.47 (broad m, 1 H); 4.90 (s, 1 H); 4.99 (d, J=18.3 Hz, 1 H)
EXAMPLE 4	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	421	419	1.11	98	b	1.03 (d, J=6.8 Hz, 3 H); 1.04 (d, J=6.8 Hz, 3 H); 1.15 (d, J=6.6 Hz, 3 H); 2.16 (m, 1 H); 2.39 (m, 1 H); 2.69 (quin, J=6.8 Hz, 1 H); 3.17 to 3.42 (partially masked m, 3 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.72 to 3.84 (m, 2 H); 4.16 (m, 1 H); 4.27 (broad d, J=18.6 Hz, 2 H); 4.47 (m, 1 H); 4.94 (d, J=18.6 Hz, 1 H)
EXAMPLE 5	(S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	446	444	1.03	98	b; [M-H+HCO2H]-: m/z 490 (base peak)	0.85 (d, J=6.8 Hz, 3 H); 2.43 (m, 2 H); 3.10 (m, 1 H); 3.19 (m, 1 H); 3.32 (m, 1 H); 3.41 (dd, J=2.9 and 11.5 Hz, 1 H); 3.48 (d, J=11.5 Hz, 1 H); 3.58 (m, 1 H); 3.68 (m, 1 H); 3.94 (broad q, J=6.8 Hz, 1 H); 4.24 (m, 1 H); 4.68 (d, J=17.1 Hz, 1 H); 4.79 (m, 1 H); 5.05 (d, J=17.1 Hz, 1 H); 7.02 (broad s, 1 H); 7.21 (broad d, J=5.1 Hz, 1 H); 8.14 (d, J=5.1 Hz, 1 H)
EXAMPLE 6	(S)-9-(2-Cyclopropyl-2-oxo-ethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	419	417	1.02	98	b	0.79 to 0.98 (m, 4 H); 1.18 (d, J=6.8 Hz, 3 H); 2.05 to 2.21 (m, 2 H); 2.39 (m, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.41 (m, 1 H); 3.57 (dd, J=2.6 and 11.3 Hz, 1 H); 3.62 (d, J=11.3 Hz, 1 H); 3.74 to 3.85 (m, 2 H); 4.18 (broad q, J=6.1 Hz, 1 H); 4.27 (dd, J=5.5 and 14.5 Hz, 1 H); 4.34 (d, J=18.1 Hz, 1 H); 4.54 (m, 1 H); 4.85 (d, J=18.1 Hz, 1 H)

EXAMPLE 6-10	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(2-oxo-propyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	393	391	0.91	98	b	1.14 (d, J=6.8 Hz, 3 H); 2.09 (s, 3 H); 2.17 (m, 1 H); 2.40 (m, 1 H); 3.17 to 3.32 (partially masked m, 2 H); 3.40 (m, 1 H); 3.56 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.74 (broad d, J=13.0 Hz, 1 H); 3.81 (dd, J=2.9 and 11.2 Hz, 1 H); 4.12 to 4.21 (m, 2 H); 4.28 (dd, J=5.3 and 14.5 Hz, 1 H); 4.51 (m, 1 H); 4.71 (d, J=18.2 Hz, 1 H)
EXAMPLE 7-10	(S)-3-Fluoro-9-((S)-2-hydroxy-propyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	395		0.96	98	b; [M-H+HCO2H]-: m/z 439 (base peak)	1.05 (d, J=6.1 Hz, 3 H); 1.21 (d, J=6.8 Hz, 3 H); 2.19 (m, 1 H); 2.37 (m, 1 H); 2.88 (dd, J=9.7 and 14.2 Hz, 1 H); 3.18 to 3.33 (partially masked m, 2 H); 3.45 (dt, J=2.7 and 11.7 Hz, 1 H); 3.59 (dd, J=2.9 and 11.5 Hz, 1 H); 3.64 (d, J=11.5 Hz, 1 H); 3.76 to 3.87 (m, 2 H); 4.01 (m, 1 H); 4.11 (dd, J=2.4 and 14.2 Hz, 1 H); 4.18 (dd, J=6.2 and 14.5 Hz, 1 H); 4.25 (broad q, J=6.8 Hz, 1 H); 4.63 (m, 1 H); 4.86 (d, J=5.6 Hz, 1 H)
EXAMPLE 8-10	(S)-2-((3R,5R)-3,5-Dimethyl-morpholin-4-yl)-9-isoxazol-5-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	414	412	1.01	98	b; [M-H+HCO2H]-: m/z 458	1.04 (d, J=6.6 Hz, 6 H); 2.27 (m, 1 H); 2.41 (m, 1 H); 3.24 (partially masked m, 1 H); 3.54 (dd, J=2.4 and 11.2 Hz, 2 H); 3.82 (m, 2 H); 3.98 (dd, J=3.2 and 11.2 Hz, 2 H); 4.27 (dd, J=5.3 and 14.3 Hz, 1 H); 4.70 (d, J=17.1 Hz, 1 H); 4.78 (m, 1 H); 4.83 (s, 1 H); 5.31 (d, J=17.1 Hz, 1 H); 6.36 (d, J=1.7 Hz, 1 H); 8.48 (d, J=1.7 Hz, 1 H)
EXAMPLE 9-10	(S)-9-[2-(2-Chloro-pyridin-4-yl)-2-oxoethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	472	470	1.04	98	b	1H NMR Spectrum (500 MHz, d in ppm, DMSO-d6): 0.72 (d, J=6.7 Hz, 3 H); 2.20 (m, 1 H); 2.44 (m, 1 H); 2.86 (dt, J=3.9 and 12.7 Hz, 1 H); 3.17 to 3.43 (partially masked m, 5 H); 3.67 (dd, J=3.4 and 11.2 Hz, 1 H); 3.96 (broad q, J=6.7 Hz, 1 H); 4.36 (dd, J=5.4 and 14.2 Hz, 1 H); 4.62 (m, 1 H); 4.78 (d, J=18.3 Hz, 1 H); 4.91 (s, 1 H); 5.61 (d, J=18.3 Hz, 1 H); 7.91 (dd, J=1.3 and 5.1 Hz, 1 H); 8.04 (d, J=1.3 Hz, 1 H); 8.68 (d, J=5.1 Hz, 1 H)

EXAMPLE 41	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	438	436	0.85	96	b	0.65 (d, J=6.4 Hz, 3 H); 2.23 (m, 1 H); 2.44 (m, 1 H); 2.85 (m, 1 H); 3.11 to 3.41 (partially masked m, 4 H); 3.63 (m, 1 H); 3.96 (broad q, J=6.4 Hz, 1 H); 4.37 (m, 1 H); 4.63 (m, 1 H); 4.73 (d, J=17.9 Hz, 1 H); 4.90 (s, 1 H); 5.68 (d, J=17.9 Hz, 1 H); 7.60 (dd, J=5.1 and 7.8 Hz, 1 H); 8.38 (d, J=7.8 Hz, 1 H); 8.84 (d, J=5.1 Hz, 1 H); 9.21 (s, 1 H) - NH not localized - presence of one mol MeOH
EXAMPLE 11	(S)-9-(3-Methylisoxazol-4-yl-methyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	414		0.96	98	b; [M-H+HCO2H]-: m/z 458 (base peak)	0.96 (d, J=6.6 Hz, 3 H); 2.20 (broad s, 4 H); 2.35 (m, 1 H); 2.98 (dt, J=3.9 and 12.7 Hz, 1 H); 3.17 to 3.38 (partially masked m, 2 H); 3.50 (dd, J=2.7 and 11.3 Hz, 1 H); 3.61 (m, 2 H); 3.83 (dd, J=3.4 and 11.5 Hz, 1 H); 4.08 to 4.21 (m, 2 H); 4.29 (d, J=16.1 Hz, 1 H); 4.60 (m, 1 H); 4.93 (s, 1 H); 5.10 (d, J=16.1 Hz, 1 H); 8.67 (s, 1 H)
EXAMPLE 21	(R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	400		0.88	98	b	0.99 (d, J=6.6 Hz, 3 H); 2.15 (m, 1 H); 2.42 (m, 1 H); 2.97 (dt, J=3.5 and 12.8 Hz, 1 H); 3.32 (partially masked m, 1 H); 3.47 (m, 1 H); 3.53 to 3.70 (m, 4 H); 3.81 (m, 1 H); 4.21 (m, 1 H); 4.74 to 4.93 (m, 3 H); 5.64 (m, 1 H); 7.15 (s, 1 H); 8.03 (s, 1 H)
EXAMPLE 31	[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-acetic acid ethyl ester	405		1.01	98	b	1.04 (d, J=6.4 Hz, 3 H); 1.17 (t, J=7.1 Hz, 3 H); 2.11 (m, 1 H); 2.39 (m, 1 H); 2.98 (dt, J=3.9 and 12.7 Hz, 1 H); 3.20 (dt, J=3.9 and 14.2 Hz, 1 H); 3.35 (dt, J=3.1 and 11.8 Hz, 1 H); 3.50 (dd, J=2.9 and 11.2 Hz, 1 H); 3.59 (m, 1 H); 3.63 (broad d, J=11.2 Hz, 1 H); 3.85 (m, 1 H); 4.03 to 4.18 (m, 4 H); 4.30 (m, 1 H); 4.48 (d, J=17.1 Hz, 1 H); 4.65 (m, 1 H); 4.93 (s, 1 H)

EXAMPLE 51	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	433		0.98	98	b	1.03 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.45 (partially masked m, 1 H); 2.56 (s, 3 H); 3.13 to 3.38 (partially masked m, 3 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.72 to 3.81 (m, 2 H); 4.14 (broad q, J=6.8 Hz, 1 H); 4.26 (dd, J=5.5 and 14.8 Hz, 1 H); 4.61 (d, J=16.9 Hz, 1 H); 4.78 (m, 1 H); 5.17 (d, J=16.9 Hz, 1 H)
EXAMPLE 61	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	389		0.95	98	b	0.94 (t, J=7.2 Hz, 3 H); 0.99 (d, J=6.6 Hz, 3 H); 2.17 (m, 1 H); 2.32 to 2.48 (m, 3 H); 2.96 (dt, J=3.9 and 12.6 Hz, 1 H); 3.20 (dt, J=3.9 and 14.4 Hz, 1 H); 3.33 (dt, J=3.1 and 11.6 Hz, 1 H); 3.49 (m, 2 H); 3.63 (d, J=11.5 Hz, 1 H); 3.83 (dd, J=3.5 and 11.6 Hz, 1 H); 4.08 to 4.17 (m, 2 H); 4.31 (dd, J=5.4 and 14.4 Hz, 1 H); 4.51 (m, 1 H); 4.77 (d, J=17.9 Hz, 1 H); 4.90 (s, 1 H)
EXAMPLE 71	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	415		0.9	98	b	0.85 (d, J=6.6 Hz, 3 H); 2.22 (m, 1 H); 2.30 (s, 3 H); 2.45 (partially masked m, 1 H); 2.88 (dt, J=3.7 and 12.7 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H);3.40 to 3.49 (m, 2 H); 3.59 (d, J=11.2 Hz, 1 H); 3.80 (dd, J=3.4 and 11.5 Hz, 1 H); 4.01 (qd, J=2.2. and 6.6 Hz, 1 H); 4.30 (dd, J=5.4 and 14.4 Hz, 1 H); 4.81 to 4.90 (m, 2 H); 4.91 (s, 1 H); 5.20 (d, J=17.4 Hz, 1 H)
EXAMPLE 81	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	463	461	0.96	89	b	1.15 (d, J=6.8 Hz, 3 H); 1.35 to 1.57 (m, 2 H); 1.65 to 1.76 (m, 2 H); 2.16 (m, 1 H); 2.40 (m, 1 H); 2.71 (m, 1 H); 3.18 to 3.41 (partially masked m, 5 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.73 to 3.91 (m, 4 H); 4.16 (broad q, J=6.8 Hz, 1 H); 4.27 (broad d, J=18.3 Hz, 2 H); 4.47 (m, 1 H); 4.95 (d, J=18.3 Hz, 1 H)

EXAMPLE 91	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	433	431	0.96	98	b	1.02 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.30 (s, 3 H); 2.47 (partially masked m, 1 H); 3.15 (m, 1 H); 3.25 to 3.38 (m, 2 H); 3.47 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.67 (m, 1 H); 3.76 (m, 1 H); 4.05 (broad q, J=6.8 Hz, 1 H); 4.29 (dd, J=5.0 and 14.3 Hz, 1 H); 4.83 (m, 1 H); 4.89 (d, J=17.4 Hz, 1 H); 5.18 (d, J=17.4 Hz, 1 H)
EXAMPLE 92	(S)-3-Fluoro-9-(2-methoxy-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	395		1.05	98	b	1.23 (d, J=6.6 Hz, 3 H); 2.08 (m, 1 H); 2.37 (m, 1 H); 3.19 to 3.52 (partially masked m, 4 H); 3.26 (s, 3 H); 3.57 to 3.68 (m, 3 H); 3.85 (broad d, J=14 Hz, 2 H); 4.16 (m, 2 H); 4.26 (broad q, J=6.6 Hz, 1 H); 4.59 (m, 1 H)
EXAMPLE 102	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	433		0.98	98	b	For this batch, all the signals are broad and the following are localized: 1.11 (d, J=6.6 Hz, 3 H); 2.16 (m, 1 H); 2.43 (m, 1 H); 2.56 (s, 3 H); 3.20 to 3.42 (partially masked m, 3 H); 3.51 to 3.68 (m, 3 H); 3.78 to 3.89 (m, 2 H); 4.30 (m, 1 H); 4.76 (d, J=16.4 Hz, 1 H); 4.84 (d, J=16.4 Hz, 1 H); 5.57 (m, 1 H)
EXAMPLE 112	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	407	405	1.01	98	b	0.94 (t, J=7.3 Hz, 3 H); 1.12 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.34 to 2.46 (m, 3 H); 3.18 to 3.32 (partially masked m, 2 H); 3.39 (dt, J=2.6 and 11.7 Hz, 1 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.74 (m, 1 H); 3.80 (dd, J=2.8 and 11.1 Hz, 1 H); 4.12 to 4.20 (m, 2 H); 4.28 (dd, J=5.1 and 14.2 Hz, 1 H); 4.50 (m, 1 H); 4.74 (d, J=18.1 Hz, 1 H)
EXAMPLE 122							

EXAMPLE 32	2-[(S)-7-Fluoro-8-((R)-3-methyl-morpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]-pyrimidin-1-yl]-N-methoxy-N-methyl-acetamide	438		0.96	98	b	1.15 (d, J=6.8 Hz, 3 H); 2.14 (m, 1 H); 2.39 (m, 1 H); 3.09 (s, 3 H); 3.19 to 3.34 (partially masked m, 2 H); 3.42 (dt, J=2.7 and 11.7 Hz, 1 H); 3.52 to 3.65 (m, 2 H); 3.71 (s, 3 H); 3.80 (m, 2 H); 4.16 (d, J=17.1 Hz, 1 H); 4.20 (m, 1 H); 4.28 (dd, J=5.8 and 14.4 Hz, 1 H); 4.56 (m, 1 H); 4.91 (d, J=17.1 Hz, 1 H)
EXAMPLE 42	(S)-9-(6-Fluoropyridin-3-yl-methyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	428		1	98	b; [M-H+HCO2H]-: m/z 472 (base peak)	0.76 (d, J=6.6 Hz, 3 H); 2.28 to 2.43 (m, 2 H); 2.90 (dt, J=3.7 and 12.7 Hz, 1 H); 3.19 to 3.32 (partially masked m, 2 H); 3.44 (m, 2 H); 3.55 (d, J=11.5 Hz, 1 H); 3.77 (dd, J=3.5 and 11.6 Hz, 1 H); 4.03 (broad q, J=6.8 Hz, 1 H); 4.21 (dd, J=5.1 and 15.4 Hz, 1 H); 4.58 (d, J=16.1 Hz, 1 H); 4.81 (m, 1 H); 4.90 (s, 1 H); 5.16 (d, J=16.1 Hz, 1 H); 7.12 (dd, J=2.6 and 8.3 Hz, 1 H); 7.86 (dt, J=2.6 and 8.3 Hz, 1 H); 8.14 (broad s, 1 H)
EXAMPLE 52	(S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	456	454	1	98	b	0.71 (d, J=6.4 Hz, 3 H); 2.21 (m, 1 H); 2.44 (partially masked m, 1 H); 2.86 (dt, J=3.1 and 12.8 Hz, 1 H); 3.14 to 3.45 (m, 5 H); 3.66 (m, 1 H); 3.96 (broad q, J=6.4 Hz, 1 H); 4.37 (m, 1 H); 4.62 (m, 1 H); 4.78 (d, J=18.3 Hz, 1 H); 4.91 (s, 1 H); 5.63 (d, J=18.3 Hz, 1 H); 7.76 (broad s, 1 H); 7.86 (broad d, J=5.1 Hz, 1 H); 8.51 (d, J=5.1 Hz, 1 H)
EXAMPLE 62	(R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	389		0.95	98	b	0.94 (t, J=7.3 Hz, 3 H); 1.03 (d, J=6.4 Hz, 3 H); 2.13 (m, 1 H); 2.33 to 2.48 (m, 3 H); 2.97 (m, 1 H); 3.25 to 3.57 (partially masked m, 5 H); 3.63 (d, J=11.0 Hz, 1 H); 3.83 (m, 1 H); 4.16 (m, 1 H); 4.24 (d, J=17.9 Hz, 1 H); 4.38 (d, J=17.9 Hz, 1 H); 4.83 (s, 1 H); 5.64 (m, 1 H)

EXAMPLE 72	(R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	415		0.92	98	b	0.97 (d, J=6.6 Hz, 3 H); 2.13 (m, 1 H); 2.42 (m, 1 H); 2.56 (s, 3 H); 2.97 (dt, J=3.9 and 12.8 Hz, 1 H); 3.33 (dt, J=2.8 and 11.7 Hz, 1 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 to 3.70 (m, 4 H); 3.83 (dd, J=3.7 and 11.2 Hz, 1 H); 4.20 (broad q, J=6.6 Hz, 1 H); 4.81 (s, 2 H); 4.84 (s, 1 H); 5.64 (m, 1 H)
EXAMPLE 82	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	487	485	1.23	98	b	1.03 (d, J=6.3 Hz, 3 H); 2.26 (m, 1 H); 2.47 (partially masked m, 1 H); 3.15 to 3.81 (partially masked m, 8 H); 4.17 (m, 1 H); 5.10 (d, J=17.4 Hz, 1 H); 5.17 (d, J=17.4 Hz, 1 H); 5.60 (m, 1 H)
EXAMPLE 92	(R)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	407	405	1.01	98	b; [M-H+HCO2H]-: m/z 451	0.94 (t, J=7.3 Hz, 3 H); 1.15 (d, J=6.8 Hz, 3 H); 2.16 (m, 1 H); 2.36 to 2.47 (m, 3 H); 3.24 (partially masked m, 1 H); 3.35 to 3.51 (m, 3 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.72 to 3.83 (m, 2 H); 4.23 (broad q, J=6.8 Hz, 1 H); 4.28 (d, J=18.1 Hz, 1 H); 4.34 (d, J=18.1 Hz, 1 H); 5.58 (m, 1 H)
EXAMPLE 03	(S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-yl-methyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]-pyrimidin-5-one	433		2.37		b	1.09 (d, J=6.8 Hz, 3 H); 1.70 (s, 3 H); 2.57 (s, 3 H); 3.23 (partially masked m, 1 H); 3.37 (m, 1 H); 3.49 to 3.63 (m, 2 H); 3.77 (m, 2 H); 4.05 (d, J=12.7 Hz, 1 H); 4.16 (m, 1 H); 4.24 (d, J=12.7 Hz, 1 H); 4.66 (d, J=17.2 Hz, 1 H); 4.72 (d, J=17.2 Hz, 1 H)

EXAMPLE 43	(S)-1-(2-Cyclopropyl-2-oxo-ethyl)-2-methyl-7-((R)-3-methyl-morpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one	401		2.36		b	0.75 to 0.99 (m, 4 H); 1.05 (d, J=6.6 Hz, 3 H); 1.56 (s, 3 H); 2.16 (m, 1 H); 2.99 (m, 1 H); 3.35 (m, 1 H); 3.47 to 3.67 (m, 3 H); 3.84 (m, 1 H); 3.95 (d, J=12.7 Hz, 1 H); 4.18 (broad d, J=12.7 Hz, 2 H); 4.36 (d, J=18.4 Hz, 1 H); 4.52 (d, J=18.4 Hz, 1 H); 4.78 (s, 1 H)
EXAMPLE 13	(2S)-1-[[1-(Difluoromethyl)pyrazol-3-yl]methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449		1.05	98	a	0.88 (d, J=6.8 Hz, 3 H); 2.20 (m, 1 H); 2.40 (mz. 1 H); 2.91 (dt, J=3.9 and 12.7 Hz, 1 H); 3.16 to 3.31 (partially masked m, 2 H); 3.45 (dd, J=2.8 and 11.5 Hz, 1 H); 3.57 (broad d, J=11.5 Hz, 2 H); 3.79 (dd, J=3.2 and 11.5 Hz, 1 H); 4.07 (m, 1 H); 4.24 (dd, J=5.0 and 14.5 Hz, 1 H); 4.50 (d, J=16.1 Hz, 1 H); 4.72 (m, 1 H); 4.89 (s, 1 H); 5.16 (d, J=16.1 Hz, 1 H); 6.39 (d, J=2.4 Hz, 1 H); 7.71 (t, J=59.2 Hz, 1 H); 8.12 (d, J=2.4 Hz, 1 H)
EXAMPLE 23	(2S)-1-(Isoxazol-3-ylmethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400		0.94	94	a	0.87 (d, J=6.8 Hz, 3 H); 2.23 (m, 1 H); 2.40 (m, 1 H); 2.92 (dt, J=3.8 and 13.0 Hz, 1 H); 3.18 to 3.33 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.6 Hz, 1 H); 3.53 (broad d, J=13.0 Hz, 1 H); 3.58 (d, J=11.6 Hz, 1 H); 3.80 (dd, J=3.5 and 11.6 Hz, 1 H); 4.09 (m, 1 H); 4.25 (dd, J=5.4 and 13.9 Hz, 1 H); 4.60 (d, J=16.4 Hz, 1 H); 4.76 (m, 1 H); 4.91 (s, 1 H); 5.20 (d, J=16.4 Hz, 1 H); 6.49 (d, J=1.7 Hz, 1 H); 8.82 (d, J=1.7 Hz, 1 H)
EXAMPLE 33	(2S)-1-[(2-Chlorothiazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	450		1.08	92	a	1.11 (d, J=6.8 Hz, 3 H); 2.03 (m, 1 H); 2.34 (m, 1 H); 3.07 (dt, J=3.9 and 13.0 Hz, 1 H); 3.16 (dt, J=4.3 and 14.1 Hz, 1 H); 3.39 (dt, J=3.2 and 11.6 Hz, 1 H); 3.54 (dd, J=2.9 and 11.6 Hz, 1 H); 3.65 (d, J=11.6 Hz, 1 H); 3.78 (broad d . J=13.0 Hz, 1 H); 3.87 (dd, J=3.2 and 11.6 Hz, 1 H); 4.15 to 4.23 (m, 2 H); 4.69 (m, 1 H); 4.75 (d, J=15.9 Hz, 1 H); 4.97 (s, 1 H); 5.17 (d, J=15.9 Hz, 1 H); 7.71 (s, 1 H)

EXAMPLE 53	(2S)-1-[(6-Chloro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.05	98	a	0.74 (d, J=6.8 Hz, 3 H); 2.30 to 2.42 (m, 2 H); 2.89 (dt, J=4.2 and 12.7 Hz, 1 H); 3.19 to 3.32 (partially masked m, 2 H); 3.43 (dd, J=2.7 and 11.6 Hz, 2 H); 3.54 (d, J=11.6 Hz, 1 H); 3.77 (dd, J=3.4 and 11.2 Hz, 1 H); 3.99 (m, 1 H); 4.22 (m, 1 H); 4.59 (d, J=16.4 Hz, 1 H); 4.81 (m, 1 H); 4.89 (s, 1 H); 5.12 (d, J=16.4 Hz, 1 H); 7.45 (d, J=8.3 Hz, 1 H); 7.73 (dd, J=2.6 and 8.3 Hz, 1 H); 8.33 (d, J=2.6 Hz, 1 H)
EXAMPLE 63	(2S)-1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400	398	0.99	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 444 (base peak)	0.91 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.41 (m, 1 H); 2.92 (dt, J=4.2 and 12.9 Hz, 1 H); 3.17 to 3.34 (partially masked m, 2 H); 3.45 (dd, J=3.1 and 11.4 Hz, 1 H); 3.53 (broad d, J=13.0 Hz, 1 H); 3.59 (d, J=11.4 Hz, 1 H); 3.80 (dd, J=3.5 and 11.4 Hz, 1 H); 4.09 (m, 1 H); 4.25 (dd, J=5.4 and 14.2 Hz, 1 H); 4.73 (d, J=16.9 Hz, 1 H); 4.81 (m, 1 H); 4.92 (s, 1 H); 5.21 (d, J=16.9 Hz, 1 H); 6.36 (d, J=1.7 Hz, 1 H); 8.48 (d, J=1.7 Hz, 1 H)
EXAMPLE 73	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456	454	1.1	98	b	0.76 (d, J=6.7 Hz, 3 H); 2.29 to 2.44 (m, 2 H); 2.89 (dt, J=3.7 and 12.7 Hz, 1 H); 3.20 to 3.32 (partially masked m, 2 H); 3.39 to 3.46 (m, 2 H); 3.51 (d, J=11.5 Hz, 1 H); 3.76 (dd, J=3.3 and 11.5 Hz, 1 H); 4.03 (m, 1 H); 4.26 (dd, J=5.4 and 15.0 Hz, 1 H); 4.74 (d, J=16.9 Hz, 1 H); 4.77 (m, 1 H); 4.92 (s, 1 H); 5.34 (d, J=16.9 Hz, 1 H); 6.31 (broad s, 1 H); 7.65 (d, J=1.5 Hz, 1 H); 7.86 (t, J=58.0 Hz, 1 H)
EXAMPLE 83							0.81 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.46 (partially masked m, 1 H); 3.06 (dt, J=2.9 and 12.8 Hz, 1 H); 3.15 (dt, J=2.8 and 11.8 Hz, 1 H); 3.31 to 3.42 (m, 3 H); 3.50 (broad d, J=11.8 Hz, 1 H); 3.56 (d, J=12.8 Hz, 1 H); 3.92 (broad q, J=6.8 Hz, 1 H); 4.34 (dd, J=5.5 and 13.8 Hz, 1 H); 4.69 (m, 1 H); 4.89 (d, J=18.3 Hz, 1 H); 5.64 (d, J=18.3 Hz, 1 H); 7.73 (ddd, J=1.2 and 4.8 and 7.8 Hz, 1 H); 7.97 (broad d, J=7.8 Hz, 1 H); 8.06 (dt, J=1.7 and 7.8 Hz, 1 H); 8.77 (broad d, J=4.8 Hz, 1 H)

24 ELP MAXE	(2S)-1-[(2S)-2-Fluoro-2-phenyl-ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		1.28	98	b	1.17 (d, J=6.6 Hz, 3 H); 2.18 (m, 1 H); 2.44 (partially masked m, 1 H); 3.06 (dt, J=3.7 and 12.7 Hz, 1 H); 3.21 to 3.31 (partially masked m, 1 H); 3.43 (dt, J=3.2 and 11.8 Hz, 1 H); 3.52 to 3.69 (m, 4 H); 3.86 (dd, J=3.2 and 11.8 Hz, 1 H); 4.16 to 4.28 (m, 2 H); 4.45 (ddd, J=1.8 and 14.7 and 35.7 Hz, 1 H); 4.75 (m, 1 H); 4.97 (s, 1 H); 5.87 (ddd, J=1.8 and 9.5 and 50.1 Hz, 1 H); 7.39 to 7.51 (m, 5 H)
93 ELP MAXE	(2S)-7-Fluoro-1-(2-methoxy-4-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.16	98	b	1.01 (d, J=6.7 Hz, 3 H); 2.40 to 2.47 (m, 2 H); 3.12 (dt, J=3.5 and 12.8 Hz, 1 H); 3.25 to 3.52 (partially masked m, 4 H); 3.55 (broad d, J=12.8 Hz, 1 H); 3.70 (dd, J=2.8 and 11.4 Hz, 1 H); 3.87 (broad s, 4 H); 4.28 (m, 1 H); 5.08 (m, 1 H); 6.90 (d, J=1.7 Hz, 1 H); 7.04 (dd, J=1.7 and 5.6 Hz, 1 H); 8.17 (d, J=5.6 Hz, 1 H)
04 ELP MAXE	(2S)-1-[(2-Chloro-4-pyridyl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462	460	1.15	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 506 (base peak)	0.85 (d, J=6.7 Hz, 3 H); 2.43 (m, 2 H); 3.11 (dt, J=3.4 and 12.5 Hz, 1 H); 3.20 (dt, J=2.3 and 11.6 Hz, 1 H); 3.25 to 3.38 (partially masked m, 1 H); 3.41 (dd, J=2.9 and 11.6 Hz, 1 H); 3.48 (d, J=11.6 Hz, 1 H); 3.58 (m, 1 H); 3.69 (m, 1 H); 3.93 (broad q, J=6.7 Hz, 1 H); 4.24 (m, 1 H); 4.65 (d, J=17.4 Hz, 1 H); 4.80 (m, 1 H); 4.99 (d, J=17.1 Hz, 1 H); 7.25 (dd, J=1.5 and 5.1 Hz, 1 H); 7.39 (broad s, 1 H); 8.31 (d, J=5.1 Hz, 1 H)
14 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	418		0.96	98	a	1.02 (d, J=6.8 Hz, 3 H); 2.21 (m, 1 H); 2.46 (partially masked m, 1 H); 3.16 (dt, J=3.4 and 12.7 Hz, 1 H); 3.23 to 3.37 (partially masked m, 2 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.67 to 3.80 (m, 2 H); 4.11 (broad q, J=6.8 Hz, 1 H); 4.27 (dd, J=5.5 and 14.3 Hz, 1 H); 4.69 (d, J=16.9 Hz, 1 H); 4.80 (m, 1 H); 5.10 (d, J=16.9 Hz, 1 H); 7.14 (d, J=0.5 Hz, 1 H); 8.03 (broad s, 1 H)

64 ELP MAXE	(2S)-1-(6-Cyclopropyl-3-pyridyl)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	454		1.08	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 498 (base peak)	0.81 to 0.99 (m, 4 H); 0.90 (d, J=6.7 Hz, 3 H); 2.13 (m, 1 H); 2.46 (partially masked m, 2 H); 3.06 (dt, J=3.2 and 12.7 Hz, 1 H); 3.22 to 3.32 (partially masked m, 1 H); 3.36 to 3.50 (m, 4 H); 3.65 (dd, J=2.4 and 11.2 Hz, 1 H); 3.72 (broad q, J=6.7 Hz, 1 H); 4.32 (m, 1 H); 4.93 (m, 1 H); 7.35 (d, J=8.3 Hz, 1 H); 7.64 (dd, J=2.4 and 8.3 Hz, 1 H); 8.35 (d, J=2.4 Hz, 1 H)
34 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-4-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	418		0.96	98	b	1.09 (d, J=6.8 Hz, 3 H); 2.14 (m, 1 H); 2.40 (m, 1 H); 3.18 to 3.34 (partially masked m, 2 H); 3.38 (dt, J=2.4 and 11.6 Hz, 1 H); 3.54 (dd, J=3.0 and 11.8 Hz, 1 H); 3.59 (d, J=11.8 Hz, 1 H); 3.80 (dd, J=2.2 and 11.8 Hz, 2 H); 4.13 to 4.25 (m, 2 H); 4.33 (d, J=16.4 Hz, 1 H); 4.69 (m, 1 H); 5.16 (d, J=16.4 Hz, 1 H); 7.98 (s, 1 H); 8.31 (s, 1 H)
44 ELP MAXE	(2S)-1-(2-Chloro-4-pyridyl)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	448		1.1	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 492 (base peak)	1.03 (d, J=6.6 Hz, 3 H); 2.42 to 2.51 (partially masked m, 2 H); 3.16 (dt, J=3.2 and 13.0 Hz, 1 H); 3.33 (dt, J=2.7 and 12.0 Hz, 1 H); 3.42 to 3.59 (m, 4 H); 3.73 (dd, J=2.7 and 11.2 Hz, 1 H); 3.88 (broad q, J=6.6 Hz, 1 H); 4.26 (m, 1 H); 5.20 (m, 1 H); 7.49 (dd, J=1.8 and 5.6 Hz, 1 H); 7.69 (d, J=1.8 Hz, 1 H); 8.45 (d, J=5.6 Hz, 1 H)
54 ELP MAXE	(2S)-7-Fluoro-1-(isoxazol-5-yl-methyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	418	416	0.97	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 462 (base peak)	1.07 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.43 (m, 1 H); 3.18 (dt, J=3.4 and 13.2 Hz, 1 H); 3.25 to 3.39 (partially masked m, 2 H); 3.50 (dd, J=3.2 and 11.7 Hz, 1 H); 3.57 (d, J=11.7 Hz, 1 H); 3.70 to 3.81 (m, 2 H); 4.11 (m, 1 H); 4.23 (dd, J=5.7 and 14.1 Hz, 1 H); 4.78 (d, J=16.9 Hz, 1 H); 4.80 (m, 1 H); 5.15 (d, J=16.9 Hz, 1 H); 6.35 (d, J=1.4 Hz, 1 H); 8.48 (d, J=1.4 Hz, 1 H)

05 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-pyridyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	414		0.87	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 458 (base peak)	0.90 (d, J=6.8 Hz, 3 H); 2.50 (masked, 2 H); 3.06 (dt, J=3.4 and 12.7 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.41 to 3.49 (m, 4 H); 3.65 (dd, J=3.0 and 11.7 Hz, 1 H); 3.73 (broad q, J=6.8 Hz, 1 H); 4.35 (m, 1 H); 5.01 (m, 1 H); 7.49 (dd, J=4.7 and 8.1 Hz, 1 H); 7.83 (ddd, J=1.5 and 2.5 and 8.1 Hz, 1 H); 8.52 (dd, J=1.5 and 4.7 Hz, 1 H); 8.57 (d, J=2.5 Hz, 1 H)
74 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	463		1.23	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 507 (base peak)	1.23 (d, J=6.8 Hz, 3 H); 2.09 (m, 1 H); 2.38 (m, 1 H); 3.19 to 3.33 (partially masked m, 2 H); 3.40 to 3.50 (m, 2 H); 3.57 to 3.66 (m, 2 H); 3.74 to 3.91 (m, 4 H); 4.08 (q, J=9.5 Hz, 2 H); 4.13 to 4.20 (m, 2 H); 4.25 (broad q, J=6.8 Hz, 1 H); 4.56 (m, 1 H)
84 ELP MAXE	(2S)-7-Fluoro-1-(2-hydroxy-2-methylpropyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	409		0.99	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 453 (base peak)	1.03 (s, 3 H); 1.14 (s, 3 H); 1.21 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.41 (m, 1 H); 3.02 (d, J=14.7 Hz, 1 H); 3.25 to 3.36 (partially masked m, 2 H); 3.43 (dt, J=2.6 and 11.7 Hz, 1 H); 3.55 to 3.66 (m, 2 H); 3.77 to 3.89 (m, 2 H); 4.14 (dd, J=6.6 and 14.4 Hz, 1 H); 4.26 (m, 1 H); 4.45 (d, J=14.7 Hz, 1 H); 4.75 (s, 1 H); 4.93 (m, 1 H)
94 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(3-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456	454	0.9	97	b	0.82 (d, J=6.7 Hz, 3 H); 2.24 (m, 1 H); 2.47 (partially masked m, 1 H); 3.05 to 3.23 (m, 2 H); 3.30 to 3.39 (m, 2 H); 3.43 (dd, J=2.7 and 11.4 Hz, 1 H); 3.53 (broad d, J=11.0 Hz, 1 H); 3.60 (broad d, J=12.7 Hz, 1 H); 4.01 (m, 1 H); 4.34 (dd, J=5.3 and 14.4 Hz, 1 H); 4.62 (m, 1 H); 4.78 (d, J=18.1 Hz, 1 H); 5.65 (d, J=18.1 Hz, 1 H); 7.61 (dd, J=4.9 and 8.1 Hz, 1 H); 8.38 (td, J=1.5 and 8.1 Hz, 1 H); 8.85 (dd, J=1.5 and 4.9 Hz, 1 H); 9.21 (d, J=1.5 Hz, 1 H)

EXAMPLE 45	(2S)-7-Fluoro-1-[(6-fluoro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	446		1.05	97	b; ES^-: $[M-H+HCO2H]^-$ m/z 490 (base peak)	0.95 (d, J=6.8 Hz, 3 H); 2.24 to 2.45 (m, 2 H); 3.16 (dt, J=3.2 and 13.0 Hz, 1 H); 3.21 to 3.38 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.52 (d, J=11.5 Hz, 1 H); 3.67 (broad d, J=13.0 Hz, 1 H); 3.72 (dd, J=2.8 and 11.7 Hz, 1 H); 4.04 (broad q, J=6.8 Hz, 1 H); 4.20 (dd, J=5.4 and 14.2 Hz, 1 H); 4.61 (d, J=16.4 Hz, 1 H); 4.78 (m, 1 H); 5.10 (d, J=16.4 Hz, 1 H); 7.12 (dd, J=2.7 and 8.4 Hz, 1 H); 7.84 (dt, J=2.7 and 8.4 Hz, 1 H); 8.13 (broad s, 1 H)
EXAMPLE 15	(2S)-1-[(6-Chloro-3-pyridyl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462		1.1	96	b; ES^-: $[M-H+HCO2H]^-$ m/z 506 (base peak)	0.93 (d, J=6.6 Hz, 3 H); 2.25 to 2.47 (m, 2 H); 3.15 (dt, J=2.9 and 13.0 Hz, 1 H); 3.27 (partially masked m, 1 H); 3.32 (dt, J=5.2 and 14.2 Hz, 1 H); 3.45 (dd, J=2.9 and 11.5 Hz, 1 H); 3.51 (d, J=11.5 Hz, 1 H); 3.65 (d, J=12.2 Hz, 1 H); 3.72 (dd, J=2.9 and 11.5 Hz, 1 H); 4.01 (broad q, J=6.6 Hz, 1 H); 4.21 (dd, J=5.2 and 14.2 Hz, 1 H); 4.63 (d, J=16.6 Hz, 1 H); 4.78 (m, 1 H); 5.07 (d, J=16.6 Hz, 1 H); 7.45 (d, J=8.3 Hz, 1 H); 7.71 (dd, J=2.4 and 8.3 Hz, 1 H); 8.31 (d, J=2.4 Hz, 1 H)
EXAMPLE 25	(2S)-1-[6-(Difluoromethyl)-3-pyridyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	464		1.1	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 508 (base peak)	0.87 (d, J=6.8 Hz, 3 H); 2.50 (partially masked m, 2 H); 3.07 (dt, J=3.2 and 12.7 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.40 to 3.49 (m, 4 H); 3.64 (dd, J=2.9 and 11.5 Hz, 1 H); 3.70 (broad q, J=6.8 Hz, 1 H); 4.36 (m, 1 H); 5.10 (m, 1 H); 7.00 (t, J=54.7 Hz, 1 H); 7.80 (d, J=8.3 Hz, 1 H); 8.05 (broad d, J=8.3 Hz, 1 H); 8.71 (broad s, 1 H)
EXAMPLE 35	(2S)-1-[(5-tert-Butyl-1,2,4-oxadiazol-3-yl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	475		1.25	98	b	0.99 (d, J=6.8 Hz, 3 H); 1.35 (s, 9 H); 2.17 (m, 1 H); 2.46 (m, 1 H); 3.18 (dt, J=3.7 and 13.0 Hz, 1 H); 3.17 to 3.37 (partially masked m, 2 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.72 (broad d, J=13.0 Hz, 1 H); 3.77 (dd, J=2.9 and 11.5 Hz, 1 H); 4.11 (m, 1 H); 4.27 (dd, J=5.3 and 14.4 Hz, 1 H); 4.63 (d, J=17.1 Hz, 1 H); 4.80 (m, 1 H); 5.19 (d, J=17.1 Hz, 1 H)

85 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(4-pyridyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	414		0.63	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 458 (base peak)	0.98 (d, J=6.6 Hz, 3 H); 2.40 to 2.57 (partially masked m, 2 H); 3.11 (dt, J=2.9 and 11.5 Hz, 1 H); 3.22 to 3.31 (partially masked m, 1 H); 3.38 to 3.54 (m, 4 H); 3.69 (dd, J=2.9 and 11.0 Hz, 1 H); 3.83 (broad q, J=6.6 Hz, 1 H); 4.31 (m, 1 H); 5.10 (m, 1 H); 7.48 (broad s, 2 H); 8.75 (broad m, 2 H)
55 ELP MAXE	(2S)-7-Fluoro-1-[(5-fluoro-2-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	446		1.09	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 490 (base peak)	0.87 (d, J=6.6 Hz, 3 H); 2.26 to 2.47 (m, 2 H); 3.11 (dt, J=3.2 and 12.7 Hz, 1 H); 3.21 (dt, J=2.0 and 11.2 Hz, 1 H); 3.34 (dt,J=4.9 and 14.2 Hz, 1 H); 3.43 (dd, J=2.9 and 11.5 Hz, 1 H); 3.51 (d, J=11.5 Hz, 1 H); 3.63 (broad d, J=13.0 Hz, 1 H); 3.71 (broad d, J=11.2 Hz, 1 H); 4.00 (broad q, J=6.6 Hz, 1 H); 4.27 (dd, J=4.9 and 14.2 Hz, 1 H); 4.61 (d, J=16.6 Hz, 1 H); 4.79 (m, 1 H); 5.16 (d, J=16.6 Hz, 1 H); 7.36 (dd, J=4.4 and 8.7 Hz, 1 H); 7.67 (dt, J=2.8 and 8.7 Hz, 1 H); 8.47 (d, J=2.8 Hz, 1 H)
65 ELP MAXE	(2S)-7-Fluoro-1-[(5-fluoro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	446		0.99	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 490 (base peak)	0.90 (d, J=6.8 Hz, 3 H); 2.38 to 2.45 (m, 2 H); 3.14 (dt, J=3.2 and 12.8 Hz, 1 H); 3.19 to 3.39 (partially masked m, 2 H); 3.44 (dd, J=2.9 and 11.5 Hz, 1 H); 3.50 (d, J=11.5 Hz, 1 H); 3.64 (broad d, J=12.7 Hz, 1 H); 3.70 (broad d, J=11.2 Hz, 1 H); 4.01 (broad q, J=6.8 Hz, 1 H); 4.21 (broad d, J=15.2 Hz, 1 H); 4.66 (d, J=16.6 Hz, 1 H); 4.81 (m, 1 H); 5.11 (d, J=16.6 Hz, 1 H); 7.59 (td, J=2.1 and 10.0 Hz, 1 H); 8.37 (broad s, 1 H); 8.44 (d, J=2.7 Hz, 1 H)
75 ELP MAXE	(2S)-7-Fluoro-1-[(2-fluoro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	446		1.06	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 490 (base peak)	0.90 (d, J=6.6 Hz, 3 H); 2.30 to 2.47 (m, 2 H); 3.11 (dt, J=3.5 and 12.8 Hz, 1 H); 3.23 (dt, J=2.4 and 11.2 Hz, 1 H); 3.35 (m, 1 H); 3.42 (dd, J=2.9 and 11.5 Hz, 1 H); 3.49 (d, J=11.5 Hz, 1 H); 3.61 (broad d, J=12.8 Hz, 1 H); 3.69 (dd, J=2.3 and 11.2 Hz, 1 H); 3.94 (m, 1 H); 4.24 (dd, J=5.3 and 14.2 Hz, 1 H); 4.65 (d, J=16.9 Hz, 1 H); 4.79 (m, 1 H); 5.03 (d, J=16.9 Hz, 1 H); 7.30 (ddd, J=2.0 and 5.0 and 7.2 Hz, 1 H); 7.72 (m, 1 H); 8.11 (broad d, J=5.0 Hz, 1 H)

EXAMPLE 95	(2S)-7-Fluoro-1-[2-(3-fluoro-2-pyridyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	474	472	1.08	98	b	0.89 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.46 (partially masked m, 1 H); 3.11 (dt, J=3.4 and 13.0 Hz, 1 H); 3.23 (dt, J=2.9 and 13.0 Hz, 1 H); 3.32 (dt, J=3.7 and 13.7 Hz, 1 H); 3.40 (d, J=11.5 Hz, 1 H); 3.45 (dd, J=2.9 and 11.5 Hz, 1 H); 3.59 (broad d, J=11.6 Hz, 1 H); 3.65 (broad d, J=13.0 Hz, 1 H); 4.00 (broad q, J=6.8 Hz, 1 H); 4.33 (dd, J=5.4 and 14.4 Hz, 1 H); 4.67 (m, 1 H); 4.84 (d, J=18.3 Hz, 1 H); 5.56 (d, J=18.3 Hz, 1 H); 7.83 (td, J=4.4 and 8.4 Hz, 1 H); 7.97 (dd, J=8.4 and 11.0 Hz, 1 H); 8.61 (d, J=4.4 Hz, 1 H)
EXAMPLE 96	(2S)-1-[2-(3-Fluoro-2-pyridyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456	454	1.02	98	b	0.75 (d, J=6.8 Hz, 3 H); 2.21 (m, 1 H); 2.43 (m, 1 H); 2.86 (dt, J=3.7 and 12.7 Hz, 1 H); 3.15 to 3.25 (m, 2 H); 3.35 to 3.45 (m, 3 H); 3.66 (dd, J=3.3 and 11.3 Hz, 1 H); 3.92 (broad q, J=6.8 Hz, 1 H); 4.35 (dd, J=5.4 and 14.4 Hz, 1 H); 4.68 (m, 1 H); 4.78 (d, J=18.1 Hz, 1 H); 4.89 (s, 1 H); 5.60 (d, J=18.1 Hz, 1 H); 7.82 (td, J=4.4 and 8.6 Hz, 1 H); 7.95 (ddd, J=1.0 and 8.6 and 11.2 Hz, 1 H); 8.61 (broad d, J=4.4 Hz, 1 H)
EXAMPLE 97	(2S)-1-[2-(2-Methoxy-4-pyridyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	468	466	1.05	98	b	0.72 (d, J=6.6 Hz, 3 H); 2.20 (m, 1 H); 2.43 (m, 1 H); 2.86 (dt, J=3.7 and 13.0 Hz, 1 H); 3.13 to 3.30 (partially masked m, 2 H); 3.34 to 3.43 (m, 3 H); 3.65 (dd, J=3.2 and 11.3 Hz, 1 H); 3.92 (s, 3 H); 3.96 (m, 1 H); 4.36 (dd, J=5.4 and 14.2 Hz, 1 H); 4.62 (m, 1 H); 4.71 (d, J=18.3 Hz, 1 H); 4.89 (s, 1 H); 5.57 (d, J=18.3 Hz, 1 H); 7.34 (broad s, 1 H); 7.44 (dd, J=1.1 and 5.4 Hz, 1 H); 8.39 (d, J=5.4 Hz, 1 H)
EXAMPLE 98	(2S)-7-Fluoro-1-[(3-methylisoxazol-4-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	432		4.18	98	I	1.09 (d, J=6.8 Hz, 3 H); 2.18 (m, 1 H); 2.19 (s, 3 H); 2.37 (m, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.37 (dt, J=2.7 and 11.7 Hz, 1 H); 3.51 to 3.63 (m, 2 H); 3.74 to 3.83 (m, 2 H); 4.12 to 4.22 (m, 2 H); 4.31 (d, J=16.1 Hz, 1 H); 4.59 (m, 1 H); 5.01 (d, J=16.1 Hz, 1 H); 8.64 (s, 1 H)

EXAMPLE 56	(2S)-1-[2-(6-Fluoro-2-pyridyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456	454	2.55	98	k	0.72 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.44 (m, 1 H); 2.83 (dt, J=3.9 and 12.7 Hz, 1 H); 3.11 to 3.39 (m, 4 H); 3.62 (m, 1 H); 3.86 (broad q, J=6.8 Hz, 1 H); 4.36 (dd, J=5.4 and 14.4 Hz, 1 H); 4.68 (m, 1 H); 4.82 (d, J=18.1 Hz, 1 H); 4.88 (s, 1 H); 5.50 (d, J=18.1 Hz, 1 H); 7.57 (dd, J=2.6 and 8.2 Hz, 1 H); 7.93 (dd, J=2.6 and 7.3 Hz, 1 H); 8.25 (m, 1 H)
EXAMPLE 36	(2S)-1-(Imidazo[1,2-a]pyridin-2-ylmethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449		0.52	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 493 (base peak)	0.83 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.41 (m, 1 H); 2.94 (dt, J=3.6 and 12.7 Hz, 1 H); 3.19 to 3.33 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.54 to 3.64 (m, 2 H); 3.80 (dd, J=3.5 and 11.6 Hz, 1 H); 4.15 (broad q, J=6.8 Hz, 1 H); 4.24 (dd, J=5.4 and 14.4 Hz, 1 H); 4.46 (d, J=15.6 Hz, 1 H); 4.79 (m, 1 H); 4.88 (s, 1 H); 5.47 (d, J=15.9 Hz, 1 H); 6.84 (dt, J=1.2 and 6.8 Hz, 1 H); 7.19 (ddd, J=1.2 and 6.8 and 9.0 Hz, 1 H); 7.48 (d, J=9.0 Hz, 1 H); 7.80 (s, 1 H); 8.46 (d, J=6.8 Hz, 1 H)
EXAMPLE 46	(2S)-1-[(4-Chloro-2-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.08	97	b	0.64 (d, J=6.8 Hz, 3 H); 2.32 to 2.45 (m, 2 H); 2.86 (dt, J=3.9 and 12.7 Hz, 1 H); 3.15 to 3.28 (m, 2 H); 3.38 (broad d, J=12.7 Hz, 1 H); 3.42 (dd, J=2.9 and 11.5 Hz, 1 H); 3.52 (d, J=11.5 Hz, 1 H); 3.76 (dd, J=3.4 and 11.7 Hz, 1 H); 4.02 (m, 1 H); 4.28 (m, 1 H); 4.58 (d, J=16.4 Hz, 1 H); 4.83 (m, 1 H); 4.85 (s, 1 H); 5.20 (d, J=16.4 Hz, 1 H); 7.39 (dd, J=2.0 and 5.4 Hz, 1 H); 7.48 (d, J=2.0 Hz, 1 H); 8.45 (d, J=5.4 Hz, 1 H)
EXAMPLE 66	(2S)-1-[(3-Chloro-4-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444	442	1.03	95	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 488 (base peak)	0.59 (d, J=6.6 Hz, 3 H); 2.43 (partially masked m, 2 H); 2.81 (dt, J=3.9 and 12.7 Hz, 1 H); 3.14 to 3.32 (partially masked m, 3 H); 3.35 (dd, J=2.9 and 11.7 Hz, 1 H); 3.47 (d, J=11.5 Hz, 1 H); 3.72 (dd, J=3.9 and 11.3 Hz, 1 H); 3.86 (dq, J=2.9 and 6.8 Hz, 1 H); 4.30 (dd, J=5.4 and 14.4 Hz, 1 H); 4.66 (d, J=17.1 Hz, 1 H); 4.85 (m, 1 H); 4.89 (s, 1 H); 5.10 (d, J=17.1 Hz, 1 H); 7.21 (d, J=4.9 Hz, 1 H); 8.42 (d, J=4.9 Hz, 1 H); 8.59 (s, 1 H)

EXAMPLE 75	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[2-oxo-3-(2-pyridyl)propyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	452	450	0.71	98	b	0.97 (d, J=6.8 Hz, 3 H); 2.15 (m, 1 H); 2.37 (m, 1 H); 2.90 (dt, J=3.7 and 13.0 Hz, 1 H); 3.20 (dt, J=4.3 and 14.5 Hz, 1 H); 3.29 (dt,J=3.2 and 11.8 Hz, 1 H); 3.43 to 3.52 (m, 2 H); 3.59 (d, J=11.3 Hz, 1 H); 3.80 (dd, J=3.2 and 11.8 Hz, 1 H); 3.92 (d, J=15.7 Hz, 1 H); 3.98 (m, 2 H); 4.28 (dd, J=4.3 and 14.5 Hz, 1 H); 4.33 (d, J=18.1 Hz, 1 H); 4.52 (m, 1 H); 4.89 (s, 1 H); 4.93 (d, J=18.1 Hz, 1 H); 7.24 to 7.30 (m, 2 H); 7.76 (dt, J=1.9 and 7.6 Hz, 1 H); 8.49 (dd,J=1.9 and 5.6 Hz, 1 H)
EXAMPLE 76	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(2-oxo-2-thiazol-2-ylethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462	460	1.06	98	b	0.92 (d, J=6.8 Hz, 3 H); 2.30 (m, 1 H); 2.52 (m, 1 H); 3.13 (dt, J=3.4 and 12.7 Hz, 1 H); 3.22 (dt, J=2.6 and 11.6 Hz, 1 H); 3.31 to 3.48 (m, 3 H); 3.56 to 3.65 (m, 2 H); 3.99 (broad q, J=6.8 Hz, 1 H); 4.39 (dd, J=5.4 and 14.5 Hz, 1 H); 4.77 (m, 1 H); 4.98 (d, J=18.1 Hz, 1 H); 5.51 (d, J=18.1 Hz, 1 H); 8.26 (d, J=3.1 Hz, 1 H); 8.36 (d, J=3.1 Hz, 1 H)
EXAMPLE 86	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(thiazol-4-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	434		1.01	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 478 (base peak)	1.00 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.43 (m, 1 H); 3.18 (dt, J=3.6 and 12.7 Hz, 1 H); 3.25 to 3.38 (partially masked m, 2 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 (d, J=11.5 Hz, 1 H); 3.69 to 3.79 (m, 2 H); 4.13 (broad q, J=6.8 Hz, 1 H); 4.22 (dd, J=6.4 and 14.4 Hz, 1 H); 4.57 (d, J=16.4 Hz, 1 H); 4.77 (m, 1 H); 5.32 (d, J=16.4 Hz, 1 H); 7.48 (d, J=2.0 Hz, 1 H); 9.04 (d, J=2.0 Hz, 1 H)
EXAMPLE 96	(2S)-1-[2-(5-Fluoro-2-pyridyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456	454	1.1	98	b	0.69 (d, J=6.8 Hz, 3 H); 2.23 (m, 1 H); 2.43 (m, 1 H); 2.82 (dt, J=3.6 and 12.7 Hz, 1 H); 3.16 (dt,J=3.4 and 11.8 Hz, 1 H); 3.20 to 3.41 (partially masked m, 4 H); 3.63 (dd, J=3.4 and 11.8 Hz, 1 H); 3.85 (broad q, J=6.8 Hz, 1 H); 4.36 (dd, J=5.4 and 14.4 Hz, 1 H); 4.68 (m, 1 H); 4.82 (d, J=18.1 Hz, 1 H); 4.87 (s, 1 H); 5.64 (d, J=18.1 Hz, 1 H); 7.96 (dt, J=2.9 and 8.8 Hz, 1 H); 8.08 (dd, J=4.6 and 8.8 Hz, 1 H); 8.77 (d, J=2.9 Hz, 1 H)
EXAMPLE 97							

EXAMPLE 16	7-Fluoro-2,2-dimethyl-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	416		1.09	98	b	0.82 (d, J=6.8 Hz, 3 H); 1.32 (s, 3 H); 1.33 (s, 3 H); 1.97 (t, J=6.2 Hz, 2 H); 2.86 (dt, J=3.6 and 12.7 Hz, 1 H); 3.09 (dt, J=3.0 and 12.0 Hz, 1 H); 3.16 (broad d, J=11.4 Hz, 1 H); 3.20 to 3.42 (partially masked m, 3H); 3.78 (m, 1 H); 3.82 (t, J=6.2 Hz, 2 H); 5.08 (broad d, J=18.7 Hz, 1 H); 5.18 (broad d, J=18.7 Hz, 1 H); 7.72 (ddd, J=1.3 and 4.8 and 7.6 Hz, 1 H); 7.98 (broad d, J=7.6 Hz, 1 H); 8.06 (dt, J=1.7 and 7.6 Hz, 1 H); 8.76 (broad d, J=4.8 Hz, 1 H)
EXAMPLE 17	1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-2,2-dimethyl-8-[(3R)-3-methylmorpholin-4-yl]-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	409		0.97	98	b	0.78 (d, J=6.7 Hz, 3 H); 1.32 (s, 6 H); 1.91 to 2.08 (m, 2 H); 2.81 (dt, J=4.0 and 12.9 Hz, 1 H); 3.18 to 3.40 (partially masked m, 3 H); 3.47 (d, J=11.3 Hz, 1 H); 3.68 to 3.97 (m, 4 H); 4.76 (d, J=17.5 Hz, 1 H); 4.81 (s, 1 H); 4.93 (d, J=17.5 Hz, 1 H); 6.27 (broad s, 1 H); 7.59 (broad s, 1 H); 7.85 (t, J=58.1 Hz, 1 H)
EXAMPLE 27	7-Fluoro-1-(isoxazol-3-yl-methyl)-2,2-dimethyl-8-[(3R)-3-methylmorpholin-4-yl]-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	378		0.95	98	b	1.04 (d, J=6.7 Hz, 3 H); 1.31 (s, 6 H); 1.95 (t, J=6.1 Hz, 2 H); 3.10 (dt, J=3.3 and 13.3 Hz, 1 H); 3.30 (masked, 1 H); 3.46 (dd, J=3.1 and 11.5 Hz, 1 H); 3.53 (d, J=11.5 Hz, 1 H); 3.64 (broad d, J=13.3 Hz, 1 H); 3.73 (dd, J=2.6 and 11.5 Hz, 1 H); 3.76 to 3.85 (m, 2 H); 4.06 (m, 1 H); 4.71 (d, J=16.8 Hz, 1 H); 4.77 (d, J=16.8 Hz, 1 H); 6.45 (d, J=1.6 Hz, 1 H); 8.77 (d, J=1.6 Hz, 1 H)
EXAMPLE 37	1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-7-fluoro-2,2-dimethyl-8-[(3R)-3-methylmorpholin-4-yl]-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	427		1.04	98	b	0.93 (d, J=6.6 Hz, 3 H); 1.30 (s, 3 H); 1.31 (s, 3 H); 2.01 (m, 2 H); 3.05 (dt, J=3.5 and 13.0 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.40 (dd, J=3.5 and 11.8 Hz, 1 H); 3.45 (d, J=11.8 Hz, 1 H); 3.51 (broad d, J=13.0 Hz, 1 H); 3.66 (dd, J=2.7 and 11.8 Hz, 1 H); 3.70 to 3.90 (m, 2 H); 3.95 (m, 1 H); 4.77 (d, J=17.5 Hz, 1 H); 4.87 (d, J=17.5 Hz, 1 H); 6.28 (broad s, 1 H); 7.60 (d, J=1.7 Hz, 1 H); 7.84 (t, J=58.1 Hz, 1 H)
EXAMPLE 47							

87- EXAMPLE	(2S)-1-(3-Fluorophenyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	413		1.19	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 457 (base peak)	0.88 (d, J=6.8 Hz, 3 H); 2.41 to 2.47 (m, 2 H); 2.83 (dt, J=3.7 and 12.7 Hz, 1 H); 3.21 (dt, J=2.9 and 11.9 Hz, 1 H); 3.26 to 3.40 (partially masked m, 3 H); 3.49 (d, J=11.5 Hz, 1 H); 3.66 to 3.75 (m, 2 H); 4.36 (m, 1 H); 4.93 (m, 1 H); 4.96 (s, 1 H); 7.14 to 7.23 (m, 2 H); 7.30 (td, J=2.2 and 10.3 Hz, 1 H); 7.47 (m, 1 H)
57- EXAMPLE	(2S)-1-[(2-Chloro-4-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444	442	1.07	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 488 (base peak)	0.64 (d, J=6.8 Hz, 3 H); 2.42 (m, 2 H); 2.85 (dt, J=3.8 and 12.5 Hz, 1 H); 3.18 to 3.38 (partially masked m, 3 H); 3.40 (dd, J=3.0 and 11.5 Hz, 1 H); 3.50 (d, J=11.5 Hz, 1 H); 3.75 (dd, J=3.5 and 11.5 Hz, 1 H); 3.93 (broad q, J=6.8 Hz, 1 H); 4.25 (dd, J=5.1 and 14.8 Hz, 1 H); 4.61 (d, J=17.1 Hz, 1 H); 4.84 (m, 1 H); 4.89 (s, 1 H); 5.04 (d, J=17.1 Hz, 1 H); 7.27 (broad d, J=5.1 Hz, 1 H); 7.40 (broad s, 1 H); 8.30 (d, J=5.1 Hz, 1 H)
67- EXAMPLE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(oxazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400		0.9	98	b	0.85 (d, J=6.7 Hz, 3 H); 2.20 (m, 1 H); 2.44 (m, 1 H); 2.89 (dt, J=3.9 and 12.7 Hz, 1 H); 3.16 to 3.32 (partially masked m, 2 H); 3.44 (dd, J=2.9 and 11.5 Hz, 1 H); 3.49 (broad d, J=13.0 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.79 (dd, J=3.5 and 11.4 Hz, 1 H); 4.08 (m, 1 H); 4.29 (dd, J=5.4 and 14.2 Hz, 1 H); 4.66 (d, J=16.6 Hz, 1 H); 4.81 (m, 1 H); 4.89 (s, 1 H); 5.15 (d, J=16.6 Hz, 1 H); 7.13 (s, 1 H); 8.01 (s, 1 H)
77- EXAMPLE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(thiazol-4-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	416		0.97	98	b	0.83 (d, J=6.8 Hz, 3 H); 2.22 (m, 1 H); 2.40 (m, 1 H); 2.92 (dt, J=3.8 and 13.0 Hz, 1 H); 3.18 to 3.22 (partially masked m, 2 H); 3.46 (dd, J=3.3 and 11.6 Hz, 1 H); 3.52 (broad d, J=13.0 Hz, 1 H); 3.58 (d, J=11.6 Hz, 1 H); 3.80 (dd, J=3.5 and 11.5 Hz, 1 H); 4.12 (m, 1 H); 4.23 (dd, J=5.6 and 14.4 Hz, 1 H); 4.52 (d, J=16.1 Hz, 1 H); 4.79 (m, 1 H); 4.88 (s, 1 H); 5.40 (d, J=16.1 Hz, 1 H); 7.49 (d, J=2.0 Hz, 1 H); 9.04 (d, J=2.0 Hz, 1 H)

28-ELP MAXE	(2S)-1-(2-Chloro-4-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	430		1.06	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 474 (base peak)	0.97 (d, J=6.8 Hz, 3 H); 2.46 (m, 2 H); 2.92 (dt, J=3.9 and 12.8 Hz, 1 H); 3.26 (partially masked m, 1 H); 3.34 to 3.46 (m, 3 H); 3.55 (d, J=11.6 Hz, 1 H); 3.76 (dd, J=3.3 and 11.6 Hz, 1 H); 3.80 (m, 1 H); 4.27 (m, 1 H); 5.05 (s, 1 H); 5.19 (m, 1 H); 7.48 (dd, J=2.0 and 5.6 Hz, 1 H); 7.68 (d, J=2.0 Hz, 1 H); 8.44 (d, J=5.6 Hz, 1 H)
97-ELP MAXE	(2S)-1-(2-Methoxy-4-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	426		1.04	98	b	0.95 (d, J=6.7 Hz, 3 H); 2.44 (m, 2 H); 2.89 (dt, J=3.4 and 13.0 Hz, 1 H); 3.20 to 3.44 (partially masked m, 4 H); 3.53 (d, J=11.6 Hz, 1 H); 3.74 (dd, J=3.3 and 11.6 Hz, 1 H); 3.79 (m, 1 H); 3.87 (s, 3 H); 4.30 (m, 1 H); 5.01 (s, 1 H); 5.06 (m, 1 H); 6.89 (broad s, 1 H); 7.03 (dd, J=1.3 and 5.6 Hz, 1 H); 8.16 (d, J=5.6 Hz, 1 H)
08-ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-2-(trifluoromethyl)-1-[6-(trifluoromethyl)-3-pyridyl]-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	464		1.21	96	b; ES^-: [M-H+HCO2H]$^-$ m/z 508 (base peak)	0.83 (d, J=6.8 Hz, 3 H); 2.43 to 2.58 (partially masked m, 1 H); 2.85 (dt, J=3.4 and 12.3 Hz, 1 H); 3.21 (dt, J=3.0 and 11.6 Hz, 1 H); 3.27 to 3.43 (partially masked m, 4 H); 3.47 (d, J=11.6 Hz, 1 H); 3.64 (broad q, J=6.8 Hz, 1 H); 3.70 (dd, J=3.0 and 11.6 Hz, 1 H); 4.38 (m, 1 H); 5.01 (s, 1 H); 5.12 (m, 1 H); 8.02 (d, J=8.3 Hz, 1 H); 8.16 (dd, J=1.7 and 8.3 Hz, 1 H); 8.81 (d, J=1.7 Hz, 1 H)
18-ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	445		1.18	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 489 (base peak)	1.11 (d, J=6.7 Hz, 3 H); 2.08 (m, 1 H); 2.37 (m, 1 H); 3.03 (dt, J=4.0 and 13.0 Hz, 1 H); 3.18 (dt, J=5.0 and 14.0 Hz, 1 H); 3.34 to 3.49 (m, 2 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.65 (broad d, J=11.5 Hz, 2 H); 3.73 to 3.92 (m, 3 H); 4.08 (broad q, J=9.5 Hz, 2 H); 4.19 (m, 3 H); 4.57 (m, 1 H); 4.93 (s, 1 H)

EXAMPLE 38	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(6-methyl-3-pyridyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	410		0.74	98	b	0.87 (d, J=6.7 Hz, 3 H); 2.40 to 2.52 (m, partially masked, 5 H); 2.82 (dt, J=3.8 and 12.8 Hz, 1 H); 3.20 (dt, J=2.9 and 11.7 Hz, 1 H); 3.31 to 3.40 (m, 3 H); 3.49 (d, J=11.5 Hz, 1 H); 3.64 to 3.74 (m, 2 H); 4.35 (m, 1 H); 4.92 (m, 1 H); 4.96 (s, 1 H); 7.31 (d, J=8.3 Hz, 1 H); 7.68 (dd, J=2.6 and 8.3 Hz, 1 H); 8.41 (d, J=2.6 Hz, 1 H)
EXAMPLE 48	(2S)-1-(2-Hydroxy-2-methyl-propyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	391		0.92	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 435 (base peak)	1.05 (s, 3 H); 1.09 (d, J=6.8 Hz, 3 H); 1.15 (s, 3 H); 2.24 (m, 1 H); 2.39 (m, 1 H); 2.98 to 3.09 (m, 2 H); 3.24 (partially masked m, 1 H); 3.36 (m, 1 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.59 (broad d, J=13.2 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.86 (dd, J=3.2 and 11.2 Hz, 1 H); 4.14 (dd, J=6.2 and 14.5 Hz, 1 H); 4.21 (m, 1 H); 4.51 (d, J=14.7 Hz, 1 H); 4.75 (s, 1 H); 4.88 (s, 1 H); 4.94 (m, 1 H)
EXAMPLE 58	(2S)-1-(6-Isopropoxy-3-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	454		1.24	98	b	0.87 (d, J=6.6 Hz, 3 H); 1.27 (d, J=6.1 Hz, 3 H); 1.29 (d, J=6.2 Hz, 3 H); 2.44 (m, 2 H); 2.84 (dt, J=3.8 and 12.8 Hz, 1 H); 3.22 (dt, J=2.9 and 11.7 Hz, 1 H); 3.30 to 3.42 (m, 3 H); 3.48 (d, J=11.6 Hz, 1 H); 3.70 (m, 2 H); 4.34 (m, 1 H); 4.88 (m, 1 H); 4.95 (s, 1 H); 5.24 (spt, J=6.2 Hz, 1 H); 6.78 (d, J=8.8 Hz, 1 H); 7.66 (dd, J=2.7 and 8.8 Hz, 1 H); 8.11 (d, J=2.7 Hz, 1 H)
EXAMPLE 68	(2S)-1-[(5-Chloro-2-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.12	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 488 (base peak)	0.67 (d, J=6.8 Hz, 3 H); 2.29 to 2.46 (m, 2 H); 2.85 (dt, J=3.8 and 12.7 Hz, 1 H); 3.21 to 3.30 (partially masked m, 2 H); 3.34 to 3.43 (m, 2 H); 3.52 (d, J=11.6 Hz, 1 H); 3.75 (m, 1 H); 3.96 (d, J=4.6 Hz, 1 H); 4.28 (dd, J=4.9 and 14.2 Hz, 1 H); 4.60 (d, J=16.6 Hz, 1 H); 4.80 (m, 1 H); 4.85 (s, 1 H); 5.19 (d, J=16.6 Hz, 1 H); 7.35 (d, J=8.4 Hz, 1 H); 7.86 (dd, J=2.6 and 8.4 Hz, 1 H); 8.52 (d, J=2.6 Hz, 1 H)

EXAMPLE 97	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(thiazol-5-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	416		0.89	98	b	1.08 (d, J=6.8 Hz, 3 H); 1.96 (m, 1 H); 2.36 (m, 1 H); 3.05 (dt, J=3.8 and 12.7 Hz, 1 H); 3.18 (dt, J=4.6 and 14.0 Hz, 1 H); 3.38 (m, 1 H); 3.53 (dd, J=3.0 and 11.7 Hz, 1 H); 3.64 (d, J=11.7 Hz, 1 H); 3.76 (broad d, J=14.0 Hz, 1 H); 3.85 (dd, J=3.2 and 11.5 Hz, 1 H); 4.19 (m, 2 H); 4.68 (m, 1 H); 4.76 (d, J=15.9 Hz, 1 H); 4.96 (s, 1 H); 5.35 (d, J=15.9 Hz, 1 H); 7.92 (s, 1 H); 8.97 (s, 1 H)
EXAMPLE 98	(2S)-1-(6-Cyclobutyl-3-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	450		1.05	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 494 (base peak)	0.83 (d, J=6.7 Hz, 3 H); 1.85 (m, 1 H); 2.00 (m, 1 H); 2.17 to 2.31 (m, 4 H); 2.46 (partially masked m, 2 H); 2.82 (dt, J=3.7 and 12.6 Hz, 1 H); 3.20 (dt, J=2.8 and 12.0 Hz, 1 H); 3.25 to 3.40 (m, 3 H); 3.46 (d, J=11.4 Hz, 1 H); 3.60 to 3.72 (m, 3 H); 4.36 (m, 1 H); 4.95 (broad s, 2 H); 7.30 (d, J=8.3 Hz, 1 H); 7.69 (dd, J=2.6 and 8.3 Hz, 1 H); 8.47 (d, J=2.6 Hz, 1 H)
EXAMPLE 99	(2S)-1-(2-Cyclopropyl-4-pyridyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	436		0.72	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 480 (base peak)	0.81 to 0.97 (m, 4 H); 0.93 (d, J=6.8 Hz, 3 H); 2.08 (m, 1 H); 2.44 (m, 2 H); 2.90 (dt, J=3.9 and 13.0 Hz, 1 H); 3.25 (dt, J=2.7 and 11.7 Hz, 1 H); 3.30 to 3.46 (m, 3 H); 3.52 (d, J=11.6 Hz, 1 H); 3.73 (dd, J=3.2 and 11.7 Hz, 1 H); 3.79 (broad q, J=6.8 Hz, 1 H); 4.31 (m, 1 H); 5.00 (s, 1 H); 5.08 (m, 1 H); 7.16 (dd, J=1.7 and 5.4 Hz, 1 H); 7.34 (d, J=1.7 Hz, 1 H); 8.40 (d, J=5.4 Hz, 1 H)
EXAMPLE 100	(2S)-1-(2-Methoxyethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	377		0.99	95	b	1.12 (d, J=6.7 Hz, 3 H); 2.07 (m, 1 H); 2.35 (m, 1 H); 3.03 (dt, J=3.7 and 12.7 Hz, 1 H); 3.17 (dt, J=4.6 and 14.1 Hz, 1 H); 3.26 (s, 3 H); 3.32 to 3.43 (m, 2 H); 3.47 to 3.56 (m, 2 H); 3.59 to 3.69 (m, 3 H); 3.86 (dd, J=3.5 and 11.4 Hz, 1 H); 4.13 to 4.25 (m, 3 H); 4.59 (m, 1 H); 4.92 (s, 1 H)

19-ELPMAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(oxazol-5-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400		0.87	98	b	1.00 (d, J=6.6 Hz, 3 H); 2.13 (m, 1 H); 2.38 (m, 1 H); 2.98 (dt, J=3.7 and 12.8 Hz, 1 H); 3.21 (m, 1 H); 3.35 (dt, J=2.7 and 11.7 Hz, 1 H); 3.50 (dd, J=2.6 and 11.5 Hz, 1 H); 3.63 (broad d, J=11.5 Hz, 2 H); 3.84 (dd, J=2.9 and 11.7 Hz, 1 H); 4.14 to 4.24 (m, 2 H); 4.58 (d, J=16.4 Hz, 1 H); 4.70 (m, 1 H); 4.92 (s, 1 H); 5.25 (d, J=16.4 Hz, 1 H); 7.08 (s, 1 H); 8.27 (s, 1 H)
29-ELPMAXE	(2S)-1-[(5-Fluoro-2-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		1.03	96	b; ES^-: $[M-H+HCO2H]^-$ m/z 472 (base peak)	0.67 (d, J=6.7 Hz, 3 H); 2.28 to 2.46 (m, 2 H); 2.85 (dt, J=3.8 and 12.7 Hz, 1 H); 3.16 to 3.32 (partially masked m, 2 H); 3.40 (m, 2 H); 3.53 (d, J=11.6 Hz, 1 H); 3.76 (dd, J=3.7 and 11.2 Hz, 1 H); 3.99 (m, 1 H); 4.28 (dd, J=5.4 and 14.2 Hz, 1 H); 4.57 (d, J=16.6 Hz, 1 H); 4.80 (m, 1 H); 4.85 (s, 1 H); 5.22 (d, J=16.6 Hz, 1 H); 7.37 (dd, J=4.5 and 8.7 Hz, 1 H); 7.67 (dt, J=2.9 and 8.7 Hz, 1 H); 8.46 (d, J=2.9 Hz, 1 H)
39-ELPMAXE	(2S)-1-[(2,5-Dimethyloxazol-4-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		1.05	98	b	1.02 (d, J=6.6 Hz, 3 H); 2.04 (m, 1 H); 2.21 (s, 3 H); 2.30 (s, 3 H); 2.37 (m, 1 H); 3.01 (dt, J=3.5 and 13.0 Hz, 1 H); 3.22 (m, 1 H); 3.35 (dt, J=2.8 and 11.8 Hz, 1 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.73 (broad d, J=13.0 Hz, 1 H); 3.85 (dd, J=3.3 and 11.4 Hz, 1 H); 4.06 (d, J=15.6 Hz, 1 H); 4.10 to 4.23 (m, 2 H); 4.60 (m, 1 H); 4.90 (s, 1 H); 5.32 (d, J=15.6 Hz, 1 H)
49-ELPMAXE	(2S)-1-[(5-Fluoro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		0.94	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 472 (base peak)	0.71 (d, J=6.7 Hz, 3 H); 2.34 to 2.47 (m, 2 H); 2.88 (dt, J=3.8 and 12.7 Hz, 1 H); 3.20 to 3.31 (partially masked m, 2 H); 3.38 to 3.45 (m, 2 H); 3.52 (d, J=11.5 Hz, 1 H); 3.76 (dd, J=3.5 and 11.5 Hz, 1 H); 4.02 (m, 1 H); 4.22 (m, 1 H); 4.62 (d, J=16.4 Hz, 1 H); 4.83 (m, 1 H); 4.89 (s, 1 H); 5.16 (d, J=16.4 Hz, 1 H); 7.61 (dt, J=2.0 and 9.8 Hz, 1 H); 8.39 (t, J=2.0 Hz, 1 H); 8.43 (d, J=2.7 Hz, 1 H)

EXAMPLE 89	(2S)-1-[(5-Chloro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.02	93	b; ES^-: $[M-H+HCO_2H]^-$ m/z 488 (base peak)	0.71 (d, J=6.6 Hz, 3 H); 2.34 to 2.45 (m, 2 H); 2.89 (dt, J=4.2 and 13.2 Hz, 1 H); 3.18 to 3.31 (partially masked m, 2 H); 3.38 to 3.46 (m, 2 H); 3.52 (d, J=11.6 Hz, 1 H); 3.76 (dd, J=3.2 and 11.0 Hz, 1 H); 4.01 (m, 1 H); 4.21 (m, 1 H); 4.60 (d, J=16.4 Hz, 1 H); 4.86 (m, 1 H); 4.89 (s, 1 H); 5.11 (d, J=16.4 Hz, 1 H); 7.82 (broad s, 1 H); 8.45 (broad s, 1 H); 8.49 (d, J=2.0 Hz, 1 H)
EXAMPLE 59	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	415		0.8	98	b	0.88 (d, J=6.7 Hz, 3 H); 2.20 (m, 1 H); 2.44 (m, 1 H); 2.46 (s, 3 H); 2.91 (dt, J=3.7 and 12.7 Hz, 1 H); 3.23 (dt, J=3.9 and 14.4 Hz, 1 H); 3.30 (dt, J=3.4 and 11.8 Hz, 1 H); 3.46 (dd, J=3.1 and 11.6 Hz, 1 H); 3.52 (broad d, J=12.7 Hz, 1 H); 3.61 (d, J=11.6 Hz, 1 H); 3.81 (dd, J=3.4 and 11.8 Hz, 1 H); 4.08 (m, 1 H); 4.28 (dd, J=5.6 and 14.4 Hz, 1 H); 4.75 (d, J=16.9 Hz, 1 H); 4.80 (m, 1 H); 4.92 (s, 1 H); 5.24 (d, J=16.9 Hz, 1 H)
EXAMPLE 69	(2S)-1-(3,3-Dimethyl-2-oxo-butyl)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	435	433	1.2	98	b	1.14 (s, 9 H); 1.17 (d, J=6.7 Hz, 3 H); 2.18 (m, 1 H); 2.38 (m, 1 H); 3.23 (dt, J=2.9 and 13.0 Hz, 1 H); 3.28 (masked, 1 H); 3.37 (dt, J=2.9 and 12.0 Hz, 1 H); 3.52 to 3.64 (m, 2 H); 3.76 to 3.83 (m, 2 H); 4.16 (m, 1 H); 4.28 (dd, J=5.8 and 14.4 Hz, 1 H); 4.36 (d, J=18.6 Hz, 1 H); 4.41 (m, 1 H); 5.15 (d, J=18.6 Hz, 1 H)
EXAMPLE 79	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449		1	98	a	1.10 (d, J=6.8 Hz, 3 H); 1.97 (m, 1 H); 2.36 (m, 1 H); 3.06 (dt, J=3.5 and 12.8 Hz, 1 H); 3.18 (dt, J=3.9 and 13.9 Hz, 1 H); 3.38 (dt, J=3.4 and 11.6 Hz, 1 H); 3.53 (dd, J=2.5 and 11.5 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.77 (broad d, J=12.8 Hz, 1 H); 3.87 (dd, J=3.4 and 11.6 Hz, 1 H); 4.14 to 4.26 (m, 2 H); 4.61 (d, J=15.9 Hz, 1 H); 4.65 (m, 1 H); 4.96 (s, 1 H); 5.24 (d, J=15.9 Hz, 1 H); 6.96 (d, J=3.9 Hz, 1 H); 7.01 (d, J=3.9 Hz, 1 H)

EXAMPLE 99	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-phenacyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	437	435	1.12	98	b	0.65 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.43 (m, 1 H); 2.82 (dt, J=3.9 and 12.7 Hz, 1 H); 3.15 (dt, J=3.1 and 11.5 Hz, 1 H); 3.20 to 3.38 (partially masked m, 4 H); 3.60 (dd, J=3.1 and 11.5 Hz, 1 H); 3.93 (broad q, J=6.8 Hz, 1 H); 4.37 (dd, J=5.0 and 14.1 Hz, 1 H); 4.62 (m, 1 H); 4.66 (d, J=17.9 Hz, 1 H); 4.88 (s, 1 H); 5.64 (d, J=17.9 Hz, 1 H); 7.56 (t, J=7.5 Hz, 2 H); 7.69 (t, J=7.5 Hz, 1 H); 8.04 (d, J=7.5 Hz, 2 H)
EXAMPLE 100	(2S)-1-[(2S)-2-Methoxy-2-phenylethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	453		1.37	98	b	1.21 (d, J=6.8 Hz, 3 H); 2.18 (m, 1 H); 2.42 (m, 1 H); 3.05 (dt, J=3.2 and 12.7 Hz, 1 H); 3.13 (s, 3 H); 3.19 to 3.32 (partially masked m, 2 H); 3.45 (dt, J=2.5 and 11.6 Hz, 1 H); 3.55 (dd, J=2.6 and 11.5 Hz, 1 H); 3.65 to 3.73 (m, 2 H); 3.88 (dd, J=2.5 and 11.6 Hz, 1 H); 4.15 to 4.32 (m, 3 H); 4.60 (m, 1 H); 4.76 (m, 1 H); 4.95 (s, 1 H); 7.27 to 7.37 (m, 3 H); 7.42 (t, J=7.5 Hz, 2 H)
EXAMPLE 101	(2S)-1-[(3-Methylisoxazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	414		0.98	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 458 (base peak)	0.92 (d, J=6.7 Hz, 3 H); 2.17 (s, 3 H); 2.22 (m, 1 H); 2.41 (m, 1 H); 2.94 (dt, J=4.0 and 13.0 Hz, 1 H); 3.17 to 3.33 (partially masked m, 2 H); 3.46 (dd, J=3.1 and 11.5 Hz, 1 H); 3.53 (broad d, J=13.0 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.81 (dd, J=3.5 and 11.4 Hz, 1 H); 4.11 (broad q, J=6.7 Hz, 1 H); 4.24 (dd, J=5.6 and 14.2 Hz, 1 H); 4.64 (d, J=16.9 Hz, 1 H); 4.78 (m, 1 H); 4.92 (s, 1 H); 5.15 (d, J=16.9 Hz, 1 H); 6.22 (s, 1 H)
EXAMPLE 102	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-[2-oxo-2-(2-pyridyl)ethyl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	438		1.1	90	b	0.76 (d, J=6.8 Hz, 3 H); 2.18 (m, 1 H); 2.43 (m, 1 H); 2.82 (dt, J=3.9 and 12.7 Hz, 1 H); 3.18 (dt, J=2.7 and 12.0 Hz, 1 H); 3.25 to 3.37 (partially masked m, 2 H); 3.53 to 3.69 (m, 4 H); 3.85 (broad q, J=6.8 Hz, 1 H); 4.80 (s, 1 H); 5.05 (d, J=18.1 Hz, 1 H); 5.23 (d, J=18.1 Hz, 1 H); 5.66 (m, 1 H); 7.71 (broad dd, J=4.9 and 7.7 Hz, 1 H); 7.96 (d, J=7.7 Hz, 1 H); 8.05 (dt, J=1.5 and 7.7 Hz, 1 H); 8.75 (broad d, J=4.9 Hz, 1 H)

EXAMPLE 301	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(oxazol-4-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400		0.9	98	b	0.94 (d, J=6.8 Hz, 3 H); 2.14 (m, 1 H); 2.38 (m, 1 H); 2.96 (dt, J=3.7 and 12.7 Hz, 1 H); 3.22 (dt, J=4.4 and 13.9 Hz, 1 H); 3.33 (dt, J=3.2 and 11.8 Hz, 1 H); 3.50 (dd, J=3.2 and 11.6 Hz, 1 H); 3.53 to 3.64 (m, 2 H); 3.83 (dd, J=3.2 and 11.8 Hz, 1 H); 4.11 to 4.24 (m, 2 H); 4.30 (d, J=15.9 Hz, 1 H); 4.70 (m, 1 H); 4.90 (s, 1 H); 5.23 (d, J=15.9 Hz, 1 H); 7.98 (s, 1 H); 8.31 (s, 1 H)
EXAMPLE 401	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(p-tolylsulfonyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	473		1.16	98	b	0.98 (d, J=6.8 Hz, 3 H); 2.40 (s, 3 H); 2.42 to 2.57 (partially masked m, 2 H); 2.93 (dt, J=3.7 and 12.8 Hz, 1 H); 3.20 (dt, J=2.6 and 11.7 Hz, 1 H); 3.34 (dd, J=2.9 and 11.7 Hz, 1 H); 3.49 to 3.85 (m, 6 H); 5.04 (s, 1 H); 5.68 (m, 1 H); 7.45 (d, J=8.5 Hz, 2 H); 7.78 (d, J=8.5 Hz, 2 H)
EXAMPLE 501	(6R)-9-(Isoxazol-5-ylmethyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	400		0.93	85	b	1.02 (d, J=6.7 Hz, 3 H); 2.21 (m, 1 H); 2.40 (m, 1 H); 3.00 (dt, J=3.8 and 12.8 Hz, 1 H); 3.34 (dt, J=2.9 and 11.6 Hz, 1 H); 3.46 to 3.67 (m, 5 H); 3.83 (dd, J=3.3 and 11.6 Hz, 1 H); 4.22 (m, 1 H); 4.87 (s, 1 H); 4.88 (d, J=16.4 Hz, 1 H); 4.96 (d, J=16.4 Hz, 1 H); 5.64 (m, 1 H); 6.39 (d, J=1.5 Hz, 1 H); 8.50 (d, J=1.5 Hz, 1 H)
EXAMPLE 601	(6R)-9-(Isoxazol-3-ylmethyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	400		0.95	94	b	1.01 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.39 (m, 1 H); 3.00 (dt, J=3.9 and 12.7 Hz, 1 H); 3.34 (dt, J=3.1 and 11.6 Hz, 1 H); 3.47 to 3.67 (m, 5 H); 3.83 (dd, J=3.7 and 11.6 Hz, 1 H); 4.23 (m, 1 H); 4.83 (s, 2 H); 4.86 (s, 1 H); 5.64 (m, 1 H); 6.47 (d, J=1.5 Hz, 1 H); 8.85 (d, J=1.5 Hz, 1 H)

EXAMPLE 701	(6R)-9-(6-Cyclopropyl-3-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	436		0.97	97	b	0.82 to 1.00 (m, 4 H); 0.97 (d, J = 6.7 Hz, 3 H); 2.12 (m, 1 H); 2.33 (m, 1 H); 2.47 (partially masked m, 1 H); 2.87 (dt, J=3.4 and 12.6 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.37 (broad d, J=11.6 Hz, 2 H); 3.51 (d, J=11.6 Hz, 1 H); 3.73 (d, J=11.0 Hz, 4 H); 4.90 (s, 1 H); 5.75 (m, 1 H); 7.33 (d, J=8.3 Hz, 1 H); 7.63 (dd, J=2.2 and 8.3 Hz, 1 H); 8.35 (d, J=2.2 Hz, 1 H)
EXAMPLE 801	(6R)-9-(2-Chloro-4-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	430		1.06	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 474 (base peak)	For this batch, all the signals are broad with: 1.08 (d, J=6.5 Hz, 3 H); 2.36 (m, 1 H); 2.50 (masked, 1 H); 3.00 (m, 1 H); 3.33 (partially masked m, 1 H); 3.41 to 3.53 (m, 2 H); 3.58 (d, J=11.5 Hz, 1 H); 3.68 to 3.85 (m, 2 H); 3.94 (m, 2 H); 5.03 (s, 1 H); 5.75 (m, 1 H); 7.49 (d, J=4.9 Hz, 1 H); 7.65 (s, 1 H); 8.38 (d, J=4.9 Hz, 1 H)
EXAMPLE 901	(6R)-9-(2-Methoxy-4-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	426		1.03	98	b	For this batch, all the signals are broad with: 1.05 (d, J=6.6 Hz, 3 H); 2.35 (m, 1 H); 2.50 (masked, 1 H); 2.95 (m, 1 H); 3.29 (partially masked m, 1 H); 3.42 (d, J=11.5 Hz, 1 H); 3.49 (d, J=13.2 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.67 (m, 1 H); 3.77 (d, J=11.5 Hz, 1 H); 3.83 to 3.95 (m, 2 H); 3.85 (s, 3 H); 4.99 (s, 1 H); 5.75 (m, 1 H); 6.84 (s, 1 H); 7.03 (d, J=5.3 Hz, 1 H); 8.12 (d, J=5.3 Hz, 1 H)
EXAMPLE 1001	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-(oxazol-4-ylmethyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	400		0.89	98	b	1.04 (d, J=6.7 Hz, 3 H); 2.14 (m, 1 H); 2.37 (m, 1 H); 3.02 (dt, J=3.9 and 12.7 Hz, 1 H); 3.36 (dt, J=3.3 and 11.6 Hz, 1 H); 3.47 to 3.70 (m, 5 H); 3.85 (dd, J=3.3 and 11.6 Hz, 1 H); 4.24 (m, 1 H); 4.63 (d, J=15.4 Hz, 1 H); 4.68 (d, J=15.4 Hz, 1 H); 4.84 (s, 1 H); 5.63 (m, 1 H); 7.99 (s, 1 H); 8.32 (s, 1 H)

411-ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-5-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	418	416	0.92	94	b; ES^-: $[M-H+HCO_2H]^-$ m/z 462 (base peak)	1.14 (d, J=6.8 Hz, 3 H); 2.13 (m, 1 H); 2.40 (m, 1 H); 3.20 to 3.34 (partially masked m, 2 H); 3.40 (dt, J=2.8 and 11.7 Hz, 1 H); 3.53 to 3.65 (m, 2 H); 3.78 to 3.87 (m, 2 H); 4.12 to 4.28 (m, 2 H); 4.61 (d, J=16.4 Hz, 1 H); 4.70 (m, 1 H); 5.18 (d, J=16.4 Hz, 1 H); 7.07 (s, 1 H); 8.27 (s, 1 H)
111-ELP MAXE	(6R)-9-[(2-Chloro-4-pyridyl)methyl]-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	444		1.05	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 488 (base peak)	0.82 (d, J=6.6 Hz, 3 H); 2.37 (m, 2 H); 2.94 (dt, J=4.0 and 12.7 Hz, 1 H); 3.30 (partially masked m, 1 H); 3.39 to 3.58 (m, 5 H); 3.78 (dd, J=3.5 and 11.4 Hz, 1 H); 4.08 (m, 1 H); 4.63 (d, J=16.6 Hz, 1 H); 4.85 (s, 1 H); 4.90 (d, J=16.6 Hz, 1 H); 5.67 (m, 1 H); 7.27 (broad d, J=5.2 Hz, 1 H); 7.39 (broad s, 1 H); 8.33 (d, J=5.2 Hz, 1 H)
211-ELP MAXE	(6R)-9-(2-Hydroxy-2-methyl-propyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	391		0.89	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 435 (base peak)	1.09 (s, 3 H); 1.11 (s, 3 H); 1.12 (d, J=6.8 Hz, 3 H; 2.07 (m, 1 H); 2.32 (m, 1 H); 3.02 (dt, J=3.9 and 12.7 Hz, 1 H); 3.32 to 3.42 (m, 2 H); 3.52 (dd, J=2.7 and 11.5 Hz, 1 H); 3.58 to 3.71 (m, 4 H); 3.80 to 3.90 (m, 2 H); 4.20 (m, 1 H); 4.56 (broad s, 1 H); 4.82 (s, 1 H); 5.65 (m, 1 H)
311-ELP MAXE	(6R)-9-(2-Isopropoxy-4-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]-pyrimidin-4-one	454		1.22	98	b	1.05 (d, J=6.7 Hz, 3 H); 1.27 (d, J=6.1 Hz, 6 H); 2.32 (m, 1 H); 2.46 (partially masked m, 1 H); 2.96 (dt, J=3.8 and 12.8 Hz, 1 H); 3.30 (partially masked m, 1 H); 3.43 (dd, J=2.9 and 11.5 Hz, 1 H); 3.49 (broad d, J=12.8 Hz, 1 H); 3.55 (d, J=11.5 Hz, 1 H); 3.68 (dt, J=5.6 and 12.8 Hz, 1 H); 3.77 (dd, J=3.4 and 11.5 Hz, 1 H); 3.84 to 3.97 (m, 2 H); 4.98 (s, 1 H); 5.26 (spt, J=6.1 Hz, 1 H); 5.74 (m, 1 H); 6.76 (d, J=1.8 Hz, 1 H); 6.99 (dd, J=1.8 and 5.7 Hz, 1 H); 8.10 (d, J=5.7 Hz, 1 H)

811-ELP MAXE	(6R)-9-[(6-Chloro-3-pyridyl)methyl]-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	444		1.08	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 488 (base peak)	0.94 (d, J=6.6 Hz, 3 H); 2.24 (m, 1 H); 2.37 (m, 1 H); 2.98 (dt, J=3.9 and 12.7 Hz, 1 H); 3.33 (dt, J=2.9 and 11.7 Hz, 1 H); 3.39 to 3.62 (m, 5 H); 3.81 (dd, J=3.3 and 11.7 Hz, 1 H); 4.17 (m, 1 H); 4.72 (d, J=15.9 Hz, 1 H); 4.82 to 4.90 (m, 2 H); 5.66 (m, 1 H); 7.48 (d, J=8.3 Hz, 1 H); 7.74 (dd, J=2.3 and 8.3 Hz, 1 H); 8.34 (d, J=2.3 Hz, 1 H)
511-ELP MAXE	(6R)-9-(6-Isopropoxy-3-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]-pyrimidin-4-one	454		1.28	98	b	0.97 (d, J=6.8 Hz, 3 H); 1.28 (d, J=6.1 Hz, 6 H); 2.30 to 2.48 (partially masked m, 2 H); 2.88 (dt, J=3.9 and 13.0 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.38 (broad d, J=11.6 Hz, 2 H); 3.50 (d, J=11.6 Hz, 1 H); 3.67 to 3.84 (m, 4 H); 4.89 (s, 1 H); 5.23 (spt, J=6.1 Hz, 1 H); 5.75 (m, 1 H); 6.78 (d, J=8.8 Hz, 1 H); 7.66 (dd, J=2.7 and 8.8 Hz, 1 H); 8.09 (d, J=2.7 Hz, 1 H)
611-ELP MAXE	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-(oxazol-5-ylmethyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	400		0.87	98	b	For this batch, all the signals are broad with: 1.10 (d, J=6.5 Hz, 3 H); 2.16 (m, 1 H); 2.38 (m, 1 H); 3.04 (m, 1 H); 3.33 to 3.60 (m, 4 H); 3.64 to 3.75 (m, 2 H); 3.86 (m, 1 H); 4.28 (m, 1 H); 4.76 (d, J=16.0 Hz, 1 H); 4.87 (s, 1 H); 4.94 (d, J=16.0 Hz, 1 H); 5.63 (m, 1 H); 7.10 (s, 1 H); 8.30 (s, 1 H)
711-ELP MAXE	(6R)-9-(2-Cyclopropyl-2-oxo-ethyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	401		0.96	97	b	0.80 to 0.95 (m, 4 H); 1.07 (d, J=6.8 Hz, 3 H); 2.03 to 2.19 (m, 2 H); 2.37 (m, 1 H); 2.99 (dt, J=3.6 and 12.7 Hz, 1 H); 3.29 to 3.68 (m, 6 H); 3.84 (dd, J=3.2 and 11.5 Hz, 1 H); 4.17 (m, 1 H); 4.42 (d, J=17.9 Hz, 1 H); 4.52 (d, J=17.9 Hz, 1 H); 4.83 (s, 1 H); 5.64 (m, 1 H)

221-ELP MAXE	(6R)-3-Fluoro-9-(2-methoxy-4-pyridyl)-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	444		1.13	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 488	For this batch, all the signals are broad with: 0.98 (d, J=6.6 Hz, 3 H); 2.33 (m, 1 H); 2.50 (masked, 1 H); 3.09 (m, 1 H); 3.28 (partially masked m, 1 H); 3.38 to 3.52 (m, 3 H); 3.58 to 3.71 (m, 3 H); 3.78 (m, 1 H); 3.85 (s, 3 H); 5.67 (m, 1 H); 7.06 (m, 1 H); 7.71 (m, 1 H); 8.16 (m, 1 H)
911-ELP MAXE	(6R)-9-(2-Cyclopropyl-2-oxo-ethyl)-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	419	417	1.02	98	b	0.80 to 0.97 (m, 4 H); 1.18 (d, J=6.8 Hz, 3 H); 2.03 to 2.22 (m, 2 H); 2.39 (m, 1 H); 3.27 (partially masked m, 1 H); 3.35 to 3.51 (m, 3 H); 3.57 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.74 to 3.87 (m, 2 H); 4.26 (m, 1 H); 4.46 (broad s, 2 H); 5.57 (m, 1 H)
021-ELP MAXE	(6R)-9-[6-(Difluoromethyl)-3-pyridyl]-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	464		1.12	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 508 (base peak)	For this batch, all the signals are broad with: 1.03 (d, J=6.6 Hz, 3 H); 2.36 to 2.55 (partially masked m, 2 H); 3.13 (m, 1 H); 3.30 (partially masked m, 1 H); 3.42 to 3.56 (m, 3 H); 3.64 to 3.94 (m, 4 H); 5.72 (m, 1 H); 6.98 (t, J=54.7 Hz, 1 H); 7.77 (d, J=7.8 Hz, 1 H); 8.04 (d, J=7.9 Hz, 1 H); 8.71 (broad s, 1 H)
121-ELP MAXE	(6R)-9-(2-Chloro-4-pyridyl)-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	448		1.13	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 492 (base peak)	1.16 (d, J=6.8 Hz, 3 H); 2.40 (m, 1 H); 2.53 (partially masked m, 1 H); 3.25 (partially masked m, 1 H); 3.38 (dt, J=2.9 and 11.5 Hz, 1 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.63 to 3.72 (m, 2 H); 3.77 (dd, J=2.9 and 11.5 Hz, 1 H); 3.98 (dd, J=7.5 and 11.5 Hz, 1 H); 4.07 (broad q, J=6.8 Hz, 1 H); 5.69 (m, 1 H); 7.49 (dd, J=2.0 and 5.6 Hz, 1 H); 7.66 (d, J=2.0 Hz, 1 H); 8.37 (d, J=5.6 Hz, 1 H)

621-ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	431		0.83	98	b	0.94 (d, J=6.8 Hz, 3 H); 2.15 (m, 1 H); 2.41 (m, 1 H); 2.67 (s, 3 H); 2.97 (dt, J=3.8 and 12.8 Hz, 1 H); 3.21 (dt, J=5.3 and 14.2 Hz, 1 H); 3.32 (dt, J=2.9 and 12.0 Hz, 1 H); 3.47 (dd, J=2.7 and 11.5 Hz, 1 H); 3.56 to 3.65 (m, 2 H); 3.81 (dd, J=3.3 and 11.4 Hz, 1 H); 4.10 (broad q, J=6.8 Hz, 1 H); 4.26 (dd, J=5.3 and 14.2 Hz, 1 H); 4.81 (m, 1 H); 4.94 (s, 1 H); 4.97 (d, J=16.4 Hz, 1 H); 5.37 (d, J=16.4 Hz, 1 H)
321-ELP MAXE	(2S)-1-[6-(Difluoromethoxy)-3-pyridyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462		1.17	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 506 (base peak)	0.88 (d, J=6.8 Hz, 3 H); 2.47 (partially masked m, 2 H); 2.84 (dt, J=3.8 and 12.7 Hz, 1 H); 3.22 (dt, J=3.1 and 11.8 Hz, 1 H); 3.30 to 3.41 (m, 3 H); 3.51 (d, J=11.5 Hz, 1 H); 3.64 to 3.76 (m, 2 H); 4.36 (m, 1 H); 4.92 (m, 1 H); 4.97 (s, 1 H); 7.16 (d, J=8.8 Hz, 1 H); 7.72 (t, J=72.6 Hz, 1 H); 7.96 (dd, J=2.7 and 8.8 Hz, 1 H); 8.28 (d, J=2.7 Hz, 1 H)
421-ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[(4-methylthiadiazol-5-yl)methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	431	429	0.93	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 475 (base peak)	1.02 (d, J=6.8 Hz, 3 H); 2.15 (m, 1 H); 2.37 (m, 1 H); 2.67 (s, 3 H); 3.02 (dt, J=3.7 and 12.8 Hz, 1 H); 3.17 (dt, J=5.1 and 14.5 Hz, 1 H); 3.36 (dt, J=3.4 and 11.6 Hz, 1 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.59 to 3.68 (m, 2 H); 3.82 (dd, J=3.4 and 11.6 Hz, 1 H); 4.10 (broad q, J=6.8 Hz, 1 H); 4.23 (dd, J=5.1 and 14.5 Hz, 1 H); 4.82 (m, 1 H); 4.99 (s, 1 H); 5.04 (d, J=16.4 Hz, 1 H); 5.13 (d, J=16.4 Hz, 1 H)
521-ELP MAXE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-[2-oxo-2-(3-pyridyl)ethyl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	456	454	0.9	98	b	0.92 (d, J=6.8 Hz, 3 H); 2.21 (m, 1 H); 2.45 (m, 1 H); 3.11 (dt, J=3.4 and 12.7 Hz, 1 H); 3.28 (partially masked m, 1 H); 3.35 (d, J=11.5 Hz, 1 H); 3.41 (dd, J=2.7 and 11.5 Hz, 1 H); 3.46 to 3.65 (m, 4 H); 4.05 (broad q, J=6.8 Hz, 1 H); 4.98 (d, J=17.9 Hz, 1 H); 5.15 (d, J=17.9 Hz, 1 H); 5.61 (m, 1 H); 7.60 (dd, J=5.1 and 7.9 Hz, 1 H); 8.34 (td, J=1.9 and 7.9 Hz, 1 H); 8.84 (dd, J=1.9 and 5.1 Hz, 1 H); 9.19 (d, J=1.9 Hz, 1 H)

031-ELP MAXE	(6R)-9-[6-(Difluoromethoxy)-3-pyridyl]-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	480		1.26	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 524 (base peak)	For this batch, all the signals are broad with: 1.05 (d, J=6.6 Hz, 3 H); 2.40 (m, 2 H); 3.12 (m, 1 H); 3.31 (m, 1 H); 3.41 to 3.59 (m, 3 H); 3.67 to 3.81 (m, 3 H); 3.88 (m, 1 H); 5.69 (m, 1 H); 7.15 (d, J=8.3 Hz, 1 H); 7.69 (t, J=72.9 Hz, 1 H); 7.95 (d, J=8.3 Hz, 1 H); 8.27 (s, 1 H)
721-ELP MAXE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-(3-methyl-2-oxobutyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	421	419	1.11	98	b	For this batch, all the signals are broad with: 1.03 (d, J=5.7 Hz, 3 H); 1.05 (d, J=5.7 Hz, 3 H); 1.16 (d, J=6.6 Hz, 3 H); 2.14 (m, 1 H); 2.39 (m, 1 H); 2.69 (spt, J=5.7 Hz, 1 H); 3.21 to 3.48 (partially masked m, 4 H); 3.53 to 3.66 (m, 2 H); 3.72 to 3.84 (m, 2 H); 4.24 (q, J=6.6 Hz, 1 H); 4.45 (d, J=18.6 Hz, 1 H); 4.52 (d, J=18.6 Hz, 1 H); 5.58 (m, 1 H)
821-ELP MAXE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-(oxazol-2-ylmethyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	418		0.94	98	b	1.12 (d, J=6.8 Hz, 3 H); 2.19 (m, 1 H); 2.44 (m, 1 H); 3.26 (partially masked m, 1 H); 3.37 (m, 1 H); 3.49 to 3.67 (m, 4 H); 3.75 to 3.85 (m, 2 H); 4.30 (broad q, J=6.8 Hz, 1 H); 4.76 (d, J=16.4 Hz, 1 H); 4.88 (d, J=16.4 Hz, 1 H); 5.58 (m, 1 H); 7.16 (broad s, 1 H); 8.04 (broad s, 1 H)
921-ELP MAXE	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-(3-methyl-2-oxobutyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	403		1.05	98	b	0.97 to 1.09 (m, 9 H); 2.11 (m, 1 H); 2.37 (m, 1 H); 2.69 (spt, J=6.7 Hz, 1 H); 2.98 (m, 1 H); 3.25 to 3.51 (partially masked m, 4 H); 3.59 (broad d, J=12.7 Hz, 1 H); 3.61 (broad d, J=11.5 Hz, 1 H); 3.82 (m, 1 H); 4.15 (m, 1 H); 4.44 (d, J=18.1 Hz, 1 H); 4.54 (d, J=18.1 Hz, 1 H); 4.83 (s, 1 H); 5.65 (m, 1 H)

431-ELP MAXE	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-(2-oxo-2-tetrahydropyran-4-ylethyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	445	443	0.9	98	b	1.05 (d, J=6.6 Hz, 3 H); 1.48 (dq, J=4.4 and 11.7 Hz, 2 H); 1.69 (m, 2 H); 2.11 (m, 1 H); 2.37 (m, 1 H); 2.71 (tt, J=3.9 and 11.7 Hz, 1 H); 2.98 (dt, J=2.9 and 12.7 Hz, 1 H); 3.25 to 3.51 (partially masked m, 6 H); 3.57 (broad d, J=12.7 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.80 to 3.91 (m, 3 H); 4.14 (broad q, J=6.6 Hz, 1 H); 4.44 (d, J=18.1 Hz, 1 H); 4.55 (d, J=18.1 Hz, 1 H); 4.84 (s, 1 H); 5.65 (m, 1 H)
331-ELP MAXE	1-[6-(Difluoromethyl)-3-pyridyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	446		1.04	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 490 (base peak)	0.84 (d, J=6.6 Hz, 3 H); 2.42 to 2.58 (masked, 2 H); 2.84 (dt, J=2.9 and 12.7 Hz, 1 H); 3.15 to 3.42 (m, 4 H); 3.47 (d, J=11.5 Hz, 1 H); 3.61 to 3.73 (m, 2 H); 4.37 (m, 1 H); 4.99 (s, 1 H); 5.07 (m, 1 H); 6.99 (t, J=54.8 Hz, 1 H); 7.79 (d, J=8.3 Hz, 1 H); 8.05 (broad d, J=8.3 Hz, 1 H); 8.70 (broad s, 1 H)
231-ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(oxetan-3-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	389		0.86	98	b	1.13 (d, J=6.8 Hz, 3 H); 2.11 (m, 1 H); 2.32 (m, 1 H); 3.04 (dt, J=3.2 and 12.7 Hz, 1 H); 3.19 (dt, J=5.1 and 14.4 Hz, 1 H); 3.34 to 3.46 (m, 2 H); 3.49 to 3.58 (m, 2 H); 3.60 to 3.69 (m, 2 H); 3.87 (dd, J=3.4 and 11.3 Hz, 1 H); 4.10 (m, 1 H); 4.21 (m, 1 H); 4.31 to 4.39 (m, 2 H); 4.44 (t, J=6.1 Hz, 1 H); 4.59 (m, 2 H); 4.66 (m, 1 H); 4.91 (s, 1 H)
131-ELP MAXE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-(2-oxo-2-tetrahydropyran-4-ylethyl)-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	463	461	0.96	98	b	1.16 (d, J=6.8 Hz, 3 H); 1.48 (m, 2 H); 1.69 (m, 2 H); 2.14 (m, 1 H); 2.39 (m, 1 H); 2.71 (tt, J=3.8 and 11.5 Hz, 1 H); 3.21 to 3.47 (partially masked m, 6 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.75 (broad d, J=13.0 Hz, 1 H); 3.80 (dd, J=2.9 and 11.5 Hz, 1 H); 3.86 (m, 2 H); 4.24 (broad q, J=6.6 Hz, 1 H); 4.46 (d, J=18.1 Hz, 1 H); 4.51 (d, J=18.1 Hz, 1 H); 5.58 (m, 1 H)

831-EXAMPLE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-[2-oxo-2-(2-pyridyl)ethyl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	456	454	1.09	92	b	0.90 (d, J=6.8 Hz, 3 H); 2.21 (m, 1 H); 2.45 (m, 1 H); 3.07 (dt, J=3.2 and 13.0 Hz, 1 H); 3.17 to 3.37 (partially masked m, 3 H); 3.50 to 3.65 (m, 4 H); 3.98 (m, 1 H); 5.14 (broad s, 2 H); 5.60 (m, 1 H); 7.72 (m, 1 H); 7.97 (d, J=8.1 Hz, 1 H); 8.05 (m, 1 H); 8.75 (broad d, J=4.6 Hz, 1 H)
531-EXAMPLE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[[(2R)-tetrahydrofuran-2-yl]methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	403		4.5	98	l	1.10 (d, J=6.8 Hz, 3 H); 1.49 (m, 1 H); 1.72 to 1.95 (m, 3 H); 2.08 (m, 1 H); 2.37 (m, 1 H); 2.95 to 3.08 (m, 2 H); 3.18 (dt, J=5.4 and 14.4 Hz, 1 H); 3.38 (dt, J=3.1 and 11.8 Hz, 1 H); 3.50 to 3.68 (m, 4 H); 3.78 to 3.89 (m, 2 H); 4.13 to 4.27 (m, 3 H); 4.33 (dd, J=2.7 and 14.4 Hz, 1 H); 4.60 (m, 1 H); 4.91 (s, 1 H)
631-EXAMPLE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[[(2S)-tetrahydrofuran-2-yl]methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	403		4.22	98	l	1.11 (d, J=6.8 Hz, 3 H); 1.58 (m, 1 H); 1.73 to 1.91 (m, 3 H); 2.11 (m, 1 H); 2.37 (m, 1 H); 3.03 (dt, J=3.4 and 12.7 Hz, 1 H); 3.19 (dt, J=5.4 and 14.5 Hz, 2 H); 3.37 (dt, J=3.1 and 11.6 Hz, 1 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 to 3.75 (m, 4 H); 3.86 (dd, J=3.1 and 11.6 Hz, 1 H); 4.08 to 4.27 (m, 3 H); 4.42 (dd, J=5.4 and 14.5 Hz, 1 H); 4.69 (m, 1 H); 4.90 (s, 1 H)
731-EXAMPLE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[[(2R)-tetrahydropyran-2-yl]methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	417		2.78	98	k	1.11 (d, J=6.8 Hz, 3 H); 1.20 (m, 1 H); 1.36 to 1.54 (m, 4 H); 1.78 (m, 1 H); 2.06 (m, 1 H); 2.35 (m, 1 H); 2.96 to 3.08 (m, 2 H); 3.18 (dt,J=5.4 and 14.4 Hz, 1 H); 3.30 to 3.43 (m, 2 H); 3.48 to 3.57 (m, 2 H); 3.62 to 3.71 (m, 2 H); 3.81 to 3.93 (m, 2 H); 4.20 (dd, J=2.0 and 14.4 Hz, 2 H); 4.27 (m, 1 H); 4.54 (m, 1 H); 4.91 (s, 1 H)

24-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[[(2S)-tetrahydropyran-2-yl]methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	417		2.63	98	k	For this batch, all the signals are broad with: 1.12 (d, J=6.6 Hz, 3 H); 1.28 (m, 1 H); 1.36 to 1.48 (m, 3 H); 1.55 (m, 1 H); 1.76 (m, 1 H); 2.16 (m, 1 H); 2.36 (m, 1 H); 2.98 to 3.11 (m, 2 H); 3.16 to 3.44 (m, 3 H); 3.56 (m, 2 H); 3.67 (m, 2 H); 3.87 (m, 2 H); 4.12 (m, 1 H); 4.26 (m, 1 H); 4.34 (m, 1 H); 4.63 (m, 1 H); 4.90 (s, 1 H)
93-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-2-(trifluoromethyl)-1-[[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]methyl]-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	469	467	2.52	98	k; ES$^-$: [M-H+HCO2H]$^-$ m/z 513 (base peak)	For this batch, all the signals are broad with: 0.89 (d, J=6.6 Hz, 3 H); 2.22 (m, 1 H); 2.45 (partially masked m, 1 H); 2.88 (m, 1 H); 3.21 to 3.32 (partially masked m, 2 H); 3.44 (d, J=11.5 Hz, 1 H); 3.51 (d, J=12.7 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.80 (d, J=11.7 Hz, 1 H); 4.03 (m, 1 H); 4.30 (m, 1 H); 4.83 (m, 1 H); 4.95 (s, 1 H); 4.98 (d, J=17.1 Hz, 1 H); 5.42 (d, J=17.1 Hz, 1 H)
04-ELP-MAXE	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-9-[2-oxo-2-(3-pyridyl)ethyl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	438	436	0.84	98	b	0.78 (d, J=6.6 Hz, 3 H); 2.18 (m, 1 H); 2.44 (m, 1 H); 2.86 (dt, J=3.4 and 12.7 Hz, 1 H); 3.22 (dt, J=2.8 and 11.8 Hz, 1 H); 3.32 to 3.43 (m, 3 H); 3.48 to 3.70 (m, 3 H); 3.95 (broad q, J=6.6 Hz, 1 H); 4.82 (s, 1 H); 4.91 (d, J=17.6 Hz, 1 H); 5.21 (d, J=17.6 Hz, 1 H); 5.68 (m, 1 H); 7.60 (dd, J=4.9 and 7.9 Hz, 1 H); 8.34 (td, J=1.7 and 7.9 Hz, 1 H); 8.83 (dd, J=1.7 and 4.9 Hz, 1 H); 9.19 (d, J=1.7 Hz, 1 H)
14-ELP-MAXE	(2S)-1-[(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		0.89	98	b	0.88 (d, J=6.8 Hz, 3 H); 0.90 (m, 2 H); 1.11 (m, 2 H); 2.19 (m, 2 H); 2.43 (m, 1 H); 2.90 (dt, J=4.0 and 13.0 Hz, 1 H); 3.17 to 3.34 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.3 Hz, 1 H); 3.51 (broad d, J=13.0 Hz, 1 H); 3.60 (d, J=11.3 Hz, 1 H); 3.81 (dd, J=3.6 and 11.6 Hz, 1 H); 4.07 (dq, J=2.7 and 6.8 Hz, 1 H); 4.28 (dd, J=5.5 and 14.5 Hz, 1 H); 4.74 (d, J=16.9 Hz, 1 H); 4.79 (m, 1 H); 4.92 (s, 1 H); 5.18 (d, J=16.9 Hz, 1 H)

EXAMPLE 641	(6R)-9-[(3-Methylisoxazol-4-yl)methyl]-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	414		0.97	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 458 (base peak)	1.07 (d, J=6.8 Hz, 3 H); 2.18 (broad s, 4H); 2.35 (m, 1 H); 3.04 (dt, J=3.9 and 12.7 Hz, 1 H); 3.23 to 3.42 (m, 3 H); 3.52 (dd, J=3.1 and 11.4 Hz, 1 H); 3.62 to 3.71 (m, 2 H); 3.85 (dd, J=3.4 and 11.5 Hz, 1 H); 4.26 (broad q, J=6.8 Hz, 1 H); 4.61 (d, J=15.4 Hz, 1 H); 4.72 (d, J=15.4 Hz, 1 H); 4.87 (s, 1 H); 5.64 (m, 1 H); 8.71 (s, 1 H)
EXAMPLE 341	(6R)-2-[(3R)-3-Methylmorpholin-4-yl]-6-(trifluoromethyl)-9-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-7,8-dihydro-6H-pyrimido[1,2-a]-pyrimidin-4-one	469	467	1.16	98	b	0.88 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.48 (m, 1 H); 2.93 (dt, J=3.7 and 12.7 Hz, 1 H); 3.30 (dt, J=3.1 and 11.6 Hz, 1 H); 3.44 (dd, J=2.9 and 11.4 Hz, 1 H); 3.47 (broad d, J=12.7 Hz, 1 H); 3.60 (d, J=11.4 Hz, 1 H); 3.65 to 3.78 (m, 2 H); 3.80 (dd, J=3.1 and 11.6 Hz, 1 H); 4.10 (broad q, J=6.8 Hz, 1 H); 4.89 (s, 1 H); 5.07 (d, J=17.3 Hz, 1 H); 5.21 (d, J=17.3 Hz, 1 H); 5.67 (m, 1 H)
EXAMPLE 441	(6R)-9-Acetonyl-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	375		0.85	98	b	1.05 (d, J=6.8 Hz, 3 H); 2.09 (s, 3 H); 2.14 (m, 1 H); 2.39 (m, 1 H); 2.98 (dt, J=3.9 and 12.7 Hz, 1 H); 3.30 to 3.58 (partially masked m, 5 H); 3.65 (d, J=11.5 Hz, 1 H); 3.84 (dd, J=3.5 and 11.4 Hz, 1 H); 4.17 (broad q, J=6.8 Hz, 1 H); 4.23 (d, J=17.7 Hz, 1 H); 4.37 (d, J=17.7 Hz, 1 H); 4.85 (s, 1 H); 5.65 (m, 1 H)
EXAMPLE 541	(6R)-3-Fluoro-9-[(3-methylisoxazol-4-yl)methyl]-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	432		1.03	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 476 (base peak)	1.17 (d, J=6.8 Hz, 3 H); 2.17 (s, 3 H); 2.21 (m, 1 H); 2.36 (m, 1 H); 3.20 to 3.47 (partially masked m, 4 H); 3.59 (dd, J=2.7 and 11.4 Hz, 1 H); 3.64 (d, J=11.4 Hz, 1 H); 3.80 to 3.87 (m, 2 H); 4.34 (broad q, J=6.8 Hz, 1 H); 4.56 (d, J=15.6 Hz, 1 H); 4.71 (d, J=15.6 Hz, 1 H); 5.57 (m, 1 H); 8.71 (s, 1 H)

051-ELP MAXE	(6R)-9-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]-pyrimidin-4-one	459	457	1.11	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 503 (base peak)	0.82 (m, 2 H); 1.04 (m, 2 H); 1.08 (d, J=6.8 Hz, 3 H); 2.10 (m, 1 H); 2.22 (m, 1 H); 2.45 (m, 1 H); 3.22 (dt, J=3.2 and 13.0 Hz, 1 H); 3.36 (dt, J=2.9 and 11.8 Hz, 1 H); 3.51 (dd, J=2.9 and 11.4 Hz, 1 H); 3.55 to 3.68 (m, 3 H); 3.73 (broad d, J=13.0 Hz, 1 H); 3.79 (dd, J=2.9 and 11.8 Hz, 1 H); 4.19 (broad q, J=6.8 Hz, 1 H); 4.87 (d, J=17.2 Hz, 1 H); 4.94 (d, J=17.2 Hz, 1 H); 5.58 (m, 1 H)
741-ELP MAXE	(6R)-9-Acetonyl-3-fluoro-2-[(3R)-3-methylmorpholin-4-yl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]pyrimidin-4-one	393	391	0.91	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 437 (base peak)	1.16 (d, J=6.8 Hz, 3 H); 2.08 (s, 3 H); 2.16 (m, 1 H); 2.39 (m, 1 H); 3.26 (partially masked m, 1 H); 3.35 to 3.50 (m, 3 H); 3.56 (dd, J=2.9 and 11.5 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.76 (broad d, J=13.2 Hz, 1 H); 3.81 (dd, J=3.2 and 11.3 Hz, 1 H); 4.23 (m, 1 H); 4.26 (d, J=17.9 Hz, 1 H); 4.32 (d, J=17.9 Hz, 1 H); 5.57 (m, 1 H)
841-ELP MAXE	(6R)-3-Fluoro-2-[(3R)-3-methylmorpholin-4-yl]-9-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-(trifluoromethyl)-7,8-dihydro-6H-pyrimido[1,2-a]-pyrimidin-4-one	433	431	0.97	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 477 (base peak)	For this batch, all the signals are broad with: 1.04 (m, 3 H); 2.21 (m,1 H); 2.30 (s, 3 H); 2.40 to 2.53 (masked, 1 H); 3.18 to 3.84 (partially masked m, 9 H); 4.22 (m, 1 H); 4.95 (s, 1 H); 5.59 (m, 1 H)
941-ELP MAXE	(2S)-8-(3,3-Dimethylmorpholin-4-yl)-1-phenacyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	451		1.17	98	b	0.98 (s, 3 H); 1.15 (s, 3 H); 2.25 (m, 1 H); 2.43 (m, 1 H); 3.10 (t, J=5.4 Hz, 2 H); 3.17 (m, 2 H); 3.29 (partially masked m, 1 H); 3.43 to 3.58 (m, 2 H); 4.35 (dd, J=5.5 and 14.4 Hz, 1 H); 4.62 (m, 1 H); 4.85 (d, J=18.3 Hz, 1 H); 5.04 (s, 1 H); 5.56 (d, J=18.3 Hz, 1 H); 7.56 (t, J=7.8 Hz, 2 H); 7.68 (t, J=7.8 Hz, 1 H); 8.02 (d, J=7.8 Hz, 2 H)

151-ELP MAXE	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-[(3S,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	463		1.05	98	b	1.15 (d, J=6.8 Hz, 3 H); 1.20 (d, J=6.6 Hz, 3 H); 1.99 (m, 1 H); 2.37 (m, 1 H); 3.19 (dt, J=5.4 and 14.4 Hz, 1 H); 3.52 (broad d, J=11.5 Hz, 2 H); 3.70 (dd, J=5.4 and 11.5 Hz, 2 H); 4.04 (broad m, 1 H); 4.14 (broad m, 1 H); 4.21 (dd, J=5.4 and 14.4 Hz, 1 H); 4.63 (broad d, J=15.9 Hz, 2 H); 4.90 (s, 1 H); 5.25 (d, J=15.9 Hz, 1 H); 6.96 (d, J=3.9 Hz, 1 H); 6.98 (d, J=3.9 Hz, 1 H)
251-ELP MAXE	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	463		1.03	88	b	1.15 (d, J=6.4 Hz, 6 H); 2.05 (m, 1 H); 2.38 (m, 1 H); 3.21 (dt, J=5.6 and 14.4 Hz, 1 H); 3.56 (m, 2 H); 3.92 to 4.03 (m, 4 H); 4.24 (dd, J=5.6 and 14.4 Hz, 1 H); 4.62 (broad d, J=16.1 Hz, 2 H); 4.89 (s, 1 H); 5.34 (d, J=16.1 Hz, 1 H); 6.95 (d, J=3.9 Hz, 1 H); 6.96 (d, J=3.9 Hz, 1 H)
351-ELP MAXE	(2S)-8-[(3R,5R)-3,5-Dimethylmorpholin-4-yl]-1-phenacyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	451		0.89	98	b	For this batch, all the signals are broad with: 0.89 (d, J=6.4 Hz, 6 H); 2.27 (m, 1 H); 2.43 (m, 1 H); 3.29 (masked, 1 H); 3.39 (m, 2 H); 3.76 (m, 2 H); 3.90 (m, 2 H); 4.39 (m, 1 H); 4.61 (m, 1 H); 4.70 (d, J=17.9 Hz, 1 H); 4.78 (s, 1 H); 5.73 (d, J=17.9 Hz, 1 H); 7.55 (t, J=7.7 Hz, 2 H); 7.68 (t, J=7.7 Hz, 1 H); 8.03 (d, J=7.7 Hz, 2 H)
451-ELP MAXE	(2S)-1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-8-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	463		1.13	95	b; ES^-: $[M-H+HCO2H]^-$ m/z 507 (base peak)	0.94 (d, J=6.4 Hz, 6 H); 2.41 (m, 2 H); 3.25 (partially masked m, 1 H); 3.49 (split d, J=11.2 Hz, 2 H); 3.78 (m, 2 H); 3.96 (split d, J=11.2 Hz, 2 H); 4.28 (m, 1 H); 4.67 (d, J=17.1 Hz, 1 H); 4.77 (m, 1 H); 4.83 (s, 1 H); 5.43 (d, J=17.1 Hz, 1 H); 6.32 (broad s, 1 H); 7.64 (d, J=1.0 Hz, 1 H); 7.85 (t, J=58.1 Hz, 1 H)

851-ELP MAXE	(2S)-8-[(3R,5R)-3,5-Dimethylmorpholin-4-yl]-1-[(3-methylisoxazol-5-yl)methyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		1	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 472 (base peak)	1.05 (d, J=6.6 Hz, 6 H); 2.16 (s, 3 H); 2.25 (m, 1 H); 2.41 (m, 1 H); 3.24 (dt, J=5.4 and 14.4 Hz, 1 H); 3.54 (split d, J=11.2 Hz, 2 H); 3.83 (m, 2 H); 3.98 (split d, J=11.2 Hz, 2 H); 4.27 (dd, J=5.4 and 14.4 Hz, 1 H); 4.60 (d, J=17.1 Hz, 1 H); 4.75 (m, 1 H); 4.83 (s, 1 H); 5.25 (d, J=17.1 Hz, 1 H); 6.23 (s, 1 H)
751-ELP MAXE	(2S)-1-[(6-chloro-3-Pyridyl)methyl]-8-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	458		1.08	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 502 (base peak)	0.91 (d, J=6.4 Hz, 6 H); 2.39 (m, 2 H); 3.28 (partially masked m, 1 H); 3.47 (split d, J=11.2 Hz, 2 H); 3.73 (m, 2 H); 3.93 (split d, J=11.2 Hz, 2 H); 4.26 (m, 1 H); 4.57 (d, J=16.6 Hz, 1 H); 4.75 (m, 1 H); 4.82 (s, 1 H); 5.22 (d, J=16.6 Hz, 1 H); 7.44 (d, J=8.3 Hz, 1 H); 7.70 (dd, J=2.4 and 8.3 Hz, 1 H); 8.30 (d, J=2.4 Hz, 1 H)
651-ELP MAXE	(2S)-1-[(2-Chloro-4-pyridyl)methyl]-8-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	458	456	1.06	97	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 502 (base peak)	0.86 (d, J=6.4 Hz, 6 H); 2.43 (m, 2 H); 3.29 (partially masked m, 1 H); 3.45 (split d, J=11.2 Hz, 2 H); 3.67 (m, 2 H); 3.91 (split d, J=11.2 Hz, 2 H); 4.28 (m, 1 H); 4.58 (d, J=17.4 Hz, 1 H); 4.80 (m, 1 H); 4.82 (s, 1 H); 5.14 (d, J=17.4 Hz, 1 H); 7.26 (broad d, J=5.1 Hz, 1 H); 7.38 (broad s, 1 H); 8.30 (d, J=5.1 Hz, 1 H)
551-ELP MAXE	(2S)-8-[(3R,5R)-3,5-Dimethylmorpholin-4-yl]-1-(oxazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	414		0.93	98	b	1.00 (d, J=6.4 Hz, 6 H); 2.22 (m, 1 H); 2.44 (m, 1 H); 3.26 (partially masked m, 1 H); 3.54 (split d, J=11.2 Hz, 2 H); 3.82 (m, 2 H); 3.97 (split d, J=11.2 Hz, 2 H); 4.32 (dd, J=5.4 and 14.4 Hz, 1 H); 4.62 (d, J=17.1 Hz, 1 H); 4.78 (m, 1 H); 4.80 (s, 1 H); 5.29 (d, J=17.1 Hz, 1 H); 7.13 (s, 1 H); 8.02 (s, 1 H)

EXAMPLE 261	(2S)-1-(2-Chloro-4-pyridyl)-8-[(3R,5R)-3,5-dimethylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		1.08	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 488 (base peak)	1.01 (d, J=6.4 Hz, 6 H); 2.45 (m, 2 H); 3.39 (m, 1 H); 3.51 (dd, J=2.9 and 11.2 Hz, 2 H); 3.63 (m, 2 H); 3.96 (dd, J=2.9 and 11.2 Hz, 2 H); 4.31 (m, 1 H); 4.91 (s, 1 H); 5.13 (m, 1 H); 7.49 (dd, J=1.7 and 5.4 Hz, 1 H); 7.70 (d, J=1.7 Hz, 1 H); 8.45 (d, J=5.4 Hz, 1 H)
EXAMPLE 951	(2S)-8-[(3R,5R)-3,5-Dimethylmorpholin-4-yl]-1-(3-pyridyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	410		0.85	98	a; ES$^-$: [M-H+HCO2H]$^-$ m/z 454 (base peak)	0.92 (d, J=6.4 Hz, 6 H); 2.41 to 2.53 (partially masked m, 2 H); 3.37 (m, 1 H); 3.47 (split d, J=11.2 Hz, 2 H); 3.54 (m, 2 H); 3.91 (split d, J=11.2 Hz, 2 H); 4.39 (m, 1 H); 4.83 (s, 1 H); 4.97 (m, 1 H); 7.47 (dd, J=4.8 and 7.9 Hz, 1 H); 7.84 (broad d, J=7.9 Hz, 1 H); 8.51 (dd, J=1.2 and 4.8 Hz, 1 H); 8.58 (d, J=2.2 Hz, 1 H)
EXAMPLE 061	(2S)-1-(3,5-Difluorophenyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	443		0.93	90	a; ES$^-$: [M-H+HCO2H]$^-$ m/z 487 (base peak)	1.42 to 1.59 (m, 2 H); 1.72 (m, 2 H); 2.44 (m, 2 H); 2.72 (broad d, J=13.4 Hz, 1 H); 2.78 (broad d, J=13.4 Hz, 1 H); 3.24 to 3.40 (partially masked m, 3 H); 4.23 (m, 2 H); 4.35 (broad d, J=14.5 Hz, 1 H); 4.93 (s, 1 H); 5.01 (m, 1 H); 7.16 to 7.34 (m, 3 H)
EXAMPLE 161	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	461		0.99	97	a; ES$^-$: [M-H+HCO2H]$^-$ m/z 505 (base peak)	1.65 to 1.85 (m, 4 H); 1.93 (m, 1 H); 2.35 (m, 1 H); 2.95 (broad d, J=13.3 Hz, 2 H); 3.16 (dt, J=5.4 and 14.2 Hz, 1 H); 3.67 to 3.87 (broad m, 2 H); 4.19 (dd, J=5.4 and 14.2 Hz, 1 H); 4.36 (m, 2 H); 4.63 (broad d, J=15.4 Hz, 2 H); 4.92 (s, 1 H); 5.18 (d, J=15.4 Hz, 1 H); 6.96 (d, J=3.9 Hz, 1 H); 7.04 (d, J=3.9 Hz, 1 H)

EXAMPLE 366	(2S)-8-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-phenacyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	449	447	0.84	98	a	1.28 (m, 1 H); 1.43 to 1.69 (m, 4 H); 2.23 (m, 1 H); 2.43 (m, 1 H); 2.59 (m, 1 H); 2.68 (m, 1 H); 3.23 (dt, J=5.3 and 14.4 Hz, 1 H); 3.372 (m, 2 H); 3.96 (m, 1 H); 4.05 (m, 1 H); 4.34 (dd, J=5.3 and 14.4 Hz, 1 H); 4.65 (m, 1 H); 4.71 (d, J=17.6 Hz, 1 H); 4.83 (s, 1 H); 5.51 (d, J=17.6 Hz, 1 H); 7.57 (t, J=7.6 Hz, 2 H); 7.69 (t, J=7.6 Hz, 1 H); 8.03 (d, J=7.6 Hz, 1 H)
EXAMPLE 367	(2S)-1-(Isoxazol-5-ylmethyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	412	410	0.79	98	a; ES$^-$: [M-H+HCO2H]$^-$ m/z 456 (base peak)	1.44 to 1.56 (m, 2 H); 1.73 (m, 2 H); 2.20 (m, 1 H); 2.40 (m, 1 H); 2.81 (m, 2 H); 3.21 (dt, J=5.4 and 14.4 Hz, 1 H); 3.53 to 3.68 (m, 2 H); 4.19 to 4.30 (m, 3 H); 4.81 (broad d, J=16.6 Hz, 2 H); 4.87 (s, 1 H); 5.10 (d, J=16.6 Hz, 1 H); 6.35 (d, J=1.7 Hz, 1 H); 8.47 (d, J=1.7 Hz, 1 H)
EXAMPLE 461	(2S)-1-[(2-Chlorothiazol-5-yl)methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462		0.94	98	a	1.65 to 1.87 (m, 4 H); 1.98 (m, 1 H); 2.34 (m, 1 H); 2.97 (m, 2 H); 3.15 (dt, J=5.0 and 14.2 Hz, 1 H); 3.75 (m, 2 H); 4.18 (dd, J=5.0 and 14.2 Hz, 1 H); 4.36 (m, 2 H); 4.67 (m, 1 H); 4.76 (d, J=15.7 Hz, 1 H); 4.93 (s, 1 H); 5.14 (d, J=15.7 Hz, 1 H); 7.73 (s, 1 H)
EXAMPLE 561	(2S)-1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	461		0.81	98	a; ES$^-$: [M-H+HCO2H]$^-$ m/z 505 (base peak)	1.35 to 1.52 (m, 2 H); 1.70 (m, 2 H); 2.22 to 2.44 (m, 2 H); 2.71 to 2.80 (m, 2 H); 3.23 (dt, J=4.6 and 14.2 Hz, 1 H); 3.47 (broad d, J=12.7 Hz, 1 H); 3.56 (broad d, J=12.7 Hz, 1 H); 4.18 to 4.29 (m, 3 H); 4.73 (m, 1 H); 4.84 (d, J=16.9 Hz, 1 H); 4.87 (s, 1 H); 5.22 (d, J=16.9 Hz, 1 H); 6.30 (d, J=1.7 Hz, 1 H); 7.65 (d, J=1.7 Hz, 1 H); 7.87 (t, J=58.1 Hz, 1 H)
EXAMPLE 661							

071-ELP MAXE	(2S)-1-[[1-(Difluoromethyl)pyrazol-3-yl]methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	461		0.83	98	a	1.38 to 1.54 (m, 2 H); 1.71 (m, 2 H); 2.18 (m, 1 H); 2.39 (m, 1 H); 2.78 (m, 2 H); 3.21 (dt, J=4.6 and 14.2 Hz, 1 H); 3.52 to 3.72 (m, 2 H); 4.19 to 4.28 (m, 3 H); 4.56 (d, J=15.9 Hz, 1 H); 4.72 (s, 1 H); 4.84 (s, 1 H); 5.05 (d, J=15.9 Hz, 1 H); 6.38 (d, J=2.6 Hz, 1 H); 7.72 (t, J=59.2 Hz, 1 H); 8.12 (d, J=2.6 Hz, 1 H)
761-ELP MAXE	(2S)-1-[(6-Chloro-3-pyridyl)methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	456		0.91	98	a; ES^-: $[M-H+HCO2H]^-$ m/z 500 (base peak)	1.23 to 1.49 (m, 2 H); 1.68 (m, 2 H); 2.24 to 2.42 (m, 2 H); 2.71 to 2.81 (m, 2 H); 3.24 (dt, J=5.2 and 14.2 Hz, 1 H); 3.47 (broad d, J=12.8 Hz, 1 H); 3.55 (broad d, J=12.8 Hz, 1 H); 4.16 to 4.26 (m, 3 H); 4.67 (d, J=16.4 Hz, 1 H); 4.81 (m, 1 H); 4.85 (s, 1 H); 5.02 (d, J=16.4 Hz, 1 H); 7.45 (d, J=8.3 Hz, 1 H); 7.74 (dd, J=2.7 and 8.3 Hz, 1 H); 8.33 (d, J=2.7 Hz, 1 H)
861-ELP MAXE	(2S)-1-(Isoxazol-3-ylmethyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	412	410	0.93	98	a; ES^-: $[M-H+HCO2H]^-$ m/z 456 (base peak)	1.40 to 1.55 (m, 2 H); 1.72 (m, 2 H); 2.20 (m, 1 H); 2.39 (m, 1 H); 2.76 to 2.84 (m, 2 H); 3.21 (dt, J=4.8 and 14.4 Hz, 1 H); 3.56 (broad d, J=12.5 Hz, 1 H); 3.66 (broad d, J=12.5 Hz, 1 H); 4.20 to 4.29 (m, 3 H); 4.67 (d, J=16.4 Hz, 1 H); 4.75 (m, 1 H); 4.86 (s, 1 H); 5.10 (d, J=16.4 Hz, 1 H); 6.48 (d, J=1.7 Hz, 1 H); 8.82 (d, J=1.7 Hz, 1 H)
961-ELP MAXE	(2S)-8-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-[2-oxo-2-(3-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	450	448	0.83	98	b	1.45 to 1.71 (m, 4 H); 2.22 (m, 1 H); 2.44 (m, 1 H); 2.60 (broad d, J=12.7 Hz, 1 H); 2.70 (broad d, J=12.7 Hz, 1 H); 3.24 (dt, J=4.6 and 14.2 Hz, 1 H); 3.39 (broad d, J=12.7 Hz, 2 H); 4.01 (d, J=5.4 Hz, 1 H); 4.07 (d, J=5.4 Hz, 1 H); 4.34 (dd, J=4.6 and 14.2 Hz, 1 H); 4.64 (m, 1 H); 4.78 (d, J=18.1 Hz, 1 H); 4.83 (s, 1 H); 5.53 (d, J=17.6 Hz, 1 H); 7.61 (dd, J=4.9 and 7.8 Hz, 1 H); 8.37 (d, J=7.8 Hz, 1 H); 8.85 (dd, J=1.5 and 4.9 Hz, 1 H); 9.20 (d, J=1.5 Hz, 1 H)

47- ELP MAXE	(2S)-8-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	450		1.01	98	b	1.26 (m, 1 H); 1.39 to 1.69 (m, 3 H); 2.22 (m, 1 H); 2.44 (m, 1 H); 2.55 to 2.71 (m, 2 H); 3.18 to 3.38 (partially masked m, 3 H); 3.97 (d, J=5.4 Hz, 1 H); 4.04 (d, J=5.4 Hz, 1 H); 4.34 (m, 1 H); 4.71 (s, 1 H); 4.81 (s, 1 H); 4.87 (d, J=18.1 Hz, 1 H); 5.58 (d, J=18.1 Hz, 1 H); 7.73 (m, 1 H); 7.97 (d, J=7.8 Hz, 1 H); 8.06 (dt, J=1.2 and 7.8 Hz, 1 H); 8.77 (broad d, J=4.5 Hz, 1 H)
17- ELP MAXE	(2S)-8-[(2R)-2-Ethylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	452		1.16	98	b	0.65 (t, J=7.5 Hz, 3 H); 0.94 to 1.26 (m, 2 H); 2.11 (dd, J=10.8 and 12.8 Hz, 1 H); 2.22 (m, 1 H); 2.45 (m, 1 H); 2.61 (dt, J=3.6 and 12.5 Hz, 1 H); 3.01 (m, 1 H); 3.10 to 3.61 (m, 4 H); 3.67 (broad d, J=12.8 Hz, 1 H); 4.35 (m, 1 H); 4.70 (m, 1 H); 4.90 (d, J=18.3 Hz, 1 H); 4.95 (s, 1 H); 5.59 (d, J=18.3 Hz, 1 H); 7.72 (ddd, J=1.4 and 4.8 and 7.5 Hz, 1 H); 7.96 (broad d, J=7.5 Hz, 1 H); 8.06 (dt, J=1.7 and 7.5 Hz, 1 H); 8.76 (ddd, J=0.8 and 1.7 and 4.8 Hz, 1 H)
27- ELP MAXE	(2S)-8-[(2S)-2-Ethylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	452	450	1.15	98	b	0.57 (t, J=7.4 Hz, 3 H); 0.83 to 1.22 (m, 2 H); 2.14 to 2.29 (m, 2 H); 2.44 (m, 1 H); 2.57 (dt, J=3.4 and 12.7 Hz, 1 H); 2.88 (m, 1 H); 3.16 to 3.33 (partially masked m, 2 H); 3.51 (broad d, J=12.7 Hz, 1 H); 3.61 (dd, J=2.9 and 11.5 Hz, 1 H); 3.71 (broad d, J=12.7 Hz, 1 H); 4.35 (dd, J=5.7 and 14.5 Hz, 1 H); 4.69 (m, 1 H); 4.94 (d, J=18.3 Hz, 1 H); 4.96 (s, 1 H); 5.57 (d, J=18.3 Hz, 1 H); 7.72 (ddd, J=1.4 and 4.8 and 7.6 Hz, 1 H); 7.97 (broad d, J=7.6 Hz, 1 H); 8.06 (dt, J=1.7 and 7.6 Hz, 1 H); 8.76 (ddd, J=0.9 and 1.7 and 4.8 Hz, 1 H)
37- ELP MAXE	(2S)-8-[(2R)-2-Methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	438		1.06	98	b	0.76 (d, J=6.1 Hz, 3 H); 2.06 (dd, J=10.6 and 13.0 Hz, 1 H); 2.22 (m, 1 H); 2.45 (m, 1 H); 2.57 (dt, J=3.6 and 12.7 Hz, 1 H); 3.10 to 3.37 (partially masked m, 3 H); 3.46 to 3.55 (m, 2 H); 3.61 (broad d, J=12.7 Hz, 1 H); 4.35 (dd, J=5.4 and 14.5 Hz, 1 H); 4.71 (m, 1 H); 4.88 (d, J=18.0 Hz, 1 H); 4.94 (s, 1 H); 5.60 (d, J=18.0 Hz, 1 H); 7.73 (ddd, J=1.4 and 4.8 and 7.6 Hz, 1 H); 7.97 (broad t, J=7.6 Hz, 1 H); 8.06 (dt, J=1.7 and 7.6 Hz, 1 H); 8.77 (ddd, J=0.9 and 1.7 and 4.8 Hz, 1 H)

EXAMPLE 570	(2S)-8-[(2S)-2-Methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	438		1.06	98	b	0.70 (d, J=6.1 Hz, 3 H); 2.13 to 2.30 (m, 2 H); 2.43 (m, 1 H); 2.52 (partially masked m, 1 H); 3.10 (m, 1 H); 3.12 to 3.34 (partially masked m, 2 H); 3.51 (m, 1 H); 3.57 (dd, J=2.9 and 11.5 Hz, 1 H); 3.65 (broad d, J=12.8 Hz, 1 H); 4.34 (dd, J=5.6 and 14.4 Hz, 1 H); 4.70 (m, 1 H); 4.91 (s, 1 H); 4.93 (d, J=18.1 Hz, 1 H); 5.55 (d, J=18.1 Hz, 1 H); 7.73 (ddd, J=1.2 and 4.5 and 7.5 Hz, 1 H); 7.97 (broad d, J=7.5 Hz, 1 H); 8.06 (dt, J=1.7 and 7.5 Hz, 1 H); 8.77 (broad d, J=4.5 Hz, 1 H)
EXAMPLE 571	(2S)-1-(3,5-Difluorophenyl)-8-[(3S)-3-(hydroxymethyl)morpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	447		0.8	98	a; ES^-: $[M-H+HCO2H]^-$ m/z 491 (base peak)	2.39 to 2.47 (m, 2 H); 2.79 (dt, J=4.2 and 12.9 Hz, 1 H); 3.14 to 3.35 (m, 4 H); 3.43 to 3.59 (m, 3 H); 3.69 (dd, J=3.2 and 11.2 Hz, 1 H); 3.88 (d, J=11.5 Hz, 1 H); 4.35 (broad d, J=15.2 Hz, 1 H); 4.60 (broad t, J=5.4 Hz, 1 H); 4.99 (m, 1 H); 5.02 (s, 1 H); 7.17 to 7.26 (m, 3 H)
EXAMPLE 671	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-[(3S)-3-(hydroxymethyl)morpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	465		0.84	95	a; ES^-: $[M-H+HCO2H]^-$ m/z 509 (base peak)	1.95 (m, 1 H); 2.36 (m, 1 H); 3.00 (dt, J=3.9 and 12.0 Hz, 1 H); 3.17 (dt, J=4.0 and 14.6 Hz, 1 H); 3.34 to 3.46 (m, 4 H); 3.69 (dt, J=6.8 and 10.0 Hz, 1 H); 3.86 (dd, J=3.9 and 12.0 Hz, 1 H); 3.91 (broad m, 1 H); 4.00 (d, J=11.5 Hz, 1 H); 4.19 (dd, J=3.0 and 14.6 Hz, 1 H); 4.63 (m, 1 H); 4.68 (d, J=15.9 Hz, 1 H); 4.76 (broad t, J=5.4 Hz, 1 H); 5.01 (s, 1 H); 5.17 (d, J=15.9 Hz, 1 H); 6.95 (d, J=3.9 Hz, 1 H); 7.02 (d, J=3.9 Hz, 1 H)
EXAMPLE 771	(2S)-1-[(5-Chloro-2-thienyl)methyl]-8-[(3S)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449		1	98	a	1.13 (d, J=6.6 Hz, 3 H); 1.93 (m, 1 H); 2.35 (m, 1 H); 3.05 (dt, J=3.8 and 12.8 Hz, 1 H); 3.17 (dt, J=5.2 and 14.7 Hz, 1 H); 3.39 (dt, J=3.2 and 11.9 Hz, 1 H); 3.53 (dd, J=3.1 and 11.6 Hz, 1 H); 3.66 (d, J=11.6 Hz, 1 H); 3.81 to 3.89 (m, 2 H); 4.15 to 4.23 (m, 2 H); 4.64 (broad d, J=15.6 Hz, 2 H); 4.97 (s, 1 H); 5.18 (d, J=15.6 Hz, 1 H); 6.96 (d, J=3.9 Hz, 1 H); 7.03 (d, J=3.9 Hz, 1 H)
EXAMPLE 871							

281-ELP MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	438	436	1.06	98	b	For this batch, all the signals are broad with: 0.81 (d, J=6.5 Hz, 3 H); 1.64 (s . 3 H); 2.87 (m, 1 H); 3.23 (partially masked m, 1 H); 3.35 to 3.49 (m, 3 H); 3.70 (m, 1 H); 3.90 (m, 1 H); 4.04 (d, J=13.0 Hz, 1 H); 4.25 (d, J=13.0 Hz, 1 H); 4.78 (s, 1 H); 4.94 (d, J=18.3 Hz, 1 H); 5.33 (d, J=18.3 Hz, 1 H); 7.73 (m, 1 H); 7.95 to 8.10 (m, 2 H); 8.78 (m, 1 H)
971-ELP MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(3-pyridyl)ethyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	438	436	0.93	98	b	0.81 (d, J=6.8 Hz, 3 H); 1.64 (s, 3 H); 2.90 (td, J=3.8 and 12.7 Hz, 1 H); 3.26 (partially masked m, 1 H); 3.36 to 3.50 (m, 3 H); 3.72 (dd, J=3.5 and 11.4 Hz, 1 H); 3.98 (broad q, J=6.8 Hz, 1 H); 4.04 (d, J=12.7 Hz, 1 H); 4.25 (d, J=12.7 Hz, 1 H); 4.79 (s, 1 H); 4.91 (d, J=18.3 Hz, 1 H); 5.24 (d, J=18.3 Hz, 1 H); 7.61 (dd, J=4.9 and 8.1 Hz, 1 H); 8.38 (td, J=1.9 and 8.1 Hz, 1 H); 8.84 (dd, J=1.9 and 4.9 Hz, 1 H); 9.22 (d, J=1.9 Hz, 1 H)
081-ELP MAXE	(2S)-1-[(2-Chloro-4-pyridyl)methyl]-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	444	442	1.05	98	b	0.81 (d, J=6.8 Hz, 3 H); 1.70 (s, 3 H); 2.93 (dt, J=3.9 and 12.5 Hz, 1 H); 3.30 (partially masked m, 1 H); 3.40 to 3.48 (m, 2 H); 3.56 (d, J=11.7 Hz, 1 H); 3.79 (dd, J=3.7 and 11.5 Hz, 1 H); 4.02 (m, 1 H); 4.05 (d, J=12.2 Hz, 1 H); 4.20 (d, J=12.2 Hz, 1 H); 4.62 (d, J=17.1 Hz, 1 H); 4.68 (d, J=17.1 Hz, 1 H); 4.80 (s, 1 H); 7.40 (broad d, J=5.4 Hz, 1 H); 7.53 (broad s, 1 H); 8.34 (d, J=5.4 Hz, 1 H)
181-ELP MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-5-ylmethyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	400		0.87	98	b	1.06 (d, J=6.8 Hz, 3 H); 1.69 (s, 3 H); 3.01 (dt, J=3.5 and 12.8 Hz, 1 H); 3.37 (dt, J=3.5 and 11.8 Hz, 1 H); 3.52 (dd, J=2.9 and 11.5 Hz, 1 H); 3.66 (broad d, J=11.5 Hz, 2 H); 3.86 (dd, J=3.5 and 11.8 Hz, 1 H); 3.93 (d, J=12.5 Hz, 1 H); 4.14 (d, J=12.5 Hz, 1 H); 4.25 (m, 1 H); 4.64 (d, J=16.8 Hz, 1 H); 4.77 (d, J=16.8 Hz, 1 H); 4.81 (s, 1 H); 7.13 (s, 1 H); 8.29 (s, 1 H)

68-EXAMPLE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-4-ylmethyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	400		0.91	98	b	For this batch, all the signals are broad with: 0.98 (d, J=6.8 Hz, 3 H); 1.69 (s, 3 H); 2.98 (dt, J=3.4 and 12.7 Hz, 1 H); 3.36 (m, 1 H); 3.48 to 3.66 (m, 3 H); 3.84 (m, 1 H); 3.92 (d, J=12.5 Hz, 1 H); 4.16 (d, J=12.5 Hz, 1 H); 4.22 (m, 1 H); 4.40 (d, J=16.6 Hz, 1 H); 4.63 (d, J=16.6 Hz, 1 H); 4.78 (s, 1 H); 8.03 (s, 1 H); 8.30 (s, 1 H)
69-EXAMPLE	(2S)-1-[(2-Chloro-4-pyridyl)methyl]-6-fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	462	460	1.11	98	b	0.97 (d, J=6.8 Hz, 3 H); 1.69 (s, 3 H); 3.20 (dt, J=3.2 and 13.0 Hz, 1 H); 3.31 (partially masked m, 1 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.54 (d, J=11.5 Hz, 1 H); 3.63 (broad d, J=13.0 Hz, 1 H); 3.73 (dd, J=2.9 and 11.5 Hz, 1 H); 4.01 (broad q, J=6.8 Hz, 1 H); 4.11 (d, J=12.4 Hz, 1 H); 4.24 (d, J=12.4 Hz, 1 H); 4.59 (d, J=17.1 Hz, 1 H); 4.65 (d, J=17.1 Hz, 1 H); 7.39 (dd, J=1.2 and 5.1 Hz, 1 H); 7.53 (broad s, 1 H); 8.35 (d, J=5.1 Hz, 1 H)
70-EXAMPLE	(2S)-6-Fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	421	419	1.12	98	b	1.03 (d, J=6.6 Hz, 3 H); 1.05 (d, J=6.6 Hz, 3 H); 1.15 (d, J=6.8 Hz, 3 H); 1.53 (s, 3 H); 2.77 (spt, J=6.8 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.39 (dt, J=2.7 and 11.5 Hz, 1 H); 3.52 to 3.63 (m, 2 H); 3.72 to 3.82 (m, 2 H); 4.04 (d, J=12.5 Hz, 1 H); 4.14 to 4.35 (m, 3 H); 4.53 (d, J=18.8 Hz, 1 H)
71-EXAMPLE	(2S)-6-Fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(2-oxo-2-tetrahydropyran-4-yl-ethyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	463	461	0.97	98	b	1.16 (d, J=6.8 Hz, 3 H); 1.38 to 1.57 (m, 2 H); 1.53 (s, 3 H); 1.65 to 1.80 (m, 2 H); 2.80 (tt, J=3.8 and 11.4 Hz, 1 H); 3.20 to 3.43 (partially masked m, 4 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.72 to 3.90 (m, 4 H); 4.04 (d, J=12.7 Hz, 1 H); 4.19 (broad q, J=6.8 Hz, 1 H); 4.23 (d, J=12.7 Hz, 1 H); 4.31 (d, J=18.8 Hz, 1 H); 4.55 (d, J=18.8 Hz, 1 H)

091- ELP MAXE	(2S)-1-(2-Cyclopropyl-2-oxo-ethyl)-6-fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	419	417	1.04	98	b	0.74 to 0.99 (m, 4 H); 1.17 (d, J=6.8 Hz, 3 H); 1.56 (s, 3 H); 2.15 (m, 1 H); 3.22 (partially masked m, 1 H); 3.40 (dt, J=2.0 and 11.5 Hz, 1 H); 3.56 (dd, J=2.7 and 11.5 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.73 to 3.85 (m, 2 H); 4.03 (d, J=13.0 Hz, 1 H); 4.20 (m, 1 H); 4.23 (d, J=13.0 Hz, 1 H); 4.35 (d, J=18.7 Hz, 1 H); 4.49 (d, J=18.7 Hz, 1 H)
781- ELP MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	403	401	1.06	98	b	0.99 to 1.07 (m, 9 H); 1.54 (s, 3 H); 2.78 (spt, J=6.9 Hz, 1 H); 2.99 (dt, J=3.7 and 12.7 Hz, 1 H); 3.34 (dt, J=2.9 and 11.7 Hz, 1 H); 3.50 (dd, J=2.8 and 11.4 Hz, 1 H); 3.56 (broad d, J=12.7 Hz, 1 H); 3.62 (d, J=11.4 Hz, 1 H); 3.82 (dd, J=3.2 and 11.7 Hz, 1 H); 3.95 (d, J=12.5 Hz, 1 H); 4.18 (broad d, J=12.5 Hz, 2 H); 4.29 (d, J=18.6 Hz, 1 H); 4.57 (d, J=18.6 Hz, 1 H); 4.78 (s, 1 H)
881- ELP MAXE	(2S)-6-Fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(3-pyridyl)ethyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	456	454	0.91	98	b	0.94 (d, J=6.8 Hz, 3 H); 1.63 (s, 3 H); 3.15 (dt, J=3.4 and 13.2 Hz, 1 H); 3.30 (partially masked m, 1 H); 3.46 (broad s, 2 H); 3.59 to 3.68 (m, 2 H); 4.03 (broad q, J=6.8 Hz, 1 H); 4.13 (d, J=12.7 Hz, 1 H); 4.30 (d, J=12.7 Hz, 1 H); 4.90 (d, J=18.6 Hz, 1 H); 5.21 (d, J=18.6 Hz, 1 H); 7.61 (dd, J=4.9 and 7.9 Hz, 1 H); 8.38 (td, J=2.0 and 7.9 Hz, 1 H); 8.85 (dd, J=2.0 and 4.9 Hz, 1 H); 9.22 (d, J=2.0 Hz, 1 H)
981- ELP MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-(2-oxo-2-tetrahydropyran-4-ylethyl)-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	445	443	0.91	98	b	1.02 (d, J=6.8 Hz, 3 H); 1.36 to 1.58 (m, 2 H); 1.53 (s, 3 H); 1.65 to 1.82 (m, 2 H); 2.81 (tt, J=3.6 and 11.3 Hz, 1 H); 2.98 (dt, J=3.6 and 12.7 Hz, 1 H); 3.30 to 3.39 (m, 3 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (broad d, J=12.7 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.79 to 3.90 (m, 3 H); 3.95 (d, J=12.5 Hz, 1 H); 4.18 (broad d, J=12.5 Hz, 2 H); 4.32 (d, J=18.8 Hz, 1 H); 4.59 (d, J=18.8 Hz, 1 H); 4.78 (s, 1 H)

491-ELP MAXE	(2S)-1-Benzyl-8-(2-methylmorpholin-4-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	409		4.06	98	c	1.00 (d, J=6.1 Hz, 3 H); 2.16 to 2.29 (m, 2 H); 2.40 (m, 1 H); 2.68 (dt, J=3.8 and 12.5 Hz, 1 H); 3.16 to 3.37 (partially masked m, 3 H); 3.68 (dd, J=3.1 and 11.4 Hz, 1 H); 3.74 (broad d, J=12.5 Hz, 1 H); 3.79 (broad d, J=13.5 Hz, 1 H); 4.23 (dd, J=6.1 and 14.4 Hz, 1 H); 4.55 (d, J=16.1 Hz, 1 H); 4.68 (m, 1 H); 4.96 (s, 1 H); 5.15 (d, J=16.1 Hz, 1 H); 7.20 to 7.26 (m, 2 H); 7.31 (t, J=7.6 Hz, 1 H)
391-ELP MAXE	(2S)-1-Benzyl-8-[2-(fluoromethyl)morpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	427		0.93	98	a	2.22 (m, 1 H); 2.40 (m, 1 H); 2.48 (masked, 1 H); 2.73 (m, 1 H); 3.19 to 3.33 (partially masked m, 2 H); 3.43 to 3.55 (m, 1 H); 3.76 (m, 2 H); 3.86 (broad d, J=12.7 Hz, 1 H); 4.19 to 4.45 (m, 3 H); 4.53 (d, J=16.1 Hz, 1 H); 4.69 (m, 1 H); 4.99 (s, 1 H); 5.19 (d, J=16.1 Hz, 1 H); 7.20 to 7.27 (m, 3 H); 7.31 (t, J=7.6 Hz, 2 H)
291-ELP MAXE	(2S)-1-Benzyl-8-[2-(fluoromethyl)morpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	427		4.01	98	c	For this batch, a 50%-50% mixture of isomers is observed with: 2.22 (m, 1 H); 2.41 (m, 1 H); 2.47 to 2.59 (partially masked m, 1 H); 2.65 to 2.78 (m, 1 H); 3.20 to 3.53 (partially masked m, 3 H); 3.76 (m, 2 H); 3.86 (broad d, J=12.7 Hz, 1 H); 4.18 to 4.46 (m, 3 H); 4.53 (split d, J=16.3 Hz, 1 H); 4.68 (m, 1 H); 4.99 (s, 1 H); 5.20 (split d, J=16.3 Hz, 1 H); 7.20 to 7.34 (m, 5 H)
191-ELP MAXE	(2S)-1-Benzyl-8-(2-methylmorpholin-4-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	409		4.05	98	c	0.99 (d, J=6.1 Hz, 3 H); 2.21 (m, 1 H); 2.32 (dd, J=10.8 and 12.8 Hz, 1 H); 2.40 (m, 1 H); 2.64 (m, 1 H); 3.17 to 3.38 (partially masked m, 3 H); 3.66 to 3.75 (m, 2 H); 3.81 (broad d, J=12.8 Hz, 1 H); 4.23 (dd, J=6.1 and 14.4 Hz, 1 H); 4.53 (d, J=15.9 Hz, 1 H); 4.67 (m, 1 H); 4.96 (s, 1 H); 5.18 (d, J=15.9 Hz, 1 H); 7.21 to 7.26 (m, 3 H); 7.31 (t, J=7.6 Hz, 2 H)

EXAMPLE 589	(2S)-1-Benzyl-8-[2-(fluoromethyl)morpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	427		0.93	98	a	2.21 (m, 1 H); 2.40 (m, 1 H); 2.55 (dd, J=10.8 and 12.7 Hz, 1 H); 2.68 (m, 1 H); 3.20 to 3.48 (partially masked m, 3 H); 3.76 (m, 2 H); 3.87 (broad d, J=12.7 Hz, 1 H); 4.19 to 4.45 (m, 3 H); 4.53 (d, J=16.1 Hz, 1 H); 4.68 (m, 1 H); 5.00 (s, 1 H); 5.20 (d, J=16.1 Hz, 1 H); 7.21 to 7.27 (m, 3 H); 7.31 (t, J=7.6 Hz, 2 H)
EXAMPLE 590	N-Methoxy-N-methyl-2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-1-yl]acetamide	420		0.9	98	b	1.02 (d, J=6.8 Hz, 3 H); 2.13 (m, 1 H); 2.36 (m, 1 H); 2.99 (dt, J=3.9 and 12.7 Hz, 1 H); 3.09 (s, 3 H); 3.21 (dt, J=5.2 and 14.2 Hz, 1 H); 3.35 (dt, J=3.4 and 11.4 Hz, 1 H); 3.47 to 3.57 (m, 2 H); 3.63 (d, J=11.5 Hz, 1 H); 3.71 (s, 3 H); 3.84 (dd, J=3.4 and 11.4 Hz, 1 H); 4.12 (d, J=17.1 Hz, 1 H); 4.18 (broad q, J=6.8 Hz, 1 H); 4.31 (dd, J=5.2 and 14.2 Hz, 1 H); 4.56 (m, 1 H); 4.91 (s, 1 H); 4.97 (d, J=17.1 Hz, 1 H)
EXAMPLE 591	N-Methoxy-2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide	406	404	0.71	97	b	1.07 (d, J=6.6 Hz, 3 H); 2.19 (m, 1 H); 2.36 (m, 1 H); 2.98 (dt, J=3.4 and 12.7 Hz, 1 H); 3.20 (dt, J=4.9 and 14.4 Hz, 1 H); 3.34 (m, 1 H); 3.46 to 3.72 (m, 3 H); 3.57 (s, 3 H); 3.79 to 3.91 (m, 2 H); 4.16 (m, 1 H); 4.27 (dd, J=4.9 and 14.4 Hz, 1 H); 4.36 (d, J=16.4 Hz, 1 H); 4.60 (m, 1 H); 4.92 (s, 1 H); 11.15 (broad s, 1 H)
EXAMPLE 592	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(4-pyridyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	396		0.57	98	b	0.92 (d, J=6.6 Hz, 3 H); 2.41 to 2.48 (m, 2 H); 2.88 (dt, J=3.7 and 12.7 Hz, 1 H); 3.23 (dt, J=3.1 and 11.9 Hz, 1 H); 3.31 to 3.42 (m, 3 H); 3.52 (d, J=11.5 Hz, 1 H); 3.70 to 3.79 (m, 2 H); 4.32 (m, 1 H); 5.01 (s, 1 H); 5.09 (m, 1 H); 7.44 (m, 2 H); 8.61 (m, 2 H)

EXAMPLE 202	(2S)-6-Fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	456	454	1.12	98	b	0.92 (d, J=6.8 Hz, 3 H); 1.64 (s, 3 H); 3.11 (m, 1 H); 3.21 to 3.84 (partially masked m, 5 H); 3.94 (broad q, J=6.8 Hz, 1 H); 4.13 (d, J=12.7 Hz, 1 H); 4.30 (d, J=12.7 Hz, 1 H); 4.95 (d, J=18.6 Hz, 1 H); 5.27 (d, J=18.6 Hz, 1 H); 7.74 (m, 1 H); 7.98 (m, 1 H); 8.07 (m, 1 H); 8.77 (d, J=4.9 Hz, 1 H)
EXAMPLE 199	(2S)-1-(2-Hydroxy-2-methyl-propyl)-2-methyl-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	405		0.95	93	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 449 and m/z 952 (base peak)	0.99 (s, 3 H); 1.10 to 1.14 (m, 6 H); 1.67 (s, 3 H); 2.10 to 2.29 (m, 2 H); 3.05 (dt, J=2.9 and 13.0 Hz, 1 H); 3.22 (d, J=15.4 Hz, 1 H); 3.36 (dt, J=2.9 and 11.8 Hz, 1 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 to 3.73 (m, 3 H); 3.82 to 3.94 (m, 2 H); 4.21 (m, 1 H); 4.29 (d, J=15.4 Hz, 1 H); 4.46 (s, 1 H); 4.94 (s, 1 H)
EXAMPLE 200	(2S)-1-[(5-Isopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	443		1.11	98	b	0.83 (d, J=6.6 Hz, 3 H); 1.28 (d, J=7.1 Hz, 6 H); 2.16 (m, 1 H); 2.43 (m, 1 H); 2.91 (dt, J=4.2 and 13.0 Hz, 1 H); 3.18 to 3.32 (partially masked m, 3 H); 3.43 to 3.52 (m, 2 H); 3.59 (d, J=11.5 Hz, 1 H); 3.80 (dd, J=3.4 and 11.5 Hz, 1 H); 4.09 (broad q, J=6.8 Hz, 1 H); 4.28 (dd, J=6.1 and 15.2 Hz, 1 H); 4.59 (d, J=16.9 Hz, 1 H); 4.80 (m, 1 H); 4.91 (s, 1 H); 5.23 (d, J=16.9 Hz, 1 H)
EXAMPLE 201	(2S)-1-[(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		1.05	98	b	0.84 (d, J=6.6 Hz, 3 H); 1.05 to 1.05 (m, 2 H); 1.19 to 1.26 (m, 2 H); 2.15 (m, 1 H); 2.30 (m, 1 H); 2.42 (m, 1 H); 2.92 (dt, J=3.7 and 12.7 Hz, 1 H); 3.18 to 3.34 (partially masked m, 2 H); 3.43 to 3.52 (m, 2 H); 3.60 (d, J=11.5 Hz, 1 H); 3.81 (dd, J=3.7 and 11.5 Hz, 1 H); 4.09 (m, 1 H); 4.27 (dd, J=5.2 and 14.4 Hz, 1 H); 4.53 (d, J=16.6 Hz, 1 H); 4.77 (m, 1 H); 4.90 (s, 1 H); 5.17 (d, J=16.6 Hz, 1 H)

602-ELP-MAXE	(2S)-1-[(5-tert-Butyl-1,2,4-oxadiazol-3-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	457		1.19	98	b	0.82 (d, J=6.6 Hz, 3 H); 1.34 (s, 9 H); 2.16 (m, 1 H); 2.44 (m, 1 H); 2.90 (dt, J=4.0 and 12.8 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.43 to 3.51 (m, 2 H); 3.59 (d, J=11.5 Hz, 1 H); 3.80 (dd, J=3.7 and 11.5 Hz, 1 H); 4.09 (m, 1 H); 4.29 (dd, J=5.4 and 14.4 Hz, 1 H); 4.60 (d, J=17.1 Hz, 1 H); 4.80 (m, 1 H); 4.91 (s, 1 H); 5.24 (d, J=17.1 Hz, 1 H)
502-ELP-MAXE	(2S)-1-[(2S)-2-Methoxy-2-phenylethyl]-8-[(1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	465		1.06	98	a	1.61 to 1.94 (m, 4 H); 2.16 (m, 1 H); 2.43 (m, 1 H); 2.93 (dd, J=2.5 and 12.7 Hz, 1 H); 3.02 (dd, J=2.5 and 12.7 Hz, 1 H); 3.13 (s, 3 H); 3.18 to 3.33 (partially masked m, 2 H); 3.71 (m, 2 H); 4.20 (dd, J=5.4 and 14.2 Hz, 1 H); 4.26 (dd, J=2.5 and 14.4 Hz, 1 H); 4.38 (m, 2 H); 4.60 (dd, J=2.5 and 9.5 Hz, 1 H); 4.76 (m, 1 H); 4.91 (s, 1 H); 7.29 to 7.38 (m, 3 H); 7.43 (t, J=7.5 Hz, 2 H)
402-ELP-MAXE	(2S)-1-[(2S)-2-Hydroxypropyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	377		0.9	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 421 (base peak)	1.05 (d, J=6.1 Hz, 3 H); 1.09 (d, J=6.6 Hz, 3 H); 2.18 (m, 1 H); 2.34 (m, 1 H); 2.87 (dd, J=9.3 and 13.9 Hz, 1 H); 3.02 (dt, J=3.8 and 12.7 Hz, 1 H); 3.18 (dt, J=4.6 and 14.4 Hz, 1 H); 3.38 (dt, J=3.5 and 11.6 Hz, 1 H); 3.49 to 3.57 (m, 2 H); 3.66 (d, J=11.5 Hz, 1 H); 3.86 (dd, J=3.5 and 11.6 Hz, 1 H); 4.04 (m, 1 H); 4.15 (dd, J=2.4 and 13.9 Hz, 1 H); 4.19 (m, 1 H); 4.22 (m, 1 H); 4.62 (m, 1 H); 4.87 (d, J=5.6 Hz, 1 H); 4.91 (s, 1 H)
302-ELP-MAXE	(2S)-7-Fluoro-1-(2-hydroxyethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	381		0.85	96	b; ES^-: $[M-H+HCO2H]^-$ m/z 425 (base peak)	1.22 (d, J=6.8 Hz, 3 H); 2.16 (m, 1 H); 2.36 (s, 1 H); 3.19 to 3.32 (partially masked m, 3 H); 3.45 (dt, J=2.3 and 11.6 Hz, 1 H); 3.55 (m, 1 H); 3.61 (m, 2 H); 3.70 (m, 1 H); 3.83 (m, 2 H); 4.08 (ddd, J=3.6 and 4.7 and 14.4 Hz, 1 H); 4.17 (dd, J=5.4 and 14.4 Hz, 1 H); 4.26 (broad q, J=6.8 Hz, 1 H); 4.61 (m, 1 H); 4.76 (t, J=5.4 Hz, 1 H)

902-ELP-MAXE	(2S)-6-Fluoro-2-methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	433		0.99	98	b	1.09 (d, J=6.8 Hz, 3 H); 1.70 (s, 3 H); 2.57 (s, 3 H); 3.22 (dt, J=3.2 and 12.7 Hz, 1 H); 3.37 (dt, J=2.9 and 11.2 Hz, 1 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.71 to 3.83 (m, 2 H); 4.05 (d, J=12.7 Hz, 1 H); 4.16 (broad q, J=6.8 Hz, 1 H); 4.24 (d, J=12.7 Hz, 1 H); 4.66 (d, J=16.9 Hz, 1 H); 4.72 (d, J=16.9 Hz, 1 H)
702-ELP-MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	415		0.91	98	b	0.92 (d, J=6.8 Hz, 3 H); 1.74 (s, 3 H); 2.31 (s, 3 H); 2.93 (dt, J=3.8 and 12.7 Hz, 1 H); 3.31 (dt, J=3.2 and 11.5 Hz, 1 H); 3.43 to 3.52 (m, 2 H); 3.61 (d, J=11.5 Hz, 1 H); 3.81 (dd, J=3.2 and 11.5 Hz, 1 H); 4.02 (d, J=12.5 Hz, 1 H); 4.06 (broad m, 1 H); 4.22 (d, J=12.5 Hz, 1 H); 4.81 (s, 1 H); 4.93 (s, 2 H)
802-ELP-MAXE	(2S)-1-[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	440		0.59	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 484; ES^+ m/z 241 (base peak)	1.16 (d, J=6.7 Hz, 3 H); 1.62 (m, 1 H); 2.20 (m, 1 H); 3.03 (dt, J=3.7 and 12.7 Hz, 1 H); 3.15 (m 1 H); 3.22 (dd, J=6.2 and 14.0 Hz, 1 H); 3.42 (m, 1 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.62 (m, 1 H); 3.67 (d, J=11.5 Hz, 1 H); 3.88 (dd, J=3.8 and 11.5 Hz, 1 H); 4.02 (m, 1 H); 4.13 to 4.27 (m, 2 H); 4.58 (dd, J=6.2 and 14.0 Hz, 1 H); 4.89 (s, 1 H); 5.09 (broad t, J=6.2 Hz, 1 H); 5.72 (broad s, 1 H); 7.35 (dd, J=4.9 and 7.9 Hz, 1 H); 7.75 (dt, J=1.8 and 7.9 Hz, 1 H); 8.44 to 8.50 (m, 2 H)

212-ELP-MAXE	(2S)-1-[(2S)-2-Hydroxy-2-(3-pyridyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	440		0.64	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 484 (base peak)	1.17 (d, J=6.8 Hz, 3 H); 2.28 (m, 1 H); 2.40 (m, 1 H); 3.07 (dt, J=3.7 and 12.7 Hz, 1 H); 3.15 (broad dd, J=10.0 and 14.0 Hz, 2 H); 3.43 (dt, J=2.9 and 11.5 Hz, 1 H); 3.56 (dd, J=2.9 and 11.5 Hz, 1 H); 3.65 (m, 1 H); 3.68 (d, J=11.5 Hz, 1 H); 3.88 (dd, J=2.9 and 11.5 Hz, 1 H); 4.22 (dd, J=4.8 and 14.0 Hz, 1 H); 4.30 (m, 1 H); 4.36 (dd, J=2.9 and 14.0 Hz, 1 H); 4.79 (m, 1 H); 4.95 (s, 1 H); 5.07 (broad dd, J=2.9 and 10.0 Hz, 1 H); 5.86 (broad s, 1 H); 7.40 (dd, J=4.9 and 7.9 Hz, 1 H); 7.76 (dt, J=1.7 and 7.9 Hz, 1 H); 8.50 (dd, J=1.7 and 4.9 Hz, 1 H); 8.54 (d, J=1.7 Hz, 1 H)
012-ELP-MAXE	(2S)-2-Methyl-8-[(3R)-3-methylmorpholin-4-yl]-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	429		0.96	98	b	0.78 (d, J=6.6 Hz, 3 H); 1.73 (s, 3 H); 2.11 (m, 1 H); 2.53 (m, 1 H); 2.55 (s, 3 H); 2.92 (dt, J=3.2 and 12.7 Hz, 1 H); 3.24 to 3.39 (partially masked m, 2 H); 3.44 to 3.51 (m, 2 H); 3.58 (d, J=11.5 Hz, 1 H); 3.80 (dd, J=3.5 and 11.6 Hz, 1 H); 4.07 to 4.15 (m, 2 H); 4.78 (d, J=17.1 Hz, 1 H); 4.89 (s, 1 H); 4.99 (d, J=17.1 Hz, 1 H)
112-ELP-MAXE	(2S)-1-[(2R)-2-Hydroxy-2-(2-pyridyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	440		0.78	98	b; ES^-: [M-H+HCO2H]$^-$ m/z 484 (base peak)	1.11 (d, J=6.8 Hz, 3 H); 2.28 (m, 1 H); 2.41 (m, 1 H); 3.04 (dt, J=3.7 and 12.7 Hz, 1 H); 3.13 (dd, J=10.0 and 13.9 Hz, 1 H); 3.22 (dt, J=5.4 and 14.4 Hz, 1 H); 3.39 (dt, J=3.1 and 11.8 Hz, 1 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.66 (d, J=11.5 Hz, 1 H); 3.79 to 3.90 (m, 2 H); 4.24 (dd, J=5.4 and 14.4 Hz, 1 H); 4.37 (m, 1 H); 4.58 (dd, J=2.7 and 13.9 Hz, 1 H); 4.77 (m, 1 H); 4.92 (m, 1 H); 5.09 (m, 1 H); 5.80 (d, J=6.1 Hz, 1 H); 7.26 (ddd, J=1.0 and 5.1 and 7.7 Hz, 1 H) ; 7.52 (d, J=7.7 Hz, 1 H); 7.81 (dt, J=1.7 and 7.7 Hz, 1 H); 8.50 (broad d, J=5.1 Hz, 1 H)

612 ELP MAXE	(2S)-1-[(2S)-2-Hydroxy-2-(2-pyridyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	440		0.68	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 484 (base peak)	1.12 (d, J=6.8 Hz, 3 H); 1.72 (m, 1 H); 2.19 (m, 1 H); 3.01 (dt, J=3.7 and 12.7 Hz, 1 H); 3.14 (dt, J=5.3 and 14.4 Hz, 1 H); 3.40 (m, 2 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.66 (d, J=11.5 Hz, 1 H); 3.68 (broad d, J=12.8 Hz, 1 H); 3.88 (dd, J=3.7 and 12.7 Hz, 1 H); 4.04 (dd, J=5.3 and 14.4 Hz, 1 H); 4.11 to 4.24 (m, 2 H); 4.53 (dd, J=5.6 and 13.9 Hz, 1 H); 4.89 (s, 1 H); 5.06 (m, 1 H); 5.66 (d, J=4.4 Hz, 1 H);7.28 (ddd, J=1.0 and 5.1 and 7.7 Hz, 1 H); 7.48 (d, J=8.1 Hz, 1 H); 7.78 (dt, J=1.7 and 7.7 Hz, 1 H); 8.50 (broad d, J=5.1 Hz, 1 H)
312 ELP MAXE	(2S)-1-[[2-(Difluoromethyl)pyrazol-3-yl]methyl]-2-methyl-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	463		1.07	98	b	0.64 (d, J=6.8 Hz, 3 H); 1.63 (m, 3 H); 2.45 (m, 2 H); 2.87 (dt, J=3.8 and 12.4 Hz, 1 H); 3.20 to 3.34 (partially masked m, 2 H); 3.38 to 3.50 (m, 3 H); 3.74 (dd, J=3.4 and 11.2 Hz, 1 H); 4.00 (broad q, J=6.8 Hz, 1 H); 4.10 (m, 1 H); 4.78 (d, J=17.6 Hz, 1 H); 4.92 (s, 1 H); 5.25 (d, J=17.6 Hz, 1 H); 6.38 (broad s, 1 H); 7.62 (d, J=1.7 Hz, 1 H); 7.86 (t, J=57.9 Hz, 1 H)
412 ELP MAXE	(2S)-1-(Isoxazol-3-ylmethyl)-2-methyl-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	414		0.99	98	b	0.79 (d, J=6.8 Hz, 3 H); 1.66 (s, 3 H); 2.26 (m, 1 H); 2.47 (partially masked m, 1 H); 2.91 (dt, J=3.7 and 12.7 Hz, 1 H); 3.25 (partially masked m, 1 H); 3.33 to 3.49 (m, 3 H); 3.56 (d, J=11.3 Hz, 1 H); 3.78 (dd, J=3.3 and 11.4 Hz, 1 H); 3.98 to 4.14 (m, 2 H); 4.75 (d, J=16.9 Hz, 1 H); 4.90 (s, 1 H); 5.06 (d, J=16.9 Hz, 1 H); 6.52 (d, J=1.7 Hz, 1 H); 8.79 (d, J=1.7 Hz, 1 H)
512 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(4-pyridylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	410		0.52	98	b	0.64 (d, J=6.7 Hz, 3 H); 2.38 to 2.45 (m, 2 H); 2.83 (dt, J=3.8 and 12.8 Hz, 1 H); 3.20 (dt, J=3.2 and 12.2 Hz, 1 H); 3.22 to 3.40 (partially masked m, 3 H); 3.49 (d, J=11.5 Hz, 1 H); 3.73 (dd, J=3.4 and 11.7 Hz, 1 H); 3.92 (m, 1 H); 4.27 (m, 1 H); 4.60 (d, J=16.9 Hz, 1 H); 4.78 (m, 1 H); 4.88 (s, 1 H); 5.08 (d, J=16.9 Hz, 1 H); 7.23 (d, J=5.6 Hz, 2 H); 8.47 (d, J=5.6 Hz, 2 H)

022 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-pyridylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	410		0.59	98	b	0.73 (d, J=6.7 Hz, 3 H); 2.27 to 2.44 (m, 2 H); 2.88 (dt, J=3.9 and 12.7 Hz, 1 H); 3.19 to 3.32 (partially masked m, 2 H); 3.39 to 3.47 (m, 2 H); 3.52 (d, J=11.5 Hz, 1 H); 3.75 (dd, J=3.5 and 11.4 Hz, 1 H); 4.01 (m, 1 H); 4.23 (dd, J=5.3 and 14.1 Hz, 1 H); 4.59 (d, J=16.1 Hz, 1 H); 4.80 (m, 1 H); 4.89 (s, 1 H); 5.15 (d, J=16.1 Hz, 1 H); 7.32 (dd, J=5.0 and 7.8 Hz, 1 H); 7.64 (d, J=7.8 Hz, 1 H); 8.43 (dd, J=1.7 and 5.0 Hz, 1 H); 8.49 (d, J=1.7 Hz, 1 H)
712 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(2-pyridylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	410		0.78	98	b	0.65 (d, J=6.8 Hz, 3 H); 2.30 to 2.46 (m, 2 H); 2.84 (dt, J=3.8 and 12.7 Hz, 1 H); 3.20 (dt, J=3.2 and 11.7 Hz, 1 H); 3.30 (partially masked m, 1 H); 3.40 (dd, J=2.7 and 11.6 Hz, 2 H); 3.51 (d, J=11.6 Hz, 1 H); 3.74 (dd, J=3.5 and 11.7 Hz, 1 H); 3.99 (m, 1 H); 4.29 (dd, J=5.2 and 14.3 Hz, 1 H); 4.58 (d, J=16.4 Hz, 1 H); 4.80 (m, 1 H); 4.85 (s, 1 H); 5.22 (d, J=16.4 Hz, 1 H); 7.23 (broad dd, J=5.0 and 7.8 Hz, 1 H); 7.28 (d, J=7.8 Hz, 1 H); 7.72 (dt, J=1.7 and 7.8 Hz, 1 H); 8.47 (broad d, J=5.0 Hz, 1 H)
812 ELP MAXE	(2S)-1-[2-(4-Fluorophenyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		1.29	97	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 485 (base peak)	1.17 (d, J=6.8 Hz, 3 H); 1.95 (m, 1 H); 2.32 (m, 1 H); 2.81 to 3.22 (m, 4 H); 3.33 to 3.47 (m, 2 H); 3.57 (dd, J=2.9 and 11.6 Hz, 1 H); 3.69 (broad d, J=11.6 Hz, 2 H); 3.89 (m, 1 H); 4.11 to 4.22 (m, 2 H); 4.28 (m, 1 H); 4.57 (m, 1 H); 4.93 (s, 1 H); 7.14 (t, J=8.3 Hz, 2 H); 7.25 (dd, J=5.6 and 8.3 Hz, 2 H)
912 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[2-(2-pyridyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	424		0.69	98	b	1.13 (d, J=6.6 Hz, 3 H); 1.95 (m, 1 H); 2.31 (m, 1 H); 2.98 to 3.24 (m, 4 H); 3.39 (dt, J=3.4 and 11.7 Hz, 1 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (m, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.72 (broad d, J=13.0 Hz, 1 H); 3.86 (dd, J=3.4 and 11.7 Hz, 1 H); 4.17 (dd, J=5.4 and 14.0 Hz, 1 H); 4.22 to 4.37 (m, 2 H); 4.56 (m, 1 H); 4.91 (s, 1 H); 7.18 to 7.28 (m, 2 H); 7.71 (dt, J=1.8 and 7.6 Hz, 1 H); 8.50 (broad d, J=4.9 Hz, 1 H)

422 ELP MAXE	(2S)-1-[(2-Fluoro-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		1	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 472 (base peak)	0.70 (d, J=6.8 Hz, 3 H); 2.34 to 2.45 (m, 2 H); 2.86 (dt, J=2.9 and 12.7 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.40 (broad dd, J=2.9 and 11.5 Hz, 2 H); 3.52 (d, J=11.5 Hz, 1 H); 3.75 (dd, J=3.4 and 11.5 Hz, 1 H); 3.97 (broad q, J=6.8 Hz, 1 H); 4.25 (m, 1 H); 4.61 (d, J=16.6 Hz, 1 H); 4.81 (m, 1 H); 4.89 (s, 1 H); 5.10 (d, J=16.6 Hz, 1 H); 7.30 (ddd, J=1.6 and 5.3 and 7.1 Hz, 1 H); 7.75 (m, 1 H); 8.10 (broad d, J=5.3 Hz, 1 H)
122 ELP MAXE	N,N-Dimethyl-2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide	404		0.82	98	b	0.99 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.35 (m, 1 H); 2.81 (s, 3 H); 2.92 to 3.03 (m, 4 H); 3.20 (dt, J=5.1 and 14.2 Hz, 1 H); 3.36 (dt, J=3.4 and 11.6 Hz, 1 H); 3.47 (broad d, J=13.0 Hz, 1 H); 3.51 (dd, J=3.1 and 11.6 Hz, 1 H); 3.65 (d, J=11.6 Hz, 1 H); 3.85 (dd, J=3.4 and 11.6 Hz, 1 H); 3.91 (d, J=16.6 Hz, 1 H); 4.20 (broad q, J=6.8 Hz, 1 H); 4.32 (dd, J=5.1 and 14.2 Hz, 1 H); 4.44 (m, 1 H); 4.90 (s, 1 H); 5.02 (d, J=16.6 Hz, 1 H)
222 ELP MAXE	N-Methyl-2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide	390		0.69	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 434 (base peak)	1.02 (d, J=6.7 Hz, 3 H); 2.22 (m, 1 H); 2.35 (m, 1 H); 2.58 (d, J=4.4 Hz, 3 H); 2.98 (dt, J=2.9 and 13.0 Hz, 1 H); 3.19 (dt, J=4.7 and 14.2 Hz, 1 H); 3.35 (dt, J=2.8 and 11.8 Hz, 1 H); 3.52 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (broad d, J=13.0 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.80 (d, J=16.1 Hz, 1 H); 3.84 (dd, J=2.9 and 11.8 Hz, 1 H); 4.16 to 4.31 (m, 2 H); 4.46 (d, J=16.1 Hz, 1 H); 4.58 (m, 1 H); 4.90 (s, 1 H); 7.86 (broad q, J=4.4 Hz, 1 H)
322 ELP MAXE	(2S)-1-[(6-Fluoro-2-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428		1.06	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 472 (base peak)	0.66 (d, J=6.7 Hz, 3 H); 2.31 to 2.47 (m, 2 H); 2.85 (dt, J=3.9 and 12.7 Hz, 1 H); 3.22 (dt, J=3.3 and 11.6 Hz, 1 H); 3.28 (partially masked m, 1 H); 3.37 to 3.44 (m, 2 H); 3.52 (d, J=11.5 Hz, 1 H); 3.75 (dd, J=3.3 and 11.6 Hz, 1 H); 4.00 (m, 1 H); 4.29 (dd, J=5.2 and 14.2 Hz, 1 H); 4.57 (d, J=16.9 Hz, 1 H); 4.82 (m, 1 H); 4.86 (s, 1 H); 5.14 (d, J=16.9 Hz, 1 H); 7.01 (dd, J=2.2 and 8.2 Hz, 1 H); 7.25 (dd, J=2.2 and 8.2 Hz, 1 H); 7.92 (q, J=8.2 Hz, 1 H)

722 ELP MAXE	(2S)-1-[(2-Isopropoxy-4-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	468		1.15	98	b; ES^+: $[M+2H]^{2+}$ m/z 234.5 (base peak); ES^-: $[M-H+HCO2H]^-$ m/z 512 (base peak)	0.67 (d, J=6.8 Hz, 3 H); 1.25 (d, J=6.2 Hz, 6 H); 2.39 (m, 2 H); 2.86 (dt, J=3.7 and 12.7 Hz, 1 H); 3.18 to 3.30 (partially masked m, 2 H); 3.33 to 3.43 (m, 2 H); 3.49 (d, J=11.5 Hz, 1 H); 3.74 (dd, J=3.4 and 11.5 Hz, 1 H); 3.97 (m, 1 H); 4.25 (m, 1 H); 4.49 (d, J=16.9 Hz, 1 H); 4.78 (m, 1 H); 4.88 (s, 1 H); 5.00 (d, J=16.9 Hz, 1 H); 5.22 (spt, J=6.2 Hz, 1 H); 6.54 (broad s, 1 H); 6.79 (dd, J=1.2 and 5.4 Hz, 1 H); 8.03 (d, J=5.4 Hz, 1 H)
522 ELP MAXE	(2S)-1-[(3-Isopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	443	441	1.07	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 487 (base peak)	0.87 (d, J=6.8 Hz, 3 H); 1.22 (d, J=6.8 Hz, 6 H); 2.22 (m, 1 H); 2.46 (partially masked m, 1 H); 2.85 (dt, J=3.7 and 12.6 Hz, 1 H); 3.02 (spt, J=6.8 Hz, 1 H); 3.17 to 3.32 (partially masked m, 2 H); 3.39 to 3.49 (m, 2 H); 3.57 (d, J=11.5 Hz, 1 H); 3.78 (dd, J=3.2 and 11.5 Hz, 1 H); 3.98 (broad q, J=6.8 Hz, 1 H); 4.31 (dd, J=5.1 and 14.4 Hz, 1 H); 4.84 (m, 1 H); 4.90 (d, J=17.1 Hz, 1 H); 4.92 (s, 1 H); 5.19 (d, J=17.1 Hz, 1 H)
622 ELP MAXE	(2S)-1-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		1.03	98	b	0.81 (m, 2 H); 0.87 (d, J=6.8 Hz, 3 H); 1.05 (m, 2 H); 2.09 (tt, J=4.7 and 8.3 Hz, 1 H); 2.20 (m, 1 H); 2.44 (m, 1 H); 2.87 (dt, J=3.5 and 12.8 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.43 (dd, J=2.7 and 11.5 Hz, 2 H); 3.58 (d, J=11.5 Hz, 1 H); 3.80 (dd, J=3.5 and 11.5 Hz, 1 H); 3.97 (m, 1 H); 4.30 (dd, J=5.4 and 14.4 Hz, 1 H); 4.84 (d, J=17.2 Hz, 1 H); 4.85 (m, 1 H); 4.92 (s, 1 H); 5.14 (d, J=17.2 Hz, 1 H)

132-ELP-MAXE	(2S)-1-[(3-tert-Butyl-1,2,4-oxadiazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	457		1.16	98	b	0.89 (d, J=6.8 Hz, 3 H); 1.27 (s, 9 H); 2.21 (m, 1 H); 2.46 (m, 1 H); 2.84 (dt, J=3.9 and 13.0 Hz, 1 H); 3.19 to 3.32 (partially masked m, 2 H); 3.43 (dd, J=2.9 and 11.5 Hz, 1 H); 3.47 (broad d, J=12.8 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.78 (dd, J=3.3 and 11.5 Hz, 1 H); 3.96 (m, 1 H); 4.31 (dd, J=5.4 and 14.4 Hz, 1 H); 4.84 (m, 1 H); 4.92 (d, J=17.4 Hz, 1 H); 4.93 (s, 1 H); 5.19 (d, J=17.4 Hz, 1 H)
822-ELP-MAXE	(2S)-1-[(6-Isopropoxy-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	468		1.22	98	b	0.84 (d, J=6.8 Hz, 3 H); 1.26 (d, J=6.1 Hz, 6 H); 2.23 (m, 1 H); 2.37 (m, 1 H); 2.94 (dt, J=3.9 and 12.8 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.51 (broad d, J=12.8 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.79 (dd, J=3.5 and 11.4 Hz, 1 H); 4.09 (m, 1 H); 4.19 (dd, J=5.5 and 14.4 Hz, 1 H); 4.41 (d, J=15.7 Hz, 1 H); 4.72 (m, 1 H); 4.89 (s, 1 H); 5.16 (d, J=15.7 Hz, 1 H); 5.19 (spt, J=6.1 Hz, 1 H); 6.67 (d, J=8.6 Hz, 1 H); 7.57 (dd, J=2.4 and 8.6 Hz, 1 H); 8.05 (d, J=2.4 Hz, 1 H)
922-ELP-MAXE	(2S)-1-[(2-Isopropoxy-3-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	468		1.28	98	b	0.70 (d, J=6.8 Hz, 3 H); 1.27 (d, J=6.2 Hz, 3 H); 1.30 (d, J=6.2 Hz, 3 H); 2.26 to 2.44 (m, 2 H); 2.87 (dt, J=2.9 and 12.5 Hz, 1 H); 3.20 to 3.32 (partially masked m, 2 H); 3.37 to 3.44 (m, 2 H); 3.49 (d, J=11.5 Hz, 1 H); 3.74 (dd, J=3.7 and 11.5 Hz, 1 H); 3.99 (broad q, J=6.8 Hz, 1 H); 4.23 (dd, J=5.5 and 14.4 Hz, 1 H); 4.35 (d, J=16.6 Hz, 1 H); 4.71 (m, 1 H); 4.87 (s, 1 H); 5.09 (d, J=16.6 Hz, 1 H); 5.30 (spt, J=6.2 Hz, 1 H); 6.88 (dd, J=5.1 and 7.5 Hz, 1 H); 7.43 (broad d, J=7.5 Hz, 1 H); 8.02 (dd, J=1.6 and 5.1 Hz, 1 H)
032-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(thiazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	416		0.94	98	b	0.87 (d, J=6.8 Hz, 3 H); 2.18 (m, 1 H); 2.43 (m, 1 H); 2.94 (dt, J=3.9 and 12.7 Hz, 1 H); 3.18 to 3.32 (partially masked m, 2 H); 3.45 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 (broad d, J=11.5 Hz, 2 H); 3.80 (dd, J=3.3 and 11.4 Hz, 1 H); 4.11 (m, 1 H); 4.27 (dd, J=5.6 and 14.4 Hz, 1 H); 4.79 (m, 1 H); 4.84 (d, J=16.4 Hz, 1 H); 4.92 (s, 1 H); 5.41 (d, J=16.4 Hz, 1 H); 7.62 (d, J=3.2 Hz, 1 H); 7.70 (d, J=3.2 Hz, 1 H)

532-ELP-MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(thiazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	434		2.39	98	k; ES$^-$: [M-H+HCO2H]$^-$ m/z 478 (base peak)	1.04 (d, J=6.6 Hz, 3 H); 2.19 (m, 1 H); 2.45 (m, 1 H); 3.19 (dt, J=2.9 and 12.7 Hz, 1 H); 3.27 to 3.37 (partially masked m, 2 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.78 (m, 2 H); 4.15 (broad q, J=6.6 Hz, 1 H); 4.26 (dd, J=5.4 and 14.4 Hz, 1 H); 4.81 (m, 1 H); 4.87 (d, J=16.6 Hz, 1 H); 5.35 (d, J=16.6 Hz, 1 H); 7.63 (d, J=3.2 Hz, 1 H); 7.71 (d, J=3.2 Hz, 1 H)
232-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-[2-oxo-2-(1-piperidyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444		2.41	98	k; ES$^-$: [M-H+HCO2H]$^-$ m/z 488 (base peak)	1.03 (d, J=6.6 Hz, 3 H); 1.32 to 1.64 (m, 6 H); 2.17 (m, 1 H); 2.34 (m, 1 H); 2.99 (dt, J=3.6 and 12.7 Hz, 1 H); 3.20 (dt, J=5.2 and 14.4 Hz, 1 H); 3.31 to 3.42 (m, 5 H); 3.52 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (broad d, J=12.7 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.84 (dd, J=3.4 and 11.3 Hz, 1 H); 3.92 (d, J=16.6 Hz, 1 H); 4.17 (broad q, J=6.6 Hz, 1 H); 4.31 (dd, J=5.2 and 14.4 Hz, 1 H); 4.44 (m, 1 H); 4.90 (s, 1 H); 5.05 (d, J=16.6 Hz, 1 H)
332-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(2-morpholino-2-oxoethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	446		0.8	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 490 (base peak)	1.04 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.36 (m, 1 H); 3.00 (dt, J=3.7 and 12.7 Hz, 1 H); 3.21 (dt, J=4.9 and 14.4 Hz, 1 H); 3.31 to 3.64 (m, 11 H); 3.67 (d, J=11.4 Hz, 1 H); 3.86 (dd, J=3.3 and 11.4 Hz, 1 H); 3.97 (d, J=16.9 Hz, 1 H); 4.20 (broad q, J=6.8 Hz, 1 H); 4.32 (dd, J=4.9 and 14.4 Hz, 1 H); 4.46 (m, 1 H); 4.91 (s, 1 H); 5.06 (d, J=16.9 Hz, 1 H)
432-ELP-MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(2-morpholino-2-oxoethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	464		0.85	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 508 (base peak)	1.16 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.38 (m, 1 H); 3.23 to 3.66 (partially masked m, 13 H); 3.78 (broad d, J=12.7 Hz, 1 H); 3.83 (dd, J=2.9 and 11.3 Hz, 1 H); 4.00 (d, J=16.9 Hz, 1 H); 4.21 (broad q, J=6.8 Hz, 1 H); 4.29 (dd, J=5.4 and 14.4 Hz, 1 H); 4.45 (m, 1 H); 5.00 (d, J=16.9 Hz, 1 H)

632-ELP MAXE	2-[(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]-N-phenyl-acetamide	452	450	1	98	b	0.84 (d, J=6.7 Hz, 3 H); 2.21 (m, 1 H); 2.40 (m, 1 H); 2.92 (dt, J=3.8 and 13.0 Hz, 1 H); 3.13 to 3.26 (m, 2 H); 3.43 (dd, J=2.9 and 11.5 Hz, 1 H); 3.49 (d, J=11.5 Hz, 1 H); 3.58 (broad d, J=13.0 Hz, 1 H); 3.70 (dd, J=3.2 and 11.5 Hz, 1 H); 4.09 (d, J=16.1 Hz, 1 H); 4.20 (m, 1 H); 4.31 (m, 1 H); 4.66 (broad d, J=16.1 Hz, 2 H); 4.89 (s, 1 H); 7.03 (t, J=7.7 Hz, 1 H); 7.29 (t, J=7.7 Hz, 2 H); 7.54 (d, J=7.7 Hz, 2 H); 10.09 (broad s, 1 H)
732-ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-oxo-2-(1-piperidyl)ethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	462		1.07	98	b	1.16 (d, J=6.8 Hz, 3 H); 1.33 to 1.66 (m, 6 H); 2.18 (m, 1 H); 2.38 (m, 1 H); 3.22 to 3.33 (partially masked m, 2 H); 3.35 to 3.47 (m, 5 H); 3.59 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.78 (broad d, J=13.0 Hz, 1 H); 3.82 (dd, J=2.9 and 11.6 Hz, 1 H); 3.95 (d, J=16.9 Hz, 1 H); 4.21 (broad q, J=6.8 Hz, 1 H); 4.29 (dd, J=5.4 and 14.4 Hz, 1 H); 4.45 (m, 1 H); 5.00 (d, J=16.9 Hz, 1 H)
832-ELP MAXE	(2S)-2-Methyl-8-[(3R)-3-methylmorpholin-4-yl]-1-(oxazol-2-ylmethyl)-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	414		0.93	98	b	0.84 (d, J=6.6 Hz, 3 H); 1.74 (s, 3 H); 2.13 (m, 1 H); 2.52 (partially masked m, 1 H); 2.90 (dt, J=3.8 and 12.8 Hz, 1 H); 3.19 to 3.39 (partially masked m, 2 H); 3.44 (dd, J=2.9 and 11.7 Hz, 1 H); 3.50 (broad d, J=12.8 Hz, 1 H); 3.57 (d, J=11.7 Hz, 1 H); 3.79 (dd, J=3.3 and 11.4 Hz, 1 H); 4.02 to 4.15 (m, 2 H); 4.81 (d, J=17.1 Hz, 1 H); 4.88 (s, 1 H); 5.00 (d, J=17.1 Hz, 1 H); 7.11 (d, J=0.7 Hz, 1 H); 7.98 (broad s, 1 H)
932-ELP MAXE							

042-ELP-MAXE	(2S)-2-Methyl-7-[(3R)-3-methylmorpholin-4-yl]-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-2-(trifluoromethyl)-3H-imidazo[1,2-a]pyrimidin-5-one	415		0.93	98	b	0.92 (d, J=6.8 Hz, 3 H); 1.71 (s, 3 H); 2.56 (s, 3 H); 2.95 (dt, J=3.4 and 12.7 Hz, 1 H); 3.32 (dt, J=3.0 and 11.2 Hz, 1 H); 3.48 (dd, J=3.2 and 11.5 Hz, 1 H); 3.53 (broad d, J=12.7 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.82 (dd, J=3.0 and 11.2 Hz, 1 H); 3.97 (d, J=12.7 Hz, 1 H); 4.12 (broad q, J=6.8 Hz, 1 H); 4.20 (d, J=12.7 Hz, 1 H); 4.69 (d, J=16.9 Hz, 1 H); 4.76 (d, J=16.9 Hz, 1 H); 4.79 (s, 1 H)
142-ELP-MAXE	(2S)-1-(2-Cyclopropyl-2-oxo-ethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	401		0.96	98	b	0.76 to 0.94 (m, 4 H); 1.05 (d, J=6.7 Hz, 3 H); 2.05 to 2.20 (m, 2 H); 2.36 (m, 1 H); 2.97 (dt, J=3.8 and 12.8 Hz, 1 H); 3.20 (dt, J=4.8 and 14.4 Hz, 1 H); 3.34 (dt, J=2.9 and 12.0 Hz, 1 H); 3.50 (dd, J=3.1 and 11.5 Hz, 1 H); 3.56 to 3.66 (m, 2 H); 3.84 (dd, J=3.1 and 11.5 Hz, 1 H); 4.11 (m, 1 H); 4.29 (m, 1 H); 4.30 (d, J=18.1 Hz, 1 H); 4.54 (m, 1 H); 4.88 (d, J=18.1 Hz, 1 H); 4.90 (s, 1 H)
242-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(2-oxo-2-thiazol-2-ylethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444	442	1	97	b	0.72 (d, J=6.6 Hz, 3 H); 2.23 (m, 1 H); 2.44 (m, 1 H); 2.82 (dt, J=3.9 and 12.7 Hz, 1 H); 3.15 (dt, J=3.1 and 11.5 Hz, 1 H); 3.24 (dt, J=5.0 and 14.5 Hz, 1 H); 3.30 to 3.39 (partially masked m, 3 H); 3.62 (dd, J=3.1 and 11.5 Hz, 1 H); 3.85 (broad d, J=6.6 Hz, 1 H); 4.36 (dd, J=5.0 and 14.5 Hz, 1 H); 4.72 (m, 1 H); 4.87 (d, J=17.7 Hz, 1 H); 4.88 (s, 1 H); 5.47 (d, J=17.7 Hz, 1 H); 8.20 (d, J=3.1 Hz, 1 H); 8.29 (d, J=3.1 Hz, 1 H)
342-ELP-MAXE	Cyclopentyl 2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetate	445		1.17	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 489 (base peak)	1.07 (d, J=6.7 Hz, 3 H); 1.48 to 1.60 (m, 6 H); 1.69 to 1.82 (m, 2 H); 2.08 (m, 1 H); 2.40 (m, 1 H); 2.98 (dt, J=3.5 and 12.8 Hz, 1 H); 3.19 (dt, J=4.8 and 14.2 Hz, 1 H); 3.33 (dt, J=3.1 and 11.8 Hz, 1 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 to 3.70 (m, 2 H); 3.84 (dd, J=3.1 and 11.8 Hz, 1 H); 4.08 (m, 1 H); 4.13 (d, J=17.4 Hz, 1 H); 4.30 (dd, J=4.8 and 14.2 Hz, 1 H); 4.40 (d, J=17.4 Hz, 1 H); 4.64 (m, 1 H); 4.93 (s, 1 H); 5.09 (m, 1 H)

742 ELP MAXE	(2S)-1-(2-Cyclopentyl-2-oxo-ethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	429	427	1.17	98	b	1.02 (d, J=6.8 Hz, 3 H); 1.49 to 1.84 (m, 8 H); 2.17 (m, 1 H); 2.37 (m, 1 H); 2.97 (m, 2 H); 3.21 (dt, J=5.3 and 14.2 Hz, 1 H); 3.32 (dt, J=3.1 and 11.6 Hz, 1 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 to 3.65 (m, 2 H); 3.82 (dd, J=3.1 and 11.6 Hz, 1 H); 4.09 (broad q, J=6.8 Hz, 1 H); 4.20 (d, J=18.1 Hz, 1 H); 4.29 (dd, J=5.3 and 14.2 Hz, 1 H); 4.50 (m, 1 H); 4.90 (s, 1 H); 4.92 (d, J=18.1 Hz, 1 H)
642 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(2-oxo-2-tetrahydropyran-4-ylethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	445	443	0.9	98	b	1.02 (d, J=6.8 Hz, 3 H); 1.36 to 1.58 (m, 2 H); 1.66 to 1.77 (m, 2 H); 2.16 (m, 1 H); 2.37 (m, 1 H); 2.72 (tt, J=3.9 and 11.4 Hz, 1 H); 2.97 (dt, J=3.8 and 13.0 Hz, 1 H); 3.21 (dt, J=5.4 and 14.2 Hz, 1 H); 3.34 (dt, J=2.2 and 11.5 Hz, 3 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (broad d, J=13.0 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.80 to 3.90 (m, 3 H); 4.10 (broad q, J=6.8 Hz, 1 H); 4.23 (d, J=18.3 Hz, 1 H); 4.30 (dd, J=5.4 and 14.2 Hz, 1 H); 4.47 (m, 1 H); 4.90 (s, 1 H); 5.01 (d, J=18.3 Hz, 1 H)
542 ELP MAXE	(2S)-7-Fluoro-1-[(5-isopropyl-1,2,4-oxadiazol-3-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	461		1.17	98	b	1.00 (d, J=6.8 Hz, 3 H); 1.28 (d, J=6.8 Hz, 6 H); 2.17 (m, 1 H); 2.46 (partially masked m, 1 H); 3.18 (dt, J=3.2 and 12.5 Hz, 1 H); 3.22 to 3.39 (partially masked m, 3 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.71 (broad d, J=12.5 Hz, 1 H); 3.78 (dd, J=3.2 and 11.3 Hz, 1 H); 4.12 (m, 1 H); 4.27 (dd, J=5.4 and 14.2 Hz, 1 H); 4.63 (d, J=16.9 Hz, 1 H); 4.79 (m, 1 H); 5.18 (d, J=16.9 Hz, 1 H)
442 ELP MAXE	(2S)-1-[(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	459		1.11	98	b	1.01 (d, J=6.8 Hz, 3 H); 1.04 (m, 2 H); 1.22 (m, 2 H); 2.16 (m, 1 H); 2.31 (m, 1 H); 2.44 (m, 1 H); 3.20 (dt, J=3.2 and 13.0 Hz, 1 H); 3.29 to 3.37 (m, 2 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.74 (broad d, J=12.8 Hz, 1 H); 3.78 (dd, J=3.2 and 11.3 Hz, 1 H); 4.13 (q, J=6.8 Hz, 1 H); 4.26 (dd, J=5.4 and 14.4 Hz, 1 H); 4.56 (d, J=16.9 Hz, 1 H); 4.77 (m, 1 H); 5.14 (d, J=16.9 Hz, 1 H)

152-ELP-MAXE	(2S)-7-Fluoro-1-[(3-isopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	461	459	1.13	97	b	For this batch, all the signals are broad with: 1.03 (d, J=6.6 Hz, 3 H); 1.22 (d, J=6.6 Hz, 6 H); 2.23 (m, 1 H); 2.47 (partially masked m, 1 H); 2.96 to 3.16 (m, 2 H); 3.25 to 3.37 (partially masked m, 2 H); 3.47 (d, J=11.5 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.64 (d, J=13.0 Hz, 1 H); 3.75 (d, J=11.0 Hz, 1 H); 4.02 (m, 1 H); 4.29 (m, 1 H); 4.84 (m, 1 H); 4.93 (d, J=17.6 Hz, 1 H); 5.17 (d, J=17.6 Hz, 1 H)
052-ELP-MAXE	(2S)-1-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	459	457	1.09	98	b	0.82 (m, 2 H); 1.02 (d, J=6.6 Hz, 3 H); 1.06 (m, 2 H); 2.09 (m, 1 H); 2.21 (m, 1 H); 2.47 (partially masked m, 1 H); 3.13 (dt, J=3.4 and 12.8 Hz, 1 H); 3.25 to 3.37 (partially masked m, 2 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.64 (broad d, J=12.8 Hz, 1 H); 3.77 (dd, J=2.9 and 11.0 Hz, 1 H); 4.02 (broad q, J=6.6 Hz, 1 H); 4.28 (dd, J=5.4 and 14.4 Hz, 1 H); 4.81 (m, 1 H); 4.87 (d, J=17.4 Hz, 1 H); 5.13 (d, J=17.4 Hz, 1 H)
942-ELP-MAXE	(2S)-1-[(3-tert-Butyl-1,2,4-oxadiazol-5-yl)methyl]-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	475	473	1.23	98	b	1.04 (d, J=6.7 Hz, 3 H); 1.27 (s, 9 H); 2.22 (m, 1 H); 2.47 (partially masked m, 1 H); 3.09 (dt, J=3.4 and 13.2 Hz, 1 H); 3.29 to 3.37 (m, 2 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 (d, J=11.5 Hz, 1 H); 3.63 (broad d, J=13.2 Hz, 1 H); 3.75 (dd, J=2.9 and 11.0 Hz, 1 H); 4.01 (broad q, J=6.7 Hz, 1 H); 4.30 (dd, J=5.4 and 14.4 Hz, 1 H); 4.83 (m, 1 H); 4.95 (d, J=17.6 Hz, 1 H); 5.17 (d, J=17.6 Hz, 1 H)
842-ELP-MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-1-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	487	485	1.21	92	b	1.00 (d, J=6.6 Hz, 3 H); 2.24 (m, 1 H); 2.48 (partially masked m, 1 H); 3.09 (dt, J=3.4 and 13.0 Hz, 1 H); 3.28 to 3.38 (m, 2 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 (d, J=11.5 Hz, 1 H); 3.62 (broad d, J=13.0 Hz, 1 H); 3.75 (dd, J=3.1 and 11.5 Hz, 1 H); 4.00 (m, 1 H); 4.30 (dd, J=5.4 and 14.4 Hz, 1 H); 4.87 (m, 1 H); 5.12 (d, J=17.9 Hz, 1 H); 5.38 (d, J=17.9 Hz, 1 H)

252-ELP-MAXE	(2S)-2-Methyl-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydropyrimido[1,2-a]-pyrimidin-6-one	417		1.08	93	b	0.99 to 1.06 (m, 9 H); 1.48 (s, 3 H); 2.08 (m, 1 H); 2.44 (td, J=3.9 and 14.9 Hz, 1 H); 2.78 (spt, J=6.8 Hz, 1 H); 2.96 (dt, J=3.7 and 12.7 Hz, 1 H); 3.23 to 3.41 (partially masked m, 2 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (broad d, J=12.8 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.82 (dd, J=3.2 and 11.2 Hz, 1 H); 4.01 to 4.15 (m, 2 H); 4.41 (d, J=18.6 Hz, 1 H); 4.81 (broad d, J=18.6 Hz, 1 H); 4.91 (s, 1 H)
352-ELP-MAXE	(2S)-1-[2-(1-Methylcyclopentyl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	443		1.26	98	b	1.04 (d, J=6.8 Hz, 3 H); 1.22 (s, 3 H); 1.35 to 1.71 (m, 6 H); 1.88 to 2.06 (m, 2 H); 2.18 (m, 1 H); 2.36 (m, 1 H); 2.98 (dt, J=3.6 and 12.8 Hz, 1 H); 3.22 (dt, J=5.4 and 14.4 Hz, 1 H); 3.31 (dt, J=3.1 and 11.6 Hz, 1 H); 3.48 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 (d, J=11.5 Hz, 1 H); 3.66 (broad d, J=12.8 Hz, 1 H); 3.81 (dd, J=3.1 and 11.6 Hz, 1 H); 4.07 (m, 1 H); 4.30 (broad d, J=18.6 Hz, 2 H); 4.44 (m, 1 H); 4.90 (s, 1 H); 5.21 (d, J=18.6 Hz, 1 H)
452-ELP-MAXE	Isopropyl 2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetate	419		1.08	98	b	1.07 (d, J=6.6 Hz, 3 H); 1.15 (d, J=6.2 Hz, 3 H); 1.17 (d, J=6.2 Hz, 3 H); 2.10 (m, 1 H); 2.39 (m, 1 H); 2.98 (dt, J=3.5 and 12.7 Hz, 1 H); 3.20 (dt, J=4.9 and 14.3 Hz, 1 H); 3.33 (dt, J=2.9 and 11.8 Hz, 1 H); 3.49 (dd, J=2.7 and 11.5 Hz, 1 H); 3.64 (broad d, J=11.5 Hz, 2 H); 3.85 (dd, J=2.9 and 11.8 Hz, 1 H); 4.08 (m, 1 H); 4.13 (d, J=17.4 Hz, 1 H); 4.30 (dd, J=4.9 and 14.3 Hz, 1 H); 4.45 (d, J=17.4 Hz, 1 H); 4.64 (m, 1 H); 4.90 (spt, J=6.2 Hz, 1 H); 4.93 (s, 1 H)
552-ELP-MAXE	(2S)-1-(3,3-Dimethyl-2-oxo-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	417	415	1.14	98	b	For this batch, all the signals are broad with: 1.04 (d, J=6.7 Hz, 3 H); 1.14 (s, 9 H); 2.17 (m, 1 H); 2.36 (m, 1 H); 2.98 (td, J=3.3 and 12.8 Hz, 1 H); 3.18 to 3.37 (partially masked m, 2 H); 3.49 (dd, J=2.5 and 11.5 Hz, 1 H); 3.56 to 3.70 (m, 2 H); 3.81 (m, 1 H); 4.09 (m, 1 H); 4.31 (m, 2 H); 4.41 (m, 1 H); 4.90 (s, 1 H); 5.23 (d, J=18.6 Hz, 1 H)

652-ELP-MAXE	(2S)-1-Acetonyl-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	375		0.85	94	b	For this batch, all the signals are broad with: 1.01 (d, J=6.6 Hz, 3 H); 2.08 (s, 3 H); 2.15 (m, 1 H); 2.38 (m, 1 H); 2.96 (m, 1 H); 3.20 (m, 1 H); 3.35 (m, 1 H); 3.50 (d, J=11.7 Hz, 2 H); 3.63 (d, J=11.7 Hz, 1 H); 3.83 (m, 1 H); 4.08 to 4.18 (m, 2 H); 4.31 (m, 1 H); 4.51 (m, 1 H); 4.74 (d, J=18.1 Hz, 1 H); 4.91 (s, 1 H)
752-ELP-MAXE	(2S)-1-[(2-Fluoro-4-pyridyl)methyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	428	426	0.97	94	b; ES^-: $[M-H+HCO2H]^-$ m/z 472 (base peak)	For this batch, all the signals are broad with: 0.63 (d, J=6.5 Hz, 3 H); 2.42 (partially masked m, 2 H); 2.85 (m, 1 H); 3.18 to 3.43 (m, 4 H); 3.50 (d, J=11.5 Hz, 1 H); 3.74 (m, 1 H); 3.94 (m, 1 H); 4.25 (m, 1 H); 4.64 (d, J=16.9 Hz, 1 H); 4.82 (m, 1 H); 4.89 (s, 1 H); 5.10 (d, J=16.9 Hz, 1 H); 7.04 (s, 1 H); 7.22 (s, 1 H); 8.14 (d, J=4.8 Hz, 1 H)
852-ELP-MAXE	(2S)-1-(2-Cyclohexyl-2-oxo-ethyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	443	441	1.25	98	b	For this batch, all the signals are broad with: 1.01 (d, J=6.7 Hz, 3 H); 1.07 to 1.36 (m, 5 H); 1.56 to 1.88 (m, 5 H); 2.15 (m, 1 H); 2.37 (m, 1 H); 2.47 (partially masked m, 1 H); 2.96 (m, 1 H); 3.19 (m, 1 H); 3.22 (partially masked m, 1 H); 3.49 (d, J=11.5 Hz, 1 H); 3.61 (m, 2 H); 3.82 (d, J=14.2 Hz, 1 H); 4.10 (m, 1 H); 4.20 (d, J=18.3 Hz, 1 H); 4.29 (m, 1 H); 4.45 (m, 1 H); 4.89 (s, 1 H); 4.98 (d, J=18.3 Hz, 1 H)
952-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(pyridazin-4-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	411		0.73	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 455 (base peak)	0.58 (d, J=6.7 Hz, 3 H); 2.38 to 2.58 (partially masked m, 2 H); 2.82 (dt, J=3.8 and 12.7 Hz, 1 H); 3.19 (dt, J=2.9 and 11.8 Hz, 1 H); 3.25 to 3.35 (partially masked m, 2 H); 3.37 (dd, J=2.9 and 11.5 Hz, 1 H); 3.48 (d, J=11.5 Hz, 1 H); 3.72 (dd, J=3.4 and 11.5 Hz, 1 H); 3.88 (m, 1 H); 4.26 (dd, J=5.4 and 14.2 Hz, 1 H); 4.69 (d, J=17.3 Hz, 1 H); 4.86 (m, 1 H); 4.89 (s, 1 H); 5.06 (d, J=17.3 Hz, 1 H); 7.51 (dd, J=2.3 and 5.3 Hz, 1 H); 9.10 (broad d, J=5.3 Hz, 1 H); 9.15 (broad s, 1 H)

062-ELPMAXE	tert-Butyl 2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetate	433		1.15	98	b	1.10 (d, J=6.6 Hz, 3 H); 1.37 (s, 9 H); 2.09 (m, 1 H); 2.38 (m, 1 H); 2.99 (dt, J=3.7 and 13.0 Hz, 1 H); 3.19 (dt, J=3.5 and 14.2 Hz, 1 H); 3.32 (dt, J=2.7 and 11.7 Hz, 1 H); 3.48 (dd, J=2.8 and 11.5 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.73 (broad d, J=13.0 Hz, 1 H); 3.86 (dd, J=2.7 and 11.7 Hz, 1 H); 4.06 (broad d, J=17.3 Hz, 2 H); 4.30 (dd, J=5.2 and 14.2 Hz, 1 H); 4.35 (d, J=17.3 Hz, 1 H); 4.62 (m, 1 H); 4.93 (s, 1 H)
162-ELPMAXE	tert-Butyl 2-[2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetyl]pyrrolidine-1-carboxylate	530	528	1.24	98	b	At 80°C, the following are localized: 1.11 (d, J=6.8 Hz, 3 H); 1.42 (s, 9 H); 1.74 to 1.95 (m, 3 H); 2.04 to 2.28 (m, 2 H); 2.40 (m, 1 H); 3.02 (dt, J=4.2 and 13.0 Hz, 1 H); 3.26 (dt, J=4.8 and 14.3 Hz, 1 H); 3.31 to 3.47 (m, 3 H); 3.52 (dd, J=2.9 and 11.6 Hz, 1 H); 3.62 (d, J=11.6 Hz, 1 H); 3.73 (broad d, J=13.0 Hz, 1 H); 3.83 (dd, J=3.2 and 11.5 Hz, 1 H); 4.06 (broad q, J=6.8 Hz, 1 H); 4.22 to 4.37 (m, 4 H); 4.91 (s, 1 H); 5.06 (d, J=18.6 Hz, 1 H)
262-ELPMAXE	Methyl 2-[(2S)-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetate	391		0.92	98	b	1.05 (d, J=6.7 Hz, 3 H); 2.11 (m, 1 H); 2.39 (m, 1 H); 2.98 (dt, J=3.8 and 13.0 Hz, 1 H); 3.20 (dt, J=5.0 and 14.4 Hz, 1 H); 3.35 (dt, J=3.2 and 11.6 Hz, 1 H); 3.50 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (broad d, J=13.0 Hz, 1 H); 3.62 (s, 3 H); 3.64 (d, J=11.5 Hz, 1 H); 3.85 (dd, J=3.2 and 11.6 Hz, 1 H); 4.12 (m, 1 H); 4.15 (d, J=17.1 Hz, 1 H); 4.30 (dd, J=5.0 and 14.4 Hz, 1 H); 4.50 (d, J=17.1 Hz, 1 H); 4.65 (m, 1 H); 4.93 (s, 1 H)
362-ELPMAXE	2-[(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide	376		0.65	97	b; ES^-: $[M-H+HCO2H]^-$ m/z 420 (base peak)	1.07 (d, J=6.6 Hz, 3 H); 2.20 (m, 1 H); 2.34 (m, 1 H); 2.99 (dt, J=3.8 and 12.8 Hz, 1 H); 3.19 (dt, J=4.4 and 14.2 Hz, 1 H); 3.36 (dt, J=3.3 and 11.8 Hz, 1 H); 3.52 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (broad d, J=11.5 Hz, 2 H); 3.77 (d, J=16.6 Hz, 1 H); 3.84 (dd, J=3.3 and 11.8 Hz, 1 H); 4.21 (broad q, J=6.6 Hz, 1 H); 4.28 (dd, J=4.4 and 14.2 Hz, 1 H); 4.50 (d, J=16.6 Hz, 1 H); 4.56 (m, 1 H); 4.91 (s, 1 H); 7.02 (broad s, 1 H); 7.39 (broad s, 1 H)

462-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(4H-1,2,4-triazol-3-ylmethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	400	398	0.7	98	b	0.79 (d, J=6.6 Hz, 3 H); 2.26 (m, 1 H); 2.41 (m, 1 H); 2.91 (dt, J=3.6 and 12.7 Hz, 1 H); 3.19 to 3.30 (partially masked m, 2 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.51 (broad d, J=13.0 Hz, 1 H); 3.57 (d, J=11.5 Hz, 1 H); 3.79 (dd, J=2.9 and 11.6 Hz, 1 H); 4.08 (broad q, J=6.6 Hz, 1 H); 4.26 (dd, J=5.6 and 14.6 Hz, 1 H); 4.47 (d, J=16.1 Hz, 1 H); 4.76 (m, 1 H); 4.87 (s, 1 H); 5.31 (d, J=16.1 Hz, 1 H); 8.22 (broad s, 1 H); 13.74 (broad m, 1 H)
562-ELP-MAXE	(2S)-1-[2-oxo-2-(4-piperidyl)ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	444	442	0.48	98	b; ES^+: $[M+2H]^{2+}$ m/z 222.5 (base peak)	1.02 (d, J=6.6 Hz, 3 H); 1.21 to 1.42 (m, 2 H); 1.69 (m, 2 H); 2.15 (m, 1 H); 2.36 (m, 2 H); 2.41 to 2.57 (partially masked m, 2 H); 2.89 to 3.01 (m, 2 H); 3.14 to 3.37 (partially masked m, 4 H); 3.49 (dd, J=2.9 and 11.5 Hz, 1 H); 3.55 to 3.65 (m, 2 H); 3.82 (dd, J=3.2 and 11.5 Hz, 1 H); 4.09 (m, 1 H); 4.20 (d, J=18.3 Hz, 1 H); 4.30 (dd, J=5.1 and 14.4 Hz, 1 H); 4.45 (m, 1 H); 4.90 (s, 1 H); 4.99 (d, J=18.3 Hz, 1 H)
662-ELP-MAXE	(2S)-1-(3-Methylbut-2-enyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	387		1.25	98	b	1.11 (d, J=6.8 Hz, 3 H); 1.65 (s, 3 H); 1.69 (s, 3 H); 2.05 (m, 1 H); 2.34 (m, 1 H); 3.01 (dt, J=3.8 and 12.8 Hz, 1 H); 3.16 (dt, J=4.9 and 14.4 Hz, 1 H); 3.37 (dt, J=3.2 and 11.2 Hz, 1 H); 3.52 (dd, J=2.9 and 11.5 Hz, 1 H); 3.62 to 3.71 (m, 2 H); 3.81 to 3.93 (m, 2 H); 4.14 to 4.24 (m, 2 H); 4.45 (m, 1 H); 4.59 (dd, J=5.4 and 14.4 Hz, 1 H); 4.90 (s, 1 H); 5.19 (t, J=5.9 Hz, 1 H)
762-ELP-MAXE	(2S)-1-(3-Fluoro-3-methyl-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	407		1.17	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 451 (base peak)	1.12 (d, J=6.8 Hz, 3 H); 1.31 (s, 3 H); 1.36 (s, 3 H); 1.85 to 2.13 (m, 3 H); 2.34 (m, 1 H); 3.04 (dt, J=3.7 and 12.8 Hz, 1 H); 3.15 (dt, J=4.2 and 14.0 Hz, 1 H); 3.30 to 3.43 (m, 2 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.64 (d, J=11.5 Hz, 1 H); 3.68 (broad d, J=12.8 Hz, 1 H); 3.85 (dd, J=3.2 and 11.5 Hz, 1 H); 4.08 (m, 1 H); 4.16 to 4.28 (m, 2 H); 4.63 (m, 1 H); 4.91 (s, 1 H)

EXEMPLE 172	(2S)-1-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	442	440	2.33	98	k	Unexploitable NMR spectrum cannot be described
EXEMPLE 862	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(2-oxo-2-tetrahydrofuran-3-ylethyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	431	429	0.87	98	b	For this batch, a 50%-50% mixture of isomers is observed with: 1.01 (m, 3 H); 1.85 to 2.23 (m, 3 H); 2.38 (m, 1 H); 2.97 (m, 1 H); 3.16 to 3.39 (partially masked m, 3 H); 3.46 to 3.86 (m, 8 H); 4.09 (m, 1 H); 4.20 to 4.34 (m, 2 H); 4.52 (m, 1 H); 4.89 (d, J=18.3 Hz, 0.5 H); 4.90 (s, 1 H); 4.93 (d, J=18.3 Hz, 0.5 H)
EXEMPLE 962	(2S)-1-[(5-Methyl-1,2,4-oxadiazol-3-yl)methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	427		0.9	98	b	1.36 to 1.56 (m, 2 H); 1.73 (m, 2 H); 2.15 (m, 1 H); 2.42 (m, 1 H); 2.56 (s, 3 H); 2.80 (m, 2 H); 3.21 (partially masked m, 1 H); 3.56 (broad d, J=12.5 Hz, 1 H); 3.66 (broad d, J=12.5 Hz, 1 H); 4.22 to 4.30 (m, 3 H); 4.63 (d, J=16.6 Hz, 1 H); 4.77 (m, 1 H); 4.85 (s, 1 H); 5.11 (d, J=16.6 Hz, 1 H)
EXEMPLE 072	(2S)-1-(2-Cyclopropyl-2-oxo-ethyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	413	411	0.95	98	b	0.76 to 0.95 (m, 4 H); 1.53 to 1.68 (m, 2 H); 1.78 (m, 2 H); 2.08 to 2.20 (m, 2 H); 2.36 (m, 1 H); 2.86 (m, 2 H); 3.19 (dt, J=4.8 and 14.2 Hz, 1 H); 3.57 to 3.71 (m, 2 H); 4.24 to 4.36 (m, 4 H); 4.55 (m, 1 H); 4.78 (d, J=17.6 Hz, 1 H); 4.85 (s, 1 H)

572 ELP MAXE	(2S)-1-(3-Methyl-2-oxobutyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	415	413	1.03	98	b	1.02 (d, J=6.8 Hz, 3 H); 1.04 (d, J=6.8 Hz, 3 H); 1.52 to 1.68 (m, 2 H); 1.77 (m, 2 H); 2.16 (m, 1 H); 2.37 (m, 1 H); 2.71 (spt, J=6.8 Hz, 1 H); 2.84 (m, 2 H); 3.20 (m, 1 H); 3.54 to 3.68 (m, 2 H); 4.25 (d, J=18.1 Hz, 1 H); 4.31 (m, 3 H); 4.47 (m, 1 H); 4.86 (s, 1 H); 4.93 (d, J=18.1 Hz, 1 H)
272 ELP MAXE	(2S)-1-(2-Cyclopropyl-2-oxo-ethyl)-7-fluoro-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	431	429	1	98	b	0.78 to 0.97 (m, 4 H); 1.61 to 1.84 (m, 4 H); 2.07 to 2.22 (m, 2 H); 2.39 (m, 1 H); 3.07 (m, 2 H); 3.28 (partially masked m, 1 H); 3.76 (d, J=12.7 Hz, 1 H); 3.82 (d, J=12.7 Hz, 1 H); 4.22 to 4.32 (m, 3 H); 4.35 (d, J=18.1 Hz, 1 H); 4.54 (s, 1 H); 4.78 (d, J=18.1 Hz, 1 H)
372 ELP MAXE	(2S)-7-Fluoro-1-(3-methyl-2-oxobutyl)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	433	431	1.09	98	b	1.01 (d, J=6.8 Hz, 3 H); 1.03 (d, J=6.8 Hz, 3 H); 1.60 to 1.81 (m, 4 H); 2.16 (m, 1 H); 2.39 (m, 1 H); 2.70 (spt, J=6.8 Hz, 1 H); 3.05 (m, 2 H); 3.28 (partially masked m, 1 H); 3.73 (d, J=12.7 Hz, 1 H); 3.80 (d, J=12.7 Hz, 1 H); 4.23 to 4.32 (m, 4 H); 4.47 (m, 1 H); 4.91 (d, J=18.3 Hz, 1 H)
472 ELP MAXE	(2S)-7-Fluoro-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	445		0.96	98	b	1.40 to 1.57 (m, 2 H); 1.72 (m, 2 H); 2.16 (m, 1 H); 2.44 (m, 1 H); 2.57 (s, 3 H); 3.01 (d, J=12.8 Hz, 1 H); 3.05 (d, J=12.8 Hz, 1 H); 3.29 (dt, J=4.2 and 14.2 Hz, 1 H); 3.72 (d, J=12.8 Hz, 1 H); 3.83 (d, J=12.8 Hz, 1 H); 4.25 (m, 3 H); 4.65 (d, J=16.6 Hz, 1 H); 4.79 (m, 1 H); 5.09 (d, J=16.6 Hz, 1 H)

672 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(4-methyl-2-oxo-pentyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	417	415	1.14	98	b	0.87 (d, J=6.7 Hz, 6 H); 1.03 (d, J=6.8 Hz, 3 H); 2.02 (m, J=6.7 Hz, 1 H); 2.17 (m, 1 H); 2.33 (d, J=6.7 Hz, 2 H); 2.38 (m, 1 H); 2.97 (dt, J=3.5 and 12.8 Hz, 1 H); 3.21 (dt, J=4.6 and 14.4 Hz, 1 H); 3.31 (dt, J=3.1 and 11.5 Hz, 1 H); 3.48 (dd, J=2.9 and 11.4 Hz, 1 H); 3.59 (broad d, J=12.8 Hz, 1 H); 3.63 (d, J=11.4 Hz, 1 H); 3.83 (dd, J=3.1 and 11.5 Hz, 1 H); 4.09 (m, 1 H); 4.13 (d, J=18.1 Hz, 1 H); 4.30 (dd, J=4.6 and 14.4 Hz, 1 H); 4.50 (m, 1 H); 4.78 (d, J=18.1 Hz, 1 H); 4.91 (s, 1 H)
672 ELP MAXE	(2S)-8-[(3S)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	403		1.04	98	b	1.02 (d, J=6.7 Hz, 3 H); 1.04 (d, J=6.7 Hz, 3 H); 1.07 (d, J=6.8 Hz, 3 H); 2.15 (m, 1 H); 2.37 (m, 1 H); 2.70 (spt, J=6.7 Hz, 1 H); 2.91 (dt, J=3.8 and 12.8 Hz, 1 H); 3.20 (dt, J=3.6 and 14.2 Hz, 1 H); 3.34 (dt, J=3.4 and 11.4 Hz, 1 H); 3.46 (dd, J=2.9 and 11.5 Hz, 1 H); 3.59 to 3.68 (m, 2 H); 3.82 (dd, J=3.4 and 11.4 Hz, 1 H); 4.03 (broad q, J=6.8 Hz, 1 H); 4.29 (m, 1 H); 4.32 (d, J=18.3 Hz, 1 H); 4.47 (m, 1 H); 4.87 (d, J=18.3 Hz, 1 H); 4.90 (s, 1 H)
772 ELP MAXE	(2S)-7-Fluoro-8-[(3S)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	421	419	1.1	98	b	1.02 (d, J=6.8 Hz, 3 H); 1.04 (d, J=6.8 Hz, 3 H); 1.16 (d, J=6.8 Hz, 3 H); 2.17 (m, 1 H); 2.39 (m, 1 H); 2.70 (spt, J=6.8 Hz, 1 H); 3.17 (broad t, J=13.2 Hz, 1 H); 3.28 (partially masked m, 1 H); 3.40 (broad t, J=11.3 Hz, 1 H); 3.54 (broad d, J=11.5 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.71 (broad d, J=13.2 Hz, 1 H); 3.80 (broad d, J=11.3 Hz, 1 H); 4.16 (m, 1 H); 4.27 (m, 1 H); 4.32 (d, J=18.3 Hz, 1 H); 4.48 (m, 1 H); 4.87 (d, J=18.3 Hz, 1 H)
872 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(5-methyl-2-oxo-hexyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449	447	1.29	98	b	0.85 (d, J=6.6 Hz, 6 H); 1.13 (d, J=6.8 Hz, 3 H); 1.35 (m, 2 H); 1.50 (spt, J=6.6 Hz, 1 H); 2.16 (m, 1 H); 2.36 to 2.46 (m, 3 H); 3.22 (dt, J=3.4 and 12.7 Hz, 1 H); 3.29 (partially masked m, 1 H); 3.39 (dt, J=2.8 and 11.6 Hz, 1 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.74 (broad d, J=12.7 Hz, 1 H); 3.80 (dd, J=2.8 and 11.6 Hz, 1 H); 4.16 (m, 1 H); 4.18 (d, J=18.3 Hz, 1 H); 4.28 (dd, J=5.4 and 14.4 Hz, 1 H); 4.49 (m, 1 H); 4.75 (d, J=18.3 Hz, 1 H)
972 ELP MAXE							

382-EL P MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-(4-methyl-2-oxo-pentyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	435	433	1.2	98	b	For this batch, all the signals are broad with: 0.87 (d, J=5.9 Hz, 6 H); 1.15 (d, J=6.4 Hz, 3 H); 2.01 (m, 1 H); 2.16 (m, 1 H); 2.33 (d, J=5.9 Hz, 2 H); 2.40 (m, 1 H); 3.17 to 3.42 (partially masked m, 3 H); 3.52 to 3.66 (m, 2 H); 3.70 to 3.86 (m, 2 H); 4.16 (d, J=18.1 Hz, 2 H); 4.28 (m, 1 H); 4.49 (m, 1 H); 4.73 (d, J=18.1 Hz, 1 H)
082-EL P MAXE	(2S)-1-(3-Ethyl-2-oxo-pentyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	431	429	1.22	96	b	0.80 (t, J=7.4 Hz, 3 H); 0.82 (t, J=7.4 Hz, 3 H); 1.06 (d, J=6.8 Hz, 3 H); 1.42 (m, 2 H); 1.58 (m, 2 H); 2.18 (m, 1 H); 2.37 (m, 1 H); 2.46 (quint, J=6.4 Hz, 1 H); 2.97 (dt, J=3.5 and 13.0 Hz, 1 H); 3.16 to 3.32 (partially masked m, 2 H); 3.47 (dd, J=2.8 and 11.4 Hz, 1 H); 3.61 (d, J=11.4 Hz, 1 H); 3.71 (broad d, J=13.0 Hz, 1 H); 3.82 (dd, J=3.2 and 11.3 Hz, 1 H); 4.02 (broad q, J=6.8 Hz, 1 H); 4.24 (d, J=18.6 Hz, 1 H); 4.29 (dd, J=5.2 and 14.2 Hz, 1 H); 4.40 (m, 1 H); 4.91 (s, 1 H); 5.01 (d, J=18.6 Hz, 1 H)
182-EL P MAXE	(2S)-1-(3-Ethyl-2-oxo-pentyl)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	449	447	1.28	98	b	0.79 (t, J=7.4 Hz, 3 H); 0.82 (t, J=7.4 Hz, 3 H); 1.18 (d, J=6.8 Hz, 3 H); 1.43 (m, 2 H); 1.57 (m, 2 H); 2.18 (m, 1 H); 2.39 (m, 1 H); 2.46 (quint, J=6.4 Hz, 1 H); 3.15 to 3.40 (m, 3 H); 3.54 (dd, J=2.9 and 11.4 Hz, 1 H); 3.60 (d, J=11.4 Hz, 1 H); 3.81 (broad d, J=11.5 Hz, 2 H); 4.16 (broad q, J=6.8 Hz, 1 H); 4.28 (broad d, J=18.6 Hz, 2 H); 4.41 (m, 1 H); 4.94 (d, J=18.6 Hz, 1 H)
282-EL P MAXE	Methyl 2-[(2S)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-6-oxo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-1-yl]acetate	409		0.98	98	b	1.17 (d, J=6.8 Hz, 3 H); 2.12 (m, 1 H); 2.42 (m, 1 H); 3.21 to 3.32 (partially masked m, 2 H); 3.42 (dt, J=2.7 and 11.6 Hz, 1 H); 3.57 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (d, J=11.5 Hz, 1 H); 3.64 (s, 3 H); 3.78 (broad d, J=13.2 Hz, 1 H); 3.83 (dd, J=2.9 and 11.3 Hz, 1 H); 4.17 (broad d, J=17.4 Hz, 2 H); 4.28 (dd, J=5.5 and 14.4 Hz, 1 H); 4.49 (d, J=17.4 Hz, 1 H); 4.65 (m, 1 H)

782 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-sec-butyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	375		1.17	98	b	0.86 (t, J=7.4 Hz, 3 H); 1.12 (d, J=6.8 Hz, 3 H); 1.33 (d, J=6.8 Hz, 3 H); 1.53 (m, 1 H); 1.87 to 2.09 (m, 2 H); 2.36 (m, 1 H); 3.02 (dt, J=3.9 and 12.8 Hz, 1 H); 3.17 (m, 1 H); 3.40 (dt, J=3.0 and 11.6 Hz, 1 H); 3.55 (dd, J=2.9 and 11.6 Hz, 1 H); 3.67 (broad d, J=11.6 Hz, 2 H); 3.87 (dd, J=3.9 and 11.6 Hz, 1 H); 3.96 to 4.19 (m, 3 H); 4.61 (m, 1 H); 4.91 (s, 1 H)
482 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-sec-butyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	375		1.17	98	b	0.82 (t, J=7.4 Hz, 3 H); 1.12 (d, J=6.8 Hz, 3 H); 1.24 (d, J=6.8 Hz, 3 H); 1.65 (m, 2 H); 1.95 (m, 1 H); 2.40 (m, 1 H); 3.02 (dt, J=3.9 and 13.0 Hz, 1 H); 3.19 (m, 1 H); 3.40 (dt, J=3.9 and 11.7 Hz, 1 H); 3.55 (dd, J=3.2 and 11.5 Hz, 1 H); 3.60 to 3.70 (m, 2 H); 3.87 (dd, J=3.9 and 11.7 Hz, 1 H); 4.07 (m, 1 H); 4.18 (m, 1 H); 4.43 (m, 1 H); 4.63 (m, 1 H); 4.91 (s, 1 H)
582 ELP MAXE	(2S)-1-(2-Hydroxy-3-methyl-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	405		1.1	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 449 (base peak)	0.87 (d, J=6.6 Hz, 6 H); 1.11 (d, J=6.8 Hz, 3 H); 1.57 (spt, J=6.8 Hz, 1 H); 2.21 (m, 1 H); 2.34 (m, 1 H); 2.89 (dd, J=10.3 and 13.9 Hz, 1 H); 3.03 (dt, J=3.8 and 12.9 Hz, 1 H); 3.19 (dt, J=4.9 and 14.4 Hz, 1 H); 3.37 (dt, J=3.7 and 11.6 Hz, 1 H); 3.53 (dd, J=3.1 and 11.4 Hz, 1 H); 3.59 (broad d, J=12.9 Hz, 1 H); 3.64 (m, 2 H); 3.85 (dd, J=3.7 and 11.6 Hz, 1 H); 4.15 to 4.30 (m, 3 H); 4.64 (m, 1 H); 4.86 (d, J=6.1 Hz, 1 H); 4.90 (s, 1 H)
682 ELP MAXE	(2S)-1-(2-Hydroxy-3-methyl-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	405		1.06	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 449 (base peak)	0.87 (dd, J=6.8 Hz, 3 H); 0.89 (dd, J=6.8 Hz, 3 H); 1.11 (d, J=6.8 Hz, 3 H); 1.59 (spt, J=6.8 Hz, 1 H); 2.20 (m, 1 H); 2.34 (m, 1 H); 2.97 to 3.07 (m, 2 H); 3.24 (partially masked m, 1 H); 3.38 (dt, J=3.1 and 11.6 Hz, 1 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 to 3.74 (m, 3 H); 3.86 (dd, J=3.4 and 11.6 Hz, 1 H); 4.09 (dd, J=5.4 and 14.3 Hz, 1 H); 4.23 (m, 1 H); 4.43 (dd, J=8.4 and 14.1 Hz, 1 H); 4.53 (d, J=4.9 Hz, 1 H); 4.59 (m, 1 H); 4.89 (s, 1 H)

192-ELP-MAXE	(2S)-1-(2-Methoxy-3-methyl-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	419		2.77	98	k	0.87 (d, J=6.5 Hz, 3 H); 0.89 (d, J=6.5 Hz, 3 H);1.12 (d, J=6.6 Hz, 3 H); 1.79 (m, 1 H); 2.11 (m, 1 H); 2.38 (m, 1 H); 2.99 to 3.11 (m, 2 H); 3.17 to 3.30 (partially masked m, 1 H); 3.27 (s, partially masked, 3 H); 3.38 (dt, J=3.1 and 11.5 Hz, 1 H); 3.45 (m, 1 H); 3.55 (dd, J=2.9 and 11.5 Hz, 1 H); 3.63 (broad d, J=12.7 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.86 (dd, J=3.1 and 11.5 Hz, 1 H); 4.10 (dd, J=6.2 and 14.3 Hz, 1 H); 4.25 (m, 1 H); 4.48 (dd, J=7.6 and 14.4 Hz, 1 H); 4.59 (m, 1 H); 4.91 (s, 1 H)
882-ELP-MAXE	(2S)-1-(2-Methoxy-3-methyl-butyl)-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	419		2.87	98	k	0.89 (d, J=7.1 Hz, 3 H); 0.91 (d, J=7.1 Hz, 3 H); 1.13 (d, J=6.8 Hz, 3 H); 1.86 (m, 1 H); 2.12 (m, 1 H); 2.40 (m, 1 H); 2.94 (dd, J=10.0 and 14.4 Hz, 1 H); 3.04 (dt, J=3.9 and 12.7 Hz, 1 H); 3.20 (dt, J=5.4 and 14.2 Hz, 1 H); 3.30 (s, 3 H); 3.34 to 3.45 (m, 2 H); 3.54 (dd, J=2.9 and 11.5 Hz, 1 H); 3.65 (broad d, J=11.5 Hz, 2 H); 3.85 (dd, J=3.3 and 11.4 Hz, 1 H); 4.15 to 4.25 (m, 2 H); 4.29 (dd, J=2.2 and 14.4 Hz, 1 H); 4.59 (m, 1 H); 4.91 (s, 1 H)
982-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(5-methyl-2-oxo-hexyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	431	429	1.22	98	b	0.85 (d, J=6.6 Hz, 6 H); 1.01 (d, J=6.8 Hz, 3 H); 1.36 (m, 2 H); 1.50 (spt, J=6.6 Hz, 1 H); 2.16 (m, 1 H); 2.38 (m, 1 H); 2.43 (dt, J=1.7 and 7.3 Hz, 2 H); 2.96 (dt, J=3.9 and 13.0 Hz, 1 H); 3.21 (dt, J=5.4 and 14.4 Hz, 1 H); 3.33 (dt, J=3.5 and 12.0 Hz, 1 H); 3.50 (dd, J=2.9 and 11.6 Hz, 1 H); 3.54 (broad d, J=13.0 Hz, 1 H); 3.62 (d, J=11.6 Hz, 1 H); 3.83 (dd, J=3.5 and 12.0 Hz, 1 H); 4.11 (m, 1 H); 4.15 (d, J=18.1 Hz, 1 H); 4.31 (dd, J=5.4 and 14.4 Hz, 1 H); 4.50 (m, 1 H); 4.79 (d, J=18.1 Hz, 1 H); 4.91 (s, 1 H)
092-ELP-MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxo-pentyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	417		1.14	98	b	For this batch, a 50%-50% mixture of isomers is observed with: 0.83 (t, J=7.4 Hz, 1.5 H); 0.84 (t, J=7.4 Hz, 1.5 H); 0.99 to 1.07 (m, 6 H); 1.32 (m, 1 H); 1.63 (m, 1 H); 2.17 (m, 1 H); 2.37 (m, 1 H); 2.56 (m, 1 H); 2.97 (dt, J=3.6 and 12.9 Hz, 1 H); 3.15 to 3.35 (m, 2 H); 3.48 (dd, J=3.1 and 11.6 Hz, 1 H); 3.61 (d, J=11.6 Hz, 1 H); 3.66 (broad d, J=12.9 Hz, 1 H); 3.82 (dd, J=3.4 and 11.0 Hz, 1 H); 4.08 (m, 1 H); 4.21 (d, J=18.5 Hz, 0.5 H); 4.26 (d, J=18.5 Hz, 0.5 H); 4.30 (m, 1 H); 4.45 (m, 1 H); 4.90 (s, 1 H); 4.96 (d, J=18.5 Hz, 0.5 H); 5.00 (d, J=18.5 Hz, 0.5 H)

592 ELP MAXE	(2S)-8-[(3R)-3-Methylmorpholin-4-yl]-2-(trifluoromethyl)-1-[[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]methyl]-3,4-dihydro-2H-pyrimido[1,2-a]-pyrimidin-6-one	469	467	1.23	98	b	0.84 (d, J=6.8 Hz, 3 H); 2.24 (m, 1 H); 2.47 (partially masked m, 1 H); 2.84 (dt, J=3.7 and 12.6 Hz, 1 H); 3.19 to 3.32 (partially masked m, 2 H); 3.41 (m, 2 H); 3.56 (d, J=11.2 Hz, 1 H); 3.77 (dd, J=3.7 and 11.2 Hz, 1 H); 3.94 (m, 1 H); 4.32 (dd, J=5.9 and 14.4 Hz, 1 H); 4.88 (m, 1 H); 4.94 (s, 1 H); 5.09 (d, J=17.4 Hz, 1 H); 5.39 (d, J=17.4 Hz, 1 H)
292 ELP MAXE	(2S)-7-Fluoro-8-[(3R)-3-methylmorpholin-4-yl]-1-[2-(6-oxa-2-azaspiro[3.3]heptan-2-yl)-2-oxoethyl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	476	474	0.8	98	a; ES^-: $[M-H+HCO2H]^-$ m/z 520 (base peak)	1.14 (d, J=6.8 Hz, 3 H); 2.13 (m, 1 H); 2.38 (s, 1 H); 3.22 to 3.32 (partially masked m, 2 H); 3.42 (dt, J=2.9 and 11.6 Hz, 1 H); 3.58 (dd, J=2.9 and 11.3 Hz, 1 H); 3.63 (d, J=11.3 Hz, 1 H); 3.74 to 3.87 (m, 3 H); 3.96 to 4.07 (m, 2 H); 4.16 to 4.36 (m, 4 H); 4.45 (m, 1 H); 4.52 (d, J=16.6 Hz, 1 H); 4.66 to 4.72 (m, 4 H)
392 ELP MAXE	(2S)-7-Fluoro-1-[2-(5-methylisoxazol-3-yl)-2-oxo-ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	460	458	1.13	98	b	0.94 (d, J=6.6 Hz, 3 H); 2.21 (m, 1 H); 2.45 (m, 1 H); 2.51 (partially masked m, 3 H); 3.12 (dt, J=3.9 and 12.9 Hz, 1 H); 3.21 to 3.36 (partially masked m, 2 H); 3.45 (m, 2 H); 3.62 (m, 2 H); 3.99 (q, J=6.6 Hz, 1 H); 4.32 (dd, J=5.2 and 14.3 Hz, 1 H); 4.68 (m, 1 H); 4.80 (d, J=18.1 Hz, 1 H); 5.24 (d, J=18.1 Hz, 1 H); 6.66 (q, J=0.8 Hz, 1 H)
492 ELP MAXE	(2S)-1-[(2R)-2-Fluoro-2-phenyl-ethyl]-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one	441		1.23	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 485 (base peak)	1.16 (d, J=6.8 Hz, 3 H); 1.79 (m, 1 H); 2.30 (m, 1 H); 3.07 (dt, J=3.7 and 12.7 Hz, 1 H); 3.19 (dt, J=5.4 and 14.6 Hz, 1 H); 3.41 (dt, J=3.1 and 11.7 Hz, 1 H); 3.54 (m, 1 H); 3.57 (dd, J = 2.5 and 11.3 Hz, 1 H); 3.64 (broad d, J=12.7 Hz, 1 H); 3.68 (d, J=11.3 Hz, 1 H); 3.88 (dd, J=3.1 and 11.7 Hz, 1 H); 4.11 (dd, J=5.4 and 14.6 Hz, 1 H); 4.26 (broad q, J=6.8 Hz, 1 H); 4.46 (m, 1 H); 4.71 (m, 1 H); 4.95 (s, 1 H); 5.93 (ddd, J=4.7 and 7.8 and 48.4 Hz, 1 H); 7.37 to 7.47 (m, 5 H)

992 ELP MAXE	(S)-3-Fluoro-9-isoxazol-3-yl-methyl-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	418		1.04	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 462 (base peak)	1.04 (d, J=6.7 Hz, 3 H); 2.23 (m, 1 H); 2.42 (m, 1 H); 3.18 (dt, J=3.7 and 12.5 Hz, 1 H); 3.23 to 3.36 (partially masked m, 2 H); 3.50 (dd, J=2.8 and 11.5 Hz, 1 H); 3.56 (d, J=11.5 Hz, 1 H); 3.71 to 3.79 (m, 2 H); 4.13 (broad q, J=6.7 Hz, 1 H); 4.24 (dd, J=5.6 and 14.2 Hz, 1 H); 4.64 (d, J=16.6 Hz, 1 H); 4.76 (m, 1 H); 5.14 (d, J=16.6 Hz, 1 H); 6.49 (d, J=1.7 Hz, 1 H); 8.83 (d, J=1.7 Hz, 1 H)
892 ELP MAXE	(S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	467		1.2	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 511 (base peak)	0.93 (d, J=6.8 Hz, 3 H); 2.30 to 2.47 (m, 2 H); 3.14 (dt, J=3.2 and 12.2 Hz, 1 H); 3.21 to 3.38 (partially masked m, 2 H); 3.46 (dd, J=2.8 and 11.5 Hz, 1 H); 3.50 (d, J=11.5 Hz, 1 H); 3.63 (broad d, J=12.2 Hz, 1 H); 3.70 (dd, J=2.9 and 11.2 Hz, 1 H); 4.03 (broad q, J=6.8 Hz, 1 H); 4.24 (dd, J=5.5 and 14.5 Hz, 1 H); 4.75 (m, 1 H); 4.79 (d, J=17.1 Hz, 1 H); 5.24 (d, J=17.1 Hz, 1 H); 6.30 (broad s, 1 H); 7.65 (d, J=1.7 Hz, 1 H); 7.85 (t, J=56.2 Hz, 1 H)
792 ELP MAXE	9-Isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methyl-morpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	360		1.01	98	b	0.90 (d, J=6.7 Hz, 3 H); 1.32 (broad s, 6 H); 1.93 (m, 2 H); 2.86 (dt, J=3.3 and 12.7 Hz, 1 H); 3.23 to 3.59 (m, 4 H); 3.71 to 3.86 (m, 3 H); 4.01 (m, 1 H); 4.71 (d, J=16.3 Hz, 1 H); 4.80 (d, J=16.3 Hz, 1 H); 4.81 (s, 1 H); 6.44 (d, J=1.3 Hz, 1 H); 8.76 (d, J=1.3 Hz, 1 H)
692 ELP MAXE	(S)-3-Fluoro-9-(3-methyl-isoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	432		1.03	90	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 476 (base peak)	1.08 (d, J=6.8 Hz, 3 H); 2.18 (s, 3 H); 2.23 (m, 1 H); 2.43 (m, 1 H); 3.13 to 3.39 (partially masked m, 3 H); 3.51 (dd, J=2.9 and 11.5 Hz, 1 H); 3.58 (d, J=11.5 Hz, 1 H); 3.70 to 3.82 (m, 2 H); 4.13 (broad q, J=6.8 Hz, 1 H); 4.23 (dd, J=5.6 and 13.9 Hz, 1 H); 4.68 (d, J=16.9 Hz, 1 H); 4.77 (m, 1 H); 5.09 (d, J=16.9 Hz, 1 H); 6.21 (s, 1 H)

003-ELP-MAXE	(S)-9-(2-Isopropoxy-ethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	405		1.19	98	b	1.05 (d, J=6.6 Hz, 3 H); 1.07 (d, J=6.6 Hz, 3 H); 1.12 (d, J=6.8 Hz, 3 H); 2.07 (m, 1 H); 2.36 (m, 1 H); 3.03 (dt, J=3.7 and 12.7 Hz, 1 H); 3.17 (dt, J=4.3 and 14.0 Hz, 1 H); 3.33 to 3.43 (m, 2 H); 3.49 to 3.58 (m, 3 H); 3.60 to 3.69 (m, 3 H); 3.86 (dd, J=3.3 and 11.4 Hz, 1 H); 4.13 to 4.25 (m, 3 H); 4.59 (m, 1 H); 4.92 (s, 1 H)
103-ELP-MAXE	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	396		0.8	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 440 (base peak)	0.86 (d, J=6.8 Hz, 3 H); 2.47 (partially masked m, 2 H); 2.82 (dt, J=3.9 and 12.8 Hz, 1 H); 3.20 (dt, J=2.9 and 11.7 Hz, 1 H); 3.25 to 3.41 (partially masked m, 2 H); 3.48 (d, J=11.6 Hz, 1 H); 3.62 to 3.73 (m, 2 H); 4.37 (m, 1 H); 4.96 (s, 1 H); 4.98 (m, 1 H); 7.48 (ddd, J=0.8 and 4.9 and 8.3 Hz, 1 H); 7.83 (ddd, J=1.5 and 2.5 and 8.3 Hz, 1 H); 8.51 (dd, J=1.5 and 4.6 Hz, 1 H); 8.57 (broad d, J=2.5 Hz, 1 H)
203-ELP-MAXE	(S)-9-(6-Cyclopropyl-pyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	436		0.99	98	b; ES^-: $[M-H+HCO2H]^-$ m/z 480 (base peak)	0.81 to 1.00 (m, 4 H); 0.85 (d, J=6.7 Hz, 3 H); 2.13 (m, 1 H); 2.44 (m, 2 H); 2.83 (dt, J=3.9 and 12.9 Hz, 1 H); 3.21 (dt, J=2.9 and 11.7 Hz, 1 H); 3.27 to 3.40 (partially masked m, 3 H); 3.49 (d, J=11.6 Hz, 1 H); 3.63 to 3.74 (m, 2 H); 4.34 (m, 1 H); 4.91 (m, 1 H); 4.95 (s, 1 H); 7.34 (d, J=8.3 Hz, 1 H); 7.63 (dd, J=2.6 and 8.3 Hz, 1 H); 8.35 (d, J=2.6 Hz, 1 H)
303-ELP-MAXE	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methyl-morpholin-4-yl)pyridin-4-yl]-2-oxoethyl}-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	537	535	1.03	96	b; ES^+: $[M+2H]^{2+}$ m/z 269 (base peak)	0.70 (d, J=6.6 Hz, 3 H); 1.12 (d, J=6.6 Hz, 3 H); 2.20 (m, 1 H); 2.43 (m, 1 H); 2.86 (dt, J=3.4 and 13.1 Hz, 1 H); 3.08 (dt, J=3.9 and 13.2 Hz, 1 H); 3.15 to 3.41 (partially masked m, 5 H); 3.48 (dt, J=3.2 and 11.9 Hz, 1 H); 3.60 to 3.68 (m, 2 H); 3.74 (d, J=11.5 Hz, 1 H); 3.87 to 4.04 (m, 3 H); 4.36 (m, 1 H); 4.43 (m, 1 H); 4.57 to 4.67 (m, 2 H); 4.90 (s, 1 H); 5.61 (d, J=18.1 Hz, 1 H); 7.08 (broad d, J=5.1 Hz, 1 H); 7.20 (broad s, 1 H); 8.32 (d, J=5.1 Hz, 1 H)

603-ELP-MAXE	(S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, isomer 1 of undetermined configuration Z or E	416		1.01	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 460 (base peak)	0.72 to 0.82 (m, 4 H); 1.07 (d, J=6.8 Hz, 3 H); 2.06 to 2.19 (m, 2 H); 2.34 (m, 1 H); 2.99 (dt, J=3.7 and 12.7 Hz, 1 H); 3.20 (dt, J=4.7 and 14.2 Hz, 1 H); 3.37 (dt, J=3.0 and 12.0 Hz, 1 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.56 (m, 1 H); 3.58 (d, J=16.9 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.86 (dd, J=3.0 and 12.0 Hz, 1 H); 4.15 to 4.27 (m, 2 H); 4.42 (m, 1 H); 4.70 (d, J=16.9 Hz, 1 H); 4.89 (s, 1 H); 10.58 (s, 1 H)
403-ELP-MAXE	(S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, isomer 2 of undetermined configuration Z or E	416		0.89	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 460 and m/z 317 (base peak)	0.49 to 0.66 (m, 4 H); 1.06 (d, J=6.8 Hz, 3 H); 1.28 (m, 1 H); 2.21 (m, 1 H); 2.40 (m, 1 H); 2.98 (dt, J=3.9 and 13.0 Hz, 1 H); 3.22 (dt, J=4.9 and 14.5 Hz, 1 H); 3.33 (dt, J=2.9 and 11.7 Hz, 1 H); 3.50 (dd, J=2.9 and 11.5 Hz, 1 H); 3.60 (d, J=11.5 Hz, 1 H); 3.62 (broad d, J=13.0 Hz, 1 H); 3.82 (dd, J=2.9 and 11.7 Hz, 1 H); 4.07 (d, J=16.9 Hz, 1 H); 4.19 (broad q, J=6.8 Hz, 1 H); 4.25 (dd, J=4.9 and 14.5 Hz, 1 H); 4.69 (m, 1 H); 4.91 (s, 1 H); 4.96 (d, J=16.9 Hz, 1 H); 10.51 (s, 1 H)
503-ELP-MAXE	(S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, isomer 1 of undetermined configuration Z or E	430		1.15	98	b	0.48 to 0.67 (m, 4 H); 1.07 (d, J=6.6 Hz, 3 H); 1.29 (m, 1 H); 2.23 (m, 1 H); 2.39 (m, 1 H); 3.00 (m, 1 H); 3.16 to 3.39 (partially masked m, 2 H); 3.48 to 3.65 (m, 3 H); 3.69 (s, 3 H); 3.84 (m, 1 H); 4.04 (d, J=17.1 Hz, 1 H); 4.15 (m, 1 H); 4.25 (m, 1 H); 4.72 (m, 1 H); 4.89 (d, J=17.1 Hz, 1 H); 4.92 (s, 1 H)

703-ELP MAXE	(S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, isomer 2 of undetermined configuration Z or E	430		1.17	95	b	0.73 to 0.89 (m, 4 H); 1.06 (d, J=6.6 Hz, 3 H); 2.07 (m, 1 H); 2.18 (m, 1 H); 2.35 (m, 1 H); 3.01 (dt, J=3.8 and 12.7 Hz, 1 H); 3.21 (dt, J=4.9 and 14.3 Hz, 1 H); 3.38 (dt, J=3.5 and 11.8 Hz, 1 H); 3.51 to 3.60 (m, 3 H); 3.65 (d, J=11.5 Hz, 1 H); 3.70 (s, 3 H); 3.86 (dd, J=3.5 and 11.8 Hz, 1 H); 4.15 to 4.28 (m, 2 H); 4.46 (m, 1 H); 4.71 (d, J=17.1 Hz, 1 H); 4.91 (s, 1 H)
803-ELP MAXE	(S)-9-(2-Cyclopropyl-oxetan-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain	429		1.17	90	b	0.37 to 0.56 (m, 4 H); 1.01 (m, 1 H); 1.07 (d, J=6.8 Hz, 3 H); 2.08 (m, 1 H); 2.39 (m, 1 H); 2.55 (m, 1 H); 3.00 (m, 1 H); 3.06 (d, J=15.4 Hz, 1 H); 3.20 to 3.41 (partially masked m, 3 H); 3.53 (broad dd, J=2.9 and 11.5 Hz, 2 H); 3.65 (d, J=11.5 Hz, 1 H); 3.86 (dd, J=3.9 and 11.7 Hz, 1 H); 4.16 to 4.29 (m, 4 H); 4.67 (d, J=15.4 Hz, 1 H); 4.85 (m, 1 H); 4.94 (s, 1 H)
903-ELP MAXE	(S)-9-(2-Cyclopropyl-oxetan-2-ylmethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain	429		1.12	83	b	0.23 to 0.46 (m, 4 H); 0.94 (m, 1 H); 1.07 (d, J=6.8 Hz, 3 H); 2.11 (m, 1 H); 2.25 to 2.46 (m, 3 H); 3.02 (dt, J=3.9 and 12.7 Hz, 1 H); 3.17 to 3.39 (partially masked m, 2 H); 3.53 (dd, J=2.9 and 11.5 Hz, 1 H); 3.61 to 3.70 (m, 3 H); 3.85 (dd, J=2.9 and 11.5 Hz, 1 H); 4.09 to 4.22 (m, 3 H); 4.43 (m, 1 H); 4.75 (m, 1 H); 4.78 (d, J=14.9 Hz, 1 H); 4.89 (s, 1 H)

313-ELP-MAXE	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyl-tetrahydro-pyran-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	459	457	0.98	80	b	1.06 (d, J=6.8 Hz, 3 H); 1.23 (s, 3 H); 1.41 to 1.49 (m, 2 H); 1.84 to 2.01 (m, 2 H); 2.19 (m, 1 H); 2.37 (m, 1 H); 2.99 (dt, J=3.9 and 13.0 Hz, 1 H); 3.23 (dt, J=4.6 and 14.4 Hz, 1 H); 3.31 (dt, J=3.1 and 11.6 Hz, 1 H); 3.46 to 3.65 (m, 6 H); 3.69 (broad d, J=13.0 Hz, 1 H); 3.82 (dd, J=3.1 and 11.6 Hz, 1 H); 4.09 (m, 1 H); 4.31 (broad d, J=18.8 Hz, 2 H); 4.43 (m, 1 H); 4.91 (s, 1 H); 5.26 (d, J=18.8 Hz, 1 H)
013-ELP-MAXE	(S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	442	440	1.07	92	b	For this batch, all the signals are broad with: 0.81 (d, J=6.6 Hz, 3 H); 2.21 (m, 1 H); 2.39 to 2.52 (masked, 4 H); 2.87 (m, 1 H); 3.18 to 3.32 (partially masked, 2 H); 3.39 (d, J=11.7 Hz, 2 H); 3.46 (d, J=11.7 Hz, 1 H); 3.70 (m, 1 H); 3.93 (m, 1 H); 4.34 (m, 1 H); 4.69 (m, 1 H); 4.75 (d, J=18.1 Hz, 1 H); 4.89 (s, 1 H); 5.25 (d, J=18.1 Hz, 1 H); 6.63 (s, 1 H)
113-ELP-MAXE	(S)-9-(2-Chloro-thiazol-5-yl-methyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	464		1.19	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 508 (base peak)	1.14 (d, J=6.4 Hz, 6 H); 2.12 (m, 1 H); 2.36 (m, 1 H); 3.19 (m, 1 H); 3.56 (m, 2 H); 3.91 to 4.04 (m, 4 H); 4.23 (m, 1 H); 4.67 (m, 1 H); 4.78 (d, J=16.1 Hz, 1 H); 4.92 (s, 1 H); 5.23 (d, J=16.1 Hz, 1 H); 7.64 (s, 1 H)
213-ELP-MAXE	(S)-2-((3R,5R)-3,5-Dimethyl-morpholin-4-yl)-9-isoxazol-3-yl-methyl-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	414	412	1.03	98	b; ES^-: $[M-H+HCO_2H]^-$ m/z 458 (base peak)	1.02 (d, J=6.4 Hz, 6 H); 2.24 (m, 1 H); 2.40 (m, 1 H); 3.24 (dt, J=5.2 and 14.2 Hz, 1 H); 3.53 (split d, J=11.2 Hz, 2 H); 3.83 (m, 2 H); 3.97 (split d, J=11.2 Hz, 2 H); 4.28 (dd, J=5.2 and 14.2 Hz, 1 H); 4.57 (d, J=16.6 Hz, 1 H); 4.73 (m, 1 H); 4.82 (s, 1 H); 5.32 (d, J=16.6 Hz, 1 H); 6.50 (d, J=1.5 Hz, 1 H); 8.83 (d, J=1.5 Hz, 1 H)

713-ELP-MAXE	(S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	450	448	0.95	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 494 (base peak)	1.16 (d, J=6.8 Hz, 3 H); 2.14 (m, 1 H); 2.27 (m, 2 H); 2.39 (m, 1 H); 3.17 to 3.34 (partially masked m, 2 H); 3.41 (m, 1 H); 3.47 to 3.68 (m, 4 H); 3.72 to 3.85 (m, 2 H); 3.95 (m, 2 H); 4.10 (d, J=17.4 Hz, 1 H); 4.19 (m, 1 H); 4.29 (m, 1 H); 4.56 (m, 1 H); 4.85 (d, J=17.4 Hz, 1 H)
413-ELP-MAXE	(S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	363		0.79	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 407 (base peak)	1.11 (d, J=6.7 Hz, 3 H); 2.15 (m, 1 H); 2.34 (m, 1 H); 3.02 (m, 1 H); 3.11 to 3.30 (partially masked m, 2 H); 3.38 (m, 1 H); 3.49 to 3.68 (m, 4 H); 3.72 (m, 1 H); 3.86 (m, 1 H); 4.07 to 4.26 (m, 3 H); 4.61 (m, 1 H); 4.76 (t, J=4.3 Hz, 1 H); 4.91 (s, 1 H)
513-ELP-MAXE	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-[2-(6-oxa-1-aza-spiro[3.3]hept-1-yl)-2-oxo-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	476	474	0.86	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 520 (base peak)	1.18 (d, J=6.8 Hz, 3 H); 2.18 (m, 1 H); 2.41 (m, 1 H); 2.55 (m, 2 H); 3.23 to 3.33 (partially masked m, 2 H); 3.41 (td, J=2.3 and 11.6 Hz, 1 H); 3.58 (dd, J=2.9 and 11.5 Hz, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.79 (d, J=13.2 Hz, 1 H); 3.86 (m, 2 H); 3.95 (m, 2 H); 4.21 (m, 1 H); 4.29 (m, 1 H); 4.45 to 4.55 (m, 4 H); 5.05 (d, J=6.6 Hz, 1 H); 5.17 (d, J=6.6 Hz, 1 H)
613-ELP-MAXE	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	464	462	1.05	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 508 (base peak)	1.18 (d, J=6.7 Hz, 3 H); 1.53 to 1.83 (m, 4 H); 2.14 (m, 1 H); 2.40 (m, 1 H); 3.23 to 3.35 (partially masked m, 2 H); 3.43 (dd, J=2.7 and 11.7 Hz, 1 H); 3.53 to 3.70 (m, 4 H); 3.77 to 3.85 (m, 2 H); 3.94 (m, 1 H); 4.05 (m, 1 H); 4.09 (d, J=17.4 Hz, 1 H); 4.20 (m, 1 H); 4.29 (m, 1 H); 4.57 (m, 1 H); 4.89 (d, J=17.4 Hz, 1 H)

123-ELP-MAXE	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	446		0.98	98	b	1.05 (d, J=6.7 Hz, 3 H); 1.61 (m, 2 H); 1.76 (m, 2 H); 2.13 (m, 1 H); 2.36 (m, 1 H); 3.00 (dt, J=3.9 and 12.7 Hz, 1 H); 3.21 (m, 1 H); 3.36 (dt, J=3.1 and 11.8 Hz, 1 H); 3.49 to 3.69 (m, 5 H); 3.85 (dd, J=3.4 and 11.2 Hz, 1 H); 3.94 (m, 1 H); 4.03 (m, 1 H); 4.05 (d, J=17.4 Hz, 1 H); 4.16 (m, 1 H); 4.30 (m, 1 H); 4.56 (m, 1 H); 4.91 (s, 1 H); 4.94 (d, J=17.4 Hz, 1 H)
813-ELP-MAXE	(S)-9-(2-Isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	432		0.89	98	b	1.03 (d, J=6.7 Hz, 3 H); 2.13 (m, 1 H); 2.26 (m, 2 H); 2.36 (m, 1 H); 2.98 (dt, J=3.7 and 12.6 Hz, 1 H); 3.21 (dt, J=3.4 and 13.9 Hz, 1 H); 3.35 (dt, J=2.6 and 11.5 Hz, 1 H); 3.45 to 3.67 (m, 5 H); 3.84 (dd, J=2.6 and 11.5 Hz, 1 H); 3.96 (m, 2 H); 4.07 (d, J=17.4 Hz, 1 H); 4.13 (broad q, J=6.7 Hz, 1 H); 4.30 (m, 1 H); 4.56 (m, 1 H); 4.89 (d, J=17.4 Hz, 1 H); 4.91 (s, 1 H)
913-ELP-MAXE	(S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	403	401	1.06	98	b	1.02 (d, J=7.1 Hz, 3 H); 1.04 (d, J=7.1 Hz, 3 H); 1.07 (d, J=6.5 Hz, 3 H); 2.16 (m, 1 H); 2.29 to 2.45 (m, 2 H); 2.70 (m, 2 H); 3.21 (m, 1 H); 3.39 (m, 2 H); 3.79 (m, 2 H); 3.93 (m, 1 H); 4.26 (d, J=18.1 Hz, 1 H); 4.30 (m, 1 H); 4.48 (m, 1 H); 4.93 (d, J=18.1 Hz, 1 H); 4.97 (s, 1 H)
023-ELP-MAXE	(S)-9-(2-Cyclopropyl-2-oxo-ethyl)-3-fluoro-2-((S)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	419	417	1.02	98	b	0.76 to 0.96 (m, 4 H); 1.19 (d, J=6.6 Hz, 3 H); 2.11 (m, 1 H); 2.18 (m, 1 H); 2.39 (m, 1 H); 3.19 (m, 1 H); 3.25 (partially masked m, 1 H); 3.42 (dt, J=2.8 and 11.6 Hz, 1 H); 3.56 (dd, J=2.7 and 11.5 Hz, 1 H); 3.62 (d, J=11.5 Hz, 1 H); 3.75 (m, 1 H); 3.82 (dd, J=2.8 and 11.6 Hz, 1 H); 4.17 (broad q, J=6.6 Hz, 1 H); 4.28 (m, 1 H); 4.39 (d, J=17.9 Hz, 1 H); 4.56 (m, 1 H); 4.74 (d, J=17.9 Hz, 1 H)

423 ELP MAXE	(S)-9-(2-Cyclopropyl-2-oxo-ethyl)-3-fluoro-2-(2-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine	419	417	1.03	98	b	0.78 to 0.95 (m, 4 H); 1.08 (d, J=6.4 Hz, 3 H); 2.09 to 2.22 (m, 2 H); 2.40 (m, 1 H); 2.61 (dd, J=10.4 and 13.2 Hz, 1 H); 2.97 (m, 1 H); 3.27 (partially masked m, 1 H); 3.40 to 3.52 (m, 2 H); 3.79 (m, 1 H); 3.92 (m, 1 H); 3.98 (broad d, J=13.2 Hz, 1 H); 4.28 (m, 1 H); 4.37 (d, J=18.1 Hz, 1 H); 4.56 (m, 1 H); 4.79 (d, J=18.1Hz, 1 H)
223 ELP MAXE	(S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	407		1.2	90	b	0.93 (d, J=6.8 Hz, 3 H); 0.95 (d, J=6.8 Hz, 3 H); 1.10 (d, J=6.8 Hz, 3 H); 1.83 (m, 1 H); 2.09 (m, 1 H); 2.38 (m, 1 H); 3.02 (m, 1 H); 3.17 to 3.42 (partially masked m, 3 H); 3.55 (dd, J=2.7 and 11.5 Hz, 1 H); 3.60 (m, 1 H); 3.66 (d, J=11.5 Hz, 1 H); 3.86 (m, 1 H); 4.15 (m, 1 H); 4.22 (m, 1 H); 4.52 (m, 1 H); 4.69 (m, 1 H); 4.72 (m, 1 H); 4.92 (s, 1 H)
323 ELP MAXE	(S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	407		1.26	95	b	0.92 (d, J=6.4 Hz, 3 H); 0.94 (d, J=6.4 Hz, 3 H); 1.10 (d, J=6.7 Hz, 3 H); 1.88 (m, 1 H); 2.10 (m, 1 H); 2.39 (m, 1 H); 3.02 (m, 1 H); 3.15 to 3.41 (partially masked m, 3 H); 3.53 (dd, J=2.7 and 11.5 Hz, 1 H); 3.57 (m, 1 H); 3.65 (d, J=11.5 Hz, 1 H); 3.84 (m, 1 H); 4.18 (m, 1 H); 4.24 (m, 1 H); 4.43 (dd, J=14.3 and 38.5 Hz, 1 H); 4.53 (m, 1 H); 4.60 (m, 1 H); 4.94 (s, 1 H)

523-ELP MAXE	(S)-9-(2-Cyclopropyl-2-fluoro-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain	405		1.17	98	b	0.22 (m, 1 H); 0.43 (m, 1 H); 0.60 (m, 2 H); 1.10 (d, J=6.7 Hz, 3 H); 1.12 (m, 1 H); 2.09 (m, 1 H); 2.39 (m, 1 H); 3.03 (m, 1 H); 3.20 (m, 1 H); 3.32 to 3.47 (m, 2 H); 3.54 (dd, J=2.7 and 11.5 Hz, 1 H); 3.61 (m, 1 H); 3.68 (d, J= 11.5 Hz, 1 H); 3.86 (m, 1 H); 4.07 to 4.29 (m, 3 H); 4.45 (ddd, J=2.2 and 15.2 and 34.5 Hz, 1 H); 4.58 (m, 1 H); 4.92 (s, 1 H)
623-ELP MAXE	(S)-9-(2-Cyclopropyl-2-fluoro-ethyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain	405		1.13	98	b	0.27 (m, 1 H); 0.39 (m, 1 H); 0.57 (m, 2 H); 1.10 (d, J=6.7 Hz, 3 H); 1.12 (m, 1 H); 2.11 (m, 1 H); 2.39 (m, 1 H); 3.02 (m, 1 H); 3.21 (m, 1 H); 3.32 to 3.49 (m, 2 H); 3.54 (dd, J=2.7 and 11.5 Hz, 1 H); 3.63 (m, 1 H); 3.67 (d, J=11.5 Hz, 1 H); 3.88 (m, 1 H); 4.10 to 4.29 (m, 3 H); 4.54 (ddd, J=6.7 and 12.4 and 14.4 Hz, 1 H); 4.70 (m, 1 H); 4.92 (s, 1 H)
723-ELP MAXE	(S)-8-Methyl-2-((R)-3-methyl-morpholin-4-yl)-9-(2-oxo-propyl)-8-trifluoromethyl-6,7,8,9-tetrahydro-pyrimido[1,2-a]pyrimidin-4-one	389		0.89	91	b	1.00 (d, J=6.8 Hz, 3 H); 1.52 (s, 3 H); 2.10 (s, 3 H); 2.13 (m, 1 H); 2.43 (m, 1 H); 2.97 (m, 1 H); 3.30 to 3.39 (m, 2 H); 3.45 to 3.53 (m, 2 H); 3.63 (d, J=11.5 Hz, 1 H); 3.83 (m, 1 H); 4.06 to 4.17 (m, 2 H); 4.31 (d, J=18.3 Hz, 1 H); 4.58 (d, J=18.3 Hz, 1 H); 4.91 (s, 1 H)

033-ELP MAXE	(S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	425		1.27	88	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 469 (base peak)	0.93 (d, J=7.3 Hz, 3 H); 0.95 (d, J=7.3 Hz, 3 H); 1.22 (d, J=6.8 Hz, 3 H); 1.83 (m, 1 H); 2.10 (m, 1 H); 2.40 (m, 1 H); 3.22 to 3.41 (partially masked m, 3 H); 3.48 (m, 1 H); 3.62 (m, 2 H); 3.82 (m, 2 H); 4.15 (m, 1 H); 4.26 (m, 1 H); 4.47 (m, 1 H); 4.68 (m, 1 H); 4.70 (m, 1 H)
823-ELP MAXE	(S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain	425		1.31	98	b	0.92 (d, J=6.5 Hz, 3 H); 0.94 (d, J=6.5 Hz, 3 H); 1.22 (d, J=6.6 Hz, 3 H); 1.87 (m, 1 H); 2.10 (m, 1 H); 2.40 (m, 1 H); 3.19 to 3.36 (partially masked m, 3 H); 3.44 (m, 1 H); 3.61 (m, 2 H); 3.79 to 3.87 (m, 2 H); 4.15 (m, 1 H); 4.26 (m, 1 H); 4.39 (ddd, J=2.0 and 14.7 and 38.2 Hz, 1 H); 4.53 (m, 1 H); 4.61 (m, 1 H)
923-ELP MAXE	(S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1-oxa-6-aza-spiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	458		0.81	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 502 (base peak)	For this batch, a 50-50 resolution of conformers is observed with: 1.02 (split d, J=6.6 Hz, 3 H); 2.11 (m, 1 H); 2.36 (m, 1 H); 2.80 (m, 2 H); 3.00 (m, 1 H); 3.19 (m, 1 H); 3.28 to 3.40 (partially masked m, 1 H); 3.49 to 3.68 (m, 3 H); 3.77 to 3.96 (m, 3 H); 4.09 (m, 1 H); 4.20 (m, 1 H); 4.29 (m, 2 H); 4.40 (m, 3 H); 4.50 (m, 1 H); 4.55 (m, 1 H); 4.91 (s, 1 H)

133-ELP MAXE	(S)-9-(2-Cyclopropyl-2-fluoro-ethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain	423		1.19	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 467 (base peak)	0.25 to 0.41 (m, 2 H); 0.52 to 0.60 (m, 2 H); 1.11 (m, 1 H); 1.21 (d, J=6.7 Hz, 3 H); 2.11 (m, 1 H); 2.41 (m, 1 H); 3.21 to 3.49 (partially masked m, 4 H); 3.57 to 3.67 (m, 2 H); 3.79 to 3.87 (m, 2 H); 4.03 to 4.30 (m, 3 H); 4.52 (m, 1 H); 4.72 (m, 1 H)
233-ELP MAXE	(S)-9-(2-Cyclopropyl-2-fluoro-ethyl)-3-fluoro-2-((R)-3-methyl-morpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain	423		1.23	98	b	0.19 (m, 1 H); 0.42 (m, 1 H); 0.55 to 0.65 (m, 2 H); 1.09 (m, 1 H); 1.21 (d, J=6.8 Hz, 3 H); 2.08 (m, 1 H); 2.40 (m, 1 H); 3.21 to 3.36 (partially masked m, 2 H); 3.40 to 3.52 (m, 2 H); 3.57 to 3.66 (m, 2 H); 3.84 (m, 2 H); 4.08 to 4.29 (m, 3 H); 4.40 (ddd, J=2.0 and 15.2 and 34.7 Hz, 1 H); 4.59 (m, 1 H)
333-ELP MAXE	(S)-3-Fluoro-2-((R)-3-methyl-morpholin-4-yl)-9-[2-(1-oxa-6-aza-spiro[3.3]hept-6-yl)-2-oxo-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]-pyrimidin-4-one	476		0.86	98	b; ES$^-$: [M-H+HCO2H]$^-$ m/z 520 (base peak)	For this batch, a 50-50 resolution of conformers is observed with: 1.15 (split d, J=6.6 Hz, 3 H); 2.11 (m, 1 H); 2.39 (m, 1 H); 2.82 (m, 2 H); 3.20 to 3.32 (partially masked m, 2 H); 3.41 (m, 1 H); 3.60 (m, 2 H); 3.74 to 3.95 (m, 4 H); 4.10 (m, 1 H); 4.19 to 4.30 (m, 3 H); 4.35 to 4.43 (m, 3 H); 4.49 (m, 1 H); 4.51 (m, 1 H)

Conditions a: the spectra were obtained on a Waters UPLC-SQD apparatus Ionization: positive and/or negative mode electrospray (ES+/-) - Chromatographic conditions: - Column: ACQUITY BEH C18 – 1.7 µm – 2.1 x 50 mm - Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid) - Column temperature: 50°C - Flow rate: 1 ml/min - Gradient (2 min): from 5% to 50% of B in 0.8 min; 1.2 min: 100% of B; 1.85 min: 100% of B; 1.95: 5% of B
Conditions b: the spectra were obtained on a Waters UPLC-SQD apparatus Ionization: positive and/or negative mode electrospray (ES+/-) Chromatographic conditions: - Column: ACQUITY BEH C18 – 1.7 µm – 2.1 x 50 mm - Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid) - Column temperature: 50°C - Flow rate: 0.8 ml/min - Gradient (2.5 min): from 5% to 100% of B in 1.8 min; 2.40 min: 100% of B; 2.45 min: 100% of B; from 100 to 5% of B in 0.05 min

Conditions c: the spectra were obtained on a Waters ZQ apparatus Ionization: positive and/or negative mode electrospray (ES+/-) Chromatographic conditions: - Column: XBridge C18 – 2.5 µm – 3 x 50 mm - Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid) - Column temperature: 70°C - Flow rate: 0.9 ml/min - Gradient (7 min): from 5% to 100% of B in 5.3 min; 5.5 min: 100% of B; 6.3 min: 5% of B
Conditions k: the spectra were obtained on a Waters ZQ apparatus Ionization: positive and/or negative mode electrospray (ES+/-) Chromatographic conditions: - Column: XSelect CSH C18 – 3.5 µm – 3 x 50 mm - Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid) - Column temperature: 55°C - Flow rate: 1.3 ml/min - Gradient (5 min): from 4% to 98% of B in 3.2 min; 3.5 min: 98% of B; 3.8 to 5 min: 4% of B

Conditions I: the spectra were obtained on a Waters XeVo - QTof apparatus

Ionization: positive mode electrospray (ES+)

Chromatographic conditions:

- Column: ACQUITY BEH C8 – 1.7 µm – 2.1 x 100 mm
- Solvents: A: H_2O (0.1% formic acid) B: CH_3CN (0.1% formic acid)
- Column temperature: 70°C
- Flow rate: 0.55 ml/min
- Gradient (11 min): from 5% to 97% of B in 8.3 min; 8.6 min: 97% of B; 9 min: 5% of B; 11 min: 5% of B

Example 334: Pharmaceutical composition

Tablets corresponding to the following formula were prepared:

Product of Example 42..... 0.2 g

Excipient for a tablet with a final weight of ..... 1 g

(details of the excipient: lactose, talc, starch, magnesium stearate).

Example 42 is taken by way of example of a pharmaceutical preparation, it being possible for this preparation to be carried out, if desired, with other products in examples in the present application.

Pharmacological section:

Experimental protocols

Study of the phosphorylation of phosphatidylinositol (PI) by Vps34 *in vitro*

This test is based on the detection of the ADP produced during the phosphorylation of PI by Vps34 in the presence of ATP. The ADP is detected by TR-FRET (Time resolved – Fluorescence Resonance Energy transfer) using the Transcreener kit sold by Cisbio (HTRF® Transcreener® ADP, reference 62ADPPEB).

The molecules are diluted 3-fold in pure dimethyl sulfoxide (DMSO, Sigma Fluka 41647), and then diluted, in a second step, in 10% DMSO in water. 2 µl of molecules are added to 96-well plates (Corning Costar 3694), followed by 8 µl of a PI (Sigma P5766) / recombinant Vps34 (Invitrogen PV5126 or produced by Sanofi) mixture in buffer A: 50 mM Hepes, 5 mM $MnCl_2$, 0.1% CHAPS, 2 mM TCEP, pH 7.1. The reaction is initiated with 10 µl


of a solution of ATP (Sigma A7699) in buffer A and lasts 1 hour at ambient temperature. The concentrations during the reaction are 1% DMSO, 10 μM ATP, 55 μg/ml PI, approximately 3 nM of Vps34 and between 0.51 nM and 10 μM for the molecules. The amount of enzyme is adapted to each batch so as to form approximately 2 μM of ADP during the reaction. In parallel, a range of ADP and of ATP for calibrating the results is prepared according to the indications of the kit. Controls not containing enzyme (negative control) or not containing molecules (positive control) are also prepared in parallel. The reaction is then blocked and visualised with the transcreener kit using 10 μl of each of the two reagents and according to the indications of the kit. The fluorescence emission is detected on a Rubystar instrument at 620 and 665 nm. The signal ratio is calculated by dividing the 665 nm signal by the 620 nm signal and then multiplying by 10 000. The signal ratios are converted into ADP concentration using the calibration range and according to the instructions of the kit. The percentages of inhibition by the molecules are calculated relative to the positive controls according to the formula (1 – signal ratio of the molecule/signal ratio of the positive control) × 100. The absolute IC50s (inhibitory concentration which gives 50% inhibition) are calculated according to a 4-parameter logistical model. Two independent experiments make it possible to calculate the mean of the IC50s. The IC50 results, in nM, obtained for the products in examples of the present invention are given in the table below.

Table of pharmacological results obtained by means of the above test

IC50 activity range in nM	Examples
<10 nM	42, 152, 163, 98, 153, 206, 32, 33, 36, 35, 37, 1, 11, 100, 99, 75, 76, 78, 38, 179, 79, 80, 101, 102, 180, 103, 71, 81, 40, 9, 154, 41, 214, 82, 215, 199, 181, 44, 84, 43, 83, 107, 85, 109, 108, 45, 86, 46, 89, 88, 87, 183, 69, 111, 255, 14, 90, 91, 93, 49, 92, 239, 94, 48, 112, 10, 50, 95, 217, 218, 284, 285, 155, 157, 114, 115, 3, 219, 257, 184, 116, 241, 258, 243, 96, 7, 6, 97, 242, 259, 260, 2, 254, 220, 158, 262, 244, 245, 221, 264, 160, 159, 118, 209, 119, 121, 122, 200, 210, 198, 120, 12, 51, 53, 52, 5, 124, 4, 224, 127, 126, 196, 128, 225, 15, 54, 16, 211, 17, 129, 204, 226, 212, 213, 18, 201, 202, 203, 19, 246, 247, 20, 248, 249, 250, 130, 251, 55, 21, 56, 131, 132, 57, 58, 227, 228, 252, 134, 135, 133, 22, 287, 286, 23, 229, 24, 59, 186, 185, 266, 267, 230, 253, 25, 189, 60, 187, 141, 231, 288, 289, 136, 137, 61, 62, 138, 139, 140, 31, 30, 232, 63, 233, 70, 65, 66, 142, 67, 26, 27, 190, 143, 28, 237, 276, 68, 144, 290, 29, 8, 146, 279, 280, 149, 147, 281, 282, 291, 283, 240, 205, 207, 294, 292, 295, 39, 293, 296, 297, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 313, 314, 315, 317, 318, 319, 323, 324, 325, 326, 327, 328, 329, 331, 332, 333
10 -100 nM	191, 192, 161, 162, 177, 151, 178, 167, 166, 165, 164, 168, 169, 34, 150, 170, 171, 77, 174, 72, 73, 74, 106, 105, 110, 182, 47, 13, 216, 256, 156, 113, 104, 261, 117, 236, 123, 223, 222, 125, 265, 197, 188, 269, 270, 271, 273, 274, 275, 145, 234, 235, 148, 208, 298, 312, 316, 320, 321, 322, 330
>100 nM	193, 194, 195, 176, 172, 173, 175, 263, 268, 64, 272, 277, 278, 238

CLAIMS

1) Products of formula (I):



in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is chosen from the following values a) to e):

a) R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

b) R1 is a $-(CH_2)_m$-Ra radical with m being the integer 1 or 2 and Ra an optionally substituted aryl or heteroaryl radical, or a -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, $-CO_2$Rd or -CONRxRy radical;

c) R1 is an alkylene radical; cycloalkyl radical; heterocycloalkyl radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cycloalkyl, heterocycloalkyl, phenyl, pyridine and alkoxy radicals, the latter phenyl, pyridine and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms;

d) R1 is an $-SO_2$-Rb radical;

e) R1 is a -CO-Re radical;

Rb is an optionally substituted alkyl, cycloalkyl, aryl or heteroaryl radical;

Rc is a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

Re is an optionally substituted alkyl, cycloalkyle, heterocycloalkyl, aryl or heteroaryl radical;

NRxRy being such that Rx and Ry, which may be identical or different, are chosen from a hydrogen atom and alkyl, cycloalkyl, alkoxy and phenyl radicals; or Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 7 ring members and optionally one or more other heteroatoms chosen from O, NH and N-alkyl;

R2 and R3, which may be identical or different, are chosen from a hydrogen atom and an alkyl radical optionally substituted with one or more fluorine atoms, it being understood that R2 and R3 are not both CF_3 and R2 and R3 are not both hydrogen; or else R2 and R3 form, together with the carbon atom to which they are bonded, a cyclic radical containing from 3 to 6 ring members and optionally one or more other heteroatoms chosen from O, S and –NRz, this cyclic radical being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and oxo, Rz, -ORz and –NRzRz' radicals; with Rz and Rz', which may be identical or different, being a hydrogen atom or an alkyl, cycloalkyl or heterocycloalkyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is substituted with the radicals R5 to R12, which may be identical or different, chosen from a hydrogen atom and methyl and ethyl radicals optionally substituted with a fluorine atom or a hydroxyl radical, it being understood that, either at least one of R5 to R12 is not a hydrogen

atom, or this morpholine residue contains a bridge defined as follows: R7 or R8 can form an ethylene bridge with R9 or R10, or else R7 or R8 can form a methylene bridge of absolute configuration R,R with R11 or R12, or else R5 or R6 can form a methylene bridge of absolute configuration R,R with R9 or R10 so as to give the following radicals:

 and the isomer of configuration R,R 

the aryl and heteroaryl radicals that Ra, Rb and Re may represent, and also the alkyl radicals that Rb and Re may represent, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl and alkoxy radicals, the latter heteroaryl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

the aryl and heteroaryl radicals that Ra, Rb and Re may represent being, in addition, optionally substituted with one or more alkyl radicals themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl and alkoxy radicals;

all the cycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being optionally substituted with one or more radicals, which may be identical or different, chosen from a fluorine atom and alkyl radicals themselves optionally substituted with one or more fluorine atoms;

all the heterocycloalkyl radicals being, in addition, optionally substituted with a CO_2alk radical, where appropriate on a nitrogen atom;


all the alkyl (alk), alkylene and alkoxy radicals above being linear or branched and containing at most 7 carbon atoms,

it being understood that one or more of the hydrogen atoms of said products of formula (I) can be a deuterium atom;

it being understood that, when p = 0 and one of R2 and R3 is an alkyl radical and the other an alkyl radical substituted with one or more fluorine atoms, then R1 is not a phenyl or pyridyl radical as defined in a) above,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

2) Products of formula (I) as defined in Claim 1, in which the morpholine residue is chosen from the following radicals:



the radicals p, q, R1, R2, R3 and R4 having the meanings indicated in Claim 1,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

3) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 2 or else p is the integer 2 and q is the integer 0;

the radicals R1, R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

4) Products of formula (I) as defined in Claim 1 or 2, in which p is the integer 0 and q is the integer 1 or else p is the integer 1 and q is the integer 0;

the radicals R1, R2, R3 and R4 and the morpholine residue having the meanings indicated in Claim 1,

said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

5) Products of formula (I) as defined in Claim 1 or 2, in which:

p and q are the integers 0 or 1 or 2 such that, if p = 0, then q = 1 or 2 and, if p = 1 or 2, then q = 0;

R1 is a phenyl or pyridyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine atoms and cycloalkyl, alkyl and alkoxy radicals, the latter alkyl and alkoxy radicals being themselves optionally substituted with one or more fluorine atoms; a $-(CH_2)_m$-Ra radical; an $-SO_2$-phenyl radical optionally substituted with an alkyl radical; a -CO-alkyl radical; an alkylene radical; or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetane, tetrahydrofuran, tetrahydropyran, alkoxy, phenyl and pyridine radicals, the latter three radicals all being optionally substituted with one or more fluorine atoms;

m is the integer 1 or 2;

Ra is a radical -CO-Rb; -C(cycloalkyl)=N-ORc; CO_2Rd; -CONRxRy; a -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl or -CO-cyclohexyl radical, all optionally substituted with one or more alkyl radicals; a -CO-morpholine, -CO-piperidyl, -CO-tetrahydrofuran, -CO-tetrahydropyran or -CO-pyrrolidine radical, all optionally substituted with one or more alkyl radicals or a CO_2alk radical, where appropriate on a nitrogen atom; or else a phenyl, pyridine, oxazole, isoxazole, oxadiazole, pyrazole, thiophene, thiazole, thiadiazole, pyridazine, benzimidazole, imidazopyridine or triazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and cycloalkyl, heterocycloalkyl, heteroaryl, alkyl and alkoxy radicals, the latter heteroaryl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rb is an alkyl, phenyl, pyridyl, thiazole, isoxazole, oxazole or oxadiazole radical, all optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine and chlorine halogen atoms and

cycloalkyl, heterocycloalkyl, phenyl, heteroaryl, alkyl and alkoxy radicals, the latter phenyl, heteroaryl, heterocyloalkyl, alkyl and alkoxy radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from fluorine atoms and hydroxyl, alkyl and alkoxy radicals;

Rc is in particular a hydrogen atom or an alkyl radical;

Rd is an alkyl or cycloalkyl radical;

NRxRy are such that Rx and Ry, which may be identical or different, are a hydrogen atom or an alkyl, alkoxy or phenyl radical or else together form a piperidyl, morpholinyl, azetidine, oxaazaspiro[3.3]heptane, isoxazolidine or {1,2}oxazinane radical;

R2 and R3 are such that:


either R2 is a hydrogen atom and R3 is the trifluoromethyl radical CF_3;

or R2 is a methyl radical and R3 is the trifluoromethyl radical CF_3;

or R2 and R3 are both a methyl radical;

R4 is a hydrogen atom, a fluorine or chlorine atom, a methyl radical or a CN radical;

the morpholine residue is chosen from the following radicals:



said products of formula (I) being in any of the possible racemic, enantiomeric and diastereoisomeric isomer forms, and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

6) Products of formula (I) as defined in any one of the other claims, corresponding to the following formulae:

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-((S)-2-hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Chloropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid ethyl ester

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-methoxy-N-methylacetamide

- (S)-9-(6-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Fluoropyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)-ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(6-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(3-fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(2-Methoxypyridin-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(6-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Imidazo[1,2-a]pyridin-2-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(4-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-3-pyridin-2-ylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Fluoropyridin-2-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 3-Fluoro-9-isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluorophenyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(6-trifluoromethylpyridin-3-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(2,2,2-trifluoroethoxy)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(6-methylpyridin-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclobutylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropylpyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2,5-Dimethyloxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]oxadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(toluene-4-sulfonyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-5-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-Isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-4-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Hydroxy-2-methylpropyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Isopropoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Chloropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Isopropoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-oxazol-5-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(2-methoxypyridin-4-yl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethylpyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(2-Chloropyridin-4-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-[1,3,4]thiadiazol-2-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Difluoromethoxypyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-[1,2,3]thiadiazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(6-Difluoromethoxypyridin-3-yl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-oxetan-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-(6-Difluoromethylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydrofuran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[1-(tetrahydropyran-2-yl)methyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(5-trifluoromethyl-[1,3,4]oxadiazol-2-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,3,4]oxadiazol-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-6-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-9-(3-methylisoxazol-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (R)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-6-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(3,3-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((3S,5S)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3S,5S)-3,5-Dimethylmorpholin-4-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-(3-methylisoxazol-5-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chloropyridin-4-yl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3,5-Difluorophenyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-5-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Chloropyridin-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(8-Oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one,

- single stereoisomer

- (S)-2-(2-Ethylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-(2-Methylmorpholin-4-yl)-9-(2-oxo-2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(3,5-Difluorophenyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-(3-hydroxymethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(5-Chlorothiophen-2-ylmethyl)-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-5-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-oxazol-4-ylmethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Chloropyridin-4-ylmethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-1-(2-Cyclopropyl-2-oxoethyl)-6-fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-2-oxobutyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-3-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-Benzyl-2-(2-fluoromethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- N-Methoxy-N-methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methoxy-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-pyridin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(2-oxo-2-pyridin-2-ylethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-methylpropyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-tert-Butyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Hydroxypropyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-((S)-2-Methoxy-2-phenylethyl)-2-(1R,5S)-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-6-Fluoro-2-methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-3-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-2-pyridin-2-ylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Isoxazol-3-ylmethyl-8-methyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(4-Fluorophenyl)ethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-pyridin-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- N,N-Dimethyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- N-Methyl-2-[(S)-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-9-(6-Fluoropyridin-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxypyridin-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-thiazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-Methylmorpholin-4-yl)-9-(2-morpholin-4-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]-N-phenylacetamide

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-1-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-Acetyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-oxazol-2-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-Methyl-7-((R)-3-methylmorpholin-4-yl)-1-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-thiazol-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid cyclopentyl ester

- (S)-9-(2-Cyclopentyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-isopropyl-[1,2,4]oxadiazol-3-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Cyclopropyl-[1,2,4]oxadiazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-isopropyl-[1,2,4]oxadiazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-tert-Butyl-[1,2,4]oxadiazol-5-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(1-Methylcyclopentyl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid isopropyl ester

- (S)-9-(3,3-Dimethyl-2-oxobutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoropyridin-4-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclohexyl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridazin-4-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid tert-butyl ester

- 2-{2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetyl}pyrrolidine-1-carboxylic acid tert-butyl ester

- [(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- 2-[(S)-8-((R)-3-Methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetamide

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4H-[1,2,4]triazol-3-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-oxo-2-piperidin-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methylbut-2-enyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-oxo-2-(tetrahydrofuran-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methyl-2-oxobutyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(5-methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((S)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((S)-3-methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(4-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(3-Ethyl-2-oxopentyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- [(S)-7-Fluoro-8-((R)-3-methylmorpholin-4-yl)-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl]acetic acid methyl ester

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-sec-Butyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-9-(2-Methoxy-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, single stereoisomer

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(5-methyl-2-oxohexyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(3-methyl-2-oxopentyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-8-trifluoromethyl-9-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-[2-(5-methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Fluoro-2-phenylethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-isoxazol-3-ylmethyl-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Difluoromethyl-2H-pyrazol-3-ylmethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 9-Isoxazol-3-ylmethyl-8,8-dimethyl-2-((R)-3-methylmorpholin-4-yl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(3-methylisoxazol-5-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isopropoxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-pyridin-3-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(6-Cyclopropylpyridin-3-yl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-{2-[2-((R)-3-methylmorpholin-4-yl)-pyridin-4-yl]-2-oxoethyl}-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-{2-Cyclopropyl-2-[(Z)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-hydroxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(E)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 1 of undetermined configuration Z or E

- (S)-9-{2-Cyclopropyl-2-[(Z)-methoxyimino]ethyl}-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, isomer 2 of undetermined configuration Z or E

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-9-(2-Cyclopropyloxetan-2-ylmethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the side chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(4-methyltetrahydropyran-4-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-[2-(5-Methylisoxazol-3-yl)-2-oxoethyl]-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Chlorothiazol-5-ylmethyl)-2-((3R,5R)-3,5-dimethylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((3R,5R)-3,5-Dimethylmorpholin-4-yl)-9-isoxazol-3-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Hydroxyethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(6-oxa-1-azaspiro[3.3]hept-1-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-(2-[1,2]oxazinan-2-yl-2-oxoethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Isoxazolidin-2-yl-2-oxoethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-2-(2-Methylmorpholin-4-yl)-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-((S)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-oxoethyl)-3-fluoro-2-(2-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the morpholine

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-8-Methyl-2-((R)-3-methylmorpholin-4-yl)-9-(2-oxopropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-3-Fluoro-9-(2-fluoro-3-methylbutyl)-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-fluoro-3-methylbutyl chain

- (S)-2-((R)-3-Methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 1 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain


- (S)-9-(2-Cyclopropyl-2-fluoroethyl)-3-fluoro-2-((R)-3-methylmorpholin-4-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, diastereoisomer 2 of undetermined absolute configuration on the asymmetric carbon of the 2-cyclopropyl-2-fluoroethyl chain

- (S)-3-Fluoro-2-((R)-3-methylmorpholin-4-yl)-9-[2-(1-oxa-6-azaspiro[3.3]hept-6-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

and also the addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

7) Process for preparing the products of formula (I) as defined in any one of the other claims, according to scheme 2 as defined hereinafter:

Scheme 2:


Deprotection
n = 0 or 1
Reductive amination
n = 0 or 1
Reduction
n = 0 or 1
CNBr
n = 0 or 1
Base
route b
route a
Chlorination
Deprotection
Electrophile
R1X T1
R1OH T2
T3
via route a: p = 1 or 2 and q = 0
and
via route b: p = 0 and q = 1 or 2
p = 1 or 2
q = 0

in which the substituents n, p, q, PG, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and alkyl have the meanings indicated for the products of formula (I) in any one of Claims 1 to 5.

8) As medicaments, the products of formula (I) as defined in any one of Claims 1 to 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

9) As medicaments, the products of formula (I) as defined in Claim 6, and also the pharmaceutically acceptable addition salts with inorganic and organic acids or with inorganic and organic bases of said products of formula (I).

10) Pharmaceutical compositions containing, as active ingredient, at least one of the products of formula (I) as defined in any one of Claims 1 to 6, or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier.

11) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment or prevention of a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, "mesangial" cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.

12) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers.

13) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of solid or liquid tumours.

14) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of cancers resistant to cytotoxic agents.

15) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of primary tumours and/or of metastases, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder and breast cancers, in melanoma, in lymphoid or myeloid haematopoietic tumours, in sarcomas, in brain, larynx and lymphatic system cancers, bone and pancreatic cancers, and in hamartomas.

16) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy.


17) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in cancer chemotherapy alone or in combination.

18) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of lysosomal diseases such as glycogenosis type II (or Pompe's disease) or Danon disease.

19) Products of formula (I) as defined in any one of Claims 1 to 6, for use thereof in the treatment of X-linked myotubular myopathies and Charcot-Marie-Tooth disease.


20) As novel industrial products, the starting products or synthesis intermediates as defined in Claim 7 as follows:

- of formulae A, B, G and N:




in which n = 1, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and PG is a protective group for amine;

- of formulae E, F, I and J:




in which q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5;

- of formulae P and H:




P



in which the substituents n, p, q, PG, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 have the definitions indicated in any one of Claims 1 to 5;

- of formula Q:



Q

in which either q = 0, one of R2 and R3 is alkyl and the other is alkyl substituted with one or more fluorine atoms, and the substituents p, PG, R1 and R4 have the definitions indicated in any one of Claims 1 to 5, or R1 is -$(CH_2)_m$-Ra with Ra being -CO-cycloalkyl, -CO-heterocycloalkyl, -CO-Rb, -C(Rb)=N-ORc, -CO_2Rd or -CONRxRy, and the substituents p, q, R2, R3 and R4 have the definitions indicated in any one of Claims 1 to 5.